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ABSTRACT: 
Exposure to harmful stimuli can render vascular endothelial cells dysfunctional, characterised by 
reduced nitric oxide (NO) bioavailibility. Endothelial dysfunction (ED) is a reversible precursor of 
ischaemic heart disease (IHD), and understanding the mechanisms underlying the development of 
ED could lead to clinical strategies in preventing/treating IHD. Very little is known about the 
responses of cardiac microvascular endothelial cells (CMECs) to pro-ED stimuli, as most studies are 
conducted on macrovascular endothelial cells.  
The current dissertation set out to comprehensively investigate the responses of cultured primary 
adult rat CMECs to known harmful stimuli, viz. hypoxia and tumor necrosis factor-alpha (TNF-α; pro-
inflammatory cytokine). We were interested to investigate whether this distinct endothelial cell type 
would develop classical features of ED, and if so, what the underlying mechanisms were. First we 
aimed to establish a baseline characterization of the CMECs under control conditions. Next, we 
developed a model of hypoxia-induced cell injury and measured apoptosis/necrosis, intracellular NO 
and reactive oxygen species (ROS), expression and activation of signalling proteins involved with NO-
biosynthesis, hypoxia and apoptosis, and differential regulation of proteins. Finally, we characterised 
CMEC responses to treatment with TNF-α. We assessed apoptosis/necrosis, intracellular NO and ROS 
levels, NO-biosynthesis pathway proteins and large-scale differential protein regulation. The above 
measurements were performed by morphological assessment (light and fluorescence microscopy), 
FACS analysis, western blotting and large-scale proteomic analyses.  
Data showed that CMECs shared many baseline features with other endothelial cell types, including 
morphological appearance, LDL-uptake, NO-production, and expression of eNOS protein. In a novel 
observation, proteomic analysis revealed the expression of 1387 proteins. Another novel finding was 
the high abundance of structural mitochondrial proteins, suggesting that CMECs require 
mitochondria for non-respiration purposes as well. High expression of vesicle, glycolytic and RAS 
signalling proteins were other features of the baseline CMECs. CMECs exposed to hypoxia responded 
by increased apoptosis/necrosis and expression of the hypoxia-marker, HIF-1α. Interestingly, hypoxic 
CMECs showed increased eNOS-NO biosynthesis, associated with increased mitochondrial ROS and 
reduced anti-oxidant systems, suggestive of oxidative stress. In accordance with the literature, 
several glycolytic proteins were up-regulated. A novel finding was the up-regulation of proteins 
involved with protein synthesis, not usually described in hypoxic cell studies. The CMECs responded 
to TNF-α-treatment by exhibiting hallmarks of ED, namely attenuated biosynthesis of PKB/Akt-eNOS-
derived NO and the development of outspoken response to oxidative stress as indicated by the up-
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regulation of several anti-oxidant systems. The data showed that TNF-α treatment elicited classical 
TNF-Receptor 1-mediated signalling characterized by the dual activation of pro-apoptotic pathways 
(BID and caspase-3) as well as the protective, pro-inflammatory IKB-alpha–NF-KB pathway.  
In conclusion, this is the first study of its kind to describe a comprehensive characterisation of CMECs 
under baseline and injury-inducing conditions. On the whole, although it appeared as if the CMECs 
shared many responses and mechanisms with more frequently researched endothelial cell types, the 
data also supplied several novel additions to the literature, particularly with the application of 
proteomics. We believe that this dissertation has provided more insights into endothelial 
heterogeneity in the vascular system and into the mechanisms adopted by CMECs when exposed to 
stimuli typically associated with cardiovascular risk. 
 
OPSOMMING: 
Blootstelling aan skadelike stimuli kan tot disfunksionaliteit van vaskulêre endoteelselle lei wat deur 
verlaagde biobeskikbaarheid van stikstofoksied (NO) gekenmerk word.  Endoteeldisfunksie (ED) is ‘n 
omkeerbare voorganger van isgemiese hartsiekte (IHD), en ‘n beter begrip van die onderliggende 
meganismes van ED kan lei tot die ontwikkeling van kliniese strategieë vir die 
voorkoming/behandeling van IHD.  Baie min is bekend oor die respons wat in kardiale 
mikrovaskulêre endoteelselle (CMECs) uitgelok word na blootstelling aan pro-ED stimuli, omdat 
meeste studies op makrovaskulêre endoteelselle uitgevoer word. 
Die huidige proefskrif het daarna gemik om die respons van primêre kulture van volwasse rot CMECs 
op bekende skadelike stimuli, nl. hipoksie en tumor nekrose faktor-alfa (TNF-α; pro-inflammatoriese 
sitokien) in diepte te ondersoek.  Ons was veral geïnteresseerd om vas te stel of hierdie spesifieke 
endoteelseltipe die klassieke kenmerke van ED sou ontwikkel, en indien wel, wat die onderliggende 
meganismes sou wees.  Eerstens het ons beoog om ‘n basislyn karaterisering van CMECs onder 
kontrole toestande daar te stel.  Vervolgens het ons ‘n model van hipoksie-geïnduseerde selskade 
gevestig en apoptose/nekrose, intrasellulêre NO en reaktiewe suurstofspesies (ROS), sowel as die 
uitdrukking en aktivering van proteine betrokke by NO-biosintese, hipoksie en apoptose en 
differensiële regulering van proteine gemeet.  Laastens het ons die respons van CMECs op 
behandeling met TNF-α gekarakteriseer.  Ons het apoptose/nekrose, intrasellulêre NO en ROS 
vlakke, NO-biosintese-seintransduksieproteïene en grootskaalse differensiele regulering van 
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proteïene gemeet.  Bg. metings is uitgevoer deur gebruik te maak van morfologiese evaluasie (lig -en 
fluoressensiemikroskopie), vloeisitometriese analises, western blot analises en proteomiese analises. 
Data het getoon dat die basislyn eienskappe van CMECs grootliks met dié van ander endoteelseltipes 
ooreenstem, insluitende morfologiese voorkoms, LDL-opname, NO-produksie en die uitdrukking van 
eNOS proteïen. In ‘n nuwe waarneming, het die proteomiese data die uitdrukking van 1387 
proteïene aangetoon. ‘n Ander nuwe bevinding was die voorkoms van ‘n groot aantal strukturele 
mitokondriale proteïene, wat daarop dui dat die CMECs mitokondria ook vir nie-respiratoriese 
doeleindes gebruik.  ‘n Hoë uitdrukking van vesikulêre, glikolitiese en RAS-seintransduksie proteïene 
was ook kenmerkend van die basislyn CMECs.  CMECS wat aan hipoksie blootgestel is, het reageer 
met ‘n verhoging in apoptose / nekrose en verhoogde uitdrukking van die hipoksie merker, HIF-1α.  
‘n Interressante bevinding was dat eNOS-NO biosintese sterk toegeneem het in die hipoksiese 
CMECs wat met verhoogde mitokondriale ROS en verlaagde anti-oksidant sisteme (aanduidend van 
oksidatiewe stres) gepaardgegaan het.  In ooreenstemming met die literatuur, is verskeie glikolitiese 
proteïene opgereguleer.  ‘n Nuwe waarneming was die opregulering van proteïene wat betrokke is 
by proteïensintese, iets wat nie normaalweg in hipoksie-studies beskryf word nie.  Die CMECs het op 
TNF-α behandeling gerespondeer deur tekens van ED te toon, naamlik ‘n afname in die NO 
afkomstig van PKB/Akt-eNOS biosintese en die ontwikkeling van uitgesproke reaksie op oksidatiewe 
stres soos aangedui deur die opregulering van verskeie anti-oksidant sisteme.  Die data het ook 
aangedui dat TNF-α behandeling tot klassieke TNF-reseptor 1 bemiddelde seintransduksie gelei het, 
wat gekenmerk was deur die tweeledige aktivering van pro-apoptotiese seintransduksiepaaie (BID 
en kaspase-3) sowel as die beskermende, pro-inflammatoriese IKB-alpha-NF-KB seintransduksiepad. 
Ten slotte: hierdie is die eerste studie van sy soort wat die kenmerke en response van CMECs onder 
basislyn en pro-besering omstandighede in diepte beskryf. Alhoewel dit oor die algemeen wil 
voorkom asof die CMECs baie in gemeen het met ander, beter nagevorste endoteelseltipes, het die 
data egter ook verskeie nuwe bevindinge tot die bestaande literatuur gevoeg, spesifiek die data 
afkomstig van die proteomiese analises.  Ons glo dat hierdie proefskrif meer insig verleen t.o.v. die 
heterogeniteit van vaskulêre endoteelselle asook t.o.v. die megansimes wat deur CMECs aangewend 
word wanneer hulle aan skadelike stimuli (geassosieer met kardiovaskulêre risiko) blootgestel word .   
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1.1  Ischaemic Heart disease (IHD) 
1.1.1  Incidence: 
Cardiovascular disease (CVD) is the number one cause of death in the world.  In 2008, 7.3 
million people died of IHD and 6.2 million from cerebrovascular disease (Mendis et al., 
2011).  According to a report by the World Health Organization (WHO) in 2011 on the top 
10 leading causes of death by broad income group 
(www.who.int/mediacentre/factsheets), IHD was the 4th most common cause of death in 
low-income countries (6.1% of deaths), the main cause of death in middle-income 
countries (13.7% of deaths) and high-income countries (13.6% of deaths) and remains the 
largest cause of deaths worldwide (12.8% of deaths) (Figure 1.1).  This surpasses the 
threat of other major communicable diseases such as tuberculosis and HIV/AIDS 
worldwide. 
According to the “Western Cape Mortality Profile – 2009 
(http://www.mrc.ac.za/bod/WesternCapeMortalityProfile2009), CVD was the highest 
cause of death in the Western Cape, followed by Diabetes (an independent risk factor for 
CVD).  Furthermore, CVD was the third highest cause of premature death (Years of Life 
Lost – YLL) in 2009 (Figure 1.2).  The Heart of Soweto (HoS) study investigated the 
emerging problem of CVD in urban black African patients presenting for the first time at 
the cardiac unit of a tertiary-care centre in Soweto (Pretorius et al., 2011).  Data from the 
HoS indicated a high prevalence of traditional cardiovascular risk factors such as 
hypertension and obesity, with almost two-thirds of the patients in the study cohort 
presenting with multiple risk factors (Pretorius et al., 2011).  Furthermore, 12% of this 
study cohort was diagnosed with coronary artery disease. Overall, the findings of the HoS 
and other studies are pointing to significant increases in the prevalence of CVD amongst 
people of African heritage in South Africa as a result of epidemiological transition and  
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Figure 1.1:   Global distribution of CVD burden (DALYs - Disability Adjusted Life Years) 
due to heart attacks, strokes and other types of CVD in males (A) and females (B) 
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Figure 1.2:   Top ten causes of mortality in the Western Cape in 2009:  A – Deaths and 
B:  premature deaths (years life lost - YLL) 
(http://www.mrc.ac.za/bod/WesternCapeMortalityProfile2009). 
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chronic diseases of lifestyle.    The profile of the HoS cohort discussed above is illustrated 
in figure 1.3.   
It is clear from the above studies and reports, that IHD is a major cause of morbidity and 
mortality in both developed and developing countries worldwide.  In addition, and of 
concern, is the fact that CVD and IHD are becoming increasingly prevalent among younger 
people and people of African heritage in South Africa.  To further stress the importance 
and burden of CVDs, it is envisaged that cardiovascular deaths will escalate to 23.4 million 
by the year 2030 (WHO, 2009). 
 
1.1.2  Vascular disease and the development of IHD: 
A multitude of factors are responsible for the development of IHD. Hypertension, 
smoking, dyslipidaemia, diabetes mellitus, physical inactivity and obesity are all 
associated with the development of atherosclerosis and IHD and considered to be major 
risk factors for cardiovascular mortality worldwide (WHO, 2009). 
Atherosclerosis, the underlying pathological phenomenon responsible for the 
development of IHD, is a chronic progressive vascular disease, characterized by plaque 
formation and subsequent fissure, erosion or rupture of the plaque with thrombosis of 
the plaque surface (Lahoz et al., 2007) A complication of coronary atherosclerosis can be 
the development of myocardial ischaemia and ultimately myocardial infarction (Choi et 
al., 2009). 
Plaque formation is characterized by the invasion of the arterial wall by circulating low 
density lipoproteins (LDL) particles, where they accumulate in the intima and undergo 
chemical modifications, such as oxidation. Modified LDL can induce endothelial cell (EC) 
activation and expression of adhesion molecules on EC surfaces. Furthermore, intimal 
macrophages can internalize modified LDL particles through scavenger receptors and 
become foam cells—a key process in the development of the atherosclerotic plaque. 
Oxidized lipids probably modulate smooth muscle cell functions, for example by  
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Figure 1.4:   Effects of LDL particles on the vessel wall (Rocha & Libby, 2009). 
 
Figure 1.5: The anatomical structures of arteries, arterioles, and capillaries (showing 
the endothelium as the barrier between the vascular space and the underlying tissues) (La 
Sala et al., 2012).   
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increasing their adhesion to macrophages and foam cells in the plaque (Rocha and Libby, 
2009) (Figure 1.4). 
Critical events in the early stages of atherosclerosis include endothelial activation and 
dysfunction (Schafer and Bauersachs, 2008; Vanhoutte PM, 2009; Södergren et al., 2010).  
The vascular endothelium regulates vascular tone and structure, cellular proliferation and 
interacts with both cellular and hormonal mediators from the circulation and the vascular 
wall (Chan and Losclzo, 2011; Mas, 2009).  EC activation is an important precursor and 
feature of atherosclerotic vessels (for detailed discussion, see Chapter 1, section 1.3.2.1).  
ECs are activated by cytokines (such as tumor necrosis factor alpha;  TNF-α), Angiotensin 
II (AngII), oxidative stress, oxidized LDL, and infectious agents  (Lee HS et al., 2010;  
Divchev and Schieffer, 2008), upon which the activated ECs express adhesion molecules 
(e.g. vascular cell adhesion molecule-1;  VCAM-1) and chemokines (e.g. monocyte chemo-
attractant protein-1;  MCP-1)(Mochizuki et al., 2010;  Kiechl et al., 2012;  Haas et al., 
2010).  Therefore, inflammatory processes play a critical role in atherogenesis.  There is 
substantial evidence indicating that impaired endothelial function is a feature of the early 
stages of atherosclerosis (Corrado et al., 2008). Endothelial dysfunction (for detailed 
discussion, see Chapter 1, section 1.3.2.2), characterized by decreased activity or bio-
availability of endothelium-derived nitric oxide (NO), is an important precursor of 
atherosclerosis and its complications (Grover-Páez et al., 2008;  Nacci et al., 2009). A 
deficiency of NO in vascular endothelium has been shown to result in vasoconstriction, 
platelet aggregation, thrombus formation, increased vascular smooth muscle 
proliferation, and enhanced leukocyte adhesion/invasion to the endothelium (Binglan et 
al., 2010;  Isenberg et al., 2008;  Moore et al., 2010;    Furie et al., 2008;  Tsihlis et al., 
2011;  Ortega et al., 2010).  
From the above, it is clear that the vascular endothelium is a primary target of harmful 
circulating stimuli associated with cardiovascular risk factor conditions.   Therefore, the 
relative state of vascular endothelial health is a critical determinant and predictor of CVD 
in general, and atherosclerosis and IHD in particular; in fact, ED has been described as the 
primum movens of coronary artery disease (Sitia et al., 2010). 
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1.2  Introduction to vascular endothelium. 
 
1.2.1 Structure and function:     
The endothelium is a thin, monolayer of cells (endothelial cells - ECs) lining the lumen of 
all blood vessels in the circulatory system, forming an interface between circulating blood 
and sub-endothelial tissues (Van der Oever et al., 2010). The adult human endothelium is 
estimated to have a surface area of between 1 to 7000 m2 (Limaye and Vadas, 2006; Mas, 
2009), consisting of 1-6 × 1013 ECs and accounting for about 1 kg of total body weight 
(Sumpio et al 2002; Limaye and Vadas, 2006). Traditionally regarded as a structural and 
selectively permeable barrier between the vascular space and the underlying tissues (see 
figure 1.5) (La Sala et al., 2012; Simionescu, 2007), we now know that the vascular 
endothelium is also a dynamic organ, with several important “house-keeping” functions in 
health and disease (Limaye and Vadas, 2006).   
ECs are flat with large central nuclei and a diameter of ~0.5 μm (Mas, 2009). ECs have a 
circular shape in capillaries and venules whereas in arteries and arterioles they are spindle 
shaped and arranged in the same direction as blood flow (Mas, 2009; Aird, 2007)(see 
figure 1.6 for a fluorescence digital image of Bovine Pulmonary Artery ECs). ECs show 
distinct phenotypic characteristics from site to site in the vascular tree (Van der Laan et 
al., 2004). This phenomenon is also referred to as endothelial heterogeneity (Aird, 2007a). 
The location of the endothelium at the interface between the blood and the vessel wall, 
bestows upon it an important role in several functions, such as vasoregulation, the 
provision of an anti-thrombotic surface facilitating laminar blood flow and selective 
permeability (McMurtry and Michelakis, 2012).  These activities are most evident in the 
microcirculation where the EC surface area: blood volume ratio is maximal (Limaye and 
Vadas, 2008).  Nutrients and macromolecules may diffuse out of the bloodstream through 
intercellular spaces (the result of cellular contraction) between ECs and may lead to tissue 
oedema/swelling (Oudega, 2012).   
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Figure 1.6:   A fluorescence digital image of Bovine Pulmonary Artery ECs (BPAEC).  
(http://micro.magnet.fsu.edu/primer/techniques/fluorescence/gallery).   Permission 
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Alternatively, nutrients and other molecules may be actively transported by transcytosis 
through the cells themselves.  The endothelium is also responsible for regulating the 
growth of the surrounding connective tissue (Brábek et al., 2010).  In its basal inactive 
state, it prevents the proliferation of smooth muscle via the secretion of transforming 
growth factor-β (TGFβ) and surface expression of haparan-like molecules (Patel et al., 
2010). When activated, however, cytokine/growth factor production by the dysregulated 
endothelium results in unchecked smooth muscle proliferation (Weakley et al., 2010). 
Enhanced secretion of platelet-derived growth factor (PDGF) along with insulin-like 
growth factor (IGF) and basic fibroblast growth factor (bFGF) by the dysfunctional 
endothelium has mitogenic effects on smooth muscle cells, and can play a role in 
atherosclerotic plaque formation (Tajsic and Morrell, 2011;  Perrault and Zahradtka, 
2011).  Endothelial activation may result from diverse insults such as disordered local 
cytokine production, viral infection, free radical formation or oxidation of lipids. 
Disruptions in endothelial function have been implicated in several diseases including 
atherosclerosis, cancer metastasis, inflammatory diseases and hypertension (Calcerrada, 
2011), diabetes mellitus, Raynaud’s disease, scleroderma, Kawasaki’s disease, vasculitides 
and in transplant rejection (Limaye and Vadas, 2006). 
Caveolae are particularly abundant in ECs (Van Nieuw Amerongen et al., 2011).  
Resembling little caves (50–100 nm in diameter) in the plasma membrane, they were 
described for the first time more than 50 years ago (Yamada, 1955). Caveolae are 
believed to be involved in various cell functions, including a number of vesicular transport 
processes such as transcytosis, endocytosis and potocytosis (Conner and Schmid, 2003, 
Johannes and Lamaze, 2002; Nabi and Le, 2003), the cholesterol homeostasis (Ikonen and 
Parton RG, 2000), intracellular sorting of proteins and lipids (Sprong et al., 2001) and the 
establishment of cell polarity (Manes et al., 2003).  It has also been proposed that 
caveolae, caveolins, and cavins play an important role in regulating EC signalling and 
function and thereby the cardiovascular and pulmonary function at cell and systemic 
levels (Sowa, 2011). Caveolae are required for the proper organization of signalling 
pathways that support numerous signalling events, through sequestration of receptors 
and downstream signalling regulators (Sowa, 2011).  Caveolin-1 is the major coat protein 
responsible for caveolae assembly (Gratton et al., 2004).  Caveolin-1 itself may positively 
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or negatively regulate signalling via direct or indirect protein–protein interactions with 
resident caveolar proteins. Experiments suggest that caveolin proteins in ECs are 
themselves regulated by intracellular signalling events (Gratton et al., 2004). Caveolin-1 
can be phosphorylated on tyrosine 14 in response to oxidative (Sotgia et al., 2012; 
Volonte et al., 2001) and shear stress (Rizzo et al., 2003), likely by src family kinases 
(Labrecque et al., 2003).  Caveolae play a critical role in the regulation of endothelial nitric 
oxide synthase (eNOS) and this has been studied intensively in recent years (Xu Y et al., 
2008). Direct interaction between endothelial nitric oxide synthase (eNOS) and caveolin-
1, the structural protein of endothelial caveolae, inhibits activity of the enzyme (by 
competing with activating Ca2+/calmodulin) and this has been confirmed by many studies 
(Bucci et al., 2000; Cohen W et al., 2004 and Gratton et al., 2004).  
Similar to most metabolically active cells, ECs contain substantial numbers of 
mitochondria (Dranka et al., 2010; Mas, 2009). Interestingly though, adenosine-5'-
triphosphate (ATP) production in ECs is relatively independent of mitochondrial oxidative 
pathways and therefore the mitochondria of ECs have been somewhat neglected. 
However, they are emerging as agents with diverse roles in modulating the dynamics of 
intracellular calcium and the generation of reactive oxygen species (ROS) and NO 
(Davidson and Duchen, 2007).  This led to a proposal that the principal role of 
mitochondria in ECs may be to release NO and ROS as signalling molecules (Quintero et 
al., 2006). Rod-shaped structures called Weibel-Palade bodies (WPBs) are uniquely 
expressed by ECs (Weibel and Palade, 1964) and are the major stores of the pro-
coagulant von Willebrand factor (vWF) and some pro-inflammatory proteins including P-
selectin (Mas, 2009).  
The thin layer of ECs, covering the internal surface of blood vessels, cardiac valves, and 
numerous body cavities, play a critical role in vascular homeostasis.  It does so by 
“sensing” changes in hemodynamic forces and blood-borne signals and “responding” by 
the release of vasoactive substances.  A critical balance between endothelium-derived 
relaxing and contracting factors maintains vascular homeostasis (Verma and Anderson, 
2002).  These factors will be discussed in more detail in the next section.  
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1.2.2 Endothelium derived factors and their role in endothelial function. 
The endothelium can release a host of factors in response to its environment and thereby 
regulate vascular homeostasis (see table 1.1).  
 
1.2.2.1 Nitric Oxide (NO) 
The binary molecule with chemical formula NO is also known as nitrogen monoxide 
(Figure 1.7). NO acts as a free radical, with key roles in both normal physiological 
processes and disease states (Gonenc et al., 2011).  Historically, NO was regarded as a by-
product of combustion of substances in the air, as found in automobile exhaust fumes, 
fossil fuel power plants, and during the electrical discharges of lightning in thunderstorms 
(Neill et al., 2008) .  The discovery that the endothelium-derived relaxing factor (EDRF) 
was in fact NO was rather astonishing, as NO had up till then been perceived as nothing 
more than a toxic environmental pollutant (Strijdom et al., 2009a).  
In fact, the discovery of that endogenously produced NO acted as an important 
cardiovascular signalling molecule resulted in the Nobel Prize for Medicine and Physiology 
being awarded to Furchgott, Ignarro and Murad in 1998 
(http://www.nobelprize.org/nobel_prizes/medicine/laureates/1998/).  It was proclaimed 
“Molecule of the Year” by Science journal 1992 (Culotta and Koshland, 1992).  It is now 
known that NO is an important cellular signalling molecule involved in many physiological 
and pathological processes (Bryan et al., 2009), and a powerful vasodilator with a short 
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Table 1.1:  Overview of the endothelium-derived vaso-active factors, responsible for regulating vascular tone (Mudau M et al., 2012). 
OVERVIEW OF ENDOTHELIUM-DERIVED VASO-ACTIVE FACTORS 
Endothelium-
derived factors 
Physiological effects Enzymatic source and mechanism of action 
Nitric Oxide (NO)  Potent vasodilator. 
 Inhibits inflammation, vascular 
smooth muscle cells (VMSCs) 
proliferation and migration, platelet 
aggregation and adhesion and 
leukocyte adhesion. 
 Regulates myocardial contractility. 
 Regulates cardiac metabolism. 
 Cardio-protective during ischaemia-
reperfusion injury. 
 
 Synthesized by the enzymes, eNOS, nNOS and iNOS, with eNOS being the major 
source of NO during physiological conditions. 
 Diffuses from ECs to underlying VSMCs where it binds to soluble guanylyl cyclase 
(sGC), leading to a cascade of events that ultimately result in vascular relaxation. 
Prostacyclin (PGI2)  Vasodilatory agent. 
 Inhibits platelet aggregation. 
 




 Exerts vasodilatory effects, 
particularly in small arteries of 
diameter ≤ 300µm. 
 
 Its identity is still under suspicion with proposed candidates such as potassium 
ions and hydrogen peroxide. 
Endothelin-1 (ET-1)  A potent vasoconstrictor.  Synthesized by endothelin-converting enzyme. 
 Exerts its effects via two receptors:  ETA expressed on ECs and ETB on WSMCs.  ETA 
receptors promote vasoconstriction, whereas ETB receptors promote NO 
production and ultimately reduction in ET-1 production. 
Thromboxane A (TXA2)  A potent vasoconstrictor. 
 
 Derived from arachidonic acid by COX-1. 
Angiotensin II (Ang II)  A potent vasoconstrictor.  Synthesized by angiotensin converting enzyme. 
 Elicits its effects via two receptors: AT1 which promotes vasoconstriction and cell 
proliferation, and AT2 which antagonizes the effects of AT1.  
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To date, a vast number of studies have indeed proven that this molecule is endogenously 
synthesized in the body and plays a vital role in maintaining a healthy cardiovascular 
system (Strijdom et al., 2009a). Owing to its gaseous and free radical nature, NO is able to 
diffuse easily between cells and tissues and react with a variety of molecules in the body 
(Strijdom et al., 2009a). Following its identification as the EDRF, it was reported that NO is 
synthesized from the amino acid L-arginine by a family of enzymes known as NO synthase 
(NOS) (Bruckdorfer, 2005).  
 
1.2.2.1.1 Nitric oxide synthases (NOS) 
NOS is the main enzymatic source of NO in the body. The enzymatic synthesis of NO is 
accomplished by three NOS isoforms: neuronal NOS (nNOS), endothelial NOS (eNOS) and 
inducible NOS (iNOS) (see Table 1.2). The activation of the first two enzymes depends on 
calcium, whereas iNOS is regarded as calcium-independent (Reuter et al., 2010). It has 
been reported that nNOS and eNOS are constitutively expressed, whereas iNOS is induced 
mainly by an immune response or inflammatory stimulation (Tsutsui M et al., 2006; 
Tsutsui M et al., 2009). However, it has been shown that iNOS is constitutively expressed 
in neurons (Buskila and Amitai, 2010), kidney (Heemskerk et al., 2009), liver (Diesen and 
Kuo, 2010), lung (Rus et al., 2010), colon (Baccari et al., 2012) and keratinocytes (Schmitz 
et al., 2012), whereas eNOS can be expressed at a level higher than its constitutive level 
under various conditions such as exercise (Gielen et al., 2011), estrogen stimulation (Hien 
et al., 2011), hyperthermia (Harris MB et al., 2003) and shear stress (Lam CF et al., 2006; 
Balligand JL et al., 2009). Hence, in light of the most current research reports, the 
expression and activity of the NOS isoforms seem to be variable and cell-specific. In the 
case of vasodilation, NO produced by ECs diffuses to the smooth muscle cells to activate 
soluble guanylate cyclase (sGC), and by doing so it causes vascular relaxation (Reuter et 
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Table 1.2:  The regulation of NOS protein expression and activity in the heart. 
Abbreviations:  +, stimulation; -, inhibition (Modified from Massion et al., 2003). 
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NO synthesis and its resulting effects depend not only on the cell type in which it is 
produced, but also on the particular conditions experienced by the cells, the organ, and 
the whole organism at the time of its production. For example, NO production by vascular 
ECs is usually continuous and in relatively small amounts, contributing to the 
maintenance of normal blood pressure and blood homeostasis (Reuter et al., 2010). 
During septic shock, however, iNOS expression is induced in vascular ECs, which in turn 
release high concentrations of NO, a process associated with vasoplegia, persistent 
hypotension, and decompensation (Reuter et al., 2010; Lopez JA et al., 2004; Ganda et al., 
2010). In another example, metabolically controlled production of NO can be affected by 
the distribution and expression of arginases (enzymes that catalyze the production of l-
ornithine and urea from l-arginine) and dimethylargininases (Bratt JM et al., 2009;  Bratt 
JM et al., 2010; Greene AL et al., 2005), limited substrate concentration (l-arginine), or 
local concentrations of citrulline (a competitive inhibitor of NG,NG-dimethylarginine 
dimethylaminohydrolase (DDAH)(Zhang P et al., 2011) and asymmetric dimethylarginine 
(ADMA)(a noncompetitive inhibitor of eNOS with a Ki of 0.4 µM (Wang CY et al., 2009) 
(see figure 1.8). Interactions of NOS isoforms with other trafficking proteins at the cellular 
and subcellular levels may also determine the fate of NO (Schilling K et al., 2006; 
Zimmermann K et al., 2002; Konig P et al., 2005; Konig P et al., 2002).  
In an article by Villanueva and Giulivi (2010), it is hypothesised that the 
compartmentalized production and effects of NO define its role in pathophysiology, and 
therefore modulating its localized production might be the key for effective 
pharmacological interventions and for understanding genetic differences in 
pathophysiology.  
 
eNOS activation and phosphorylation 
The activity of eNOS is largely determined by posttranslational modifications such as 
multisite phosphorylation, subcellular localization, and eNOS-protein interactions (Schulz 
et al., 2009).  The eNOS phosphorylation sites associated with enzyme activation includes 
Ser1177 and Ser633, whereas the phosphorylation site at Thr495 inhibits eNOS catalytic  
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Figure 1.8:  Metabolite-controlled production of NO. NO is produced by NOS from l-
arginine. NO can interact with specific targets, such as soluble guanylyl cyclase (sGC) and 
cytochrome c oxidase (CCO), or with other molecules, such as superoxide anion, to trigger 
nitrosative stress. High levels of citrulline (mM range) inhibit NG,NG-dimethylarginine 
dimethylaminohydrolase (DDAH), resulting in an increase in ADMA. ADMA, in turn, is a 
potent NOS inhibitor. Arginine concentrations can be modulated by the activity of 
arginases, which catalyze the formation of l-ornithine and urea from l-arginine. 
Dimethylarginine (DMA). Enzyme names are in green blocks in italic.   (Adapted from 
Villanueva and Giulivi, 2010). 
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activity  (Schulz et al., 2009; Chen Z et al., 2009). Site-specific phosphorylation also occurs 
at Ser114 and Ser615, but the functional consequences remain unclear (Schulz et al., 
2009).   
Several upstream kinases which modulate eNOS activity have been identified, including 
protein kinase B (PKB/Akt), protein kinase A (PKA), protein kinase C (PKC), and 
Ca2+/calmodulin-dependent protein kinase (CaMK)II (Schulz et al., 2009).  5' AMP-
activated protein kinase (AMPK) has also been shown to enhance eNOS activity by direct 
phosphorylation at Ser1177 (Bradley et al., 2010) and by promoting its association with 
heat shock protein 90 (HSP 90) (Schultz et al., 2009).   
Other findings suggest that trafficking of eNOS from plasmalemmal to intracellular 
structures is part of a physiological cycle highly sensitive to the state of cell activation 
(Rafikov et al., 2011).  The dynamic trafficking of eNOS between cell surface and 
intracellular compartments is supported in part by its close interaction with the scaffold 
protein caveolin (Parton RG et al., 2013). In addition to regulating eNOS subcellular 
localization, the stable interaction with caveolin leads to the inhibition of eNOS enzyme 
activity in basal conditions (Chen Z et al., 2012). Upon increases in intracellular calcium 
([Ca2+]i), Ca2+/calmodulin (CaM) displaces the inhibitory binding of caveolin to eNOS and 
allows enzyme activation (Kolluru GK et al., 2010). Similarly, increasing vascular flow 
(“shear stress”) and pressure in an in situ artery perfusion model rapidly leads to 
activation of caveolar eNOS with apparent eNOS dissociation from caveolin and 
association with calmodulin (Ando and Yamamoto, 2011).  
This suggests a bimodal mechanism of regulation of NO production reflecting dynamic 
changes in the eNOS/caveolin and eNOS/CaM interactions (Kolluru GK et al., 2010). 
However, the identification of both HSP 90 as a chaperone protein interacting with eNOS 
(Taipale et al., 2010) and phosphorylation sites within eNOS sequence (Butt et al., 2000;  
Bernier et al., 2000;  Michell et al., 2001;  Hill et al., 2010) added more complexity to the 
post-translational regulation of eNOS. In the case of VEGF stimulation, both the 
interaction of eNOS with HSP 90 and its phosphorylation by PKB/Akt were shown to 
promote NO production in ECs (Koch and Claesson-Welsh, 2012). Interestingly, each of 
these regulatory processes, i.e. HSP 90 binding or PKB/Akt phosphorylation, seems to 
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work by increasing the “apparent” sensitivity of the enzyme to Ca2+/CaM (Balligand et al., 
2009). However, while the former promotes CaM association to eNOS (upon agonist-
induced increase in [Ca2+]i) (Kolluru GK et al., 2010), the latter appears to reduce CaM 
dissociation from activated eNOS (when [Ca2+]i returns to basal levels) (Kolluru GK et al., 
2010; Moccia et al., 2012; McCabe et al., 2000).  
 
1.2.2.1.2 The physiological effects of NO in the heart 
NO-sGC- cyclic guanylyl monophosphate (cGMP) signalling  
Once NO is released from its attachment to the ferric or ferrous ion within the haem 
group of NOS, it may readily diffuse from its point of biosynthesis and reach sGC in a 
variety of other cells.  The sensitivity of sGC to NO is within the nanomolar range 
(Russwurm and Koesling, 2004;   Rodríguez-Juárez and Aguirre, 2007;   Hall CN and 
Garthwaite, 2009) and this property converts it into an undisputed primary physiological 
effector for NO.  The mechanism by which sGC is activated by NO is complex and poorly 
understood (Cary et al., 2006).   
New knowledge concerning the regulatory pathways for gene expression activation 
governed by the cGMP–cyclic guanosine monophosphate kinase I (cGKI) has emerged, 
based on the seminal observation that cGKI is able to translocate to the nucleus (Casteel 
et al., 2008; Pilz and Casteel, 2003) as well as an increasing list of physiological substrates 
phosphorylated by cGKI (Francis et al., 2010), thus conferring a multifaceted role to this 
enzyme.  The underlying mechanisms and potential relationships with the classical NO–
cGMP pathway of cGKI, cyclic guanosine monophosphate kinase II (cGKII), need to be 
further elucidated (Martinez-Ruiz et al., 2011).  Signalling by cGMP is terminated through 
the action of phosphodiesterases (PDEs), a class of proteins composed of 11 known 
families in mammals and derived from 21 genes (Martinez-Ruiz et al., 2011). Tissue and 
substrate specificities (for cGMP or cyclic adenosine monophosphate (cAMP)) are major 
determinants of their action and it is now well established that PDEs 5, 6, and 9 show high 
specificity for cGMP degradation (Martinez-Ruiz et al., 2011) (see figure 1.9).  After the 
significant scientific and social impact of the clinical use of PDE 5 inhibitors for erectile  
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Figure 1.9:  Classical mode of action of NO in vascular smooth muscle by activation of sGC 
and generation of cGMP (modified in part from Martínez-Ruiz et al., 2011). Once this 
nucleotide is synthesized, a series of reactions triggered by the activation of cGMP-cGKI 
occurs, the final consequence being a decreased intracellular Ca2+ concentration. These 
reactions involve the participation of partner proteins such as IRAG, Rho, and Rho kinase 
and calcium channels. The decreased levels of Ca2+ result in the uncoupling of contractile 
proteins, myosin phosphatase target subunit 1 / myosin light-chain phosphatase 
(MYPT1/MLCP) and vascular relaxation. The cGMP signal is terminated by specific 
phosphodiesterases (PDEs) (Martínez-Ruiz et al., 2011). 
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dysfunction, these enzymes have become major targets for therapeutic approaches 
(Wong ML et al., 2006).   
 
Effects on myocardial contractility: inotropic and lusitropic actions 
Many diverse and often contradictory effects of NO or NO donors on myocardial function 
have been reported (Cotton JM et al., 2002).  Recently, though, it is believed that NO 
generally acts to fine tune and optimize cardiac pump function (Cotton JM et al., 2002). 
Studies have shown that low (sub-micromolar) concentrations of NO exert modest 
positive inotropic effects, which may serve to enhance basal cardiac function (Rastaldo et 
al., 2007; Pavlovic et al., 2013).    Another study demonstrated a similar effect in normal 
human subjects undergoing cardiac catheterization, in whom intracoronary NOS 
inhibition with L-NMMA caused a small reduction in the maximal rate of left ventricular 
pressure development (LV dP/dt max), independent of changes in cardiac loading (Cotton 
JM et al., 2001).  An increasing body of data suggests that NO derived both from eNOS 
located in sarcolemmal caveolae and nNOS located probably in the sarcoplasmic 
reticulum (SR) of the cardiac myocyte may modulate central events of excitation–
contraction coupling such as calcium influx through sarcolemmal L type channels and the 
release and re-uptake of calcium by the SR (Carnicer et al., 2012; Nediani et al., 2011).  
The precise physiological role of these effects remains unclear, but there is a clear 
suggestion of a fundamental autoregulatory role for NO in intra-cardiomyocyte calcium 
cycling (Cotton JM et al., 2002). 
Slightly higher concentrations of NO (but still within “physiological” ranges) enhance 
cardiomyocyte relaxation and diastolic function (Cotton JM et al., 2002). A few studies 
showed that endothelium derived NO accelerates relaxation and reduces diastolic tone in 
a range of experimental preparations and species (Shah and MacCarthy, 2000; Rastaldo et 
al., 2007; Pavlovic et al., 2013).  The underlying mechanism of these effects is thought to 
be a cGMP induced reduction in myofilament responsiveness to calcium (Rastaldo et al., 
2007; Pavlovic et al., 2013;  Layland et al., 2002), an action that is also supported by 
studies conducted in anaesthetized pigs (Heusch et al., 2000).   
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Similar to the effects on contractile function, NO generated locally within the myocardium 
also modulates basal heart rate (Cotton JM et al., 2002).  In particular, NO exerts biphasic 
effects on atrial firing rate and automaticity through modulation of the hyperpolarisation 
activated pacemaker current, If (Tamargo et al., 2010).  Low concentrations of NO donors 
increase the rate whereas higher concentrations are negative chronotropic (Cotton JM et 
al., 2002). A final important effect of endothelium derived NO on basal cardiac function is 
the reversible inhibition of myocardial O2 consumption, independent of contractile 
function, which has been demonstrated both in vitro (Ziolo et al., 2008) and in vivo, in 
large animals (Heusch et al., 2000).  The underlying mechanism involves effects on the 
mitochondrial electron transport chain and may be at least partly cGMP independent. 
This action, like the others previously discussed, may be considered as potentially 
beneficial for global cardiac function (Cotton JM et al., 2002). 
Intra-cardiac NO generation is cyclical, with a vigorous rise around the time of early 
diastolic filling, and augmented by increased chamber stretch (preload) (Tousoulis et al., 
2012).  It has therefore been suggested that mechanical stimuli (e.g. stretch and shear), 
whose qualitative and quantitative characteristics are determined largely by cardiac 
contractile properties and loading conditions, may serve to match contractile functions of 
the heart to altered workload on a beat-to-beat basis (Cotton JM et al., 2002). As an 
example, experimental studies have shown that endogenous NO enhances the Frank-
Starling response in the isolated heart (Angelone et al., 2012).  Furthermore, NO has been 
shown to play an important role in the stretch induced activation of cardiac muscle (Vila-
Petrof et al., 2001).   
NO is also reported to modulate inotropic, chronotropic, and dromotropic responses to β 
adrenoceptor stimulation; low concentrations enhance and high concentrations reduce β 
adrenergic response (Collins and Rodrigo, 2010).  NO also elicits both acute and chronic 
lusitropic myocardial effects (Bronzwaer and Paulus, 2008).  Acute lusitropic effects of NO 
affect myocardial relaxation and diastolic distensibility, whereas chronic lusitropic effects 
of NO mainly influence myocardial diastolic distensibility (Bronzwaer and Paulus, 2008).  
In mechanically stressed myocardium, high NO bioavailability also preserves LV diastolic 
function through chronic effects on calcium handling, cardiomyocyte hypertrophy, and 
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extracellular matrix deposition, as evident, respectively, from transgenic mice with 
cardiomyocyte-specific NOS1 overexpression subjected to transverse aortic constriction 
(Loyer et al., 2008), from transgenic mice with cardiomyocyte-specific eNOS 
overexpression subjected to permanent coronary artery ligation (Shimokawa and Tsutsui, 
2010) and from numerous experimental rat models chronically treated with NOS 
enhancers or NOS inhibitors (Bronzwaer and Paulus, 2008). 
 
1.2.2.1.3 Metabolic effects of NO 
NO does not only affect myocardial contractile function. Both endogenous and exogenous 
NO has been shown to exert metabolic effects on the myocardium (Brutsaert, 2003).  
Metabolic effects, such as decreased myocardial oxygen consumption (Brutsaert, 2003; 
Trochu et al., 2000) the regulation of mitochondrial metabolism by direct inhibition of the 
respiratory chain (Stumpe et al., 2001), as well as utilization of energy substrates by 
reducing myocardial glucose uptake (Tada et al., 2000). These effects are suggestive of a 
putative cardioprotective mechanism for NO (Brutsaert, 2003).  NO has also been shown 
to inhibit electron transfer in the mitochondria (Förstermann U and Sessa, 2012). In 
addition, NO has been shown to directly activate the mitochondrial KATP channels (Sasaki 
et al., 2000), suggesting that NO might play a crucial role in what was regarded as the 
candidate end-effector of ischaemic preconditioning (IP)-protection. Furthermore, a 
possible role for NO derived from iNOS in the induction of apoptosis has been shown in 
neonatal mouse cardiomyocytes treated with the cytokine TNF-α (Song et al., 2000). 
 
1.2.2.1.4 NO in myocardial hypoxia 
 
NO production during hypoxia/ischaemia 
Most studies suggest that the production of NO increases during ischaemia, at least in the 
early stages (up to ±30 min) (Shah & McCarthy, 2000).  In one study, exercise has been 
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shown to protect against myocardial ischaemia, because of an increase in NO signalling 
(Calvert et al., 2011).  Another study reported that β3 adrenoreceptor-stimulation by 
increased NOS, improves ischaemia/reperfusion injury (Aragón et al., 2011).  An 
important stimulus for the increase in NO production may be hypoxia (Beleslin-Čokić et 
al., 2011). An augmented release of NO from coronary ECs contributes to hypoxic 
coronary vasodilatation (Crimi et al., 2012). NO production by isolated cardiomyocytes 
was also increased by hypoxia (Obal et al., 2012).  The increase in NO production during 
ischaemia may serve to maintain coronary blood flow and myocardial function (Shah & 
McCarthy, 2000).  Following prolonged severe ischaemia, however, the production of NO 
may decline (Yang G et al., 2010).  
 
Myocardial reperfusion / reoxygenation and beneficial effects of NO 
Indirect NO-mediated improvement of contractile function can occur via (1) antiplatelet-
adhesive and –aggregatory activity, leading to improvement in coronary blood flow 
(Mattapally and Banerjee, 2011); (2) decreased expression of adhesion molecules, such as 
P-selectin and intercellular adhesion molecule-1, on coronary ECs, resulting in decreased 
leukocyte adhesion (Hurd et al., 2012); (3) prevention of the “no-reflow” phenomenon, 
whereby microvascular perfusion remains impaired, despite the re-establishment of 
epicardial coronary artery patency (Shah & McCarthy, 2000). Potential mechanisms by 
which NO may exert direct beneficial effects include (1) a reduction in O2 demand, leading 
to improvement in O2 supply-demand balance (Umbrello et al., 2013); (2) reduction in 
myofilament responsiveness to Ca2+ (Jin CL et al., 2013) and/or sarcolemmal Ca2+ influx 
(Kuster et al., 2010), which would reduce the effects of Ca2+ overload; and (3) scavenging 
of ROS and thus a “cytoprotective” effect (Wink et al., 2011). 
 
Detrimental effects of NO during ischaemia-reperfusion 
Several investigators have also reported detrimental effects of endogenous NO during 
ischaemia-reperfusion (Shah and McCarthy, 2000).   For example, postconditioning 
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improved contractile function in the human myocardium by a NOS inhibitor or by a ROS 
scavenger, mercaptopropionylglycine (Lemoine et al., 2010). In isolated rat hearts 
subjected to brief hypoxia at constant coronary flow, the addition of SNP at 
reoxygenation was detrimental, in marked contrast to addition of the drug during hypoxia 
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1.2.2.1.5 NO in the heart – summary 
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1.2.2.2  Prostacyclin & Thromboxane A2 
Although NO is the best described endothelium-derived factor in the physiology and 
pathophysiology of endothelial function, it cannot explain all endothelium-dependent 
responses.  Other endothelium-derived factors, such as prostacyclin (prostaglandin I2, 
PGI2) and thromboxane A2 (TXA2) also play an important role in maintenance of the 
vascular homeostasis (Fetalvero et al., 2007).    
PGI2 and TXA2 are products of the cyclooxygenase (COX) pathway and have earned 
considerable attention in cardiovascular research because of their distinct effects on 
vascular functions (Pecchi et al., 2009; Belton et al., 2000) (Figure 1.10).   
PGI2 is a major prostanoid generated by ECs, and is a potent vasodilator and an inhibitor 
of leukocyte adhesion and platelet aggregation. Therefore, PGI2 is considered to be both 
anti-atherothrombotic and cardioprotective (Smith DD et al., 2010). On the other hand, 
TXA2 is a potent inducer of vasoconstriction, platelet activation, and platelet adhesion, 
and is a pro-atherogenic prostanoid. Since TXA2 and PGI2 exert opposing effects in the 
vasculature, their relative concentrations in the circulation and microenvironment are 
critical for the normal cardiovascular function and prevention of atherosclerotic 
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Figure 1.10:   The COX pathways. Schematic representation of the prostanoids produced 
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1.2.2.3  Endothelium–derived hyperpolirizing factor (EDHF) 
Multiple molecular mechanisms regulate blood vessel relaxation, with NO well-
established as the predominant mediator of endothelium-dependent vasorelaxation (NO 
was initially termed, EDRF (Murad F, 2006; Furchgott and Zawadzki, 1980; Ignarro et al., 
1987).  Whereas NO acts by both cyclic GMP (cGMP)-dependent and cGMP-independent 
mechanisms to influence calcium disposition and sensitivity (Moncada S and Higgs, 2006), 
blood vessel relaxation and tone can also additionally be mediated by endothelium-
dependent hyperpolarization (Feletou M and Vanhoutte, 2007; Cohen RA, 2005; Griffith 
TM, 2004).  Numerous substances have been advanced as putative EDHFs, including 
arachidonic acid metabolites, PGI2, epoxyeicosatrienoic acids (EETs) derived from 
cytochrome P450, lipoxygenase [12-(s)-hydroxyeicosatetraenoic acid (12-S-HETE)], ROS, 
hydrogen peroxide (H2O2), potassium ions (K+), vasoactive peptides, as well as NO itself 
(Feletou M and Vanhoutte, 2007;  Cohen RA, 2005;  Griffith TM, 2004;  Liu et al., 2011).  It 
has also been suggested that EDHF function may be mediated through direct coupling 
between endothelial and smooth muscle cells by myoendothelial gap junctions composed 
of connexions (Feletou M and Vanhoutte, 2007;  Cohen RA, 2005;  Griffith TM, 2004).  
Recently, hydrogen sulfide (H2S) has been shown to be a major EDHF (Mustafa et al., 
2011), formed in vascular ECs from cysteine by cystathionine γ-lyase (CSE), which is 
calcium-calmodulin dependent (Yang G et al., 2008).  Whereas CSE appears to play a 
significant role in the cardiovascular system, two other enzymes have also been shown to 
generate H2S in various tissues, namely cystathionine β-synthase (CBS) and 3-
mercaptopyruvate sulfurtransferase (3-MST) (Mustafa et al., 2011).  In blood vessels 
however, CBS appears to play a negligible role in the production of H2S (Zhao et al., 2001), 
whereas the precise role of 3-MST has yet to be defined, despite its presence in vascular 
endothelium (Shibuya et al., 2009).  Acetylcholine-mediated blood vessel relaxation, 
however, is markedly reduced in CSE-deleted mice, which manifests as increased blood 
pressure comparable to levels in mice lacking eNOS (Yang G et al., 2008; Huang PL et al., 
1995).   
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1.2.2.4  Endothelin-1 (ET-1) 
The endothelins constitute a super family of peptides that are structurally similar to 
sarafotoxins found in snake venom (Bourque et al., 2011).  There are three distinct 
encoded isoforms (ET-1, ET-2, and ET-3), and although all isoforms are involved in 
vascular function (Barton et al., 2008); ET-1 is the dominant isoform in the cardiovascular 
system and is therefore the most often studied (Bourque et al., 2011).  ET-1 is synthesized 
predominantly in vascular ECs, although it is also synthesized in vascular smooth muscle 
cells, extravascular tissues such as the spleen, pancreas, lung, and nervous system, and 
glomerular and epithelial cells within the kidney (Ruef et al., 2001; Bourque et al., 2011).  
ET-1 exerts its functions by binding to G protein-coupled ET receptors, which are 
expressed in several tissues, including the myocardium, lung, pancreas, spleen, and 
nervous system, as well as in vascular tissues (Bourque et al., 2011).  Two receptors for 
endothelins, named ETA and ETB, have been identified (Bourque et al., 2011).  ETA 
receptors are located within the vascular smooth muscle cells (VSMC), whereas ETB 
receptors are located on both the endothelium as well as on VSMC (Bourque et al., 2011).  
In the vasculature, ETA receptors are made up of ETA1 and ETA2 subtypes, distinguished by 
their sensitivity to the endothelin receptor antagonist BQ-123; the BQ-123-sensitive ETA1 
receptor is located in VSMC of most arteries and represents the dominant subtype 
(Iwasaki et al., 2000), whereas the BQ-123-insensitive ETA2 receptor has been localized in 
human and rabbit saphenous veins (Nishiyama et al., 1995; Sudjarwo et al., 1994).  ETB 
receptors consist of ETB1 and ETB2 subtypes, and can be broadly distinguished by their 
endothelial and smooth muscle cell localization, respectively (Dashwood and Tsui, 2002; 
Haynes et al., 1995; Masaki et al., 1991). Binding of ET-1 to ETA and ETB receptors in VSMC 
results in vasoconstriction, whereas the predominant effect of ET-1 binding to ETB 
receptors in the endothelium is increased NO and prostacyclin synthesis (Little et al., 
2008; Schiffrin, 2005).  Whereas ET-1 binds both ETA and ETB receptors, evidence suggests 
ET-11–31 (Rossi et al., 2002) selectively binds ETA receptors (Mazzocchi et al., 2000; 
Rebuffat et al., 2001; D’Orleans-Juste P, 2006), although evidence that ET11–31 binds ETB 
receptors and mediates NO release also exists (Niwa Y et al., 2000).  Whether ET-11–32 
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preferentially binds one endothelin receptor over the other is not yet known (Bourque et 
al., 2011).  
 
1.2.2.5  Angiotensin II (Ang II) 
Ang II is another endothelial-derived factor that regulates vascular function and structure. 
Ang II is the major bioactive peptide of the renin-angiotensin system (RAS) (Cat and 
Touyz, 2011).  Ang II, produced systemically and in ECs, is a potent vasoactive peptide that 
also stimulates vascular smooth muscle cell growth, inflammation, and fibrosis through a 
myriad of signalling pathways (Touyz and Schiffrin, 2000;   Mehta JL and Griendling, 2007;   
Lemarié and  Schiffrin, 2010).   Accordingly, Ang II plays an important physiological role in 
maintaining vascular tone by regulating immediate vasoconstriction, in addition to a 
pathophysiological role in CVDs such as hypertension, atherosclerosis, and heart failure, 
conditions that are associated with ED, vascular hyperreactivity, and structural 
remodelling (Cat and Touyz, 2011).  Ang II exerts its diverse actions via two G protein–
coupled receptors (GPCRs), namely Ang II type 1 receptors (AT1R) and type 2 receptors 
(AT2R)( Cat and Touyz, 2011).  The AT1R mediates most of the pathophysiological actions 
of Ang II.  AT2R is associated with antiproliferative, pro-apoptotic, and vasodilatory 
actions of Ang II and tends to counteract effects of the AT1R (Mehta JL and Griendling, 
2007).  Signalling pathways induced by Ang II/AT1R involve interactions with several 
heterotrimeric G proteins coupled to second messengers and cytosolic proteins, including 
phospholipase C (PLC), phospholipase A2 (PLA2), and phospholipase D (PLD) (Touyz and 
Schiffrin, 2000).  In addition Ang II/AT1R regulates the activation of NADPH oxidase 
through the activation of many receptor and nonreceptor tyrosine kinases and serine 
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1.2.3 Endothelial heterogeneity, macrovascular vs. microvascular ECs and 
cardiac EC subtypes. 
 
1.2.3.1 General endothelial heterogeneity 
EC phenotypes are differentially regulated in space and time, giving rise to the 
phenomenon of “EC heterogeneity” (Aird WC, 2007a).  Beyond the specification to 
arterial, venous, or lymphatic fate, it is currently recognized that ECs undergo further 
differentiation specific to the vascular bed or organ in which they reside (Atkins et al., 
2011).  This phenotypic heterogeneity is the primary mechanism by which the 
endothelium carries out a myriad of vital functions, including control of microvascular 
permeability, vessel wall tone, coagulation and anticoagulation, inflammation, and 
angiogenesis (Aitsebaomo et al., 2008;  Aird WC, 2007a;  Aird WC, 2007b).  Endothelial 
heterogeneity is also responsible for the varied and diverse responses across differing 
vascular beds to pathological stimuli and disease states (Molema G, 2010; Davies et al., 
2010; Kwaan and Samama, 2010). The phenotypic heterogeneity of the endothelium of 
the various organ and vascular beds has been highly studied (Aitsebaomo et al., 2005; 
Aird WC, 2007a; Aird WC, 2007b).  Remarkably, despite these detailed observations, the 
molecular mechanisms of endothelial heterogeneity remain largely unknown (Atkins et 
al., 2011).  In recent years, the study of ECs in several vascular beds has made significant 
strides in elucidating some of these molecular mechanisms (Atkins et al., 2011). 
 
1.2.3.1.1 Structural Classification of Vascular Endothelium 
Based on structural content, vascular endothelium can be classified into 3 main structural 
types: continuous, which is further subdivided into fenestrated or nonfenestrated, and 
discontinuous (or sinusoidal) (Aird WC, 2007a) (see figure 1.11). 
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Continuous Nonfenestrated 
Continuous nonfenestrated endothelium is found predominantly in arteries, veins, and 
capillaries of the brain, skin, muscle, heart, and lung (Atkins et al., 2011).  Tight junctions 
and adherens junctions are the 2 main types of barrier forming intercellular junctions 
found in this type of endothelium (Dejana E, 2004; Bazzoni and Dejana, 2004).  Their 
expression is variable across the endothelial tree, with higher expression in the 
continuous endothelium of arterioles compared to capillaries and venules (Atkins et al., 
2011).  Molecules cross continuous nonfenestrated endothelium by the active process of 
transcytosis, which is mediated by specialized structures including caveolae and vesiculo-
vacuolar organelles (Atkins et al., 2011).  Caveolae, flask-shaped, non-coated membrane 
invaginations (≈70 nm in diameter) that usually open to the luminal or abluminal side 
(Stan RV, 2005;  Parton RG and Simons, 2007),  are present in all types of endothelium, 
but have a particularly high expression in continuous nonfenestrated capillary ECs 
(Bendayan M, 2002).  Caveolin-1 is the main structural component of caveolae and is 
regulated by distinct transcriptional mechanisms in ECs (Kathuria et al., 2004).  Vesiculo-
vacuolar organelles also contain caveolin-1 and are focal collections of membrane bound 
vesicles of variable size that span the cytoplasm of the ECs (Dvorak AM et al., 1996); they 
are mostly found in venules with continuous nonfenestrated endothelium (Dvorak AM 
and Feng, 2001).  
 
Continuous Fenestrated 
This class of ECs typically occurs at locations that are characterized by increased filtration 
or increased trans-endothelial transport and is found in capillaries of all exocrine and 
endocrine glands, digestive tract mucosa, and the kidney (e.g., glomeruli and a 
subpopulation of renal tubules) (Atkins et al., 2011). Fenestrae are trans-cellular pores 
(≈70 nm in diameter) that extend through the full width of ECs and are thought to allow 
rapid exchange of molecules between the circulation and the surrounding tissue 
(Simionescu et al., 1974).  The majority of fenestrae contain a thin diaphragm across their 
opening that acts as a molecular filter (Atkins et al., 2011).  The type II membrane 
Stellenbosch University  http://scholar.sun.ac.za
P a g e  | - 35 - 
 
  Chapter One 
  
glycoprotein plasmalemmal vesicle–associated protein-1 is currently the only molecular 
protein localized to the diaphragm (Stan et al., 1999), and it has been discovered to be 
both necessary and sufficient for diaphragm formation in cultured ECs (Stan et al., 2004;  
Ioannidou et al., 2006).  Other diaphragm-containing components of continuous 
endothelium include caveolae and transendothelial channels, which are patent pores 
spanning the ECs from the luminal to abluminal side (Stan RV, 2007).  Compared with 
nonfenestrated endothelium, continuous fenestrated endothelium is more permeable to 
water and small solutes (Atkins et al., 2011).  
 
Discontinuous Fenestrated 
This class of ECs is found in certain sinusoidal vascular beds, most notably the liver and 
bone marrow, which lack a well-formed basement membrane (Atkins et al., 2011). 
Discontinuous fenestrated ECs are characterized by large heterogeneous fenestrae (100 
to 200 nm in diameter) without diaphragms (Braet and Wisse, 2002).  They have few 
caveolae and contain clathrin-coated pits and vesicles, which play an important role in 
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Figure 1.11: ECs in arteries, veins, and capillaries.  Selected phenotypic differences 
between ECs in arteries, veins, postcapillary venules, and capillaries. ALK1 (activin-
receptor-like kinase 1); Depp (decidual protein induced by progesterone); Dll4 (delta-like 
4); EPAS -1 (endothelial PAS domain protein 1); NRP1 (neuropilin 1); TE (transendothelial) 
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1.2.3.2  Endothelial Heterogeneity in the Heart 
ECs can have different effects on cardiac function, depending on their organization in the 
heart (Brutsaert, 2003).  In the heart, ECs can be categorised based on their proximity and 
interaction with the cardiomyocytes (Strijdom and Lochner, 2009c).  It is important to 
distinguish between the function of the cardiac ECs in the myocardial capillaries and at 
the endocardium (collectively referred to as cardiac endothelium) and the function of the 
coronary vascular endothelium in the major epicardial and smaller intramyocardial 
coronary arteries and veins (Brutsaert, 2003). ECs from larger coronary arteries, which 
constitute the coronary vascular endothelium (Figure 1.12),  lie distant from 
cardiomyoctes (Strijdom and Lochner, 2009c) The vascular endothelium controls coronary 
artery function, by indirectly controlling coronary blood supply to the myocardium 
(Brutsaert, 2003).    
Cardiac ECs in the myocardial capillaries (cardiac microvascular ECs: CMECs) and in the 
endocardial endothelium (EECs) are in close proximity to adjacent cardiomyocytes. The 
nature of the interactions between CMECs and EECs on the one hand and cardiomyocytes 
on the other, depends on intercellular distance and cell number ratio (Brutsaert, 2003).  
The cell number ratio, in turn, depends on the capillary-to-cardiomyocyte ratio and 
intercapillary distance (varies in species and cardiac sampling site) (Brutsaert, 2003).   The 
distance between each CMEC and the closest cardiomyocyte is approximately 1μm. This 
strategic arrangement facilitates endothelial cell-to-cardiomyocyte paracrine signalling 
(Brutsaert, 2003). Although EECs and CMECs share common features in their effects on 
subjacent cardiomyocytes, these two cardiac EC types are, however, not identical. They 
differ with regard to developmental, morphological, and functional properties, the major 
difference probably resulting from the way in which they perceive and transmit signals 
and from their different hierarchic position and contribution within the overall 
endothelial system (Brutsaert, 2003) (see figure 1.13). 
The close proximity between the CMECs and cardiomyocytes allow for bi-directional 
cellular communication and signalling between these cell types (Brutsaert, 2003).  These 
direct effects include regulating metabolism, growth, contractility and rhythmicity in 
cardiomyocytes and are mediated by autocrine and paracrine secretion of substances 
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such as NO, ET-1, prostacyclins and a variety of growth factors (Brutsaert 2003; Hsieh et al 



















Stellenbosch University  http://scholar.sun.ac.za
P a g e  | - 39 - 
 




Figure 1.12:    Classification of ECs in the heart. The classification is based on the 
proximity to, and direct paracrine influence on cardiomyocytes. Coronary vascular ECs are 
situated in the larger coronary arteries and veins, and have no direct effects on 
cardiomyocyte function. Their biological effects are similar to those of endothelium 
elsewhere in the body (maintenance of vascular homeostasis). Conversely, the cardiac ECs 
(endocardial ECs, EECs) and cardiac micro-vascular ECs (CMECs) have greater direct 
effects on cardiomyocyte function via the release of paracrine messengers such as NO 
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Figure 1.13:   Cardiac ECs: Endocardial ECs (EECs) and cardiac microvascular ECs (CMECs), 
endothelium. The ventricular wall (inset) consists of the epicardium, the myocardium, and 
the endocardium. The endocardium includes a fibroelastic layer, a basement membrane, 
and a luminal layer of ECs, i.e., the EE [top left transmission electron microscopy (TEM) 
micrograph]. The distance between the CMECs (top right TEM micrograph) and 
cardiomyocytes is usually <1 μm; between EECs and cardiomyocytes, the distance ranges 
from 1 μm in small mammals to >50 μm in humans. Analogous, and additive, myocardial 
actions of EECs and CMECs result in contractile twitch prolongation and increased peak 
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force development. The traces in the bottom panel represent isometric twitches (force, f 
vs. time, t traces) from isolated papillary muscles with intact EECs and CMECs, compared 
with twitches from muscles after selective EEC damage (−EE) by quick immersion of the 
papillary muscle in 0.5% Triton X-100 and to twitches from muscles with CMEC 
dysfunction (−VE) induced by a bolus injecƟon of diluted Triton X-100 in a Langendorff 
heart before isolation of the papillary muscle. Endothelial damage or dysfunction induced 
premature relaxation and concomitantly decreased peak force development (modified 




Figure 1.14: ECs in the heart.  A:  The three main endothelial compartments of the 
heart: the epicardial arteries, myocardial microvessels, and the endocardium (including 
valves) and selected side-specific differences in gene expression on aortic valve leaflets.  
B:  Comparison of properties between EECs and CMECs.  C:  Examples of bidirectional 
crosstalk between CMECs and cardiomyocytes. VEGF and PDGF-AB are released by 
cardiomyocyte, whereas signal transducer and activator of transcription-3 (STAT3) is an 
intracellular transcription factor involved in regulating the expression of paracrine factors. 
BMP indicates bone morphogenetic protein (Aird, 2007b). 
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1.2.3.3 Cardiac microvascular endothelial cells (CMECs).  
As mentioned previously, the endothelium in the heart is categorised into two subtypes, 
namely the coronary vascular endothelium and the cardiac endothelium (Strijdom and 
Lochner, 2009c). The coronary vascular endothelium constitutes the epicardial coronary 
arterial and venous ECs, and the intra-myocardial coronary arterial and venous ECs, 
whereas the cardiac endothelium constitutes the CMECs (> 90 % myocardial capillary 
derived) and EECs (Strijdom and Lochner, 2009c).  Most cardiac endothelium-based 
studies employ ECs harvested from the larger blood vessels of the heart. Studies focusing 
on the properties and behaviour of myocardial capillaries and myocardial capillary-
derived ECs (CMECs) under various physiological and pathophysiological conditions are 
few and far between, and their role in the context of particularly endothelial injury such 
as ED remains poorly understood. 
Microvascular ECs lack vascular smooth muscle cells (VSMCs) and therefore the NO 
released by these EC subtypes is very unlikely to be involved in the regulation of vascular 
tone (Strijdom and Lochner, 2009c). Given the close proximity between CMECs and 
cardiomyocytes, the NO released from CMECs is likely to regulate the function and 
activity of underlying cardiomyocytes, in addition to maintaining integrity of the cardiac 
endothelium.  Therefore, any injury to the CMECs and their subsequent response to it, 
could have a direct impact on the underlying cardiomyocyte and as a result, on 
myocardial function.  For this reason, it is imperative that more studies are undertaken to 
investigate pathophysiological conditions (such as ED) in CMECs, and to explore the 
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1.3 Endothelial responses to harmful stimuli. 
1.3.1 Vascular endothelium is a target of harmful stimuli. 
The chronic presence of cardiovascular risk factors and resulting exposure to harmful 
circulating stimuli associated with these conditions, eventually overwhelm the defense 
mechanisms of the vascular endothelium, hence compromising its integrity and ultimately 
initiating ED (Deanfield et al., 2007).  For the purpose of this study, only some of these 
harmful stimuli will be discussed. 
 
1.3.1.1 Tumour Nerosis factor alpha (TNF-α), Asymmetric dimethylarginine 
(ADMA), hypoxia, hyperglycaemia, oxidized-low density lipoprotein (LDL) 
and oxidative stress. 
As mentioned previously, the location of the endothelium at the interface between 
circulating blood and the vessel wall endows upon it an obligatory role in vasoregulation, 
the provision of an anti-thrombotic surface facilitating laminar blood flow, and selective 
permeability (Limaye and Vades, 2007). As a natural consequence, its distinct location 
makes the endothelium a primary target of circulating harmful stimuli.   
 
1.3.1.1.1 TNF-α:   
TNF-α, a 17 kDa polypeptide, was originally discovered as a molecule released by 
macrophages in endotoxin exposed rabbits that resulted in hemorrhagic necrosis of 
experimental tumors (Carswell et al., 1975). Now TNF-α is considered one of the most 
important cytokines and major effector of macrophage-mediated host defense and tissue 
injury, while also playing a crucial role in innate and adaptive immunity, cell proliferation, 
and apoptotic processes (Pober et al., 2006).  
Several mechanisms have been suggested for the induction/activation of NOS by TNF-α. 
Yoshizumi et al. (1993) showed that TNF-α markedly reduced mRNA levels of constitutive 
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(cNOS) in human umbilical vein ECs (HUVECs) in a dose- and time-dependent manner 
without changing the rate of cNOS gene transcription.  Another study, however, 
suggested that TNF-α increases eNOS activity in HUVECs (De Palma et al., 2006). 
Activation of eNOS by TNF-α requires activation of PKB/Akt, a known eNOS activator, via 
sphingosine-1-phosphate (Sph1P) receptor activation (Zhang H et al., 2009).  Sph1P 
receptor is activated by Sph1P, a sphingolipid involved in proliferation, survival, migration 
and differentiation of these cells, generated through neutral sphingomyelinase 2 (N-
SMase2) and sphingosine kinase 1 (SK1) activation (De Palma et al., 2006).  
According to Zhang H et al. (2009), TNF-α-mediated activation of eNOS can lead to 
increased NO generation, which exerts protective effects on dendritic cell (DC) adhesion 
to endothelium induced by TNF-α itself. It has also been suggested that TNF-α may 
increase iNOS expression by activating nuclear factor κB (NF-κB) (Zhong L et al., 1999).  
TNF-α-induced iNOS mRNA expression in microvascular ECs could be decreased by 
rooperol (a dicatechol from the South African plant Hypoxis rooperi) administration, 
which is an anti-inflammatory agent in the treatment of several inflammatory disorders 
(Bereta et al., 1997).  In HUVECs, the effect of TNF-α on iNOS expression was not affected 
by statin treatment, whereas reduced eNOS expression was reversed by rosuvastatin and 
ceruvastatin by inhibiting HMG-CoA (3-hydroxy-3-methylglutaryl-CoA) reductase and 
subsequent blocking of isoprenoid synthesis (Jantzen et al., 2007).   
Evidence suggests that TNF-α impairs endothelium-dependent and NO-mediated 
vasodilation in various vascular beds, e.g. mouse coronary arterioles (Gao et al., 2007), rat 
coronary arterioles (Picchi et al., 2006), cat carotid arteries (Aoki et al., 1989) and bovine 
small coronary arteries (Ahmad et al., 2002). Picchi et al., (2006) demonstrated that ED in 
pre-diabetic metabolic syndrome is a result of the effects of TNF-α and the subsequent 
production of O2− (superoxide radical).   
Myocardial I/R has been shown to increase the expression of TNF-α, which induced 
activation of XO (xanthine oxidase) and the production of O2−, leading to coronary ED 
(Zhang et al., 2006). Gao et al. (2007) showed that advanced glycation end-product (AGE)/ 
receptor for AGEs (RAGE) and NF-κB signalling play a pivotal role in elevating circulating 
and/or local vascular TNF-α production (Zhang et al., 2009). The increased TNF-α 
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expression induces the production of ROS, leading to ED in Type 2 diabetes (Zhang et al., 
2009). Therefore, from the findings of these studies, it seems that ED associated with 
TNF-α in pathophysiological conditions is linked to excess production of ROS and a 
decrease in NO bioavailability (Zhang et al., 2009). 
Although some studies have shown that TNF-α induces increased NO, there are also 
studies where the opposite observation was made, and that this phenomenon is likely to 
be concentration (Chen TG et al., 2011) and time (Tsou et al., 2010) dependent in in vitro 
studies.  According to some studies, TNF-α appears to decrease the bioavailability of NO 
by (i) diminishing the production of NO (Goodwin BL et al., 2007;  Picchi et al., 2006;  
Ahmad et al., 2002;  Greenberg et al., 1993), and (ii) enhancing the removal of NO (Gao et 
al., 2007).  Picchi et al. (2006) reported that the real-time production of NO in isolated 
coronary arteries from ZOF rats (Zucker Obese Fatty rats; a model of pre-diabetic 
metabolic syndrome) and acetylcholine (ACh)-induced NO production were significantly 
lower in ZOF rats compared with lean control rats. This result suggested that higher 
concentrations of circulating TNF-α and protein expression of TNF-α diminished NO 
bioavailability in ZOF rat coronary arteries via the decreased expression of eNOS (Figure 
1.15).  
Many studies have shown that the direct effects of TNF-α on eNOS are via down-
regulating eNOS activation and expression and diminishing NO production in diverse 
vasculatures (Goodwin BL et al., 2007; Picchi et al., 2006;  Ahmad et al., 2002;  Greenberg 
et al., 1993). In addition to eNOS, other factors are also involved in regulating NO 
production, such as a functional citrulline/NO cycle (Xie et al., 2000; Goodwin BL et al., 
2004;  Hattori et al., 1994;  Husson et al., 2003). The citrulline/NO cycle is regulated by 
ASS (argininosuccinate synthase) (Zhang et al., 2009).  NO is synthesized from the 
conversion of L-arginine to L-citrulline mediated by eNOS, and ASS catalyses the rate-
limiting step in the arginine regeneration through the citrulline/NO cycle and appears to 
be co-coordinately regulated with eNOS activity (Oyadomari et al., 2001)(Figure 1.15). 
Goodwin BL et al. (2007) have shown that TNF-α diminished the mRNA and protein 
expression of ASS in aortic ECs and directly resulted in the reduced production of NO.  
Gao and co-workers (Gao et al., 2007;  Picchi et al., 2006) reported that TNF-α impaired 
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NO-mediated vasodilation in Type 2 diabetic coronary arterioles. A neutralizing antibody 
to TNF-α decreased the formation of ROS (O2−, ONOO− and H2O2) and improved NO-
mediated vasodilation.  TNF-α stimulates the endothelial generation of ROS by activation 
of NADPH oxidase, perhaps via the subunits gp91phox, NOX-1, p47phox and p22phox 
(Figure 1.15).   
NO has been implicated as the major mediator of endothelium-dependent relaxation, 
but, as discussed previously, EDHF also plays an important role in regulating vascular tone 
and vasoreactivity, particularly in resistance blood vessels, where a small change in 
membrane potential causes a significant change in diameter (Feletou M and Vanhoutte, 
2006).  Type 2 diabetes impairs EDHF-mediated vasodilation (De Vriese et al., 2000); 
however, the mechanisms have not been clearly elucidated. For example, the role of TNF-
α in EDHF-mediated vascular dysfunction is controversial.  Wimalasundera et al. (2003) 
reported that TNF-α did not inhibit EDHF-dependent vasodilation, whereas Gillham et al. 
(2008) observed a direct effect of TNF-α on EDHF-mediated vasodilation in human 
omental arteries by incubation of 1 nmol/l TNF-α for 1 or 2 hours. Their results showed 
that TNF-α impaired EDHF-mediated dilation.  In addition, Kessler et al. (1999) found that 
TNF-α reduced EDHF synthesis with direct measurement of hyperpolarization in porcine 
coronary arteries, and Park et al. (2008) showed that EDHF-mediated dilation in coronary 
arterioles from Type 2 diabetic mice (dbTNF−/dbTNF−) was enhanced compared with 
Type 2 diabetic (db/db) mice. The possible mechanism of impaired EDHF-mediated 
vasodilation by TNF-α may be via epoxyeicosatrienoic acid (EETs), which is regarded as 
one of the candidate EDHF’s.  EETs are synthesized in the ECs from arachidonic acid (AA) 
through cytochrome P450 oxygenase (Zhang et al., 2009).  TNF-α down-regulated the 
protein expression of cytochrome P450 2C, which is the major family of cytochrome P450 
mono-oxygenases in porcine aortic ECs (Kessler et al., 1999) (Figure 1.15). 
NO and ROS may play a dual role (i.e., inhibiting or promoting) in TNF-α-induced EC 
apoptosis (Xia et al., 2006).   Changes associated with endothelial apoptosis are 
embedded in a complex array of interdependent events that will be discussed in more 
detail below. These changes can affect many aspects of endothelial function, and may be 
directly linked to some manifestations of disease, such as atherosclerosis, allograft 
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vasculopathy, hypertension, congestive heart failure (CHF) and sepsis and associated 
syndromes (Stefanec, 2000).   
Apoptotic ECs release interleukin 1 (IL-1) (Liew et al., 2010; Dignat-George and Boulanger, 
2011), which will have several important effects:  (1) IL-1 may enhance apoptosis of ECs 
(Liew et al., 2010); (2) it may enhance endocytosis of apoptotic bodies by surrounding ECs 
(Dignat-George and Boulanger, 2011) and (3) IL-1 activates neighboring ECs through the 
activation of nuclear factor kB (NFkB) (Grivennikov et al., 2010; Partridge et al., 2007;  
Meziani et al., 2008).  While activation of NFkB may protect the EC from apoptosis 
(Mattson and Meffert, 2006) in an environment that is likely to be predominantly pro-
apoptotic, it can also lead to the expression and release of adhesion molecules for 
inflammatory cells and production of pro-inflammatory cytokines (Zhang, 2008).  
Leukocytes may adhere, transmigrate, release proteases, cause additional endothelial 
injury and lead to the development of inflammatory changes in the vessel wall (Stefanec, 
2000). Release of adhesion molecules prevents further leukocyte adherence (Gawaz et al., 
2005), but may at the same time cause leukocyte activation and lead to release of 
additional pro-inflammatory mediators or proteases (Ouedraogo et al., 2007; Gawaz et 
al., 2005), thereby giving rise to endothelial injury or apoptosis in nearby or distant 
endothelial surfaces.  It has been suggested that mediators other than IL-1 participate in 
the above events (Stefanec, 2000), such as TNF-α.   
Secretion of TNF-α by the endothelium has been demonstrated in vitro (Luan et al., 2010).  
TNF-α plays a major role in inflammatory responses, causing apoptosis by signalling via 
the death receptors (Basuroy et al., 2006).  Signalling via “death receptors,” such as the 
TNF-α receptor 1 (TNFR-1/CD120a), can trigger ECs to undergo apoptosis (Brouard et al., 
2002). Cross-linking of TNFR-1 leads to the recruitment of intra-cytoplasmic signal 
transduction molecules, e.g. TNF receptor-associated death domain (TRADD), Fas-
associated death domain (FADD), and receptor-interacting protein (RIP) (Brouard et al., 
2002; Chen G and Goeddel, 2002). These molecules form the death-inducing signalling 
complex (DISC), which activates serine proteases, referred to as caspases (Thorburn, 
2004). Caspase activation by DISC occurs via FADD-dependent recruitment and proximal 
catalytic cleavage/activation of pro-caspase-8 into the active form of caspase-8 (Brouard 
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et al., 2002; Reed, 2000), which activates additional pro-caspases into active caspases, 
e.g. caspase-3, that execute the terminal phase of apoptosis (Reed, 2000).  
The mitochondrion plays a key role in the initiation and amplification of the apoptotic 
process (Norberg and Zhivotovsky, 2010).  During apoptosis, it releases cytochrome c, 
which disrupts its electron transport chain. While normal oxidative phosphorylation loses 
some 1 to 5% of electrons to superoxide production, this percentage increases with loss 
of cytochrome c from the mitochondria of the apoptotic cell (Norberg and Zhivotovsky, 
2010; Serviddio et al., 2011).  The freely diffusible NO and newly produced superoxide 
react to form peroxynitrite, itself a toxic and pro-apoptotic substance (Gregersen and 
Bross, 2010).  NO is consumed in this reaction and is not available for its normal role in 
vasodilatation, inhibition of platelet aggregation, and prevention of endothelial apoptosis, 
as well as inhibition of vascular smooth muscle cell proliferation and leukocyte adhesion 
(Gregersen and Bross, 2010; Lamas, 2010; Pae et al., 2010).  
Normal anti-coagulant properties of vascular endothelium are lost during apoptosis 
(Stefanec, 2000). The surface of the apoptotic cell exhibits increased tissue factor pro-
coagulant activity, as well as reduced surface thrombomodulin, heparan sulfate, and 
tissue factor pathway inhibitor expression (Aksu et al., 2012).  This leads to increased 
thrombin formation by both adherent and detached apoptotic ECs. Prostacyclin 
production is decreased during endothelial apoptosis (Levi and van der Poll, 2010).  This 
might, apart from a reduced anti-apoptotic effect (Levi and van der Poll, 2010), lead to 
loss of inhibition of platelet activation (Levi and van der Poll, 2010).  Both activated 
platelets and thrombin can enhance inflammatory and pro-apoptotic events through 
activation of leukocytes and ECs (Harlan, 2010; Jennings, 2009).  Complement activation 
via the alternative pathway has been observed on apoptotic ECs (Chen W et al., 2010).  
While this activation may enhance the clearance of apoptotic cells by phagocytes, it can 
also activate leukocytes and ECs, and mediate additional endothelial injury or apoptosis 
(Stefanec, 2000).   
Adrenomedullin (vasodilation; Nishikimi et al., 2011) and ET-1 (vasoconstriction; Thorin 
and Webb, 2010) levels are elevated in circumstances associated with endothelial 
equilibrium disturbance (Stefanec, 2000). Both were found to have an 
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autocrine/paracrine antiapoptotic effect on ECs (Nishikimi et al., 2011; Thorin and Webb, 
2010).  Their secretion in circumstances associated with endothelial injury, activation, and 
apoptosis is controlled independently (Trimarchi, 2011), and may represent a mechanism 
that limits endothelial damage and enhances its recovery, while adjusting vascular tone 
and blood flow in the distribution of disturbed endothelial-derived vasomotor control. 
It is clear from the above discussion that in the case of in vitro studies, the effects of TNF-
α on NO production, ROS production and cell viability varies between different EC types, 
and is concentration and time-dependent.  In view of this, data from various in vitro 
studies on the effects of TNF-α are often contradictory (please refer to Table 1.3 for a 
summary of the effects of different concentrations of TNF-α on ECs focusing on the NOS-
NO biosynthesis pathway, oxidative stress and cell viability measurements). Therefore the 
exact mechanisms by which TNF-α exerts its effects at various time points and 
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Figure 1.15:  Role of TNF-α in ED.  TNF-α reduces the production of NO through the 
inhibition of the enzyme expression of argininosuccinate synthase (ASS) and eNOS, and 
enhances the removal of NO through the increase in NADPH-dependent O2− production to 
react with NO to form ONOO−.  As a consequence, TNF-α decreases the bioavailability of 
NO resulting in reduced induction of vascular smooth muscle relaxation.  TNF-α also 
diminishes EETs, one of the candidate EDHFs, via the inhibition of cytochrome P450 (CYP 
450) enzyme activity (Zhang et al., 2009).  
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Table 1.3: Selection of in vitro EC studies investigating the effects of TNF-α stimulation. 
 
TNF-α treatment Cell / in vitro model NOS-NO measurements Oxidative stress Viability Reference 
100 U / ml;  30 min Coronary microvascular ECs Not performed ↑NADPH-oxidase (p47) Not performed Li C  et al., 2002, 2005 
50 ng / ml;  0 – 60 min;  max 
6 hrs 
HUVECs NO measurements not 
performed;   
↑phospho eNOS;   
↑phospho PKB/Akt 
Not performed Not performed De Palma et al., 2006 
5-10 ng / ml;  10 min BAECs ↓Nitrogen Oxide (NOx);  
↓phospho eNOS;  ↓phospho 
PKB/Akt (insulin and flow 
stimulated) 
Not performed Not performed Kim HJ et al., 2006a 
300 U / ml;  1 h;  max 4 hrs HUVEC hybrid Not performed Superoxide / ROS levels 
unchanged 
Not performed Arai et al., 1998 
100 pg / ml;  48 hrs BAECs NO measurements not 
performed;   
↓ eNOS protein;   
↓ eNOS gene promoter 
activity;   
↓NOS acƟvity 
Not performed Not performed Anderson et al., 2004 
0.1, 1, 10 ng / ml;  1 hr HUVECs Not performed ↑ Mitochondrial ROS ↑ Necrosis at 10 ng / ml 
TNF-α 
Corda et al., 2001 
10 ng / ml;  16 hrs Intrapulmonary arterial 
segments 
NO measurements not 
performed;   
↑ eNOS staining 
(immunohistochemistry) 
↑superoxide levels (via 
↑NADPH-oxidase activity);   
↑nitrated protein staining 
Not performed Muzaffar et al., 2004 
40 ng / ml;  24 hrs HUVEC (ECV304) ↑Nitrites+Nitrates;   
eNOS measurements not 
performed 




Wang P et al., 1994 
2 ng / ml;  8 hrs Human coronary artery ECs Unchanged nitrites+nitrates 




Not performed Not performed Jiang J et al., 2010 
40 ng / ml;  24 hrs HUVEC (ECV304) ↑nitrites+nitrates (Griess);  ↑ROS producƟon ↑ Apoptosis; Xia et al., 2006 
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↑Nitrotyrosine protein ↑ LDH release 
↓ MTT staining 
5 – 1000 pg / ml;  24 hrs HUVECs Unchanged 
nitrites+nitrates (Griess);  
eNOS measurements not 
performed 
↑OxidaƟve stress Unchanged viability 
(trypan blue staining) 
Scalera et al., 2003 
0.1 – 30 ng / ml;  18 hrs HUVECs NO measurements not 
performed;   
↑ciƩruline levels;   
eNOS measurements not 
performed 
Not performed Not performed Radomski et al., 1993 
40 ng / ml;  24 hrs HUVECs ↑Nitrites+Nitrates (Griess);  
 eNOS measurements not 
performed 
Not performed ↑ Apoptsosis Luo et al., 2006 
0.1 – 3 ng / ml;  4 – 24 hrs HUVECs NO measurements not 
performed;   
↓cNOS mRNA 
Not performed Not performed Yoshizumi et al., 1993 
50 ng / ml;  30 min – 24 hrs Bovine pulmonary 
microvessel ECs 
↓Nitrites (Griess) at 4 hrs;  
unchanged at 24 hrs;  ↓eNOS 
protein at 24 hrs 
Not performed Unchanged viability (trypan 
blue staining) 
Bove et al., 2001 
20 ng / ml;  1 – 24 hrs HUVECs Not performed ↑Superoxide 
↑ Mitochondrial ROS 
↑ ↓ Apoptosis depending 
on ROS source 
Desphande et al., 2000 
0 – 50 ng / ml;  20 – 30 hrs Bovine pulmonary artery 
ECs 
Not performed Not performed ↑ Apoptosis Polunovsky et al., 1994 
10 ng / ml;  24 hrs BAECs ↓eNOS mRNA and protein;   
↓nitrite levels 
Not performed Not performed Goodwin BL et al., 2007 
20 ng / ml;  24 hrs HUVECs / BAECs NO measurements not 
performed;   
↓eNOS mRNA stability and 
protein 
Not performed Not performed Yan et al., 2008 
60 000 U / ml Microvascular and 
macrovascular ECs 
↑Nitrites and ↑iNOS mRNA 
(TNF-α + Interferon-gamma;   
TNF-α + lipopolysaccharide 
Not performed Not performed Geiger et al., 1997 
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Table 1.4:  Summary of the detrimental effects of TNF-α in the heart (Sack, 2002). 
 
 The effect of TNF-α on cardiac contractile function has been shown to be both 
concentration- and time-dependent with a minimal threshold, seemingly required to 
induce a negative inotropic effect (Yokoyama T et al., 1993). 
• TNF-α expression and peptide production are up-regulated in the adult heart in 
response to pressure overload and in response to stretch in isolated cardiac myocytes 
(Kapadia et al., 1997; Yokoyama T et al., 1997). These hemodynamic loads elicit 
cardiomyocyte hypertrophy and extracellular matrix remodeling as phenotypic alterations 
that are thought to be adaptive responses in order to maintain normal cardiac 
contractility and homeostasis (Sack, 2002). 
• The association of inflammation with atherosclerosis is now fairly well established 
(Mehta JL and Li, 1999;  Ross, 1999) and the expression of pro-inflammatory cytokines 
such as TNF-α have been identified throughout the full spectrum of atherosclerotic 
development (Sack, 2002). 
• The inflammatory reaction has been well documented in patients following 
percutaneous coronary intervention (Inoue et al., 1999;  Kamijikkoku et al., 1998) and the 
expression of TNF-α has been shown to be elevated in restenotic lesions retrieved by 
arthrectomy (Clausell et al., 1995). 
• TNF-α is thought to play an integral role in the inflammatory reaction present in 
myocarditis (Feldman & McNamara, 2000;   Satoh et al., 2000;  Seko et al., 1997). 
• Myocardial TNF-α production has been well documented during acute myocardial 
ischaemia with or without reperfusion (Irwin et al., 1999; Meldrum DR et al., 1998a;  
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Cardioprotective properties of TNF-α: 
Apart from the detrimental effects of TNF-α, as described above, it was also shown in a 
study by Lecour et al. (2005) that TNF-α can protect the myocardium.  It does so by 
mimicking classic ischaemic preconditioning (IPC) in a dose- and time-dependent manner, 
activating the signal transducer and activator of transcription-3 (STAT-3) signalling 
pathway (Lecour et al., 2005).   
 
1.3.1.1.2 Asymmetric dimethylarginine (ADMA):   
ADMA was first described by Vallance et al. (1992a) as an endogenous inhibitor of NOS.  
Since then, the role of this molecule in the regulation of endothelial NO synthesis has 
increasingly attracted attention, especially as a novel cardiovascular risk factor (Böger RH, 
2004).  ADMA is found to be elevated in renal failure, CVD and diabetes mellitus (Böger, 
2003b; Von Haehling et al., 2010; Vallance et al., 1992b).  A low ratio of Arginine to ADMA 
(Arg/ADMA ratio) is also a marker of ED (Böger et al., 2007). Prospective investigations of 
ADMA have highlighted its role as a predictor of CVD events or death in patients with 
established coronary artery disease (Krempl et al., 2005; Lu et al., 2003; Schnabel et al., 
2005), advanced renal failure (Zoccali et al., 2001) or other high-risk conditions (Böger, 
2006). 
ADMA is released when methylated proteins are degraded into their amino acid 
components during hydrolytic protein turnover (see figure 1.16) (Böger et al., 2003b).  
Enzymatic degradation of ADMA by dimethylarginine dimethylaminohydrolases (DDAH) 
has attracted much attention (Böger RH, 2004).  DDAH degrades ADMA to dimethylamine 
and l-citrulline.  DDAH activity is found in almost all tissues, with high activities in kidney 
and liver (Kimoto et al., 1995). There are two allelic isoforms of this enzyme, DDAH-1 and 
DDAH-2, which show different tissue expression patterns (Leiper JM et al., 1999).  DDAH-1 
is present in many tissues that also express neuronal NO synthase, whereas DDAH-2 is 
mainly present in vascular tissues that co-express eNOS (Leiper JM et al., 1999).  DDAH 
activity is reduced by oxidative stress induced by TNF-α or oxidized LDL in vitro (Ito et al., 
1999); moreover, it is modulated by S-nitrosylation (Leiper JM et al., 2002).  
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Figure 1.16: Schematic overview of biochemical pathways related to ADMA. 
Methylation of arginine residues within proteins or polypeptides occurs through N-
methyltransferases, which utilize S-adenosylmethionine as a methyl group donor. After 
proteolytic breakdown of proteins, free ADMA is present in cytoplasma. It can also be 
detected circulating in human blood plasma. ADMA acts as an inhibitor of NOS by 
competing with the substrate of this enzyme, l-arginine, and causes ED and, 
subsequently, atherosclerosis. ADMA is eliminated from the body via urinary excretion 
and, alternatively, via metabolism by the enzyme DDAH to citrulline and dimethylamine 
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Targets of ADMA: 
ADMA inhibits all 3 isoforms of NOS and is approximately equipotent with the 
pharmacological NOS inhibitor, L-NMMA (Vallance et al., 1992a; MacAllister RJ et al., 
1994).  In addition to blocking NO formation, L-NMMA treatment may uncouple NOS and 
lead to the generation of superoxide (Olken et al., 1993; Pou et al., 1999), and it is likely 
that ADMA can do the same.  
 
Degradation of ADMA (The DDAHs): 
Although symmetric dimethylarginine (SDMA) (the methylarginine that does not inhibit 
NOS) is eliminated almost entirely by renal excretion, ADMA and L-NMMA are extensively 
metabolized (McDermott, 1976; Ogawa T et al., 1987).  The major metabolic route is to 
citrulline and dimethylamine, a reaction catalyzed by DDAH (Ogawa T et al., 1989; Kimoto 
et al., 1995).   
 
Cellular ADMA: 
ADMA is generated within cells (Fickling SA et al., 1993; Ueno et al., 1992) and there is 
evidence that the cellular levels alter with pathophysiology (Vallance and Leiper, 2004). 
Although the precise concentration of ADMA within cells is unclear, ECs concentrate 
methylarginines so that if methylarginines are added to culture medium, the 
concentrations in the cell rise to approximately 5-fold higher than in surrounding medium 
(Bogle et al., 1995).  This concentration of methylarginines is probably attributable to 
transport by the arginine transport system referred to as the Y+ transporter (Bogle et al., 
1995).  ECs express both protein arginine methyltransferases (PRMTs) and DDAHs 
(MacAllister RJ et al., 1996) and inhibition of DDAH leads to significant accumulation of 
ADMA (MacAllister RJ et al., 1996; Ito et al., 1999; Ueda et al., 2003).  Furthermore, 
functional studies in vascular rings suggest that inhibition of DDAH produces changes in 
endothelial function consistent with substantial concentrations of ADMA in the vicinity of 
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eNOS (MacAllister RJ et al., 1996).  The overall output of ADMA from ECs presumably is a 
balance between rates of arginine methylation, rates of degradation of proteins 
containing methylated arginine, rates of metabolism of ADMA by DDAHs, and the rates of 
active extrusion from the cell (Vallance and Leiper, 2004).  The relative importance of 
each component is not yet known, but the metabolic capacity of DDAH is high and it 
seems likely that DDAH activity will usually be the major determinant of overall ADMA 
levels within a cell.   
ADMA is relatively stable and can diffuse between cells (Vallance and Leiper, 2004).  The 
ADMA generated in one cell is capable of inhibiting NOS in another cell (Fickling SA et al., 
1999).  This interaction has been clearly demonstrated for macrophages and ECs (Fickling 
SA et al., 1999) and presumably may also occur for smooth muscle cells and ECs (Vallance 
and Leiper, 2004).  This raises the possibility that ADMA provides a mechanism by which 
smooth muscle cells may signal to the endothelium (Vallance and Leiper, 2004).   
 
Cardiovascular Effects of ADMA: 
ADMA inhibits NOS and produces the effects expected of an isoform-nonselective NOS 
inhibitor (Achan et al., 2003; Kielstein et al., 2004; Barba et al., 2000).  It elevates blood 
pressure, causes vasoconstriction, impairs endothelium-dependent relaxation, and 
increases EC adhesiveness (Vallance et al., 1992b; Achan et al., 2003;  Boger et al., 
2000b).  Extrapolation from other NOS inhibitors suggests that long-term exposure to 
ADMA would be expected to enhance atherogenesis and produce sustained hypertensive 
damage to end organs (Cayatte et al., 1994;  Naruse et al., 1994).   
In the heart, ADMA reduces heart rate and cardiac output, and other NOS inhibitors have 
similar effects (Achan et al., 2003;  Kielstein et al., 2004).  Left ventricular hypertrophy is 
also a feature of prolonged NOS inhibition (Vallance and Leiper, 2004).    
ADMA also inhibits angiogenesis in animal models (Jang et al., 2000).  Furthermore, DDAH 
overexpression promotes angiogenic processes in cells in culture (Smith CI et al., 2003) 
and in experimental tumors in vivo (Kostourou V et al., 2002, 2003).  DDAH 
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overexpression is also associated with an increase in vascular endothal growth factor 
expression, and this seems to be important in promoting the angiogenesis (Smith CI et al., 
2003). 
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Table 1.5:    ADMA in a nutshell (Vallance and Leiper, 2004). 
Known Not Known 
ADMA is a competitive inhibitor of NOS Whether endogenous ADMA 
concentrations increase sufficiently to 
inhibit NO production in vivo 
 
ADMA is a product of protein turnover Whether DDAH activity is the major 
determinant of ADMA levels in vivo 
 
ADMA is metabolized by DDAH Whether ADMA has a causal role in 
pathophysiology 
 
ADMA is cleared by the kidney Other than for renal failure, the data on 
changes with disease states 
are not consistent and the reason is not 
clear 
 
Exogenous ADMA inhibits NO generation 








Infused ADMA reduces cardiac output and 




Plasma ADMA concentration is increased 
in some disease states associated with 
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1.3.1.1.3 Hypoxia:   
The metabolic and molecular changes in response to hypoxia/reoxygenation have been 
extensively investigated and reviewed, which has greatly contributed to our 
understanding of the pathophysiological modifications observed in organs subjected to 
ischaemia and reperfusion, including the heart (Michiels et al., 2000). In view of their 
location at the inner lining of blood vessels, ECs are particularly and frequently exposed to 
variations in oxygen tension (Michiels et al., 2000), and it is known that hypoxic 
conditions have profound effects on endothelial function (Michiels et al., 2000).   
 
Endothelial cell–neutrophil interactions (see figure 1.17):   
One of the most pronounced effects of hypoxia on ECs is to increase EC adhesiveness for 
neutrophils (Nathan, 2006; Millar et al., 2007).  This phenomenon has been observed 
both in vitro and in vivo (Ploppa et al., 2010) during hypoxia only, independent of 
subsequent reoxygenation. 
In general, leukocyte emigration from the blood stream occurs through a sequential 
three-step process mediated by several adhesion molecules as well as 
chemoattractant/activator molecules (Muller, 2009).  The initial rolling phase is mediated 
by selectins and consists in a slowing down of the leukocyte movement at the surface of 
the endothelium. Subsequently, firm adherence occurs via the interaction of the 
leukocyte β2-integrins with ligands such as intercellular adhesion molecule-1 (ICAM-1). 
This binding requires activation of the integrins by exposure of the neutrophils to 
chemoattractant/activator molecules like interleukin-8 or platelet-activating factor (PAF) 
(Kumar SD et al., 2011).  Finally, transmigration through the endothelium occurs, 
triggered by a gradient of chemotactic factors (Williams et al., 2011). 
Some molecular basis for hypoxia-induced adherence of neutrophils to ECs has been 
untangled and the data obtained from human umbilical vein ECs (HUVECs) are 
summarized in Figure 1.17 (Michiels et al., 2000). It follows the general pattern 
mentioned above and is the consequence of EC activation by hypoxia.  
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The hypoxia signalling cascade involves different pathways necessary for rapid cell 
activation or for the regulation of gene expression; it seems to be dependent on the cell 
type and varies according to the degree of hypoxia (Clerk et al., 2007). In differentiated 
HUVEC exposed to oxygen deficiency, the initiating event of the EC activation is a 
decrease in the mitochondrial respiratory chain activity (Shimoda and Polak, 2007). A 
decrease in mitochondrial potential has been observed in liver sinusoidal ECs exposed to 
hypoxia (Alchera et al., 2010). Moreover, direct inhibition of the respiratory chain in 
HUVECs also leads to enhanced neutrophil adherence (DiStasi and Ley, 2009).   
Different second messengers may be responsible for the hypoxia-induced activation of 
ECs.  Firstly, a reduction in cAMP concentration is observed in hypoxic ECs, which may be 
responsible for an increased vascular leakage (Kolluru GK et al., 2008). Secondly, an 
increase in the cytosolic calcium concentration is observed in differentiated HUVECs 
(Østergaard et al., 2007; Boisseau et al., 2009).  Calcium ion regulates the activity of 
various enzymes and is a mediator of signal transduction for thrombin, histamine or 
bradykinin stimulation in ECs. An elevated calcium concentration activates phospholipase 
A2 in hypoxic ECs (Lambert et al., 2006), leading to the synthesis of high amounts of 
prostaglandins (Farooqui and Horrocks, 2006). Increased PGI2 release from bovine 
pulmonary artery ECs (El-Haroun et al., 2008) and from HUVECs (Camacho et al., 2011) 
and increased PGI2, prostaglandin F2alpha (PGF2α), prostaglandin D2 (PGD2) and 
prostaglandin E2 (PGE2) release from HUVECs were indeed observed under hypoxia (Wang 
Y, 2010), while in some experimental models, a decrease was observed (Yang Y et al., 
2013). It was suggested by a review from Crosswhite and Sun (2010) that the hypoxia-
induced synthesis of prostanoids also inhibits NO production via an autocrine negative 
feedback mechanism which could partially explain the frequently observed decrease of 
EDRF release by ECs in hypoxia.  Mizukami et al. (2007) have demonstrated that hypoxia 
induces COX-2 expression via the activation of the NF-κB p65 transcription factor in 
human ECs. These data indicate that, under hypoxia, both COX and phospholipase A2 
activity increases, which could account for the increase in prostaglandin synthesis in ECs 
exposed to hypoxia. 
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Activation of phospholipase A2 in hypoxic ECs not only allows a large release of 
prostaglandins but also the synthesis of PAF (Schildknecht and Ullrich, 2009; Goracci et 
al., 2010).  In vivo and in vitro studies showed that PAF is a neutrophil-activating agent 
promoting this adherence to the endothelium after hypoxia or ischaemia (Badimon et al., 
2012; Dumas et al., 2012).  Different structurally unrelated PAF antagonists as well as the 
inhibition of PAF synthesis by oleic acid indeed block neutrophil adherence to hypoxic ECs 
(Dumas et al., 2012). According to a review by Closse et al. (2010), hypoxia alone induces 
a calcium-dependent exocytosis of the Weibel–Palade bodies.  As mentioned before, 
these organelles, typical of ECs, store the vWF.  This exocytosis leads to the release of 
vWF and to the overexpression of P-selectin which then sustains neutrophil binding 
(Nurden, 2011). This explains why hypoxia-induced neutrophil adherence can be blocked 
by antibodies against P-selectin (Gleissner et al., 2008; Millar et al., 2007).  In addition to 
PAF and P-selectin, the hypoxia-induced neutrophil adherence also requires the 
neutrophil β2 integrin CD18 (Parmley et al., 2007; Barletta et al., 2012) as well as the 
endothelial ICAM-1 (DiStasi and Ley, 2009).   
Neutrophils not only adhere but are also activated when in contact with hypoxic HUVECs 
(Gupta et al., 2010). This activation is characterized by an increased cytosolic calcium 
concentration, by the release of high amounts of superoxide anion and by the synthesis of 
leukotriene B4 (Nathan et al., 2006).  They are also sensitive to hypoxic conditions 
(Walmsley et al., 2005). Hypoxia per se is able to increase CD18/CD11b expression at the 
surface of neutrophils, resulting in an enhanced adhesion to ECs (Uzel and Holland, 2012). 
On the other hand, hypoxia has been shown to decrease free radical production and 
cytokine synthesis by neutrophils in response to various stimuli (Victor et al., 2005; Watt 
et al., 2005). It must be noted that the contact of neutrophils with activated ECs not only 
results in adherence and activation but also in delayed apoptosis, thereby prolonging 
their useful life (Watt et al., 2005). In conclusion, hypoxia per se is able to activate the ECs 
as well as to initiate all stages of recruitment, rolling, adhesion and activation of 
neutrophils in ischemic organs (Holyer, 2011). 
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Tissue remodeling:   
The vascular tone is regulated under normal conditions through the release by ECs of 
both vasorelaxing molecules such as NO and prostacyclin and vasoconstricting agents like 
ET-1 (Sprague and Khalil, 2009).  
Hypoxia differentially affects pro-vasodilation and pro-vasoconstriction molecules, which 
ultimately creates a condition favorable for the development of vasoconstriction (Li YSJ et 
al., 2005).  Indeed, the basal and agonist-stimulated release of pro-vasodilatation factors 
by ECs is quickly inhibited by hypoxia (Deanfield et al., 2007) and NO production remains 
very low even after long periods of hypoxia (24–48 h) (Bertuglia and Giusti, 2005). This 
seems to be due to a decrease in eNOS expression (Jin HG et al., 2006).  Hypoxia generally 
enhances the release of ET-1 by ECs in vitro (Pak et al., 2007); however, in other studies, a 
decrease was observed (Weigand et al., 2006; Modesti et al., 2006). In vivo, an increase in 
ET-1 circulating level was observed and this was correlated with an induction of ET-1 gene 
transcription in lungs (Whitman et al., 2008). 
The effect of hypoxia on the release of endothelial-released mitogenic molecules has 
previously been described (Shao et al., 2011). PGF2α and basic bFGF were identified as the 
pro-vascular smooth muscle mitogenic mediators (Shao et al., 2011). bFGF seems to be 
released from intracellular stores by hypoxic ECs since there is no induction of its 
synthesis by hypoxia (Ahn et al., 2008).  Other mitogens, such as platelet-derived growth 
factor-B (PDGF-B), have also been detected in ECs subjected to sustained hypoxia (Ahn et 
al., 2008).  The presence of PDGF and of ET-1, which also has mitogenic properties for 
smooth muscle cells, contributes to the pro-proliferative activity present in conditioned 
media from ECs undergoing sustained hypoxia (Stenmark et al., 2006). In conclusion, the 
increased production of these different mitogens combined with the suppression of 
endothelial NO synthase would be expected to accelerate smooth muscle cell growth and 
to induce vascular remodeling (Robertson et al., 2012).  
In addition to increase the release of growth factors, hypoxia stimulates the production of 
some extracellular matrix proteins, such as thrombospondin-1 in human ECs (Carmeliet, 
2003). Thrombospondin-1 modulates smooth muscle cell proliferation and migration and 
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may be a negative regulator of angiogenesis (Carmeliet, 2003). Chronic in vivo hypoxic 
exposure indeed induces medial hypertrophy of pulmonary vessels (Stenmark et al., 2005; 
Stenmark et al., 2006).  Cell proliferation and matrix deposition in hypoxia reflects an 
imbalance between pro-proliferative and anti-proliferative stimuli, most of them derived 
from the endothelium. 
EC proliferation itself is also affected by hypoxia (Kiefer et al., 2002). The most potent and 
specific mitogen for the ECs is vascular endothelial growth factor (VEGF) (Otrock et al., 
2007). It is known to initiate angiogenesis in vivo (Hicklin and Ellis, 2005).  Its expression is 
upregulated by hypoxia in numerous cell types including ECs (Ferrara et al., 2003). In 
addition, an increased expression of the VEGF receptor Flt-1 (Ferrara et al., 2003) and a 
functional upregulation of the VEGF receptor KDR or Flk-1 by hypoxia (Ferrara et al., 2003) 
have been reported in response to hypoxia, which can be responsible for the stronger 
VEGF-induced mitogenic response of hypoxic ECs compared to normoxia. 
The release of all these cytokines and growth factors by hypoxic ECs is generally the result 
of a complex cascade of processes which ends with the activation of transcription factors 
(Michiels et al., 2000), such as activator protein 1 (AP-1) (Bergman et al., 2003), nuclear 
factor-interleukin-6 (NF-IL-6) (Haddad and Hisham, 2005), nuclear factor kappa beta (NF-
κB) (Haddad and Hisham, 2005) and Egr-1 (Lo et al., 2001).  However, the prototype of the 
transcription factors regulated by hypoxia is hypoxia inducible factor-1 (HIF-1) (Semenza 
GL, 2000).  HIF-1 is a ubiquitous basic helix-loop-helix Per Arnt Sim (PAS) heterodimer 
which is activated by hypoxia (Olechnowicz and Peet, 2010).  It is composed of the two 
subunits, HIF-1α and HIF-1β or aryl/hydrocarbon receptor nuclear translocator (ARNT), 
the former being upregulated by hypoxia (Qingdong and Costa, 2006).   
Possible mechanisms of HIF-1 induction include protein stability and degradation by 
proteasome, phosphorylation, redox processes and HSP 90 binding regulating intracellular 
localization, or a combination of these mechanisms (Wenger, 2002; Bruick, 2003).  Redox 
processes, for example involving H2O2, initiated by a postulated haem oxygen sensor have 
been proposed (Veal et al., 2007).  The mitochondrion, which generates ROS in higher 
amounts under hypoxic conditions, is another possible candidate (Kietzmann and Görlach, 
2005).   
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It is therefore clear that hypoxia strongly affects the regulatory pathways of ECs as well as 
of smooth muscle cells, leading to the activation of several transcription factors and to 
the release of cytokines and growth factors. The end result is the formation of conditions 
favorable to vasoconstriction and proliferative activity, participating in the remodeling of 
the vascular wall (Rey and Semenza, 2010). 
Physiological relevance:   
The finding that the endothelial expression of some growth factors, cytokines as well as 
other genes is influenced by variations in oxygen concentration has physiological 
implications (Michiels et al., 2000). Two main cascades of reactions have been 
characterized depending on the duration of the oxygen deficiency. Following acute 
hypoxia, ECs become activated and neutrophil adherence is observed (Granger DN and 
Senchenkova, 2010b).  One consequence of this process is the development of a local 
inflammatory reaction in ischaemic organs which is worsened by reperfusion 
(reperfusion-injury) (Gourdin et al., 2009). When chronic hypoxic conditions persist, the 
expression of growth factors, cytokines and pro-coagulation molecules is increased 
(Gourdin et al., 2009).  Several pathological conditions are known to be linked to hypoxic 
conditions of which three will be briefly discussed below. 
 
Metabolic effects of hypoxia on ECs: 
Hypoxia alters metabolic pathways in a number of ways, for instance, by inhibiting the 
oxygen-dependent process of mitochondrial oxidative phosphorylation (OXPHOS), 
hypoxia compromises ATP generation, thus placing a heavier reliance on glycolysis as an 
energy source (Denko, 2008; Frezza and Gottlieb, 2009). Increased glycolysis provides a 
rapid way to generate ATP albeit at the expense of large quantities of glucose, as 
reflected by raised lactic acid levels (Weljie and Jirik, 2011). The latter, in combination 
with the decreased ability of mitochondria to utilize protons in ATP generation, leads to 
intra-tumoural acidosis (Zhou J et al., 2006).  The events triggered by hypoxia depend to a 
large extent on the activity of the transcriptional regulator HIF-1α and its partner HIF-1β 
(Weljie and Jirik, 2011).  
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The HIF-1α/HIF-1β complex activates the transcription of multiple genes relevant to the 
“Warburg effect”, specifically, genes encoding glucose transporters and glycolytic 
pathway enzymes (Harris AL, 2002; Kim et al., 2006b; Papandreou et al., 2006). The 
phosphatidylinositol 3-kinase (PI3K) pathway via activation of PKB/Akt has also been 
implicated in the genesis of the “Warburg effect” by upregulating HIF-1 levels (Robey and 
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Figure 1.17: Metabolic and biochemical responses of ECs to hypoxia leading to their 
activation and to the adherence and activation of neutrophils. ICAM-1, intercellular 
adhesion molecule-1; LTB4, leukotriene B4; PAF, platelet-activating factor; PGF2α, 
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Hypoxia as a cause of ED: 
Previous studies have shown that exposure to chronic intermittent hypoxia (CIH) impairs 
endothelium-dependent vasodilation in the skeletal muscle and cerebral circulations 
(Phillips et al., 2004; Tahawi et al., 2001). In these studies there was strong evidence that 
a vascular decrease in NO bio-availability (Phillips et al., 2004; Tahawi et al., 2001) and 
increased O2- levels (Phillips et al., 2006; Troncoso Brindeiro et al., 2007) were possible 
underlying factors. 
A decrease in NO bio-availability is considered to be the hallmark of ED (Imrie et al., 
2010).  Increased scavenging of NO by O2- would be expected to decrease NO bio-
availability, thereby impairing endothelium-dependent dilation (Marcus et al., 2012). The 
mechanisms leading to CIH-induced stimulation of O2- production in vascular tissue are 
unknown; however, available evidence points to a role for the renin–angiotensin system 
(RAS) (Marcus et al., 2012). Chronic infusion of Ang II elicits hypertension and ED by 
increasing O2- production from NADPH oxidase (Virdis et al., 2011). Ang II-induced 
stimulation of O2- production from NADPH oxidase requires activation of the Ang II type-I 
receptor (AT1R) (Paravicini and Touyz, 2006). Circulating Ang II is increased in patients 
with obstructing sleep apnea (OSA) (Moller et al., 2003) and experimental animals 
exposed to CIH (Yuan et al., 2004).  
 
Hypoxia modulates NOS activity and NO bio-availability: 
Hypoxia may influence NO production, NO tissue concentration, and NOS expression by 
several mechanisms (Manukhina et al., 2006): (i) limitation of NO production due to 
inadequate NOS substrate O2; (ii) effect of O2 on NOS feedback inhibition; (iii) modulation 
of NO bio-availability; (iv) induction of HIF-1 and other NOS transcription factors; (v) 
changes in intracellular Ca2+ concentration and Ca2+ influx; and (vi) induction of NOS-
regulating heat shock proteins.  
Acute, profound hypoxia can lead to decreased NO production by all three NOS isoforms 
(Weigand et al., 2011).  Less severe hypoxia, suppresses NO synthesis only moderately, 
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and this effect of hypoxia is blunted by increased Ca2+ influx, which activates 
Ca2+/calmodulin-dependent NOS isoforms (Manukhina et al., 2006). In severe hypoxia, 
Ca2+ activation of NOS cannot compensate for reduced O2 availability, and NO deficiency 
may develop (Prabhakar and Semenza, 2012; Wagner et al., 2013).  
NO can bind to NOSFe2+, forming a haem-NO complex (NOSFe2+ NO), which prevents the 
haem from binding O2 and thus increases the apparent Km for O2 (Dweik, 2005). By this 
mechanism, NO feedback inhibits NOS, so that the enzyme functions at only a fraction of 
its catalytic capacity. During steady state NO synthesis, between ~70% and 90% of NOS 
exists as a ferrous-NO complex (Daff, 2010).  Feedback inhibition of NOS by NO is 
modulated by O2 concentration, since O2 and NO compete for the haem iron (Daff, 2010). 
Furthermore, the rate of decay of the haem iron-NO complex is dependent on O2 
concentration; as O2 concentration decreases, less NO is displaced by O2 and NO 
production declines (Daff, 2010). As the haem-NO complex subsequently dissociates and 
then binds O2, the active enzyme (NOSFe3+) is regenerated (Porasuphatana, 2001). The 
sensitivity of the ferrous-NO complex to O2 influences the overall NOS response to O2.  It 
is primarily by this mechanism, rather than the effect of O2 as a substrate, that NOS 
produces NO in proportion to the O2 concentration across the physiologic range (0–250 
μM) (Tsai, 2010).  
The response to chronic hypoxia also involves altered expression of NOS genes 
(Manukhina et al., 2006). Some studies have demonstrated hypoxic down-regulation of 
eNOS expression in pulmonary ECs (Girgis et al., 2003). Hypoxia reduced eNOS mRNA 
and/or protein in pulmonary artery ECs (Morrell et al., 2009). These hypoxia effects were 
presumably due to both decreased transcription and destabilization of eNOS mRNA 
(Manukhina et al., 2006).  Similarly, other reports also demonstrated reduced eNOS 
expression in human umbilical vein and bovine aortic ECs exposed to low PO2 (Prieto et 
al., 2011; Chatterjee and Catravas, 2008). Reduced eNOS expression resulted from 
decreased eNOS mRNA stability and eNOS promoter activity (Morrell et al., 2009). Post-
translational regulation of iNOS by prolonged hypoxia was demonstrated in murine 
macrophages (Daniliuc et al., 2003), in which 24-hr exposure to hypoxia (PO2 23 ± 1.4 mm 
Hg) lowered iNOS activity but did not affect iNOS protein content. In these cells, hypoxia 
Stellenbosch University  http://scholar.sun.ac.za
P a g e  | - 70 - 
 
  Chapter One 
  
disrupted interactions of iNOS with the cytoskeletal protein α-actinin 4, causing iNOS 
displacement from the submembranal regions, a location which may be important for 
normal iNOS activity (Daniliuc et al., 2003).  
Moderate hypoxia (4.8% O2) can result in Ca2+ entering cells and activating eNOS (Ray, 
2009). However, more prolonged hypoxia will terminate the Ca2+ entry and decrease NO 
synthesis (Rautureau and Schiffrin, 2012).  
It is clear from the above discussion that hypoxia per se can be regarded as an important 
harmful stimulus to the vascular endothelium. 
 
1.3.1.1.4 Hyperglycaemia:   
Hyperglycaemia is the major causal factor in the development of ED in patients with 
diabetes mellitus (see figure 1.18) (De Vriese et al., 2000).  Clinical trials have identified 
hyperglycaemia as the key determinant in the development of chronic diabetic 
complications (Hadi and Al Suwaidi, 2007).  The formation of advanced glycation end 
products (AGEs) is an important biochemical abnormality accompanying diabetes mellitus 
and inflammation in general (Hadi and Al Suwaidi, 2007).  As can be seen in figure 1.18, it 
is proposed that the development of oxidative stress serves as a putative final pathway in 
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1.3.1.1.5 Oxidized low density lipoprotein (Ox-LDL):   
Oxidation of low-density lipoproteins in the body has been associated with various 
pathological conditions, including atherosclerosis (Stroka et al., 2012; Levitan et al., 2010).  
Elevated oxidized low-density lipoproteins (ox-LDL) levels in the bloodstream have been 
identified as a risk factor for development of coronary artery disease and plaque 
formation (Berliner et al., 2001; Diaz et al., 1997; Holvoet P et al., 2001; Holvoet P et al., 
1998; Toshima et al., 2000).  Exposure of the vascular endothelium to ox-LDL leads to EC 
injury and dysfunction, including disruption of cell–cell adhesion (Gardner et al., 1999; 
Liao L and Granger, 1995), as well as impairment of NO release (Blair et al., 1999).   
 
Oxidized LDL and endothelial injury / ED: 
Endothelial activation and/or dysfunction are widely accepted to be the earliest events in 
atherosclerosis (Li and Mehta, 2005).  Ox-LDL is known to enhance the expression of pro-
inflammatory genes, leading to monocyte recruitment to the vessel wall (Li and Mehta, 
2000) and dysfunction of vascular ECs.    LOX-1 activation by Ox-LDL causes endothelial 
changes that are characterized by activation NF-κB through increased ROS, subsequent 
induction of adhesion molecules, and endothelial apoptosis (Chen M et al., 2002). It is 
cytotoxic to ECs via the generation of free radicals (Cominacini et al., 2000; Li and Mehta, 
2000) and impairs NOS gene expression and its activity (Mehta Jl et al., 2001). Ox-LDL 
triggers activation of inflammatory signalling pathways, such as CD40/CD40L (Li et al., 
2003a), and increases gene expression and activity of matrix metalloproteinases (MMP-1 
and -3) (Li et al., 2003b) in ECs.  
 
Oxidized LDL and its receptor LOX-1 in endothelium: 
The biological effects of ox-LDL are mediated via its receptors. A number of scavenger 
receptors for ox-LDL, such as SR-A1/II, CD36, SR-B1, and CD68, have been identified on 
smooth muscle cells and monocytes/macrophages (Stephen et al., 2010).  However, these 
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receptors are not present on ECs in any significant amount (Stephen et al., 2010). It has 
been suggested that vascular ECs in culture and in vivo internalize and degrade ox-LDL 
through a receptor-mediated pathway that does not involve the macrophage scavenger 
receptors (Kume et al., 1991).  Sawamura et al. (1997) first identified oxidized low-density 
lipoprotein receptor-1 (LOX-1) as a critical molecule that is responsible for ox-LDL uptake 
by ECs.  Ox-LDL uptake via LOX-1 causes endothelial activation (Kita T, 1999). 
Furthermore, uptake of ox-LDL in ECs (internalization) and subsequent extrusion may be a 
mechanism by which ox-LDL is transported to the subendothelial region (Li and Mehta, 
2005).  
Experimental studies have shown that ox-LDL causes injury to ECs via activation of 
different signal transduction pathways such as those involving PKC and MAPK (Li and 
Mehta, 2005).  Ren et al. (2000) suggested that PKCβ may mediate ox-LDL-induced gene 
expression of plasminogen activator inhibitor-1 (PAI-1:  serine protease inhibitor that 
functions as the principal inhibitor of tissue plasminogen activator and urokinase, the 
activators of plasminogen and hence fibrinolysis), while Li et al. (2003a) showed that ox-
LDL induces the activation of PKCβ, which plays an important role in the expression of 
matrix metalloproteinases (MMPs) and collagenase activity in ECs.  Collectively, MMPs 
can degrade all components of the extracellular matrix (ECM), thereby influencing many 
important processes, such as cell proliferation, differentiation, migration, and death, as 
well as cell–cell interactions (Elkington et al., 2005).  In contrast, other PKC isoforms (α, δ 
and γ) did not change ox-LDL-induced MMP expression (Li and Mehta, 2005). Other 
studies (Li and Mehta, 2000a, b) showed that the activation of MAPK p42/44 plays a 
critical role in ox-LDL-induced gene expression of adhesion molecules, monocyte 
adhesion to ECs, and apoptosis.  In addition, they found that the pathological effects of 
ox-LDL are mediated by its receptor LOX-1 in ECs.  Cominacini et al., (2000) observed that 
ox-LDL increases intracellular free radical generation and activates the pro-inflammatory 
transcription factor NF-κB in bovine ECs.  It is important to note that ox-LDL might 
activate different signalling pathways, which in turn interact with each other. These 
interactions may reflect the complicated cross-talk between intracellular signalling 
pathways induced by ox-LDL and other pro-atherogenic signals (Li and Mehta, 2005).  
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Ox-LDL and atherosclerosis: 
The importance of ox-LDL in atherosclerosis was first established by employing the 
antioxidant probucol in atherosclerosis-prone hyperlipidaemic WHHL (The Watanabe 
heritable hyperlipidaemic) rabbits (Kita T et al., 1987).  This study showed the significance 
of the oxidative state in atherogenesis. A pro-oxidant state and formation of ox-LDL are 
potent mitogens for smooth muscle cells (Yang CM et al., 2001). Furthermore, ox-LDL is 
taken up by the macrophages, which facilitates foam cell development (Yang CM et al., 
2001).  
To elucidate the role of ox-LDL in plaque instability in coronary artery disease, Ehara et al. 
(2001) measured plasma ox-LDL levels in patients with acute myocardial infarction, 
unstable angina pectoris, and stable angina pectoris.  Plasma ox-LDL levels in patients 
with acute myocardial infarction were higher than in patients with unstable or stable 
angina pectoris. Serum levels of total, HDL, and LDL cholesterol did not differ among 
different patient groups. Post-mortem studies of patients who died of acute myocardial 
infarction revealed that the culprit coronary lesion contained abundant macrophage-
derived foam cells with distinct positivity for ox-LDL and its receptors. These results 
strongly suggested an important role for ox-LDL in the formation of plaque instability in 
human coronary atherosclerotic lesions. In addition, in another study, the same authors 
found that plasma ox-LDL levels were higher in patients with diabetes mellitus than in 
those without diabetes mellitus (Ehara et al., 2002).  In another study, soluble LOX-1 
levels were shown to be significantly higher in the serum of patients with acute coronary 
syndrome than that of the control subjects (Hayashida et al., 2005). Soluble LOX-1 may 
well become a future biomarker for early diagnosis of acute coronary syndrome 
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1.3.1.1.6 Oxidative stress:   
Risk factors / diseases associated with oxidative stress: 
Oxidative stress has been positively linked with CVD, since oxidation of LDL in the vascular 
endothelium is a precursor to plaque formation (Li JM and Mehta, 2005). Oxidative stress 
also plays a role in the ischaemic cascade due to oxygen reperfusion injury following 
hypoxia (Nijs et al., 2006), which can result in stroke and myocardial infarction.  
Cellular mechanisms of oxidative stress: 
There are many ROS that play a central role in vascular physiology (Figure 1.19) and 
pathophysiology, the most important of which are NO, superoxide (O2−), hydrogen 
peroxide (H2O2) and peroxynitrite (ONOO−) (Griendling KK and Fitzgerald, 2003). NO is 
normally produced by eNOS in the vasculature, but in inflammatory states, iNOS can be 
expressed in macrophages and smooth muscle cells (Griendling KK and Fitzgerald, 2003) 
as well as ECs (Zou et al., 2004) and contribute to NO production.  
Superoxide results from one electron reduction of oxygen by a variety of oxidases (Figure 
1.19).  When superoxide is produced together with NO (particularly when NO is 
generated in high amounts), the two molecules can rapidly react to form the highly 
reactive molecule, peroxynitrite (Griendling KK and Fitzgerald, 2003).  Peroxynitrite is an 
important mediator of lipid peroxidation and protein nitration, including the oxidation of 
LDL, which has dramatic pro-atherogenic effects (Griendling KK and Fitzgerald, 2003).  In 
the absence of immediately accessible NO, O2− is rapidly dismutated to the more stable 
H2O2 (by superoxide dismutase, SOD), which is then further converted to H2O by either 
catalase or glutathione peroxidase (Griendling KK and Fitzgerald, 2003) (see figure 1.19).  
The effects of O2− and H2O2 on vascular function depend critically on the amounts 
produced. When formed in low amounts intracellularly, they can act as intracellular 
second messengers, modulating the function of biochemical pathways that mediate such 
responses as growth of vascular smooth muscle cells (VSMCs) and fibroblasts (Griendling 
KK and Fitzgerald, 2003).  Higher amounts of ROS can cause DNA damage, significant 
toxicity, or even apoptosis, as demonstrated in ECs (Niwa K et al., 2002) and smooth 
muscle cells (Deshpande et al., 2002).  
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Figure 1.19:  Vascular ROS. Highlighted in gray are some of the most important ROS in 
vascular cells. Oxidases convert oxygen to O2−, which is then dismutated to H2O2 by 
superoxide dismutase (SOD). H2O2 can be converted to H2O by catalase or glutathione 
peroxidase (GSH-Px) or to hydroxyl radical (·OH) after reaction with Fe2+.  In addition, O2− 
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Figure 1.20: Coupled vs. uncoupled eNOS. (A) In healthy vascular endothelium, there is 
an increased BH4 to BH2 ratio. BH4 binds to the ferrous-dioxygen domain complex in the 
oxygenase domain which results in a coupling reduction of molecular O2 to L-arginine 
oxidation and synthesizes NO. (B) In diseased conditions, BH4 is limited and becomes 
oxidized to BH2 increasing the BH2/BH4 ratio to promote uncoupled eNOS. The electron 
transfer is uncoupled from L-arginine, the ferrous-dioxygen complex dissociates, and SO is 
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Cellular and Enzymatic Sources of ROS in the Vessel Wall: 
ROS are derived from specific enzymatic or chemical reactions (Griendling KK and 
Fitzgerald, 2003).  NO is produced in ECs by activation of eNOS during the normal 
functioning of the vessel wall. Vasodilator hormones raise intracellular Ca2+, leading to an 
increase in eNOS activity and NO release (Bonomini et al., 2012).  Physical forces, such as 
shear stress, activate eNOS via PKA- or Akt-dependent phosphorylation (Balligand et al., 
2009).  Pathophysiological expression of iNOS in both macrophages and vascular smooth 
muscle cells (VSMCs) elevates cytokine levels, resulting in localized inflammation (Sprague 
and Kahlil, 2009). This, in turn, results in production of NO in the absence of further 
stimuli (Sprague and Kahlil, 2009). Moreover, under some circumstances, eNOS becomes 
uncoupled and O2− is generated rather than NO (Yang Z et al., 2006; Schmidt TS and Alp, 
2007) (Figure 1.20).  The NOS enzymes are thus potentially important sources of both NO 
and O2−, depending on the surrounding environment (Griendling KK and Fitzgerald, 2003).  
Virtually all types of vascular cells produce O2− and H2O2 (Griendling KK et al., 2000a).  In 
addition to mitochondrial sources of ROS, O2− and/or H2O2 can also be generated by other 
sources (Figure 1.21) (Griendling KK and Fitzgerald, 2003).  Two of the most important 
sources in bloodvessels under normal conditions are thought to be cytochrome P450 and 
the membrane-associated NADPH oxidase(s) (Rajagopalan et al., 1996; Fleming et al., 
2001).  A cytochrome P450 isozyme homologous to Cytochrome P450 2C9 (CYP 2C9) (an 
important cytochrome P450 enzyme with a major role in the oxidation of both xenobiotic 
and endogenous compounds) has been identified in coronary arteries and has been 
shown to produce O2− in response to bradykinin (Buttery et al., 1996).  NADPH oxidases, 
similar in structure to the neutrophil respiratory burst NADPH oxidase, but producing less 
O2− over a longer period of time, have been identified in vascular cells (Bedard and 
Krause, 2007).  The endothelial, VSMC, and fibroblast enzymes are not identical, but have 
distinct subunit structures and mechanisms of regulation (Griendling KK et al., 2000a).   
NADPH oxidase proteins are major sources of ROS (Bedard and Krause, 2007; Brandes et 
al., 2010; Lambeth, 2004).  All NADPH oxidases contain a core subunit, termed NOX, 
which catalyzes the transfer of electrons from NADPH to molecular O2 and leads to ROS 
generation.  Five NOX isoforms (NOX1–5) have been identified, which form the basis of 
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distinct NADPH oxidases (Murdoch et al., 2011).  In the vasculature, NOX2 and NOX4 are 
expressed in the endothelium (Bedard and Krause, 2007).  
All NOX enzymes utilize NADPH as an electron donor and catalyse the transfer of 
electrons to molecular oxygen to generate O2- and/or H2O2 (Sirker et al., 2011).  The 
enzymes require association with different subunits for their activation and also exhibit 
differences in activity (see figure 1.22, table 1.6). NOX2 and 4 bind to a smaller p22phox 
subunit, which is essential for enzyme activity (Von Löhneysen et al., 2010).  NOX2 is 
normally activated after cell stimulation by specific agonists (e.g. G-protein coupled 
receptor agonists such as Ang II, growth factors, cytokines and mechanical forces), which 
induce the association of regulatory subunits and activation of the enzyme (Sirker et al., 
2011).  The cytosolic regulatory subunits for NOX2 are p47phox, p67phox, p40phox and 
Rac1 (Sirker et al., 2011).  However, NOX4 is constitutively active and does not require 
association with regulatory subunits, with regulation thought to occur mainly by changes 
in expression level (Sirker et al., 2011) (see table 1.6).  Furthermore, findings from several 
laboratories indicated that NOX4 predominantly generates H2O2 in contrast to NOX2, 
which generates O2- (Dikalov et al., 2008; Martyn et al., 2006; Serrander et al., 2007). The 
biochemical basis for this property of NOX4 has recently been suggested to be related to 
the structure of its third extracytosolic loop, which differs significantly from those of 
NOX2 and contains a highly conserved histidine moiety which may prevent O2- release or 
may provide protons for O2- dismutation (Takac et al., 2011).  NOX2 (also known as 
gp91phox oxidase) was the first NADPH oxidase to be identified, being responsible for the 
phagocytic oxidative burst of neutrophils (Sirker et al., 2011). Its neutrophil activity is 
important for non-specific host defence against microbial organisms and deficient activity 
of the oxidase results in chronic granulomatous disease (CGD), a condition in which 
affected children develop recurrent infections and inflammation (Holland, 2010). NOX2 
has subsequently been found to be expressed at lower level in other inflammatory cells as 
well as in ECs, cardiomyocytes, fibroblasts and VSMC (Sirker et al., 2011). NOX4 is 
reported to be expressed in all cardiovascular cell types although its in vivo level of 
expression in healthy cardiovascular tissues remains to be precisely defined (Sirker et al., 
2011).  
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Although the protein expression of p22phox largely depends on the presence of the NOX 
proteins, a link between the mRNA expression of the scaffolding protein and the ROS 
formation has been demonstrated (Brandes et al., 2010). The mRNA expression of 
p22phox itself is redox sensitive as it is regulated by the transcription factors activator 
protein-1 (AP-1) (Brewer et al., 2006) and NFκB (Cevik et al., 2008). Antioxidants such as 
catalase (Manea A et al., 2007) or red wine polyphenols (Manea A et al., 2008) are able to 
counteract the induction of p22phox by stress-inducing signals such as Ang II or 
hypertension. 
Ang II, tumor necrosis factor-α, thrombin, and PDGFall increase oxidase activity and raise 
intracellular levels of O2− and H2O2 in VSMCs (Griendling KK et al., 2000a).  Ang II and 
lactosylceramide activate the EC NADPH oxidase enzyme, whereas fibroblasts increase 
O2− production in response to Ang II, tumor necrosis factor-α, interleukin-1, and platelet-
activating factor (Griendling KK et al., 2000a). Physical forces, including cell stretch, 
laminar shear stress, and the disturbed oscillatory flow that occurs at branch points, are 
also potent activators of O2− production in ECs (Balligand et al., 2009). There are two 
major mechanisms by which hormones and physical forces activate the NADPH oxidase: 
(1) acutely, whereby expressed enzyme is activated by phosphorylation, GTPase activity, 
and production of relevant lipid second messengers (Zafari et al., 1999); and (2) 
chronically, when expression of rate-limiting subunits of the enzyme is induced, thereby 
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Figure 1.21:  Potential sources of ROS in ECs. Many enzymes, including those in the 
mitochondrial electron transport chain, xanthine oxidase, COXs, lipoxygenases, 
myeloperoxidases, cytochrome P450 monooxygenase, uncoupled NOS, haem oxygenases, 
peroxidases, and NADPH oxidases, produce ROS. According to their location in the cell, 
these ROS are generated intracellularly, extracellularly, or in specific intracellular 
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Figure 1.22: Schematic representation of NOX2 and NOX4 and oxidases.  NOX2 requires 
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Table 1.6: The activity, regulation and expression of the main NOXs in the cardiovascular system (specifically the endothelium) (Sirker et 
al., 2011). 
 
 NOX2 NOX4 
Constitutive activity Absent or very low 
 
High 
Binding to p22phox 







p67phox, p47phox, p40phox, Rac 
 
None 
Control Post-translational modifications of regulatory subunits. 
 
Transcriptional. Can be regulated by Poldip2. 
Cell expression Endothelial cells, cardiomyocytes, fibroblasts, human 
vascular smooth muscle, inflammatory cells. 
 
Endothelial cells, cardiomyocytes, fibroblasts, 
vascular smooth muscle cells. 
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Biochemical Consequences of ROS Production in the Vessel Wall: 
As noted above, ROS are involved in some of the most fundamental functions of the 
vessel wall (Griendling KK and Fitzgerald, 2003). NO is a critically important mediator of 
endothelium-dependent vasodilation, whereas O2− and H2O2 mediate VSMC growth, 
differentiation, and apoptosis (Griendling KK and Fitzgerald, 2003). The lipid peroxidation 
and protein nitration induced by ONOO− are some of the earliest atherogenic events 
(Pacher et al., 2008). Because macrophages release ROS extracellularly, they activate 
matrix metalloproteinases (MMPs) MMP-2 and MMP-9 (Galis et al., 1995; Rajagopalan et 
al., 1996).  Once activated, MMPs can degrade the collagen-based extracellular matrix, 
contributing to weakening of the fibrous cap and plaque rupture (Galis et al., 1995).  In 
VSMCs, ROS exert their effects via activation of specific intracellular signalling pathways 
and can profoundly influence both normal physiology and the course of vascular disease. 
Furthermore, it is becoming evident that stable products of ROS may also influence 
cellular function by adduction of signalling molecules or by serving as incidental ligands 
for both membrane and nuclear receptors in vascular cells (Griendling KK and Fitzgerald, 
2003).  
Just as NO mediates vasodilation by activating the VSMC guanylate cyclase, O2− and H2O2 
can alter the activity of selected intracellular proteins.  Unlike NO, no specific target for 
these ROS has been identified, nor has the identity of the actual reactive species been 
elucidated, although in vitro studies show that both O2− and H2O2 are able to inhibit 
protein phosphatases (Griendling KK and Fitzgerald, 2003). O2− and H2O2 or their products 
can modulate the activity of signalling pathways. For example, attenuation of agonist-
induced ROS production by antisense inhibition of NADPH oxidase expression in VSMCs 
leads to reduction of Ang II–induced hypertrophy, platelet-derived product-stimulated 
tissue factor expression, and serum-induced growth (Görlach et al., 2000; Ushio-Fukai et 
al., 1996; Suh et al., 1999).  These effects appear to be mediated in part through 
activation of the c-Src, p38 mitogen-activated protein kinase, and the cell survival kinase 
(Akt) in the case of Ang II, and extracellular signal-regulated kinases in the case of PDGF 
(Touyz and Schiffrin, 2000).  These signalling pathways, in turn, control gene expression 
(Griendling KK et al., 2000b). In some cases, regulation of the gene is redox sensitive 
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because of the susceptibility of these upstream signalling pathways to ROS (Griendling KK 
et al., 2000b). However, the affinity of certain transcription factors for their cognate DNA 
binding sites can also be directly modified by ROS, particularly nuclear factor-κβ and 
activator protein-1 (AP-1) transcription factors (Kunsch and Medford, 1999).   
ROS regulate several general classes of genes, including adhesion molecules and 
chemotactic factors, antioxidant enzymes, and vasoactive substances (Griendling KK and 
Fitzgerald, 2003).  Some of these are clearly an adaptive response, such as the induction 
of superoxide dismutase and catalase by H2O2 (Lu et al., 1993).  Upregulation of adhesion 
molecules (VCAM-1, intracellular adhesion molecule-1) and chemotactic molecules 
(monocyte chemotactic protein-1) by oxidant-sensitive mechanisms is of particular 
relevance to vascular pathology (Kunsch and Medford, 1999).  These molecules promote 
adhesion and migration of monocytes into the vessel wall. Conversely, transcriptional 
induction of adhesion molecules by cytokines is inhibited by NO donors in a cyclic 
guanosine monophosphate–independent manner (Spiecker et al., 1998).  These 
mechanisms combine to suppress adhesion molecule expression in the normal vessel wall 
and induce its expression in vasculopathies (Spiecker et al., 1998).  
 
1.3.1.2  Cardiovascular risk factors associated with harmful stimuli. 
 
1.3.1.2.1 Diabetes mellitus (including insulin resistance and hyperglycaemia). 
Both type 1 and type 2 diabetes are independent risk factors for the development of 
accelerated atherosclerosis, IHD and CVD in general (Esper et al., 2006).  Similarly, type 1 
diabetes mellitus, insulin resistance and type 2 diabetes mellitus have been shown to be 
strongly associated with the development of ED (Potenza et al., 2009).  In fact, the 
temporal progression from insulin resistance to type 2 diabetes mellitus has been 
postulated to be mirrored by the progression of ED to atherosclerosis (Hsueh et al., 2004).  
ED observed in diabetes mellitus is primarily attributable to (1) oxidative stress (increased 
O2– generation due to upregulated expression of NADPH oxidase), and (2) increased 
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formation of advanced glycation end-products (AGEs) (Guzik et al., 2002;  Avogaro et al., 
2008).   
Hyperglycaemia, one of the main features of diabetes mellitus, results in non-enzymatic 
glycation of intracellular and extracellular proteins and lipids, which leads to the 
generation of AGEs. The latter subsequently accumulate in the vascular wall and reduce 
NO activity by quenching NO (Guzik et al., 2002;  Avogaro et al., 2008).  AGEs also bind to 
specific surface receptors, called receptors for AGEs (RAGE), which are expressed on cells 
such as monocytes, macrophages and VSMCs, resulting in the amplification of an 
inflammatory response (Guzik et al., 2002;  Avogaro et al., 2008), increased vascular 
permeability and oxidative stress (Soldatos et al., 2005).  Hyperglycaemia is also known to 
activate PKC, which decreases eNOS activity, leading to reduced NO and increased ET-1 
production (Avogaro et al., 2008).  In the setting of ED, endothelin receptor type B (ETB) -
mediated vasodilatory effects of ET-1 are blunted and therefore the vasoconstrictory 
state predominates (Versari et al., 2009a).  PKC also enhances the expression of adhesion 
molecules such as ICAM, VCAM and E-selectin (Avogaro et al., 2008), which are associated 
with EC activation.  ED has been reported to occur early in insulin resistance (Hsueh et al., 
2004).  Often insulin resistance is associated with central adiposity and hence the 
metabolic syndrome, i.e. hypertriglyceridaemia, low high-density lipoprotein (HDL) levels, 
high low-density lipoprotein (LDL) levels and hypertension, all of which could potentially 
favour the development of ED and eventually atherogenesis (Hsueh et al., 2004).  
 
1.3.1.2.2 Dyslipidaemia (including hypercholesterolaemia). 
Dyslipidaemia includes increased circulating lipids including cholesterol and triglycerides, 
a state which can predispose to ED (Mudau M et al., 2012).  Possible mechanisms 
underlying dyslipidaemia-induced ED include: (1) upregulation of NADPH oxidase, 
increased O2– production and oxidative stress (Furukawa et al., 2004), (2) increased 
plasma levels of asymmetric dimethylarginine (ADMA) (Soldatos et al., 2005), and (3) 
oxidation of LDL (Sawamura, 2004).  As mentioned previously, ADMA is an endogenous 
inhibitor of eNOS and competes with L-arginine for the same binding site on eNOS, thus 
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resulting in eNOS uncoupling, increased O2– production and hence decreased NO 
production (Vallance et al., 1992a). Plasma concentrations of ADMA have been reported 
to be increased in hypercholesterolaemia (Böger et al., 1998;  Böger et al., 2003b), and 
this biomarker is considered to be both an indicator and risk factor of ED (Böger et al., 
1998).  In addition to scavenging NO, excess O2– modifies LDL cholesterol to form ox-LDL, 
which plays a major role in the development of endothelial activation and atherogenesis 
(Zeibig et al., 2011).  Ox-LDL has been reported to promote ET-1 production (Boulanger et 
al., 1992), expression of adhesion molecules and chemoattractants (Mallat and Tedgui, 
2005), as well as VSMC migration and proliferation (Sawamura et al., 2004).  Furthermore, 
ox-LDL can be engulfed by macrophages forming foam cells which adhere to the vessel 
wall and contribute to the initiation of an atherosclerotic plaque (Sawamura et al., 2004).  
Both LDL and ox-LDL have been shown to increase the activity of S-adenosylmethionine-
dependent methyltransferases, which lead to the upregulation of ADMA synthesis (Böger 
et al., 2000a). Thus, LDL and ox-LDL may be responsible for the increased plasma levels of 
ADMA in hypercholesterolaemia (Warnholtz et al., 2001).  LDL or ox-LDL can also 
upregulate caveolin-1 synthesis and consequently inhibit eNOS activity (Davignon et al., 
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Figure 1.23:  Pathophysiological effects and the interplay between increased plasma 
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1.3.1.2.3 Hypertension 
ED is a prominent underlying feature of hypertension (Bhatt et al., 2011), and patients 
with hypertension have been shown to demonstrate reduced flow-mediated dilatation, 
characterized by blunted forearm blood flow in response to vasodilatory stimuli such as 
acetylcholine (Tang EH and Vanhoutte, 2010), which is known as the gold standard of 
clinical detection techniques of ED.  Increased production of ROS and endothelial-derived 
contracting factors (EDCFs) such as ET-1, Ang II, PGH2 and TXA2, and decreased NO 
bioavailability are all observed in patients with hypertension (Versari et al., 2009b; Tang 
EH and Vanhoutte, 2010).  Shear stress is known to be one of the most important 
mechanisms of inducing NO-mediated vasodilation in both the micro- and 
microvasculature (Paniagua et al., 2001;  Hadi et al., 2005). However, this response is 
reduced or absent in hypertensive patients (Paniagua et al., 2001).  In addition to this, 
Iaccarino et al. (2004) observed decreased PKB/Akt-dependent activation of eNOS in a 
model of spontaneously hypertensive rats (SHR).  In another study, the role of oxidative 
stress and ED in the development of hypertension in spontaneously hypertensive rates 
was investigated (Bhatt et al., 2011) and showed that early treatment with the 
antioxidant resveratrol was associated with reduced oxidative stress markers, improved 
endothelium-dependent vasodilatation and an attenuation in the development of 
hypertension in these animals. 
 
1.3.1.2.4 Smoking 
Tobacco smokers exhibit decreased NO bioavailability, increased levels of ox-LDL, and 
impaired flow-mediated vasodilation, all indicative of ED (Puranik et al., 2003).  Passive 
smoking has recently also been implicated in impairment of endothelial function (Puranik 
et al., 2003; Barnoya and Glantz, 2005).  It appears that the harmful effects of smoking on 
ECs are dose dependent and reversible upon smoking cessation (Puranik et al., 2003).  As 
with other CVD risk factors, oxidative stress appears to be the major mechanistic link 
between smoking and ED (Puranik et al., 2003;  Burke and FitzGerald, 2003).  Cigarette 
smoke is rich in free radicals and directly delivers free radicals to the body (Valavanidis et 
Stellenbosch University  http://scholar.sun.ac.za
P a g e  | - 90 - 
 
  Chapter One 
al., 2009).  Besides being the supplier of free radicals, cigarette smoke facilitates 
endogenous release of ROS via activation of inflammatory cells (Burke and FitzGerald, 
2003; Antoniades et al., 2008).  Furthermore, smoking has been reported to decrease the 
levels of HDL cholesterol, which is known to have anti-ED and anti-atherosclerotic 
properties (Katusic, 2007).   
 
1.3.1.2.5 Aging 
One of the recognised predisposing factors of ED is increasing age (Katusic, 2007; Herrera 
MD et al., 2010b).  It is thought that the ability of ECs to produce NO is reduced with aging 
(Vanhoutte, 2002).  Furthermore, some studies have reported reduced expression and 
activity of eNOS as well as decreased expression of a major downstream target molecule 
of NO, soluble guanylyl cyclase (sGC) in VSMCs, and its activity in older animals 
(Vanhoutte, 2002).  In addition to the decreased NO production, other endothelial-
derived relaxing factors (EDRFs) (prostacyclin and EDHF) are also reduced, while 
endothelial-derived contracting factors (EDCFs) such as ET-1 and COX-derived 
prostanoids, and ROS production are increased (Herrera MD et al., 2010b; Vanhoutte, 
2002).  Plasma levels of ADMA are also known to rise with increased age (Vanhoutte, 
2002).  Another mechanism that could contribute to reduced NO levels in aging may be 
the increased activity of arginase I (Katusic, 2007; Herrera MD et al., 2010b).  Arginase I is 
an enzyme that catalyses conversion of L-arginine to L-ornithine and urea, and it thus 
competes with eNOS for L-arginine (Katusic, 2007).  Therefore, the increased activity of 
this enzyme as observed with advancing age may result in uncoupling of eNOS, reduced 
NO production and as a result ED (Katusic, 2007; Herrera MD et al., 2010b).  The balance 
between EDRFs and EDCFs is lost with advancing age, establishing aging as a risk factor for 
the development of ED (Matsumoto et al., 2007). Moreover, aging is often associated 
with co-morbid conditions such as diabetes, hypertension and hypercholesterolaemia, 
further exacerbating the risk of developing ED, atherosclerosis and ultimately CVDs 
(Herrera MD et al., 2010b).   
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1.3.1.2.6 Other known factors that contribute to ED 
Apart from the cardiovascular risk factors listed and discussed above, it is important to 
mention that there are several other known factors that also contribute to the 
development of ED.  These factors are briefly listed below: 
 Obesity and associated low grade inflammation 
 Infectious diseases (e.g. HIV and elevated inflammatory markers) 
 Hormonal influences (e.g. menopause, sex steroids) 
 Arthritis 
 Inflammatory bowel disease 
 Genetic predisposition to ED 
 
 
1.3.2 Early endothelial responses to harmful stimuli 
Chronic exposure of the endothelium to cardiovascular risk factors and the harmful 
circulating stimuli associated with these conditions, will eventually overwhelm the 
defense mechanisms of the vascular endothelium, compromising its integrity and 
ultimately initiating endothelial activation, dysfunction and atherosclerosis (Deanfield et 
al., 2007;  Yang G et al., 2010) (Figure 1.24). 
 
1.3.2.1  Endothelial Activation 
Endothelial activation refers to a specific change in the endothelial phenotype, 
characterized most notably by an increase in endothelial-leukocyte interactions and 
permeability, which is pivotal to inflammatory responses in both physiological and 
pathological settings (Alom-Ruiz et al., 2008).  It is also associated with the early stages of 
atherosclerosis and sepsis (Alom-Ruiz et al., 2008).  As a result of activation, the 
endothelium releases so-called Weibel–Palade bodies (López and Chen, 2009).  Weibel–
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Palade bodies, as mentioned previously, store and release two principal molecules, vWF 
and P-selectin, and thus play a dual role in hemostasis and inflammation (Babich et al., 
2008). An intact and healthy endothelium expresses various anticoagulants, such as tissue 
factor (TF) pathway inhibitor, thrombomodulin, endothelial protein C receptor, and 
heparin-like proteoglycans (Esmon CT and Esmon NL, 2011). In addition, ECs express the 
ectonucleotidase CD39/NTPDase1, which metabolizes the platelet agonist adenosine 
diphosphate (ADP). Finally, ECs also release the platelet inhibitors NO and prostacyclin 
(Watson, 2009; Atkinson et al., 2006).  However, activated ECs down regulate expression 
of the anticoagulant protein thrombomodulin, and up regulate expression of the 
procoagulant protein TF (Moore et al., 2010).  Endothelial activation also leads to the 
expression of various adhesion molecules on the surface of the endothelium, such as P-
selectin, E-selectin, and vWF, that capture leukocytes, platelets, and microvesicles (MVs) 
(Ley et al., 2007;  Williams et al., 2011;  Pinsky et al., 1996). 
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Figure 1.24: Exposure of ECs to cardiovascular risk factors and the resultant 
pathophysiological changes, i.e. endothelial activation and dysfunction, with progression 
to atherosclerosis if risk-factor exposure is sustained (adapted from Mudau M et al., 
2012). 
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1.3.2.2 Endothelial Dysfunction (ED) 
 
1.3.2.2.1 Definition and features 
Under physiologic conditions, endothelial stimulation induces the production and release 
of NO, which diffuses to surrounding tissue and cells and exerts its role in maintaining 
vascular homeostasis by relaxing vascular smooth muscle cells, and by preventing 
leukocyte adhesion and migration into the arterial wall, muscle cell proliferation, platelet 
adhesion and aggregation, and adhesion molecule expression (Luscher and Vanhoutte, 
1990; Taddei et al., 2003).  However, under pathophysiological conditions (including the 
presence of cardiovascular risk factors and exposure to harmful circulating stimuli) the 
endothelium undergoes functional and structural changes leading to a loss of its 
protective role and transforming it into a pro-atherosclerotic structure (Luscher and 
Vanhoutte, 1990).  The fundamental feature of ED is reduced NO bioavailability and can 
be the consequence of either reduced production by eNOS or an increased removal or 
scavenging by ROS (Luscher and Vanhoutte, 1990; Taddei et al., 2003). Upon the 
reduction of NO bioavailability, ECs implement various physiological pathways in an 
attempt to compensate (Versari et al., 2009b).  For instance, endothelium-dependent 
vasodilation is still possible due to compensatory production and release of endothelium-
derived vasodilators other than NO, such as endothelium-derived hyperpolarizing factors 
(EDHF) (Versari et al., 2009b). Along with NO deficiency, a dysfunctioning endothelium 
also becomes the source of other substances and mediators that are detrimental to the 
arterial wall, including ET-1, tromboxane A2, prostaglandin H2, and ROS (Taddei et al., 
2003). ED, secondary to the harmful effects of cardiovascular risk factors, has been 
implicated in the pathogenesis of atherosclerosis and thrombosis, both for the loss of its 
protective capability and for the induction of pro-atherothrombotic mechanisms (Versari 
et al., 2009b;  Taddei et al., 2003;  Brunner et al., 2005).  
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1.3.2.2.2 Proposed mechanisms of ED 
According to the latest consensus in literature, oxidative stress appears to be the 
common underlying cellular mechanism for the development of ED in most, if not all, 
cardiovascular risk factor conditions (Mudau M et al., 2012).  In general, cardiovascular 
risk factors seem to be associated with upregulation of ROS sources, especially NADPH 
oxidase (Chhabra, 2009; Förstermann U and Munzel, 2006).  Other sources of ROS such as 
xanthine oxidase, COX and mitochondria are also implicated (Guzik et al., 2002).  As 
described earlier, even eNOS can become a potential ROS generator when it is uncoupled 
(Förstermann U and Munzel, 2006).   
Harmful effects of vascular oxidative stress include increasing VSMC proliferation 
(resulting in thickening of the vascular wall), EC apoptosis, and increased expression and 
activity of MMPs, which are involved in the establishment of an atherosclerotic plaque 
(Puranik and Celermajer, 2003).  Oxidative stress comprises an imbalance in the rate of 
oxidant production and the levels of antioxidant activity (increased oxidant production vs. 
decreased anti-oxidant levels) (Pennathur and Heinecke, 2007).  Under physiological 
conditions, the enzyme SOD regulates the levels of O2– (Landmesser U et al., 2006). 
Increased O2– generation will overwhelm the defensive mechanisms of SOD, leaving O2– 
free to react with other molecules, especially NO, for which it has a greater affinity 
(Landmesser U  et al., 2006).  In fact, the reaction between O2– and NO has been reported 
to occur much faster (rate constant = 6.7 × 109 m/s) than that of dismutation of O2– by 
SOD (rate constant = 2.0 × 109 m/s)(Huang PL, 2003).The reaction between O2– and NO 
leads to the generation of the highly reactive and harmful reactive nitrogen species (RNS), 
peroxynitrite (ONOO-), which is one of the most potent inducers of ED (Yokoyama M, 
2004).     
High levels of peroxynitrite are cytotoxic, since essential cellular molecules such as DNA, 
lipids and proteins are exposed to oxidative damage (Mudau M et al., 2012). In addition 
to being cytotoxic, peroxynitrite damages the the eNOS structure (leading to eNOS 
uncoupling; see Figure 1.25, which further adds to the vicious cycle observed in ED 
(Kuzkaya, 2003) (Pacher et al., 2007)(Figure 1.26). For a more detailed discussion of eNOS 
uncoupling, see section 1.3.2.2.2.1 below)  
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The development of inflammation is another commonly described mechanism of ED 
(Libby et al., 2002).  Under physiological conditions, the endothelium regulates vascular 
inflammation (including the expression of adhesion molecules and promotion of 
leukocyte adhesion) via the release of NO (Osto and Cosentino, 2010).  It therefore 
follows that during ED, characterized by reduced NO levels sustained vascular 
inflammation will ensue, which is detrimental to the vascular system.  However, several 
studies have reported that inflammation is not only a mechanistic consequence of ED, but 
also an inducer of ED; hence, inflammation is widely recognised as a risk factor for CVD 
(Libby et al., 2002;  Szmitko et al., 2003).  Furthermore, there seems to be a causal 
relationship between oxidative stress and inflammation (Madamanchi et al., 2005). 
Oxidative stress may enhance vascular inflammation signalling pathways (Madamanchi et 
al., 2005), and conversely inflammatory cells are known to be major sources of O2– 
(Clempus and Griendling, 2006).  Inflammation is often associated with the 
overexpression of inflammatory cytokines such as tumour necrosis factor-alpha (TNF-α) 
and interleukin-1 (IL-1) (Blake and Ridker, 2001).  These inflammatory cytokines in turn 
prompt ECs or macrophages to express adhesion molecules such as VCAM-1 and ICAM-1, 
MCP-1, interleukin-6 (IL-6) resulting in a state of endothelial activation, which is regarded 
by some as a precursor of ED (Blake and Ridker, 2001).   
The role of TNF-α in ED has received considerable attention in recent years, and a causal 
link is now well established (Mudau M et al., 2012).  TNF-α has been reported to promote 
ROS formation via activation of NADPH oxidase and xanthine oxidase (Zhang W et al., 
2009).  For example, Gao et al. (2007) reported that TNF-α induces ED via increased 
NADPH oxidase activity in coronary arterioles of mice with type 2 diabetes.  In addition, 
TNF-α has been implicated in the downregulation of eNOS expression (and therefore 
decreased NO production) by accelerating eNOS mRNA degradation (Hamburg and Vita, 
2005; Zhang W et al., 2009; Stenvinkel, 2001).  According to Zhang C et al., (2006a) ED 
observed in myocardial ischaemia–reperfusion injury may be attributable to increased 
TNF-α expression via the enhancement of xanthine oxidase activity.  TNF-α induces the 
gene expression of various inflammatory cytokines and chemokines, either dependently 
or independently of the activation of transcriptional factors, such as NF-κB and AP-1. This 
TNF-α-mediated signalling initiates and accelerates atherogenesis, thrombosis, vascular 
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remodelling, vascular inflammation, endothelium apoptosis, vascular oxidative stress and 
impaired NO bioavailability, which contribute to the blunted vascular function.  Dietary 
supplements and exercise have been previously shown to favourably reduce the risk of 
vascular dysfunction by inhibiting TNF-α production and (or) TNF-α-mediated signalling 
(Zhang H et al., 2009).  
Other harmful stimuli-induced mechanisms associated with the development of increased 
oxidative stress and decreased eNOS activation/eNOS uncoupling include activation of 
cholesterylester transport protein (CETP), downregulation of lipoprotein lipase, 
downregulation of peroxisome-proliferator activated receptor (PPAR), downregulation of 
PKA, activation of caveolin, activation of rho-kinase and downregulation of sphingosine-1-
phosphate (Balakumar et al., 2008). 
Vasquez-Vivar et al. (2002) described the role of BH4 in the balance between NO and O2– 
formation from eNOS. In the absence of BH4, eNOS becomes uncoupled and cannot reach 
its normal NO-generating abilities (Rafikov et al., 2011). Once eNOS becomes uncoupled 
due to decreased bioavailability of BH4, the uncoupling process becomes self-propagating, 
since uncoupled eNOS generates O2–, which will in turn oxidize the remaining BH4 
(Landmesser U et al., 2003).  As mentioned previously, O2– may react with NO, forming 
peroxynitrite (Beckman and Koppenol, 1996).  The increased activity of enzymes such as 
NADPH oxidases ignites a cascade of ROS formation by producing O2– (Gielis et al., 2011).  
Bursts of peroxynitrite generation oxidize BH4 to BH3, further increasing eNOS uncoupling, 
starting a bonfire of ROS production by eNOS (Gielis et al., 2011), effectively bestowing 
upon eNOS the dubious role as a ROS-generating enzyme.  The various reactions of 
peroxynitrite when occurring during the reaction of peroxynitrite with enzymes, 
macromolecules and lipids, have been shown to influence cellular functions. Peroxynitrite 
can also lead to irreversible nitration of tyrosine residues on other cellular proteins 
(Szabo, 2003), such as superoxide dismutase, cytoskeletal actin, neuronal tyrosine 
hydroxylase, cytochrome P450 and prostacyclin synthase (Greenacre and Ischiropoulos, 
2001), causing impaired phosphorylation and enzymatic dysfunction (Kuzkaya et al., 
2003).   
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Importantly, elevated eNOS expression, without a parallel increase in BH4, results in eNOS 
uncoupling because of an imbalance between the cofactor and the enzyme (Bendall et al., 
2005). Crabtree et al. (2009) investigated the stoichiometry of intracellular BH4/eNOS 
interactions and demonstrated a striking linear relationship between eNOS activity and 
cellular BH4 levels, with eNOS uncoupling occurring when the eNOS: BH4 molar ratio 
exceeded 1. Increasing intracellular BH2 concentrations in the presence of a constant 
eNOS:BH4 ratio was sufficient to induce eNOS-dependent O2– production, indicating that 
eNOS/BH4 reaction stoichiometry has a tandem role with the intracellular BH4:BH2 ratio 
(rather than absolute plasma concentrations of BH4) in determining eNOS uncoupling, 
even when exogenous oxidative stress is absent (Crabtree et al., 2009).  In another study, 
Heiss et al. (2009) demonstrated that a decrease in BH4 levels activated nuclear factor, 
erythroid derived 2 (NF-E2)-related factor, which leads to a reduction in eNOS protein 
levels in human ECs. Thus, the stoichiometric balance between BH4 and eNOS is 
maintained, eNOS is kept in a coupled state, and ROS production is reduced. It was shown 
that murine ECs contain large amounts of dihydrofolate reductase (DHFR) and that 
reduction of DHFR activity by methotrexate, or genetic knockdown of DHFR by RNA 
interference, resulted in oxidation of BH4 to BH2 with subsequent eNOS uncoupling 
(Crabtree et al., 2009).  DHFR can regenerate BH4 from BH2 and preserve eNOS coupling 
by helping to maintain a better BH4:BH2 ratio, especially when both are scarce (Crabtree 
et al., 2009). 
The role of l-arginine (the main substrate of eNOS) in maintaining eNOS in a coupled state 
is not clear (Gielis et al., 2011).  It is unlikely that plasma l-arginine levels would fall below 
the critical concentration for eNOS activity in vivo, as the plasma level of l-arginine is 30 
times higher than the eNOS (Crabtree et al., 2009).  In addition, l-arginine itself is recycled 
by the cell (Simon et al., 2003).  An increased intracellular breakdown by arginases, 
however, can lead to a very local, subcellular decrease in intracellular l-arginine (Bachetti 
et al., 2004; Xu W et al., 2004).  As such, arginases, expressed in ECs can compete with 
eNOS for their shared substrate (l-arginine) (Bachetti et al., 2004) and can therefore also 
have downregulating effects on eNOS (Xu W et al., 2004).  The endogenous eNOS 
inhibitor (ADMA) directly inhibits eNOS by competing with l-arginine for the same binding 
site; however, ADMA has also been shown to inhibit cellular l-arginine uptake by ECs 
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(Palm et al., 2007).  Therefore, a decreased l-arginine: ADMA ratio can result in reduced 
NO formation by eNOS (Böger, 2007).  Indeed, Antoniades et al. (2009) demonstrated a 
strong inverse association between serum ADMA and levels of eNOS dimer, in both 
human arteries and human veins. Furthermore, increased ADMA plasma concentrations 
are associated with oxidative stress within the vessels and the development of ED (Sydow 
and Munzel, 2003).  From these findings, it appears that changes in ADMA 
concentrations, rather than changes in l-arginine levels, trigger eNOS uncoupling 
(Förstermann U and Munzel, 2006).  The ZnS4 cluster in the eNOS oxygenase domain, 
formed by a zinc ion and two cysteine residues from each monomer, is positioned 
equidistant from each haem group and is responsible for the maintenance of the integrity 
of the BH4 binding site (Raman et al., 1998). Mutation in this cluster prevents the binding 
of zinc, BH4, or l-arginine and eliminates enzyme activity (Förstermann U and Munzel, 
2006), suggesting that stabilization of the dimer interface by the zinc thiolate center is 
one of the keys for catalytic activity. Exposing the isolated eNOS enzyme to peroxynitrite, 
a by-product of the interaction between excessive NO and O2−, leads to the oxidation of 
the zinc thiolate cluster, which uncouples eNOS (Förstermann U and Munzel, 2006).  
Recently, Chen W et al. (2010) demonstrated that the dimer stabilization induced by BH4 
does not require zinc occupancy in this thiolate cluster. Although peroxynitrite treatment 
induced loss of Zn binding and compromised eNOS activity, incubation with a zinc 
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Figure 1.25: Schematic overview of eNOS uncoupling. In the presence of sufficient BH4, 
the eNOS dimer produces abundant amounts of NO (thick arrow) and a small fraction of 
ROS (thin arrow). BH4 binds the oxygenase domain of eNOS and stabilizes the dimer. 
However, in absence of BH4, when there is more BH4 oxidized to BH2, the eNOS dimer will 
uncouple into two monomers, which are less efficient in the production of NO and 
generate large amounts of ROS (thick arrow). ROS generated by uncoupled eNOS further 
oxidize BH4 (Gielis et al., 2011). 
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Figure 1.26: Oxidative and nitrosative stress. O2– anion (O2–) released from sources such 
as NADPH oxidase, mitochondria and xanthine oxidase is dismutated to hydrogen 
peroxide (H2O2) by superoxide dismutase (SOD), which is then converted to water and 
oxygen by catalase. However, O2– has a higher affinity for NO than SOD, and when NO is 
in excess, it preferentially combines with NO to produce peroxynitrite with various 
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1.3.3 Progression to atherosclerosis 
It is now widely recognised that deleterious alterations of endothelial physiology such as 
observed in ED, not only represent a key early step in the development of atherosclerosis, 
but are also involved in plaque progression and the occurrence of atherosclerotic 
complications (Kinlay and Ganz, 1997)(see figure 1.27).  Although the association between 
cardiovascular risk factors and atherosclerotic disease is well documented, the 
mechanism by which these risk factors induce lesion formation and lead to events is not 
entirely defined (Chhabra, 2009). Given its strategic location, biological properties and 
barrier-like function, the EC layer is likely to serve as the ‘missing link’ between any given 
risk factor and its detrimental vascular effects (Halcox et al., 2002).  In fact, ED has 
previously been described as the primum movens (“first cause”) of future cardiovascular 
complications (Bruyndonckx et al., 2013). 
Most, if not all risk factors that are related to atherosclerosis and cardiovascular 
morbidity and mortality, including traditional and nontraditional risk factors, are also 
found to be associated with ED (Cai and Harrison, 2000).  Many of these risk factors, 
including dyslipidaemia, hypertension, diabetes and smoking are associated with 
overproduction of ROS and/or increased oxidative stress (Cai and Harrison, 2000)(Figure 
32).  By reacting with NO, ROS may reduce vascular NO bioavailability and promote cell 
damage (Tomasian et al., 2000).  Hence increased oxidative stress is considered a major 
mechanism involved in the pathogenesis of ED (Vogel et al., 1998; Tomasian et al., 2000; 
Quyyumi et al., 1995).   
The probability of developing ED increases with the number of risk factors present in an 
individual, but the potential to alter endothelial function may vary between risk factors 
(Celermajer et al., 1994).  Taken together, the status of endothelial function represents an 
integrated index of both the overall cardiovascular risk factor burden and the sum of all 
vasculoprotective factors in any given individual (Deedwania, 2000).  Moreover, given its 
pivotal role in the atherogenic process, ED may be regarded as the “ultimate risk of the 
risk factors” indicating the existence of a specific pro-atherogenic vascular milieu which is 
associated with perfusion abnormalities and cardioavascular events (Bonetti et al., 2003). 
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Figure 1.27: The central role of ED in the causation and progression of atherosclerosis. 
ED not only denotes impaired endothelial dependent vasodilatation, but also represents a 
state of endothelial activation which is characterized by a pro-inflammatory, proliferative 
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1.3.4  Clinical relevance of endothelial function 
The assessment of endothelial function may emerge as an integral adjuvant test for 
evaluation of the vulnerable patients at risk for future cardiovascular events (Lerman and 
Zeiher, 2005).  In fact, the detection of ED can be a lifesaving clinical tool as ED is an early 
pathophysiological phenomenon and precursor of atherosclerosis. As such, ED is often 
regarded as both a predictor and surrogate marker of CVD, and therefore an important 
link between cardiovascular risk factors and disease (see figure 1.28).  A few tests for 
evaluating endothelial function exist and will be discussed briefly below (Lekakis et al., 
2011; Deanfield et al., 2007). 
According to Deanfield et al., (2007) such tests should be safe, noninvasive, reproducible, 
repeatable, cheap, and standardized between laboratories (see table 1.7).  The results 
should also reflect the dynamic biology of the endothelium throughout the natural history 
of atherosclerotic disease, define subclinical disease processes, as well as provide 
prognostic information for risk stratification in the later clinical phase.  No single test 
currently fulfills these requirements, and a panel of several tests is therefore needed to 
characterize the multiple facets of endothelial biology. Based on the above requirements, 
see table for a summary of current available tests and their advantages and disadvantages 
(Deanfield et al., 2007). 
Several pharmacological approaches have also been demonstrated to improve or reverse 
ED, although their effect is never selective and usually also target one or more traditional 
cardiovascular risk factors (Versari et al., 2009b) (see table 1.7).   
Lastly, but most important, the structural and functional integrity of the endothelium is 
crucial to maintain vascular homeostasis and prevent atherosclerosis.  The endothelium is 
increasingly becoming a surrogate end point of the therapeutic approach to 
cardiovascular risk, as demonstrated by its inclusion among markers of organ damage in 
the latest European hypertension guidelines (Mancia et al., 2007). Although ED is only 
considered a marker of cardiovascular risk, investing in the development of techniques to 
easily and noninvasively explore endothelial function at a low cost will improve the 
effectiveness of patients’ cardiovascular therapy in the clinical setting tremendously.
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Figure 1.28:  ED: the pathophysiological link between risk factors and CVD. 
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Table 1.7:   Methods for Clinical Assessment of Endothelial Function (Deanfield et al., 2007). 
Technique (Outcomes measure) Noninvasive Repeatable Reproducible* Reflects Biology Reversible Predicts 
Outcome† 
Cardiac catheterization (change in 
diameter, change in coronary blood 
flow) 
- - +/- + + + 
Venous occlusion plethysmography 
(change in forearm blood flow) 
- +/- +/- + + + 
Ultrasound FMD (change in brachial 
artery diameter): GOLD STANDARD 
+ + +/- + + +Ŧ 
PWA (change in augmentation index) + + +/- + - - 
PCA (change in reflective index) + + +/- + - - 
PAT (change in pulse amplitude) + + +/- + - - 
+ indicates supportive evidence in literature; -, insufficient evidence; FMD, flow-mediated dilatation; PWA, pulse wave analysis; PCA, pulse contour analysis; and PAT, pulse 
amplitude tonometry. 
*Reproducibility of PWA, PCA, and PAT has been less extensively investigated than FMD. 
†Studies that link PWA, PCA, and PAT to outcome have not yet been reported. 
Ŧ FMD is currently the gold standard for noninvasive assessment of conduit artery endothelial function because there is considerable clinical trial experience, validation, a 
firm link to biology, and association with cardiovascular events.
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B.  Motivation and Aims. 
 
(i)  Problem identification, rationale and motivation  
 
From the literature, it is clear that a healthy vascular endothelium is a prerequisite for a 
healthy cardiovascular system. It is now widely accepted that EC injury, particularly when 
it manifests as ED, is not only a mere predictor of future adverse cardiovascular events, 
but also a reversible precursor of atherosclerosis and its sequelae, so that early clinical 
intervention strategies can prevent atherogenesis and coronary artery disease. It is for 
this reason that there are currently numerous on-going clinical studies to determine the 
optimal diagnostic tools for clinical detection of ED, something that has eluded us until 
now. Important, however, is the fact that both basic scientists and clinicians have now 
come to realize the importance of early detection of ED. 
The distinct location of cardiac microvascular ECs in the myocardial capillary network 
bestows upon them a unique role not only in the maintenance of cardiac vascular 
homeostasis, but also as regulators of myocardial function. Furthermore, the myocardial 
capillary network is regarded as the primary target of end-organ damage in the heart in 
conditions such as hypertension and diabetes mellitus. It is therefore surprising that so 
few EC-based studies have investigated and characterized this unique EC subtype, not 
only under baseline conditions, but also their response to the effects of harmful stimuli 
commonly associated with cardiovascular risk factors and disease. In our literature 
research, for example, we could only find one study that analysed the CMEC proteome 
with only 22 proteins being positively identified. 
The main aim of this study was therefore to fill the gaps in literature by undertaking a 
comprehensive characterization of CMECs under baseline, unstimulated conditions, and 
after exposure to two physiologically and clinically relevant harmful stimuli. A wide 
variety of techniques was employed and many end-points, including morphology, 
function, viability, signal transduction events and large-scale protein expression patterns 
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were investigated. In the absence of any previous such wide-ranging studies on CMECs, I 
set out to establish and characterize in vitro models of EC injury in CMECs, with the 
objective to reproduce a classical model of ED 
 
(ii)   Aims of the study 
In view of the fact that the purpose of the study was to characterize adult rat CMECs and 
their responses under baseline conditions and in conditions of injury induction, it was 
decided that this study would not be hypothesis-driven. Hence, the following aims were 
formulated: 
 
Aim 1: Baseline characterization of commercially purchased primary CMEC cultures. 
Previous attempts in our laboratory to harvest, isolate and culture CMECs from adult rat 
hearts proved to be technically difficult and the resulting cultures were frequently 
contaminated by other non-ECs. In view of this, we opted to purchase our cells 
commercially from a US-based company. The first aim of my study was therefore to 
validate the purity of the purchased CMECs, and comprehensively characterize the cells 
under normal, baseline conditions.  The reduction in cellular NO levels is one of the gold 
standards used to detect EC injury / ED in vascular ECs. In view of this, the second part of 
this aim was to determine and compare the effect of treatment with a variety of 
potentially harmful stimuli often associated with cardiovascular risk factors and diseases 
on NO production in the CMECs.  
 
Aim 2:  Characterization and investigation of hypoxia-induced responses in CMECs. 
Vascular ECs are frequently subjected to conditions of low PO2 as a result of their 
strategic location at the interface between the vascular wall and circulating blood. 
Furthermore, hypoxia is a recognized risk factor for the development of ED. However, few 
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studies have investigated the effects of hypoxia on CMECs, and therefore the third aim of 
this study was to comprehensively characterize the responses of CMECs to hypoxia. 
 
Aim 3:  Characterization and investigation of TNF-α-induced responses in CMECs. 
The development of systemic and local inflammation is associated with many 
cardiovascular risk factors and disease, including diabetes mellitus, obesity and 
atherosclerosis, and TNF-α is regarded as one of the primary pro-inflammatory cytokines 
mediating the harmful effects of inflammation. Vascular ECs are major targets of 
circulating TNF-α, which has been shown to induce ED in many in vitro and in vivo studies. 
In view of this, the third aim of the study was to comprehensively characterize the 
responses of the CMECs to TNF-α stimulation and establish whether ED could be induced.   
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CHAPTER TWO   
Materials & Methods 
 
The purpose of this chapter is to describe the general materials and methods used for the 
majority of experiments throughout the study. Whenever materials and methods were used 
that only applied to specific studies or experiments, descriptions will be supplied in the 
relevant results chapters. 
 
2.1  Materials 
 
 
2.1.1  General materials used 
 
 Life Technologies (Carlsbad, California, USA):  Attachment Factor (a sterile solution 
containing gelatin as an attachment factor for cell cultures); Tryspin (a solution 
containing 2.5 % trypsin) and Dihydroethidium (DHE).    
 Calbiochem (San Diego, CA, USA):  4,5-diaminofluorescein-2/diacetate (DAF-2/DA).  
 Sigma-Aldrich (St Louis, Mo, USA):  Human recombinant tumor necrosis factor (TNF)-
α; Oleanolic Acid (OA); Asymmetric dimethyl-arginine (ADMA); Dihydrorhodamine-1, 
2, 3 (DHR-123); 2′, 7′-Dichlorofluorescein (DCF); 2,3-Dimethoxy-1,4-naphthoquinone 
(DMNQ); Diethylamine NONOate diethylammonium salt (DEA/NO).  
 Cell Signaling Technologies (Beverly, MA, USA):  Antibodies for the detection of: 
eNOS, phospho-eNOS (Ser 1177); PKB/Akt, phospho PKB/Akt (Ser 473); caveolin-1; 
heat shock protein 90 (HSP 90); cleaved caspase-3; cleaved poly (ADP-ribose) 
polymerase (PARP); and IКβα. 
 Santa Cruz Biotechnologies (Santa Cruz, CA, USA): Antibodies for the detection of: 
p22-phox, nitrotyrosine and iNOS antibodies. 
 Bio-Legend (Biochom-Biotech) (San Diego, CA, USA):    Alexa Fluor 647 Annexin V, 
Propidium iodide (PI) solution, Annexin V binding buffer and cell staining buffer. 
 AEC Amersham (Buckinghamshire, UK):  Enhanced chemiluminescence (ECL) 
detection reagent, ECL hyperfilm, and Horseradish peroxidise-linked anti-rabbit IgG. 
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 Millipore (Billerica, MA, USA):  Polyvinylidene difluoride (PVDF) membrane 
(Immobilon™-P); authentic peroxynitrite. 
 All other chemicals were of Analar grade and were purchased from Merck 
(methanol, standard salts for solutions and buffers, dimethyl sulfoxide (DMSO), etc). 
 
2.2  Cardiac microvascular endothelial cells (CMECs) 
 
Adult rat CMECs were purchased commercially from VEC technologies (Rensselaer, New 
York, USA). The microvascular endothelial cell harvesting technique employed by the 
company has previously been described (Nishida et al., 1993; Piper et al., 1990), and 
ensured the highest possible myocardial capillary-derived CMEC yield, precluding 
contamination by non-endothelial cells. Cells were received in 75 ml fibronectin coated 
tissue culture flasks and grown in microvascular endothelial growth medium (EGM) 
(Clonetics EGM-2MV; Lonza, Walkersville, MD) until they were fully confluent. The growth 
medium was supplemented with 10 % fetal bovine serum (FBS) (Highveld Biological, RSA), 
standard endothelial growth factors (vascular endothelial growth factor – VEGF, human 
epidermal growth factor – hEGF, human fibroblastic growth factor hFGF, long chain human 
insulin-like growth factor - R3-IGF-1), ascorbic acid, hydrocortisone and antibiotics 
(gentamicin and amphotericin B). The cells were grown in a tissue culture incubator (NuAire, 
Plymouth, USA) under standard atmospheric conditions: 21 % oxygen, 5 % carbon dioxide, 
40-60 % humidity and temperature maintained at 37 °C.  Confluent cells (cells evenly 
distributed and completely covering the growth surface of the flask) were removed from 
culture by the addition of pre-heated (37 °C) trypsin.  Following addition of trypsin, the 
flasks were placed back into the incubator for a further five minutes to allow for trypsin-
induced detachment of cells from the surface (this was verified by microscopic observation).  
When completely detached from the surface, the trypsin-cell mixture was collected, 
resuspended in growth medium and centrifuged at a 1000 rpm for 3 minutes at 4°C. After 
centrifugation, the trypsin-containing supernatant was aspired and the cell pellets used to 
make cell stocks for future use. Briefly, pellets were carefully added to a cryo-vial containing 
“freezing” solution (90 % foetal bovine serum (FBS), 5 % growth medium and 5 % DMSO) 
and stored in liquid nitrogen.   
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2.2.1  Passaging procedure:   
Cell pellets were removed from liquid nitrogen storage, seeded on 35 mm petri dishes and 
grown until enough petri dishes were available for experimentation.  Briefly, the cell pellet-
freezing solution mixtures were allowed to thaw, and the cell pellets then gently 
resuspended in the solution by a Pasteur pipette. Fresh growth medium was added to the 
freezing solution for enrichment, and cells subsequently seeded onto two 35 mm pre-
coated (Attachment Factor) petri dishes.  Cells were allowed to attach overnight, and the 
medium replaced with freshly prepared growth medium (supplemented with 10 % FBS) the 
next morning.  Cells were allowed to grow to confluency, at which point they were 
trypsinised (as described above), resuspended in freshly prepared growth medium (10% 
FBS) and re-seeded to four pre-coated petri dishes in a 1:2 ratio.  Passaging continued in a 
1:2 ratio until sufficient petri dishes were available for experiments. With each passage the 
cells are labeled with the date and the number of passages done.  This enabled us to (i) 
establish a time-frame for the growth of the cells from seeding to confluency and, (ii) ensure 
that the number of passages was closely monitored, as we previously established that 
culture purity begins to decline after 8 passages. See Figure 2.1 for a diagrammatic 
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Figure 2.1: Procedure for passaging and labeling of cells. 
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All experiments were performed on cell cultures grown to confluency, thereby securing cell 
cycle arrest at the G0 phase as a result of cell-to-cell contact. Cell cycle arrest is known to 
cause cessation of any further cell proliferation (mitotic activity), thereby minimising 
possible cell cycle variability when evaluating experimental results (Viñals and Pouysségur, 
1999). Other cell-cycle synchronization protocols employed by researchers include 
roscovitine treatment and serum starvation (Cho et al., 2005).  Serum starvation protocols 
will be examined and discussed in more detail in Chapter 5 (characterization and 
investigation of TNF-α-induced responses in CMECs). 
Subcultures of the 5th to 7th generations were used for experiments, as the cells were still 
morphologically and functionally viable, and passaging cells to these generations provided 
sufficient numbers of plates for statistically acceptable sample sizes. Petri dishes were 
randomly assigned to respective control and experimental groups.  Specific experiments 




2.3  Methods 
 
2.3.1  General methods used in this study. 
 
 
2.3.1.1  Flow cytometric analyses 
 
Flow cytometric analyses of all fluorescent probes were performed on a Becton-Dickinson 
FACSCalibur flow cytometer (Franklin Lakes, NJ), located in the Stellenbosch University-BD 
Flow Cytometry Unit, Dept of Biomedical Sciences, Faculty of Medicine and Health Sciences. 
Fluorescence data were analyzed with Cellquest Pro® (version 5.2.1) software (Becton-
Dickson and Co, San Jose, CA). All flow cytometry protocols were previously developed in 
our laboratory and published elsewhere (Strijdom et al., 2004b and 2006).  For all 
experiments, a total of 5 000-10 000 cells were routinely analyzed per sample. In order to 
ensure inter-sample consistency during the acquisition and analysis process of a specific 
experimental series, cell populations of control samples were gated according to their side 
scatter (cell granularity) and forward scatter (cell size), which excluded debris and non-
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cellular particles from the analysis (Figure 2.3 A). The gate coordinates determined for 
control samples were retained and applied to all subsequent experimental samples in a 
particular flow cytometry session.  Once gating has been completed, samples were analysed 
by measuring mean fluorescence intensity as obtained from a histogram (Figure 2.3 B).  
Unless stated otherwise, all flow cytometry data were expressed as:  Mean fluorescence 
intensity as % of control (control adjusted to 100 %). The procedure as described above, 
applied for the majority of our fluorescence-based analyses.  
Flow cytometers are able to analyze several thousand particles every second, in "real time," 
and can actively separate and isolate particles having specified properties. A flow cytometer 
is similar to a microscope, except that, instead of producing an image of the cell, flow 
cytometry offers "high-throughput" (for a large number of cells) automated quantification 
of set parameters. A flow cytometer has five main components (see figure 2.2): 
 a flow cell - liquid stream (sheath fluid), which carries and aligns the cells so that 
they pass single file through the light beam for sensing 
 a measuring system - commonly used are measurement of impedance (or 
conductivity) and optical systems - lamps (mercury, xenon); high-power water-
cooled lasers (argon, krypton, dye laser); low-power air-cooled lasers (argon (488 
nm), red-HeNe (633 nm), green-HeNe, HeCd (UV)); diode lasers (blue, green, red, 
violet) resulting in light signals 
 a detector and Analogue-to-Digital Conversion (ADC) system - which generates 
forward scatter (FSC)  and side scatter (SSC)  as well as fluorescence signals from 
light into electrical signals that can be processed by a computer 
 an amplification system - linear or logarithmic 
 a computer for analysis of the signals. 
 Channels: FL-1H: Excitation :  488 nm / emission: 530 nm (argon laser); 
FL-2H: Excitation: 488 nm / emission: 585 nm (argon laser); 
FL-3H: Excitation: 488 nm / emission: 670 nm (argon laser); 
FL-4H: Excitation: 635 nm / emission: 661 nm (red diode laser). 
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Figure 2.2: Schematic diagram of a flow cytometer, showing focusing of the fluid sheath, 
laser, optics (in simplified form, omitting focusing), photomultiplier tubes (PMTs), analogue-
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Figure 2.3: A:  A representative density dot plot of a CMEC representative sample 
showing the forward scatter (FSC-H; X axis), which measures cell size, and side scatter (SSC-
H; Y axis) which measures cell granularity. The population of interest subjected to analysis is 
selected by the gate (R1) as shown.  The “warmer” the colour, the denser the population of 
cells.  B:  A representative histogram plot of a CMEC representative sample showing the FL1-
H channel (FL1-H; X axis), which measures fluorescence intensity in the FL1-H channel, and 
number of events (Events; Y axis) which measures the number of cells counted.  This 
histogram represents only the “gated” population in A.  
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2.3.1.1.1 Cell viability Measurements 
For cell viability investigations, cells were removed from culture by trypisinisation, washed 
sequentially in staining and binding buffer (BioLegend) and subsequently treated with 
propidium iodide (PI; 5 μM) and Annexin V conjugated with Alexa Fluor® 647 (5 µM), 
incubated at room temperature in the dark for 15 min, and finally subjected to flow 
cytometric analysis. PI fluorescence was analysed in the FL2-H channel, and Annexin V in the 
FL4-H channel. Cell membrane permeability (loss of membrane integrity) grants the PI probe 
entrance into the cell which subsequently stains the nucleus. Therefore, cells demonstrating 
PI uptake and increased PI-fluorescence are deemed necrotic. Apoptotic cells are identified 
by increased fluorescence as a result of the binding of Annexin V to phosphatidylserine 
protein, which in viable cells is normally located on the internal surface of the plasma 
membrane, but translocates to the external surface of the plasma membrane during 
apoptosis. PI and Annexin V staining therefore distinguishes between cells undergoing 
necrosis and apoptosis respectively (Figure 2.4 and figure 2.5) (Wilkins et al., 2002). The 
assay furthermore allows the investigator to measure necrosis and apoptosis simultaneously 
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Figure 2.4: A:  Density plot of a representative sample showing the sub-population of cell 
samples staining positively with PI (necrosis).  B:  Histogram plot, showing the corresponding 
PI fluorescence intensity. M1 refers to the % cells of the gated population (19.3%) that 
stained positively with PI. 
 
Figure 2.5: A:  Density plot of a representative sample showing the sub-population of cell 
samples staining positively with Annexin V (apoptosis).  B:  Histogram plot, showing the 
corresponding Annexin V fluorescence intensity. M1 refers to the % cells of the gated 
population (25.2%) that stained positively with Annexin-V. 
Stellenbosch University  http://scholar.sun.ac.za
P a g e  | - 120 - 
 






Figure 2.6 A density plot showing the simultaneous measurement of necrosis and 
apoptosis in one sample (PI measured in the FL2-H channel on the Y-axis and Annexin-V 
measured in the FL4-H channel on the X-axis), showing the percentage of viable (Left lower 
quadrant), early apoptotic (Right lower quadrant), late apoptotic (Right upper quadrant) and 
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2.3.1.1.2 Nitric Oxide (NO) Measurements 
Intracellular levels of NO were directly measured using flow cytometry-based procedure 
with the NO-specific DAF-2/DA fluorescent probe as previously developed in our laboratory 
and published elsewhere (Strijdom et al 2004b and 2006).  Upon reacting with NO, DAF-
2/DA is oxidized to diaminofluorescein-triazol (DAF-2T), which emits a green fluorescence 
analyzed in the FL1-H channel. At the end of the experiments, cells were washed with 
phosphate buffered saline (PBS) and incubated with 10 μM DAF-2/DA at 37 °C for 3 hours.  
After 3 hours, DAF-2/DA was washed out, cells removed from culture by trypisinisation and 
resuspended in probe-free PBS for flow cytometric analysis.   
The NO-specificity of the DAF-2/DA probe was regularly and randomly tested with the 
positive control NO donor, diethylamine NONOate diethylammonium salt (DEA/NO; 100 
µM) (from concentration determination studies in figure 2.8 A), which was administered to 
DAF-2/DA-containing cells at t = 1h for 2 hours as shown in Figure 2.7.   
As a standard procedure, all experiments included probe-free absolute control samples (to 
determine the autofluorescence of the cells) and DAF2/DA-containing control samples, in 
addition to the experimental samples containing DAF-2/DA. A significant increase in baseline 
fluorescence between absolute control samples and DAF-2/DA-containing samples 
confirmed that the DAF-2/DA uptake was sufficient (See figure 2.8B for a representative 
histogram depicting DAF-2/DA fluorescence). 
CMECs exposed to 100µM DEA/NO (2 hours) showed a significant increase in DAF-2/DA 
mean fluorescence intensity (128.36 ± 5.75 % vs. 100 % control: p < 0.05) compared to 
untreated controls (see figure 2.8A). CMECs exposed to 500µM DEA/NO (2 hours), showed a 
significant increase in DAF-2/DA mean fluorescence intensity (120.46 ± 3.67 % vs. 100 % 
control: p < 0.05) compared to untreated controls (see figure 2.8A). CMECs exposed to 1mM 
DEA/NO (2 hours), showed a significant increase (191.06 ± 34.96 % vs. 100 % control: p < 
0.05) in DAF-2/DA fluorescence compared to untreated controls (see figure 2.8A).   
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Figure 2.7: Positive control protocol with the NO donor, DEA/NO, to validate the NO-
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Figure 2.8: A: Measurement of DAF-2/DA fluorescence following treatment with 
increasing DEA/NO (100µM, 500µM & 1mM) concentrations for 30 minutes.  Sample size:  n 
= 3 - 4 / group. 
B: Histogram showing mean fluorescence intensity measured in absolute control, DAF-
2/DA-control and positive control (DEA/NO (100 µM) + DAF-2/DA) samples respectively 
(analyzed in the FL1-H channel). 
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2.3.1.1.3 ROS Measurements 
ROS production in CMECs was measured with the following fluorescent probes: DHE 
(relatively specific for O2-) (Nazarewicz et al., 2013), DHR-123 (ROS detection, previously 
shown to be sensitive for peroxynitrite and mitochondrial O2-) (Valez et al., 2012; Tiede et 
al., 2011) and DCF (sensitive for H2O2) (Rhee et al., 2010).   
DHE and DHR-123 protocols: After experimental treatment, cells were washed with PBS and 
treated with either 5μM DHE or 2µM DHR-123 in PBS and incubated at 37 °C for 3 hours as 
previously described (Navarro-Antolin et al., 2001; Strijdom et al., 2006). After 3 hours, 
probe-containing PBS was washed out and cells removed from culture by trypisinisation. 
Cells were resuspended in probe-free PBS and DHE and DHR-123 fluorescence was analyzed 
by flow cytometry in channels FL2-H and FL3-H respectively (Figure 2.10 B & 2.12 B). The 
specificity of the DHE and DHR-123 probes was regularly and randomly tested with positive 
control ROS donors, namely (i) 2, 3-dimethoxy-1, 4-naphthoquinone (DMNQ; 100 µM) (from 
concentration determination studies in figure 2.10 A), administered to DHE-containing cells 
at t = 1h for 2 hours as shown in Figure 2.9, and (ii) authentic peroxynitrite (ONOO-; 100 µM) 
(from concentration determination studies in figure 2.12 A) administered to DHR-123-
containing cells at t = 1h for 2 hours as shown in Figure 2.11.     
DCF protocols: After experimental treatment, cells were washed with PBS and samples were 
treated with 10µM DCF and incubated at 37 °C for 60 minutes, after which probe-containing 
PBS was washed out and cells removed from culture by trypisinisation. Cells were 
resuspended in probe-free PBS and DCF fluorescence was analyzed by FACS in channel FL2-
H (Figure 2.14 B).  The specificity of the DCF probe was regularly and randomly tested with 
positive control ROS donor, namely H2O2 (100 µM) (from concentration determination 
studies in figure 2.14 A), administered to DCF-containing cells at t = 30 min for 30 minutes as 
shown in Figure 2.13. 
CMECs exposed to 10µM DMNQ (2 hours) showed a significant increase in DHE mean 
fluorescence intensity (156.13 ± 10.01 % vs. 100 % control: p < 0.05) compared to untreated 
controls (see figure 2.10A). CMECs exposed to 100µM DMNQ (2 hours), showed no change 
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in DHE mean fluorescence intensity (189.53 ± 10.09 % vs. 100 % control) compared to 
untreated controls (see figure 2.10A).  
CMECs exposed to 100µM peroxynitrite (2 hours) showed a significant increase in DHR-123 
mean fluorescence intensity (186.40 ± 1.35 % vs. 100 % control: p < 0.05) compared to 
untreated controls (see figure 2.12A). CMECs exposed to 500µM peroxynitrite (2 hours), 
showed a significant increase in DHR-123 mean fluorescence intensity (131.62 ± 12.51 % vs. 
100 % control: p < 0.05) compared to untreated controls (see figure 2.12A).  CMECs exposed 
to 1mM peroxynitrite (2 hours), showed no change in DHR-123 mean fluorescence intensity 
(104.03 ± 8.36 % vs. 100 % control) compared to untreated controls (see figure 2.12A). 
CMECs exposed to 100µM H2O2 (30 minutes) showed a significant increase in DCF mean 
fluorescence intensity (397.74 ± 78.38 % vs. 100 % control: p < 0.05) compared to untreated 
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Figure 2.9: Positive control protocol with the O2- donor, DMNQ, to validate the relative 
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Figure 2.10: A: Measurement of DHE fluorescence following treatment with 
increasing DMNQ concentrations (10µM & 100µM) for 30 minutes.  Sample size:  n = 3 - 4 / 
group. 
B: Histogram showing mean fluorescence intensity measured in absolute control, DHE-
control and positive control (DMNQ (100 µM) + DHE) samples respectively (analysed in the 
FL2-H channel). 
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Figure 2.11: Positive control protocol with authentic peroxynitrite, to validate the relative 
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Figure 2.12: A: Measurement of DHR-123 fluorescence following treatment with 
increasing authentic peroxynitrite concentrations (100µM, 500µM & 1mM) for 30 minutes.  
Sample size:  n = 3 – 4 / group. 
B: Histogram showing mean fluorescence intensity measured in absolute control, DHR-
123-control and positive control (ONOO- (100 µM) + DHR-123) samples respectively 
(analysed in the FL3-H channel). 
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Figure 2.14: A: Measurement of DCF fluorescence following treatment with H2O2 
(100 µM) for 30 minutes.  Sample size:  n = 3 – 4 / group.  
B:  Histogram showing mean fluorescence intensity measured in absolute 
control, DCF-control and positive control (H2O2 (100 µM) + DCF) samples respectively 
(analysed in the FL2-H channel). 
 
Stellenbosch University  http://scholar.sun.ac.za
P a g e  | - 132 - 
 
  Chapter Two 
 
2.3.1.2  Western blot analyses 
 
NOS Signalling: Total and phosphorylated eNOS (1:1000 dilution; 10 – 20 minutes exposure) 
and PKB / Akt (1:1000 dilution; 5 – 10 minutes exposure) and total HSP 90 (1:1000 dilution;  
3 – 5 minutes exposure), caveolin-1 (1:1000 dilution; 1 – 5 minutes exposure) and iNOS 
(1:200 dilution; 1 – 3 minutes exposure) were measured to investigate NOS signaling 
mechanisms.  
Oxidative Stress: The membrane bound NADPH oxidase subunit, p22-phox (1:200 dilution; 3 
– 5 minutes exposure), was used to measure nicotinamide adenine dinucleotide phosphate 
(NADPH) oxidase activity as previously described (Griendling KK et al., 2000a). 
Nitrosative Stress: The ability of the highly reactive NO-derived radical, ONOO- 
(peroxynitrite) to nitrosylate tyrosine residues of cellular proteins and form nitrotyrosine, is 
an indication of nitrosative stress (Dalle‐Donne et al., 2005). Nitrotyrosine (1:500 dilution; 1 
minute exposure) expression was therefore measured as a marker of nitrosative stress. 
NFКβ signalling: Activation of the NFКβ pathway is usually an indication of a pro-
inflammatory response (Ben-Neriah and Karin, 2011).  Upon activation of this pathway, IКβα 
dislodges from the NFКβ complex and undergoes proteasomal degradation; therefore, a 
reduction in IКβα protein levels is a marker of NFКβ activation (Hoffmann A et al., 2002). 
IКβα (1:1000 dilution; 5 – 10 minutes exposure) protein expression was therefore measured 
to investigate activity of the NFКβ pathway.   
Apoptosis: Cleaved caspase-3 (1:1000 dilution; 5 – 10 minutes exposure) and cleaved PARP 
(1:500 dilution; 5 - 10 minutes exposure) were measured to investigate apoptosis signalling.   
Equal protein loading validation: β-tubulin (1:1000 dilution; 5 minute exposure) expression 
was measured to confirm equal protein loading in all samples.  
General Western blotting protocol (see figures 2.15 & 2.16): To extract protein, CMECs 
from 140x tissue culture dishes representing 4th – 7th generation cells were pooled (10 
culture dishes per sample to ensure that enough protein will be yielded) for a final total of 
14 samples (each sample represented an experimental intervention). CMECs were removed 
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from culture by trypsinization, collected in 15 ml centrifugation tubes (centrifuged at 1000 
rpm for 3 minutes) and resuspended in 1.5ml eppendorff tubes and centrifuged a final time 
at 1000 rpm for 3 minutes to form cell pellets. Zirconium oxide beads (bead size: 0.15 mm) 
were added to each cell pellet-containing tube, followed by addition of 800 µl lysis buffer 
consisting of: 20 mM Tris; 1mM EGTA; 150 mM NaCl; 1mM β-glycerophosphate; 1 mM 
sodium orthovanadate; 2.5 mM tetra-sodium diphosphate; 1 mM PMSF; 0.1 % sodium 
dodecylsulfate (SDS); 10 μg/ml aprotinin; 10 μg/ml leupeptinin; 50 nM NaF and 1 % triton-
X100. Following this, the cell pellets, zirconium beads and lysis buffer were homogenized in 
a Bullet Blender™ (Next Advance, Inc., NY, USA) at speed setting 5 for three cycles of 3-5 
minutes each, with a resting period of 5 minutes in between.  After homogenization, the 
tubes were centrifuged at 10 000 rpm for 10 minutes, the supernatant was collected (see 
Figure 2.17) and the protein content determined by the Bradford protein assay (Bradford, 
1976). Based on the Bradford assay findings, a lysate was prepared containing Laemmli 
buffer (4% SDS, 20% glycerol, 10 % 2-mercaptoethanol, 0.004 % bromphenol blue and 0.125 
M Tris HCl) (Laemmli, 1970) (making up half of the total lysate volume), lysis buffer and 
supernatant, which ensured a final protein content of 50 μg/10 μl per sample.  Cell lysate 
proteins of equal amounts were subsequently loaded onto a 7.5 % (for eNOS and iNOS); 10 
% (for PKB/Akt, nitrotyrosine, HSP 90, caveolin-1 and cleaved PARP, IКβα), 12 % (for p22-
phox) and 15 % (for cleaved caspase-3) SDS-polyacrylamide gel and transferred onto PVDF 
membrane (Immobilon™-P, from Millipore).  Non-specific binding sites on membranes were 
blocked with 5 % fat-free milk in Tris-buffered saline, 0.1 % tween-20 (Merck).   
Following Western blotting, membranes were probed with the specific rabbit polyclonal 
primary antibodies (anti-eNOS, anti- PKB/Akt, anti-HSP 90, anti-caveolin-1, anti-cleaved 
caspase-3, anti-cleaved PARP and anti-IКβα), and (anti-p22-phox, anti-nitrotyrosine and 
anti-iNOS).  The membranes were subsequently exposed to the secondary antibody, 
horseradish peroxidise-linked anti-rabbit IgG.  The ECLTM system was employed to observe 
the immunoreactions.  The same membranes were stripped of primary and secondary 
antibodies with 0.2M NaOH and re-probed (where applicable) for phosphorylated proteins 
with specific rabbit polyclonal primary antibodies (anti-phospho eNOS ser 1177, anti-
phospho PKB/Akt ser 474).  As the stripping method is known to be incomplete, it must be 
noted that there might still be residual binding of primary antibody with the total protein 
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left when membranes are re-probed for phosphorylated proteins.  The method of first 
probing for total proteins, followed by stripping and subsequently probing for 
phosphorylated proteins is indeed flawed but is the optimized method for the current 
western blotting system that we are utilizing.  All the membranes were then stripped again 
of primary and secondary antibodies with 0.2M NaOH and re-probed with specific rabbit 
polyclonal primary antibodies for expression of anti-β-tubulin.  Films were analyzed by 
densitometry (UN-SCAN-IT, Silk Scientific, Orem, UT, USA).  All Western blot data were 
expressed as a ratio of control with the number of control pixels adjusted to 1 (n = 3-4 / 
experimental group for all Western blot investigations).   
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Figure 2.15: Protocol for sample preparation from cells to Bradford Assay. 
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Figure 2.16: Example of a typical gel setup for a 14 sample western blot analyses. 
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2.3.1.3  Proteomics analyses (see Figure 2.17 for overview) 
 
 
2.3.1.3.1 Protein isolation  
Protein extraction was achieved by exactly the same method as described above for the 
Western blot analysis.   
 
2.3.1.3.2 One dimensional sodium dodecyl sulfate polyacrylamide gel electrophoresis 
(1-D SDS-PAGE) followed by in-gel trypsin digestion.  
Cell lysates of equal protein contents (50 µg / 10µl) were loaded onto a 7.5 % SDS-
polyacrylamide gel and proteins separated by means of electrophoresis.  The gel was then 
removed from the electrophoresis chamber and stained with 0.5% Coomassie Blue G-250 
(Sigma Chemical Co, St Louis, MO, USA) (prepared in 50 % methanol / 10 % acetic acid) for 
approximately 5 minutes. The stain was discarded and the gel briefly rinsed with MilliQ 
water, after which it was unstained with 40 % HPLC grade methanol / 10 % acetic acid. The 
unstaining solution was replaced every 10 - 20 minutes until faint bands appeared, and 
continued until bands were clearly visible.  
Each of the SDS-PAGE lanes was loaded with lysates from the respective experimental 
samples. In order to facilitate the trypsin digestion, each lane of the SDS-PAGE gel was 
further subdivided into 5 fractions, cut into smaller cubes and washed twice with water 
followed by 50 % (v / v) acetonitrile for 10 min. The acetonitrile was replaced with 50 mM 
ammonium bicarbonate and incubated for 10 min. This procedure was repeated two more 
times. All the gel pieces were then incubated in 100 % acetonitrile until they turned white, 
after which the gel pieces were dried in vacuo. Proteins were reduced with 10 mM DTT for 1 
h at 57 °C. This was followed by brief washing steps of ammonium bicarbonate followed by 
50 % acetonitrile before proteins were alkylated with 55 mM iodoacetamide for 1 h in the 
dark. Following alkylation, gel pieces were washed with ammonium bicarbonate for 10 min 
followed by 50 % acetonitrile for 20 min, before being dried in vacuo. The gel pieces were 
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digested with 100 µl of 10 ng / µl trypsin solution at 37 ⁰C overnight. The resulting peptides 
were extracted twice with 70 % acetonitrile in 0.1 % formic acid for 30 min, and then dried 
and stored at -20 ⁰C. Dried peptides were dissolved in 5 % acetonitrile in 0.1 % formic acid 
from which 10 µl injections were prepared for nano-LC chromatography. 
 
2.3.1.3.3 Filter Aided Sample Separation:  
In some of the proteomics analyses, protein extraction was performed by means of an 
alternative method, namely the Filter Aided Sample Separation (FASP) method. For FASP, 
samples were dissolved in SDT lysis buffer (4 % SDS, 100 mM Tris-HCl pH 7.6, 0.1 M DTT (the 
latter was added freshly just before use)) to reach a final protein concentration of 600 µg / 
ml. Following this, 400 µl sample was mixed with 400 µl UA buffer (8 M urea, 100 mM Tris-
HCl, pH 8.5) and placed on the filter (Amicon Ultra 0.5 centrifugal filter, 10 kDa, Millipore, 
Ireland), and centrifuged for 40 min at 14 000 × g. This was followed by the addition of 200 
µl UA and further centrifugation at 14 000 × g for 40 min. The proteins were then alkylated 
by the addition of 100 µl of 0.05 M iodoacetaminde in UA, mixed and incubated for 5 min 
before centrifugation at 14 000 × g for 30 min. This was followed by the addition of 100 µl of 
UB (8 M urea, 0.1 M Tris-HCl pH 8.0), centrifugation for 30 min at 14 000 × g, and the 
procedure repeated once. After centrifugation, 100 µl of a 50 mM ammonium bicarbonate 
solution was added, centrifuged at 14 000 × g for 30 min and repeated once.  
Next, 40 µl trypsin (Promega, Madison, WI, USA) was added and incubated at 37 °C for 17 
hours in a wet chamber. The following morning the filter was placed in a clean Eppendorf 
tube and centrifuged for 40 min at 14 000 × g, followed by the addition of 40 µl 0.5 M NaCl 
solution and further centrifugation for 20 min at 14 000 × g. Finally, the solution was 
acidified by the addition of 2.4 µl formic acid (FA). The filtrate was desalted using C18 
StageTips (Thermo Fischer Scientific, USA) according to the manufacturer’s instructions. The 
desalted solution was dried in vacuo and stored at -20 ⁰C. Dried peptides were dissolved in 5 
% acetonitrile in 0.1 % FA from which 10 µl injections were prepared for nano-LC 
chromatography. 
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Figure 2.17:  Workflow for identifying proteins in CMECs. An equal amount of protein (50 ug 
/ 10 ul) was loaded onto the gel and 600 ng / µl protein loaded for the FASP method 
respectively. The gel was stained using Coomassie blue and cut into 5 fractions for in-gel 
trypsin digestion. Peptides from the gel were extracted and prepared for LC-MS/MS. For 
those experiments in which proteins were separated and digested by the FASP method, 
proteins were trypsinised on the FASP membrane and subsequently extracted and prepared 
for LC-MS/MS. All MS/MS spectra were searched using Thermo Proteome Discoverer 
software (version 1.3) against in-house versions of Mascot, Sequest, X!tandem and 
Andromeda. For final data analyses, the identified proteins from all the search engines were 
combined to obtain a final list of proteins present in the CMEC proteome. (Diagram courtesy 
of Dr Salome Smit: Proteomics Unit, Central Analytical Facility, University of Stellenbosch). 
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Figure 2.18: A: The LTQ Orbitrap Velos mass spectrometer situated in the Proteomics 
Unit of the University of Stellenbosch (Thermo Fischer Scientific, USA).  B:  Nano-
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2.3.1.3.4 Mass spectrometry (see Figure 2.18). 
All mass spectrometry analyses were performed on a Thermo Scientific EASY-nLC II 
connected to a LTQ Orbitrap Velos mass spectrometer (Thermo Fischer Scientific, USA) 
equipped with a nano-electrospray source. For liquid chromatography, separation was 
performed on an EASY-Column pre-column (2 cm, ID 100 µm, 5 µm, C18), and then an EASY-
column (10 cm, ID 75 µm, 3 µm, C18) with a flow rate of 300 nl / min. The gradient used was 
from 5-15 % B for 5 min, 15-35 % B for 90 min, 35-60 % B for 10 min, 60-80 % B for 5 min 
and kept at 80 % B for 10 min. Solvent A consisted of 100 % water in 0.1 % FA, and solvent B 
consisted of 100 % acetonitrile in 0.1 % FA.  
The mass spectrometer was operated in data-dependent mode to automatically switch 
between Orbitrap-MS and LTQ-MS/MS acquisition. Data were acquired using the Xcaliber 
software package (Thermo Fischer Scientific, USA). The precursor ion scan MS spectra (m/z 
400 – 2000) were acquired in the Orbitrap mode with resolution R = 60000 (number of 
accumulated ions: 1 x 106). The 20 most intense ions were isolated and fragmented in a 
linear ion trap (number of accumulated ions: 1.5 x 104) using collision-induced dissociation. 
The lock mass option (polydimethylcyclosiloxane; m/z 445.120025) enabled accurate mass 
measurements in both the MS and MS/MS modes. In data-dependent LC-MS/MS 
experiments, dynamic exclusion was applied with 60 s exclusion duration. Mass 
spectrometry conditions were as follows: 1.8 kV, capillary temperature of 250 °C, with no 
sheath and auxiliary gas flow. The ion selection threshold was 500 counts for MS/MS and an 
activation Q-value of 0.25 and activation time of 10 ms were also applied for MS/MS.  
 
2.3.1.3.5 Proteomic data analysis 
Thermo Proteome Discoverer 1.3 software (Thermo Fischer Scientific, USA) was used to 
identify proteins via automated database searching (Mascot, Matrix Science, UK, and 
Sequest, Thermo Fischer Scientific, USA) of all tandem mass spectra against the UniProtTM 
rat database. Carbamidomethyl cysteine was set as fixed modification, and oxidized 
methionine, N-acetylation and deamidation (NQ) as variable modification. The precursor 
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mass tolerance was set to 10 ppm, and fragment mass tolerance set to 0.8 Da.  Two missed 
tryptic cleavages were allowed. Proteins were considered positively identified when they 
were identified with at least 2 tryptic peptides per protein, a Mascot score threshold of 20, 
Sequest score threshold of 1.5 (p < 0.05), and a protein and peptide posterior error 
probability (PEP) of at least 0.01. Percolator (part of Mascot) was used for peptide validation 
with a maximum delta Cn of 0.5, and decoy database searches with a FDR of 0.02 and 0.05 
with validation based on the q-value. Further protein identification was performed with the 
X!tandem search engine (Craig and Beavis, 2004) via the online UniProt rat database. 
Carbamidomethyl cysteine was set as fixed modification, and oxidized methionine, N-
acetylation and deamidation (NQ) as variable modification. Proteins were considered 
positively identified when they were identified with p-score of more than 72 as determined 
by the X!tandem software. The false positive identification rate was calculated to be an 
average of 1.4 %.  Andromeda’s Maxquant 1.2.2.5 proteomics software package (Cox et al., 
2011) was used for protein identification with a protein and peptides PEP of at least 0.01 
and 2 unique peptides per protein. For a diagrammatic representation of the SDS PAGE / in-
gel trypsinization and filter-aided sample preparation (FASP) / in-solution trypsinization 
methods, mass spectrometry and data analysis. 
Where indicated, differential protein regulation between two experimental groups were 
analysed by the Maxquant proteomics software package, and proteins were only considered 
differentially regulated with a protein and peptide PEP of 0.01, up or down regulation of ≥ 
1.5-fold and a p-value of p < 0.05.  
 
2.3.1.3.6  Functional annotation analyses of proteins 
Functional annotation analyses of the identified proteins in the CMECs were performed by 
submitting protein lists to the functional annotation tool of DAVID (The Database for 
Annotation, Visualization and Integrated Discovery) Bioinformatics Resources 6.7 (Huang 
DW et al., 2009) The DAVID functional annotation tool allocates functionally related 
proteins from the submitted lists to specific Gene Ontology (GO) terms, and in this study, we 
were interested in the significantly represented GO terms determined by cellular 
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component, biological process and molecular function properties respectively.  Another 
analysis tool offered by DAVID is the functional annotation cluster tool.  Grouping 
functionally related GO terms into functional annotation clusters further assist in making 
sense of the proteome in terms of cellular functions and processes. In this regard, the P-
value and fold enrichment of each annotation cluster indicate to which degree that cluster is 
overrepresented within the submitted dataset; clusters with p-values < 0.05 and larger fold-




2.4  Statistical analyses  
 
All data in this dissertation are expressed as mean ± standard error of the mean (SEM).  
Statistical analyses were performed with a Student’s t-test (for comparison of two groups) 
or one-way analysis of variance (ANOVA) (with Bonferroni post-hoc test if p < 0.05; for 
comparison of more than 2 groups).  Data achieving a p-value of < 0.05 were considered 
statistically significant. Graph Pad Prism ® version 5.01 software was used for all analyses. 
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Characterization of primary CMEC cultures 
 
3.1  Introduction  
As mentioned previously, the distinct location of CMECs in the myocardial capillary network 
bestows upon them a unique role not only in the maintenance of vascular homeostasis, but 
also as regulators of myocardial function. Endothelial heterogeneity is particularly evident in 
specific organs such as the heart (Hendrickx et al., 2004), where the myocardial capillaries 
and the endothelial cells that line them are regarded as primary targets of, and critical role-
players in end-organ damage in the heart resulting from hypertension, diabetes mellitus and 
ischaemic heart disease (Lu L et al., 2007). CMECs show distinct morphological and 
structural adaptations compared to other endothelial cell types, such as the expression of 
fewer tight and gap junctions, shallower intercellular clefts, no microvilli and relatively more 
caveolae and intracellular vesicles (Aird, 2007a). These adaptations suggest that CMECs 
form a rather leaky endothelial layer and are specialized to perform transcytosis-mediated 
transfer of materials (Aird, 2012). In view of the intimate CMEC-cardiomyocyte 
arrangement, cardiomyocytes are regarded as the primary cellular recipients of paracrine 
messengers secreted by CMECs, such as NO and endothelin-1. Therefore, CMECs are now 
recognized as important regulators of myocardial function (Brutsaert, 2003).  
Despite the limited availability of data on CMEC structure and function, almost no 
information is available on the CMEC proteome.  In the only previous proteomics-based 
study (partly) dedicated to rat coronary microvascular endothelial cells, a two-dimensional 
gel electrophoresis (2-DE) approach was followed, in which only 22 proteins were positively 
identified (Lu L et al., 2007). The field of vascular proteomics has considerable shortcomings. 
Relative to other cell types, surprisingly little is known about the endothelial proteome in 
general, which is further confounded by the fact that 80% of all endothelial proteomic 
studies are conducted on one distinct endothelial cell type, viz. human umbilical venous 
endothelial cells (HUVECs) (Richardson et al., 2010). The over reliance on HUVECs as a 
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research model does not consider the reality that endothelial cells show considerable 
structural and functional diversity across the vascular tree (Aird, 2007b), leaving other 
physiologically important endothelial cell subtypes, such as the CMECs, relatively under 
investigated (Mayr et al., 2004).  
Despite the fact that endothelial NO bio-availability is regarded as one of the gold standards 
in the assessment of endothelial cell function and health, surprisingly few studies utilise the 
direct measurement of intracellular NO-levels as an end-point when investigating the effects 
of harmful stimuli. Furthermore, findings are variable, often due to differences in 
experimental conditions, endothelial cell types used, and inconsistent concentrations and 
treatment times of harmful stimuli (see Table 1.3, Chapter 1 for variable in vitro effects of 
TNF-α on endothelial cells). 
In summary, from the literature it is evident and surprising that so few endothelial cell-
based studies have investigated and characterized CMECs, not only in view of their strategic 
location the myocardium, but also in view of their status as important role-players under 
physiological and pathophysiological conditions.  Therefore, in this chapter we have set out 
to comprehensively characterize adult rat CMECs under baseline (unstimulated) conditions, 
and after exposure to a variety of harmful stimuli (using intracellular NO-levels as end-
point).   
 
3.2  Specific Aims 
 To characterize the morphology and purity of the commercially purchased CMECs. 
 To establish whether the CMECs express an array of selected proteins important for 
the purposes of this study. 
 To characterize the baseline proteome of these cells. 
 To examine the effects of various putative harmful stimuli on intracellular NO-levels 
in the CMECs. 
 
Stellenbosch University  http://scholar.sun.ac.za




3.3 Morphology, functional characterization and baseline protein expression of 
CMECs. 
 
3.3.1  Morphology and functional characterization 
In order to assess the morphology of the cells, they were photographed with a standard 
light microscope.  A typical “cobblestone” monolayer morphology was observed, a distinct 
characteristic of cultured endothelial cells (Nishida et al., 1993; Piper et al., 1990) (see 
Figure 3.1).  The presence of non-endothelial cells was negligible (on average, less than 10% 
of the total cell population was of non-endothelial origin).  In addition, functional 
characterization was performed by measuring uptake of acetylated low density lipoprotein 
labeled with 1,1'-dioctadecyl-3,3,3',3'-tetramethylindo-carbocyanine perchlorate (Dil-ac-
LDL)(Biomedical Technologies, Stoughton, MA, USA).  This fluorescent probe is specific for 
endothelial cells (Nishida et al., 1993; Piper et al., 1990), and recognized as a marker of 
endothelial cell purity.  Acetylated-low density lipoprotein (Ac-LDL) is taken up by 
endothelial cells via the "scavenger cell pathway" of LDL metabolism.  Once a lipoprotein 
that contains DiI is taken up by a cell, the lipoprotein molecule is acted upon by lysosomal 
enzymes and the DiI accumulates in lysosomal membranes. Thus, cells that metabolize 
lipoproteins at different rates will accumulate varying amounts of DiI and endothelial cells 
are known to metabolise lipoproteins at a much higher rate that other cell types (Voyta et 
al., 1984).  Briefly, CMECs were incubated with 10 ug / ml Dil-ac-LDL at 37°C for 4 hours. The 
probe was subsequently washed out, and cells were removed from culture by trypsinisation, 
resuspended in PBS and the % fluorescent cells analyzed by flow cytometry in the FL2-H 
channel.  A high fluorescence uptake (80 – 100 % of the total gated cell population) 
indicates endothelial cell purity, and no experiments were conducted on CMEC subcultures 
with < 80 % purity (see Figure 3.2).  See Figure 3.3 for a fluorescence microphotograph of 
LDL-staining CMECs in culture. 
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Figure 3.1: Validation of morphological appearance. Representative microphotograph 
(Carl Zeiss standard upright light microscope, West Germany) of a confluent CMEC culture 
(10x magnification) demonstrating a typical cobblestone appearance, commonly associated 
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Figure 3.2: Flow cytometric analysis of the percentage cells staining positively for the Dil-
ac-LDL fluorescent probe in cells from different culture generations. The red histogram 
represents autofluorescence (probe-free sample) and the black histogram the cells treated 
with Dil-ac-LDL. On average CMEC cultures demonstrated >93% positive staining. 
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Figure 3.3: Validation of endothelial cell purity. Representative fluorescence 
microphotograph of LDL-staining CMECs in culture (20x magnification) clearly shows the 
bright red-staining endothelial cells that have taken up the fluorescently-labeled LDL 








Stellenbosch University  http://scholar.sun.ac.za




3.3.2  Expression of proteins involved with NOS-NO biosynthesis in CMECs. 
In order to establish whether the CMECs express proteins that are crucial role-players in the 
NOS-NO biosynthesis pathway (an important end-point for the purposes of this study), we 
measured the expression of: eNOS, PKB/Akt, HSP 90, caveolin-1, iNOS and nNOS. Lysates of 
untreated samples were prepared (as previously described in chapter two) to yield a final 
protein content of 50µg / 10µl.  These samples were subsequently loaded onto a 7.5% (for 
eNOS – 140 kDa, iNOS – 130 kDa, nNOS – 160 kDa, PKB/Akt – 58 kDa and HSP 90 – 90 kDa) 
and 12% (for Caveolin-1 – 20 kDa) SDS-polyacrylamide gel and transferred onto PVDF 
membrane (Immobilon™-P, from Millipore).  Non-specific binding sites on membranes were 
blocked with 5 % fat-free milk in Tris-buffered saline, 0.1 % tween-20 (Merck).   
Following Western blotting, membranes were probed with the specific rabbit polyclonal 
primary antibodies (anti-eNOS, anti-iNOS, anti-nNOS, anti-PKB/Akt, anti-HSP 90 and anti-
caveolin-1).  The membranes were subsequently exposed to the secondary antibody, 
horseradish peroxidise-linked anti-rabbit IgG.  The ECLTM system was employed to observe 
the immunoreactions.   We found that all the above proteins (eNOS, iNOS, nNOS, PKB/Akt, 
HSP 90 and caveolin-1), which all play central roles in endothelial cell NOS-NO signalling 
(Cortese-Krott et al., 2011; Kuhr et al., 2010; Basuroy et al., 2011; Xu Q et al., 2012; Briand 
et al., 2011) were expressed in baseline CMECs (see Figure 3.4).  The expression of nNOS is 
particularly interesting, as we are not aware of any previous studies that demonstrated the 
presence of this NOS isoform in CMECs. nNOS expression has previously been demonstrated 
in HUVECs (Chakrabarti et al., 2012) and peri-microvascular nNOS-derived NO was found to 
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Figure 3.4: Total baseline expression of selected NOS-NO signalling proteins in the 
CMECs. In addition to the expression of all three of the main known NOS isoforms (eNOS, 
iNOS and nNOS) in the CMECs, we could also establish that HSP 90 and caveolin-1, both 
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3.4  Comprehensive characterisation of the baseline CMEC proteome. 
CMECs under baseline conditions were analysed by a method as previously described in 
chapter 2 (see figure 3.5 for an overview of the workflow followed). Following the 
identification of the proteins, the data were submitted to DAVID Bioinformatics Resources 
(version 6.7) for functional annotation analyses.  
The SDS-PAGE gel method followed by LC-MS/MS identified a total of 1387 proteins and 
13290 peptides in CMECs under baseline conditions (the complete list of identified proteins 
will be forwarded to the reviewers electronically). In order to optimize proteome coverage, 
four different search engines were consulted for protein identification. Mascot positively 
identified 801 proteins, whereas Sequest identified 1115 proteins (102 proteins unique to 
Sequest), X!tandem identified 747 proteins (29 proteins unique to X!tandem), and 
Maxquant identified 927 proteins (178 proteins unique to Maxquant).  
Classification of the identified proteins according to molecular weight (Mr), showed that 
73% of the proteins appeared in the 20-100 kDa range, with only 8% under the range of 20 
kDa and 19% larger than 100 kDa. Classification based on the distribution of isoelectric point 
(pI) indicated that 10% of the proteins identified had a pI smaller than 5, and 5% had a pI 
larger than 11. The majority of the identified proteins had a pI between 5 and 8, which 
constituted 62% of the proteome. A total of 23% of the proteins fell in the 8-10 pI range. 
This is in contrast to a previous study on rat coronary microvascular endothelial cells that 
showed more spots in the alkaline pI range (Lu L et al., 2007), and another 2-DE based study 
on HUVECs where more than 60% of the proteins were in the acidic pI range (Bruneel et al., 
2003). A possible explanation for this apparent inconsistency might be that MS based 
proteomic investigations such as the current study have no bias towards pI or Mr, whereas 
2-D gel based approaches are constrained by the pH and Mr (Pietrogrande et al., 2002;  
Smolka et al., 2002; Roe and Griffin, 2006).  
The proteome data succeeded in complementing the light microscopy and dil-ac-LDL uptake 
validations in characterizing the CMECs as vascular endothelial cells. For a list of 12 
identified proteins, known to be predominantly or exclusively expressed in vascular 
endothelial cells, see Table 3.1. In an effort to place the proteomic findings of the present 
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study in a broader context, we investigated whether other proteomic-based endothelial cell 
studies in the literature had reported on, or identified the expression of identical or similar 
proteins. The results are summarized in Table 3.2. Next, we performed functional 
annotation analyses on the identified proteins in the baseline CMECs according to their 
expression in Gene Ontology (GO) terms (DAVID Bioinformatics Resources) (Huang DW et 
al., 2009). We also analyzed the proteomic data by submitting the baseline CMEC protein 
list to the functional annotation cluster tool of DAVID, which groups functionally related GO 
terms in annotation clusters. The top 10 most enriched functional annotation clusters of the 
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Figure 3.5: Workflow for identifying proteins in CMECs under baseline conditions. 
Protein extraction was performed by SDS-PAGE / in-gel trypsinisation. Proteins were 
separated by the Thermo Scientific EASY-nLCTM II nano-flow liquid chromatography system 
connected to a LTQ Orbitrap VelosTM mass spectrometer (Thermo Fischer Scientific, USA) 
equipped with a nano-electrospray source. Finally, proteins were identified by submitting 
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Table 3.1: List of identified proteins in the baseline CMEC proteome known to be 
predominantly expressed in vascular endothelial cells (the complete list of identified 
proteins is available on request). 
 
Protein Identification Accession Number 
1. Angiopoeitin-2 O35462 
2. Angiotensin converting enzyme P47820 
3. Basal cell adhesion molecule Q9ESS6 
4. Caveolin-2 Q2IBC5 
5. CD151 antigen (platelet-endothelial tetraspan antigen-3) Q9QZA6 
6. Endothelial cell-selective adhesion molecule Q6AYD4 
7. Endothelial protein C receptor F1M7Q9 
8. Intercellular adhesion molecule 2 Q6AXM6 
9. Nitric oxide synthase F1LQC7 
10. Nitric oxide synthase, endothelial Q62600 
11. Platelet-endothelial cell adhesion molecule Q3SWT0 
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Table 3.2: Comparison of selected proteins identified in the baseline CMECs of the present study with those identified in other studies 
performed on similar or other endothelial cell types.   
Protein Name CMECs CorMECs BMECs CAECs AECs 
      
1. Glyceraldehyde-3-phosphate dehydrogenase + + + – – 
2. Alpha-enolase + – – + – 
3. ATP synthase subunit beta, mitochondrial + – – – + 
4. ATPase, H+ transporting  + – – – + 
5. Chaperonin subunit 8 (Theta) + + + – – 
6. Chloride intracellular channel protein 4 + + + – – 
7. Cytosol aminopeptidase + + + – – 
8. Fructose-bisphosphate aldolase A + – – + + 
9. Macrophage-capping protein + + + – – 
10. Ornithine aminotransferase, mitochondrial + + + – – 
11. PDZ and LIM domain protein 1 + + + – – 
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12. Peptidyl-prolyl cis-trans isomerase A; cyclophilin A + – – + + 
13. Peptidyl-prolyl cis-trans isomerase D + + + – – 
14. Peroxiredoxin-2 + – – – + 
15. Prohibitin + – – + – 
16. Spectrin alpha chain + – – – + 
17. Stress-induced-phosphoprotein 1 + – – – + 
18. Succinyl-CoA:3-ketoacid-coenzyme A transferase 1, mitochondrial + – – – + 
19. Vesicle amine transport protein 1 homolog + + + – – 
20. Vesicle-associated membrane protein-associated protein A + + + – – 
21. Vesicle-associated membrane protein-associated protein B + + + – – 
22. Vimentin + – – + + 
 
CMECs: CMECs of the present study; CorMECs: Coronary microvascular endothelial cells from Lu L et al. (2007); BMECs: Brain microvascular 
endothelial cells (Lu L et al., 2007); CAECs: Coronary artery endothelial cells (Yu et al., 2004); AECs: Aorta endothelial cells (Almofti et al., 2006). 
+ Positively identified and reported; --- Not identified and / or reported.  
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Figure 3.6: Functional annotation analysis (DAVID Bioinformatics) of the proteins identified in baseline CMECs showing the top 10 most 
enriched annotation clusters with their respective enrichment scores and GO terms. 
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3.5 The effect of various harmful stimuli on the NO production of CMECs – FACS 
analysis. 
As part of our endeavours to characterise the CMECs, we investigated the response of the 
CMECs to several harmful stimuli commonly associated with cardiovascular risk factors or 
disease states. As end-point, we measured the intracellular NO-production in the CMECs. 
These experiments were performed as part of our initial baseline pilot studies to optimise 
the use of the DAF-2/DA probe, the measurement of DAF-2/DA fluorescence by flow 
cytometry, and finally also to assist in selecting which stimuli will eventually be 
comprehensively studied in the later chapters of this dissertation. 
In these initial pilot studies, CMECs were treated for 24 hours with angiotensin II (100 nM), 
high glucose concentration (25 mM), hypoxia (O2 < 0.6 %), ox-LDL (40 µg/ ml), ADMA (500 
M), and TNF-α (5 ng / ml and 20 ng / ml).     
Interestingly, treatment with angiotensin II, glucose, hypoxia and ox-LDL induced significant 
increases in NO production after 24 hours. Conversely, ADMA and TNF-α (20 ng / ml) 
treatment resulted in a significant decrease in NO production, whereas TNF-α (5 ng / ml) 
had no effect on NO-production.   
CMECs exposed to:  100 µM DEA/NO (2 hours) showed a significant increase (128.36 ± 5.75 
% vs. 100 % control: p < 0.05); 100 nM Angiotensin II (24 hours) showed a significant 
increase (109.68 ± 4.67 % vs. 100 % control: p < 0.05);  25 mM glucose (24 hours) showed a 
significant increase (114.42 ± 5.59 % vs. 100 % control: p < 0.05); < 0.6 % O2 (24 hours) 
showed a significant increase (144.09 ± 11.60 % vs. 100 % control: p < 0.05); 40 µg / ml 
oxidized-LDL (24 hours) showed a significant increase (128.82 ± 4.99 % vs. 100 % control: p < 
0.05); 500 µM ADMA (24 hours) showed a significant decrease (88.47 ± 2.25 % vs. 100 % 
control: p < 0.05);  5 ng / ml TNF-α (24 hours) showed no change (100.71 ± 5.04 % vs. 100 % 
control: p < 0.05) and 20 ng / ml TNF-α (24 hours) showed a significant decrease (74.02 ± 
1.61 % vs. 100 % control: p < 0.05) in DAF-2/DA fluorescence compared to untreated or 
normoxic controls (see figure 3.7). 
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Figure 3.7: Intracellular NO-levels measured by the mean fluorescence intensity of DAF-
2/DA (expressed as a percentage of control; control = 100%).  DEA/NO was used as a 
positive control for DAF-2/DA.  A significant increase is indicated as * and a significant 
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3.6  Discussion 
3.6.1 Characterization of the morphology, culture specificity and expression of 
critical proteins involved with NOS-NO biosynthesis in CMECs. 
Previous studies have characterized vascular endothelial cells in terms of morphology, by 
observing that the cultured cells grow as a single layer and adopt a “cobble-stone” 
appearance (Nishida et al., 1993).  Using a standard light microscope with a 10x 
magnification, we confirmed that the CMECs demonstrate the typical cobble-stone 
appearance (see figure 3.1).  Other studies have also verified the “purity” of endothelial cell 
cultures by staining with the fluorescent probe, Dil-Ac-LDL. Positive staining has been 
confirmed by fluorescent microscopy (Scheller et al., 2012; Ma, 2012) or by flow cytometric 
analysis of Dil-ac-LDL fluorescence with flow cytometry (Eggermann et al., 2003; Von 
Ballmoos et al., 2010).   We were able to show that the CMECs stained positively for Dil-ac-
LDL, by fluorescent microscopy (figure 3.3) and flow cytometric analysis, which indicated 
that the percentage positively staining cells was > 90 % up to the 7th generation (see figure 
3.2). 
In a separate series of experiments, we showed that the CMECs expressed baseline proteins 
commonly associated with endothelial cell NOS-NO signalling, namely all three NOS 
isoforms: eNOS (Liu G et al., 2012), iNOS (Raphael et al., 2010) and nNOS (Chakrabarti et al., 
2012), as well as HSP 90 (Desjardins et al., 2012) and caveolin-1 (Malan et al., 2013), and 
PKB/Akt, one of the major upstream activators of eNOS (Fournier et al., 2012) (see figure 
3.4).  Other researchers have also shown that eNOS (Scheller et al., 2012; Zhang P et al., 
2011), HSP 90 (Dib et al., 2012; Miwa et al., 2013), caveolin-1 (Davalos et al., 2010; Jagielska 
et al., 2012), iNOS (Siamwala et al., 2010; Namdar et al., 2012) and PKB/Akt (Strijdom et al., 
2009b; Wang L et al., 2012) are expressed in CMECs.  The expression of nNOS has been 
shown in various cell types, namely neurons (Chao et al., 1996; Vizzard et al., 1994), 
myocytes (Silvagno et al., 1996; Gath et al., 1997), epithelial cells (North et al., 1994;  Asano 
et al., 1994), Macula densa cells (Schricker et al., 1996; Wang Y et al., 1997), mast cells 
(Shimizu et al. ,1997), gonadotrophs and folliculostellate cells (Ceccatelli et al., 1993; Iwai et 
al., 1995) as well as neutrophils (Wallerath et al., 1997).  Expression of nNOS in endothelial 
cells have also been shown, namely in HUVECs (Chakrabarti et al., 2012). However, although 
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nNOS is clearly expressed in other endothelial cell types (e.g. HUVECs) and non-endothelial 
cell types, the expression of nNOS has, as far as we are aware, not previously been 
demonstrated in CMECs; therefore this appears to be a novel finding. 
 
3.6.2  The CMEC proteome under baseline conditions.  
At least 12 proteins, known to be predominantly or exclusively expressed in vascular 
endothelial cells (Table 3.1), were identified in the CMECs. These proteins are associated 
with a wide range of endothelial-specific functions: endothelial cell adhesion (basal cell 
adhesion molecule, endothelial cell-selective adhesion molecule, intercellular adhesion 
molecule and CD151 antigen / platelet-endothelial cell adhesion molecule); angiogenesis 
(angiopoeitin-2); angiotensin biosynthesis (angiotensin converting enzyme, ACE); nitric 
oxide synthesis (endothelial nitric oxide synthase, nitric oxide synthase and caveolin) and 
blood coagulation (endothelial protein C receptor and von Willebrand factor). The 
identification of these proteins serves to demonstrate the value of proteomics in 
complementing more traditional endothelial cell purity validation techniques 
(morphological light microscopic appearance and dil-ac-LDL uptake:  Figures 3.1, 3.2 and 
3.3).  
Next, we attempted to contextualize our proteomic data by undertaking a review of the 
literature to compare our findings with those of proteomics-based studies on other vascular 
endothelial cell types (Table 3.2). Twenty-two proteins with a relatively wide range of 
functions were randomly selected from our protein list and compared to lists of identified 
proteins in rat coronary microvascular endothelial cells (Lu L et al., 2007), rat brain 
microvascular endothelial cells (Lu L et al., 2007), human coronary artery endothelial cells 
(Yu et al., 2004), and rat aortic endothelial cells (Almofti et al., 2006). Approximately 50 % of 
the selected proteins in our study were also identified and reported in the rat coronary 
microvascular endothelial cell and rat brain microvascular endothelial cell study (Lu L et al., 
2007), suggesting a significant similarity in the protein expression between the CMECs and 
the other two microvascular endothelial cell types.  Of the selected proteins in our study, 
~23 % was identified and reported in a study on human coronary arterial endothelial cells 
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(Yu et al., 2004), and ~ 41 % in a study performed on rat aortic endothelial cells (Almofti et 
al., 2006).  
In order to gain a better understanding of how the 1387 identified proteins are functionally 
linked, the protein list was submitted to the functional annotation tool of DAVID 
Bioinformatics System (Huang DW and Lempicki, 2009). The cytosolic component (GO term: 
0005829) represented the highest % protein count (28.4 %; p-value: 2.6 x 10-58; 3.2 fold 
enrichment), whereas 9.4 % of the total identified proteins was associated with the 
membrane component (GO term: 0005624; p-value: 3.6 x 10-5; 1.6 fold enrichment), which 
is higher than previously reported in brain microvascular endothelial cells (5 %) (Pottiez et 
al., 2010), but lower than in corneal endothelial cells (~28 %) (Dyrlund et al.,2012).  
One of the outstanding features of the cellular component analysis was the high 
representation of mitochondrial cellular component proteins (GO term: 0005739; 23.3 % 
protein count; p-value = 2.1 x 10-28; 2.3 fold enrichment) in our cells. We were unable to 
find any other endothelial-based study reporting anything similar. In fact, our findings 
closely resembled the % mitochondrial protein count in muscle cells as previously shown in 
human skeletal muscle cells (~22 %) (Hojlund et al.,2008). The highly enriched mitochondrial 
protein component is remarkable in view of the fact that mitochondrial proteins on average 
make up only 5 % - 10 % of total cellular proteins (Hojlund et al., 2008; Rabilloud, 2008) and 
that endothelial mitochondria comprise 5 %, 10 % and 11 % of the total endothelial cell 
volume in the liver (Blouin et al., 1977), rat aortic endothelial cells (Ungvari et al., 2008), and 
metabolically active blood-brain barrier endothelial cells (Kluge et al., 2013) respectively. 
When we applied functional annotation cluster analysis (Figure 3.5), the mitochondrial 
membrane and mitochondrial inner membrane proteins collectively represent the third 
most enriched cluster in the CMECs (enrichment score: 15.5). These findings suggest that 
the CMECs seem to be quite distinct with regards their mitochondrial abundance compared 
to other endothelial cell types. A representative fluorescence microphotograph of 
MitotrackerTM -stained cells, demonstrating mitochondrial abundance in the CMECs is 
shown in Figure 3.8. 
 
Stellenbosch University  http://scholar.sun.ac.za







Figure 3.8: Mitochondrial abundance (structures stained bright red) in CMECs stained 
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Interestingly, the highly enriched mitochondrial cellular component cluster was not 
matched by classical ATP-generating mitochondrial processes and functions such as the 
tricarboxylic acid cycle (TCA cycle; cluster no. 12; enrichment score 6.7; not shown), fatty 
acid oxidation (cluster no. 47; enrichment score: 2.1; not shown) and ATP synthesis coupled 
proton transport (cluster no. 51; enrichment score: 2.0; not shown). The relatively low 
representation of these energy generating mitochondrial functions may be due to the fact 
that endothelial mitochondria are generally not regarded as the primary source of cellular 
ATP, rather they are thought to act as sensors in cellular signalling responses, sensors of 
local oxygen levels, sources of NO and ROS, and regulators of Ca2+ homeostasis (Kluge et al., 
2013; Davidson and Duchen, 2007). In fact, glycolytic metabolism has previously been 
shown to be the predominant source of endothelial cellular energy, supplying between 75 % 
and 99 % of endothelial ATP in aortic and coronary microvascular endothelial cells 
respectively (Davidson and Duchen, 2007; Culic et al., 1997; Spahr et al., 1989; Mertens et 
al., 1990). These reports are supported by our own annotation cluster data. The clusters 
containing glycolytic processes such as carbohydrate catabolism, glucose catabolism and 
hexose catabolism (cluster no. 4; enrichment score: 15.1; Figure 3.5), and glucose 
metabolism, monosaccharide metabolism and hexose metabolism (cluster no. 8; 
enrichment score: 10.8; Figure 3.5) were significantly more enriched than mitochondrial 
energy metabolism processes.  
Vesicles and related cellular component GO terms occupied the 6th most enriched 
functional annotation cluster in the CMECs (enrichment score: 11.9; Figure 3.5), and 
proteins associated with vesicles (GO term: 0031982) represented 11.6 % of the total 
identified proteins (p-value: 3.7 x 10-13; fold enrichment: 2.3). Furthermore, the biological 
process of vesicle-mediated transport achieved a 7.5 % protein count (GO term: 0016192; p-
value: 2.6 x 10-9; fold enrichment: 2.4), similar to previous observations in neurons (~7.5 % 
protein count and fold enrichment: 3) (Estrada-Bernal et al., 2012). The high degree of 
enrichment associated with vesicles and vesicular transport in our cells is not unexpected, as 
CMECs are known to express a greater abundance of vesicles than other cardiac endothelial 
types (Brutsaert, 2003; Aird, 2007a). In addition to vesicles, capillary endothelial cells 
express high concentrations of caveolae (Benyadan, 2002; Aird, 2007), which facilitates the 
process of vesicle-mediated transcytosis via vesiculo-vacualor organelles (VVOs) (Benyadan, 
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2002). Cardiac capillary endothelial cells are particularly enriched with VVOs. Indeed, our 
own analyses showed that both vacuoles (GO term: 0005773; protein count: 2.7 %; p-value: 
0.03; fold enrichment: 1.7) and caveolae (GO term: 0005901; protein count: 1.2 %; p-value: 
0.02; fold enrichment: 2.7) featured as enriched cellular components in the CMECs.  
The functional annotation cluster comprising the Ras superfamily of small GTPases also 
featured prominently in the CMEC proteome (cluster no. 9; enrichment score: 9.7; Figure 
3.5). More than 25 proteins belonging to the Ras superfamily were identified, including 
members of the Ras, Rho and Rab subfamilies. Rab GTPases are primarily involved with the 
regulation of vesicular transport (Wennerberg et al., 2005), and it came as no surprise that 
Rab proteins were particularly well represented in the CMECs (18 Rab proteins were 
identified out of 61 known Rab proteins (Wennerberg et al., 2005). The Rho GTPases are 
known to regulate cell adhesion and microvascular permeability (Spindler et al., 2010), and 
our cells expressed prominent Rho subfamily proteins, including Rac2, Cdc42, RhoC and 
RhoG, as well as several proteins associated with Rho-signalling (e.g. Rho-associated protein 
kinase 2, Rho GTPase-activating protein and Rho GDP-dissociation inhibitor). 
In addition to the above, the full range of cellular protein metabolism, from translation, 
protein transport and localization to protein breakdown by proteasomal processes was well 
represented in the baseline CMEC proteome (See Figure 3.6). 
 
3.6.3 The effect of various harmful stimuli on the NO production of CMECs (FACS 
analysis). 
In a series of initial pilot studies to characterise the CMECs with regards to their response to 
a variety of harmful stimuli, we exposed the cells to angiotensin II, high glucose 
concentrations, hypoxia, oxidised LDL, ADMA and TNF-α, and measured the response in 
terms of intracellular NO-production. These are all factors that have previously been shown 
to reduce endothelial NO bio-availability and hence induce endothelial dysfunction. In view 
of this, we assessed the CMEC responses to 24 h treatment with the stimuli by the 
measurement of intracellular NO-production. 
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3.6.3.1 Angiotensin II (100 nM for 24 hours): 
Elevated angiotensin II levels have been observed in patients with atherosclerotic risk 
factors, including hypertension, diabetes, and renal dysfunction (Cai et al., 2003, Harrison 
DG et al., 2003a). It has also been shown to mediate endothelial dysfunction and promote 
vascular inflammation and atherogenesis (Harrison DG et al., 2003b; Arruda et al., 2005; 
Kunieda et al., 2006).   
According to a study by Hill-Kapturczak et al., (1999), addition of physiological 
concentrations of angiotensin II (10-8 M) caused a rapid release of NO from porcine 
pulmonary artery endothelial cells (PPAEs).  This angiotensin II-stimulated NO release from 
PPAE cells required extracellular L-arginine and was inhibited by L-nitro-arginine methyl 
ester. In another study, the same cell line as above was treated with 100nM of angiotensin II 
for 1 minute, 15 minutes and 8 hours (Li JM et al., 2007a).  They showed an increase in 
MAPK activation, which led to an angiotensin receptor type 2-dependant increase in eNOS 
expression in PAECs.   In a study by Saito et al. (1996), cultured bovine endothelial cells were 
treated with 10-7 M angiotensin II and this led to an increase in NOx production.  Lastly, 
another study also reported an increase in NO in a microvascular endothelial cell type, thus 
supporting our findings (Bayraktutan and Ülker, 2003).  They treated rat coronary 
microvascular endothelial cells (rCMECs) with different dosages of angiotensin II (1 – 
10μmol/l) and found an enhancement in NO release.  All the above studies support our 
finding of increased NO in CMECs after 24 hour treatment with angiotensin II (see figure 
3.7).  
In contrast to the above mentioned studies, another study found that treatment of BAECs 
with angiotensin II (200nM) treatment  was associated with increased cellular O2- 
production and decreased endothelial NO bio-availability (Doughan et al., 2008).    Also, 
Chapulsky and Cai (2005) found in BAECs that endothelial NADPH-oxidase-derived H2O2 
down-regulates dihydrofolate reductase (DHFR) expression in response to angiotensin II, 
resulting in tetrahydrobiopterinn (H4B) deficiency and uncoupling of eNOS.  Lastly, a study 
by Desideri et al. (2003) showed that angiotensin II increased NADPH-oxidase activity in 
HUVECs, promoted ROS generation, reduced NOS activity, increased NO breakdown and 
consequently impaired NO availability in these cells. 
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From the above discussion, we speculate that the decrease in NO that was found in some of 
the studies, was possibly due to an overproduction of O2- , which would lead to it binding to 
available NO (forming OONO-).  Any excess NO that is produced is thus being “mopped” up 
by the large amounts of O2- produced under these circumstances in the cells (Pacher et al., 
2007).   
In our hands, in vitro treatment with angiotensin II also led to an increase in NO production.  
This might be explained by the activation of the angiotensin receptor type 2 (ATR2), which 
could lead to activation and phosphorylation of the PI3K - PKB/Akt signalling pathway 
(Herrera MD and Garvin, 2010a), which is the opposite of the NO deacreasing effect of 
angiotensin receptor type (ATR1) stimulation (Desideri et al., 2003).  PKB/Akt can then in 
turn phosphorylate eNOS at Ser1177 and subsequently lead to an increased production in 
NO (Herrera MD and Garvin, 2010a). Further exploration of the mechanisms underlying the 
increased NO production did not fall within the scope of the pilot studies. 
 
3.6.3.2 In vitro simulation with hyperglycaemia: Glucose (25 mM for 24 hours): 
Hyperglycaemia is one of the main characteristic features of type 1 and 2 diabetes and plays 
a pivotal role in diabetes-associated microvascular complications. Although hyperglycaemia 
also contributes to the occurrence and progression of macrovascular disease, other factors 
such as dyslipidaemia, hyperinsulinaemia, and adipose-tissue-derived factors play a more 
dominant role. A mutual interaction between these factors and endothelial dysfunction 
occurs during the progression of the disease (Bakker et al., 2009). 
Our finding that high glucose levels (25 mM) resulted in increased NO production after 24 
hours (see figure 3.7), was supported by a previous study on human aortic endothelial cells 
(HAECs) in which exposure to high glucose increased eNOS gene and protein expression, and 
NO release (Cosentino et al., 1997). This was also shown in cultured retinal endothelial cells, 
where treatment with high glucose (25 mM), lead to an increase in expression and activity 
of eNOS compared to normal glucose (5 mM) treated cells (El-Remessy et al., 2003).  A study 
by Sobrevia et al. (1996) showed that exposure to elevated glucose was associated with a 
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selective stimulation of L-arginine transport (system y+), which was paralleled by an increase 
in basal release of NO. 
In contrast to these findings, other groups demonstrated reduced basal NO production in 
response to high glucose, with a concomitant reduction in eNOS expression in human 
coronary artery endothelial cells (HAECs) and bovine aortic endothelial cells (BAECs) (Ding et 
al., 2000; Du et al., 2001). In a study by Salt et al. (2003) it was demonstrated that insulin-
stimulated NO production was abolished in HAECs cultured in 25 mmol / l glucose and they 
hypothesized that this inhibition of insulin-stimulated NO production was a consequence of 
reduced expression or activity of insulin signalling proteins.  
The increase in NO that was observed in our experiments might be explained by either the 
selective stimulation of L-arginine transport as in one of the above supporting studies 
(Sobrevia et al., 1996) or an upregulation of eNOS (Cosentino et al., 1997; El-Remessy et al., 
2003).  Chronic exposure to high levels of glucose is also associated with a marked increase 
of O2− production and will lead to an imbalance between NO and O2− (Ding et al., 2000) and 
while the levels of NO produced outweighs the levels of O2- produced (as might be the case 
in our study), NO production will not be negatively affected.  However increased NO 
production in aorta endothelial cells reported by Cosentino et al. (1997), for example, was 
coupled with an even greater increase in generation of O2- when the exposure to high 
glucose levels was prolonged, which eventually led to the inactivation of NO. Further 
exploration of the underlying mechanisms did not fall within the scope of the initial pilot 
studies. 
 
3.6.3.3  Hypoxia (O2 < 0.6 %) 
The response of the CMECs to hypoxia is addressed in detail in the next chapter. 
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3.6.3.4 Oxidised-LDL (40 µg / ml for 24 hours): 
As mentioned before, atherosclerosis is the accumulation of cholesterol and other lipids in 
the artery and numerous studies have demonstrated that ox-LDL causes endothelial 
dysfunction and accelerates atherosclerosis (Wong WT et al., 2011).  Ox-LDL stimulates 
endothelium to secrete MCP-1, which induces filtration and entrapment of ox-LDL into the 
sub-endothelial space, leading to differentiation of monocytes into “foam” macrophage 
(Tabata et al., 2003).  Ox-LDL is also capable of inducing proliferation and migration of 
vascular smooth muscle cells by increasing the expression of platelet-derived growth factor 
(Taguchi et al., 2000).  Ox-LDL may enhance the pro-coagulant activity of endothelium, 
which may easily lead to thrombosis and finally atherosclerosis (Ann and Paul, 2001).  Lastly, 
another possible effect is that ox-LDL activates G1 protein-coupled scavenger receptors, 
which will in turn deactivate the l-arginine pathway and reduce the activity of NO synthase 
(Tanner et al., 1991). 
Functionally, the vascular release of NO is abnormal in the setting of hypercholesterolaemia 
(Jin RC and Loscalzo, 2010).  The mechanisms underlying this abnormality are likely 
multifactorial (Ramasamy et al., 1998).  Studies of vessels from animals with short-term 
hypercholesterolaemia showed that endothelial production of NO was not suppressed, but 
paradoxically increased (Minor et al., 1990).  It has also been shown that oxidized LDL can 
increase eNOS mRNA levels in low concentrations and decrease the eNOS expression at high 
concentrations (Hirata et al., 1995).  In the latter study, bovine aortic endothelial cells 
(BAECs) were treated for up to 24 hours with ox-LDL at low concentrations (10 µg / ml) and 
high concentrations (100 µg / ml).  Some researchers proposed that lysophosphatidyl 
choline (LPC) in ox-LDL can increase eNOS expression in endothelial cells in a dose-
dependent fashion (Minor et al., 1990; Zembowicz et al., 1995).  Another important 
component of ox-LDL is 13-HPODE (13-hydroperoxyoctadecadienoate) (Jiang X et al., 2012).  
The major polyunsaturated fatty acid present in LDL is linoleic acid which is converted to 
oxidized linoleic acid during the atherosclerotic process (Egert et al., 2009).  13-HPODE has 
potent biological effects that include the induction of interleukin-1 and VCAM-1 expression 
(Qin et al., 2013).  Minor et al. (1990) hypothesized that HPODE is a candidate molecule 
which might mediate the effect of oxidized LDL on increased NO production. One of the 
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mechanisms by which HPODE might increase nitric oxide production is by up-regulating the 
eNOS gene expression in atherosclerotic vessels (Minor et al., 1990). 
In contrast to the up-regulation of eNOS-NO biosynthesis found in the above mentioned 
studies, Liao JK et al., (1995) reported that oxidized-LDL (0 – 100 μg / ml) caused a time- and 
concentration-dependent decrease in steady-state eNOS mRNA and enzyme activity in 
human endothelial cells.  This downregulation was found to occur principally at the 
posttranscriptional level, resulting in a reduction in eNOS mRNA half-life from 36 to 10 
hours.  Very high levels of native LDL were found to decrease eNOS mRNA expression (Vidal 
et al., 1998).  Other previous studies also showed that ox-LDL impairs the release of NO 
from endothelial cells (Chin et al., 1992; Kugiyama et al., 1990).  Ox-LDL promotes the 
recruitment of inflammatory cells to the vessel wall, which may increase local production of 
ROS leading to the inactivation of NO (Granger D et al., 2010a).  There is evidence that ox-
LDL and products of lipid peroxidation can react with NO directly and eliminate its biological 
activity (Chin et al., 1992; O’Donnell et al., 1999). Ox-LDL was also shown to decrease eNOS 
protein levels in endothelial cells (Liao JK et al., 1995), thus potentially decreasing 
production of NO. Finally, products of lipid peroxidation, including lysophosphatidylcholine, 
may interfere with signal transduction and receptor-dependent stimulation of NOS activity 
(Kugiyama et al., 1990; Keaney et al., 1996) and with activation of guanylyl cyclase (Schmidt 
K et al., 1992). 
Finally, in a study by Grafë et al. (1998), cardiac microvascular and macrovascular ECs were 
isolated from human hearts and treated with ox-LDL to show that these cell types respond 
differently to ox-LDL.  Briefly, they speculate that the preferential localization of 
atherosclerotic lesions in the macrovasculature may in part be due to a higher susceptibility 
of macrovascular (than microvascular) endothelial cells to ox-LDL. The relatively reduced 
susceptibility of microvascular endothelial cells to the NO-lowering effects of ox-LDL could 
be a further explanation for our observations. 
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3.6.3.5 ADMA (500 µM for 24 hours): 
As mentioned above, ADMA is an endogenous inhibitor of NOS produced by endothelial 
cells (Anderssohn et al., 2010). ADMA has been associated with impaired endothelial 
function in humans (Juonala et al., 2007), and clinical evidence suggests that serum ADMA 
may be a novel cardiovascular risk factor (Maas et al., 2007; Schnabel et al., 2005).  
A recent study assessed the effects of ADMA treatment (0 – 500 µM) on HUVECs and it was 
shown that ADMA treatment up to 10 µM had no effects on nitrite and nitrate levels. 
However, above this concentration, nitrite and nitrite/nitrate accumulation was significantly 
decreased by ADMA (Mohan and Fung, 2012).  In another study, it was suggested that 
ADMA increases oxidative stress by uncoupling of NOS (Pritchard et al., 1995). In this 
situation optimal electron flow within the two catalytic domains of NOS is impaired and 
molecular oxygen becomes the sole electron acceptor and NOS generates O2- radicals 
(Pritchard et al., 1995).  Böger et al. (2000a, b) showed that ADMA concentration 
dependently increases O2- production by cultured human endothelial cells.  In another study 
the same group presented data where the inhibition of NOS by ADMA decreases NO 
production in HUVECs (Bode-Böger et al., 2005).  All the above studies support the 
significant decrease in intracellular NO levels observed in the CMECs after 24 hours of 
treatment with ADMA (500 µM), which is to be expected given the fact that ADMA inhibits 
NO production (see figure 3.7).   
 
3.6.3.6 TNF-α (5 ng / ml and 20 ng / ml for 24 hours): 
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3.7  Conclusion 
In this chapter, we supplied a characterisation of adult rat CMECs under baseline conditions. 
Apart from the morphological and fluorescence-labeled validation of cell purity, we 
demonstrated that the CMECs express an array of signalling proteins essential in the NOS-
NO biosynthesis pathway. Additionally, we also showed that iNOS, and interestingly, nNOS 
were expressed, indicating that these cells express the full battery of the principal NOS 
isoforms. The western blotting measurements of some selected proteins related to the 
generation of NO were important for the purposes of this study, as changes in the NOS-NO 
biosynthesis pathway would form an integral end-point for the rest of our investigations.  
The most novel aspect of this chapter was the comprehensive characterisation of the 
baseline CMEC proteome. We are only aware of one study in the literature that partially 
reported on the baseline proteome of CMECs, in which 22 proteins were positively 
identified. All in all, 1387 proteins were identified in our CMECs. Therefore, to our 
knowledge, this study is the most extensive documentation of any mammalian CMEC 
proteome to date and represents a novel addition to existing vascular proteomic databases.  
An outstanding feature of the baseline CMEC proteome was the surprisingly high 
enrichment of mitochondrial proteins, mainly those denoted as cellular component 
proteins. There is no evidence in the literature of previous studies reporting on similar 
observations in any other vascular endothelial cell type. The uniquely high abundance of 
mitochondrial proteins observed in our CMECs (protein count as % of total proteins: ~ 23%) 
may point to a distinct role for their mitochondria, which was apparently not related to ATP 
synthesis under baseline conditions. CMECs participate in an important functional and 
regulatory cross-talk with cardiomyocytes, and given the frequent exposure of the 
myocardial capillary endothelium to varying degrees of oxygen tension, it is possible that 
the mitochondria of CMECs have a particularly important role as the oxygen sensors of the 
myocardium. Such an essential function would conceivably require high numbers of 
mitochondria.  The high enrichment of vesicle proteins in my view serves as confirmation of 
the role of CMECs in capillary transcytosis.  The high enrichment of RAS signalling proteins 
(25 Ras GTPase proteins, and 18 Rab proteins), most likely supplies support for the 
involvement of vesicular transport and finally, the high enrichment of glycolitic proteins, 
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confirms previous observations in other endothelial cell types that glycolysis is the main 
energy source in these cell types.   
In the final section of this chapter, we show the results of some of my very initial pilot 
studies in which we evaluated the CMECs with regard to their response to various harmful 
stimuli commonly associated with cardiovascular risk factors and disease states.  By 
subjecting these cells to the various stimuli as listed in figure 3.7 and assessing intracellular 
NO production as an endpoint, we were given a very basic “snapshot” of CMEC responses to 
24 hour exposure to these stimuli. Interestingly, almost all of the stimuli seemed to have an 
increasing effect on the NO production of these cells (except for ADMA and TNF-α at 20 ng / 
ml).  Initially we expected that these substances would reduce the NO bio-availability and 
therefore assist in providing us with an in vitro model for endothelial dysfunction. However, 
as will become evident in later chapters, endothelial cell injury and responses suggestive of 
dysfunction are not necessarily marked by reduced NO production, at least not within the 
time-frames of our in vitro experiments.  Although various other pilot studies (many of them 
not included) were conducted in order to assist me in selecting the harmful stimuli on which 
we would focus in the rest of this dissertation, the initial NO-production investigations were 
a good starting point, and helped us to optimise the fluorescent probe – FACS analysis 
technique in the CMECs. 
After some contemplation, we decided to focus on hypoxia and TNF-α treatment as the 
injury-inducing models of choice. These will be described in detail in the following chapters. 
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Characterization and investigation of hypoxia-induced responses in CMECs 
 
4.1  Introduction  
The metabolic and molecular changes in response to hypoxia have been extensively 
investigated and reviewed and have largely contributed towards the knowledge of the 
pathophysiological events in organs subjected to hypoxia, including the heart (Michiels et 
al., 2000).  As discussed in detail in chapter one (page 60), endothelial cells (ECs) are, due to 
their location, frequently exposed to variations in oxygen tension (Michiels et al., 2000).  It 
has been shown that hypoxic conditions indeed have profound effects on endothelial 
function (Tang N et al., 2004; Deanfield et al., 2007).   
Previous studies have shown that exposure to chronic intermittent hypoxia impairs 
endothelium-dependent vasodilation in the skeletal muscle and cerebral circulations 
(Phillips et al., 2004; Tahawi et al., 2001). These studies strongly suggested that a vascular 
decrease in NO bio-availability (Phillips et al., 2004; Tahawi et al., 2001) and increased O2- 
levels (Phillips et al., 2006; Troncoso Brindeiro et al., 2007) were possible underlying factors. 
As mentioned before, a decrease in NO bio-availability is considered to be the hallmark of 
ED (Imrie et al., 2010).  The decrease in NO bio-availability observed in many previous 
endothelial cell-based studies could be due to a few processes, such as an increase in 
scavenging of NO by O2- (Marcus et al., 2012).  Hypoxia may influence NO production, NO 
tissue concentration, and NOS expression in variable manners by several mechanisms 
(Manukhina et al., 2006).  These mechanisms include:  (i) limitation of NO production due to 
reduced O2 levels (O2 is an essential requirement for NOS-mediated conversion of l-arginine 
to NO); (ii) effect of O2 on NOS feedback inhibition; (iii) modulation of NO bio-availability; 
(iv) induction of HIF-1 and other NOS transcription factors; (v) changes in intracellular Ca2+ 
concentration and Ca2+ influx; and (vi) induction of NOS-regulating heat shock proteins.  
Exposure to hypoxia can indeed lead to a decrease in NO production by all three NOS 
isoforms (Weigand et al., 2011).   
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The response to hypoxia also involves altered expression of NOS genes (Manukhina et al., 
2006). Some studies have demonstrated hypoxic down-regulation of eNOS expression in 
pulmonary endothelial cells (Girgis et al., 2003). Others showed that hypoxia reduced eNOS 
mRNA and/or protein in pulmonary artery endothelial cells (Morrell et al., 2009). In another 
endothelial cell study investigating the effects of 24 hours hypoxia, it was found that the 
transcription of eNOS in HUVECs exposed to hypoxia (< 1% O2) was significantly repressed 
(Fish et al; 2010).  Conversely, previous studies from our own group demonstrated 
significant increases in the expression of eNOS in hypoxic CMECs, which was accompanied 
by increased NO-production (Strijdom et al; 2006). In the same study by Strijdom et al. 
(2006), it was further shown that iNOS-specific inhibition did not alter hypoxia-induced NO-
production, thereby excluding increased iNOS activity as a possible source of NO. From the 
above it is clear that the available data on hypoxia-induced changes in endothelial cells are 
not always consistent, particularly with regard to NOS-NO biosynthesis. In view of this, we 
aimed in this chapter to comprehensively characterise the CMECs and their responses to 
hypoxia. 
For the purposes of this chapter, we aimed to establish a hypoxic protocol that could induce 
significant, but not lethal injury in the CMECs.  One of the novel aspects of this chapter were 
the proteomic analysis studies, in order to explore global protein expression and differential 
protein regulation patterns. A careful review of the literature has revealed that there is no 
evidence of studies in which large-scale differential protein regulation in hypoxic CMECs has 
been investigated. This is an important gap that has to be addressed in order to fully 
understand how this distinct endothelial cell subtype responds to hypoxia on subcellular, 
molecular level. Overall, it is evident from the literature that the relatively few studies have 
investigated CMECs in the context of hypoxia, which is a gap that we have attempted to fill 
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4.2  Methods  
CMECs were cultured and grown as described previously (page 111).  The first part of this 
chapter describes the establishment and validation of the hypoxia protocol.  The CMECs 
were exposed to a 6, 18 and 24 hours hypoxia by lowering the atmospheric O2 (0.6 % O2, 5 
% CO2, balance: N2, 40-60 % humidity, incubation temperature: 37 °C) in a multi-gas tissue 
culture incubator (Sanyo Biomedical, Japan).  After conducting pilot studies, we found that 
at 1 % O2 there was no change in cell viability (as measured by PI and Annexin V) compared 
to normoxic samples (data not shown).  We therefore set the O2 at 0.6 % (which was the 
lowest O2 concentration achievable with the incubator) and found that this concentration 
succeeded in inducing a significant reduction in cell viability; hence, the rest of the 
investigations were performed at 0.6 % O2.  Control, normoxic CMECs were incubated under 
standard atmospheric conditions for 6, 18 and 24 hours (21 % O2, 5 % CO2, 40-60 % 
humidity, incubation temperature: 37 °C) (see figure 4.1 for hypoxia protocol). Validation of 
hypoxia-induced reduction in cell viability was performed by flow cytometric analysis of the 
% propidium iodide-staining (necrosis) and annexin-V-staining (apoptosis) cells using a 
commercially available kit (Alexa Fluor® 647 Annexin V conjugate / propidium iodide; 
BioLegend, San Diego, CA, USA) as described in chapter 2. We also validated the induction of 
a hypoxic state by performing western blot analysis of HIF-1α expression (an important 
protein marker of hypoxia) in CMECs exposed to 24 hours of hypoxia. 
In the second part of the study, we explored the NO-synthesis response of the CMECs to 24 
hours of hypoxia by investigating the eNOS-NO biosynthesis pathway. This was achieved by 
measuring the expression of eNOS protein by western blotting and intracellular NO 
production with DAF-2/DA (as described in chapter 2, page 121).  Furthermore, we were 
interested in whether oxidative stress was induced in the hypoxic CMECs. In this regard, we 
investigated whether the hypoxia protocol (24 hours) resulted in an increase in ROS 
generation. We chose to measure ROS production by FACS analysis of dihydrorhodamine-
123 (DHR-123; Sigma Chemical Co, St Louis, MO, USA) mean fluorescence intensity. The 
DHR-123 fluorophore has previously been shown to localise in mitochondria and fluoresce 
when oxidized (Tiede et al., 2011), and could therefore be an indicator of mitochondrial ROS 
formation. However, we and others have demonstrated that DHR-123 was also sensitive for 
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peroxynitrite (ONOO-) (Strijdom et al., 2009c; Navarro-Antolin et al., 2001). Furthermore, 
we were interested to establish whether hypoxia had any regulatory effects on the activity 
of the superoxide producing NADPH-oxidase enzyme by measuring the expression of p22 
phox (a surrogate marker of NADPH-oxidase activity) with western blotting.  In the final set 
of investigations in this part of the chapter, we determined whether the 24 hours hypoxia 
protocol induced nitrosative stress by measuring the expression of nitrotryosine. 
In the third part of the chapter, the CMEC proteome was comprehensively investigated in 
terms of large-scale protein expression and differential regulation patterns after subjecting 
CMECs to a 24 hour hypoxia protocol as described above. Preparation of samples for 
proteomics analysis was performed by the filter-aided sample preparation (FASP) technique 
followed by in-solution trypsinisation (described in detail in chapter 2, page 138). A total of 
3 samples were prepared for normoxic and hypoxic groups respectively.  See figure 4.2 for 
an overview of the workflow followed for proteomic analyses of hypoxic CMECs. Data 
analysis (including functional annotation analyses of proteins) of proteomics results, were 
performed as described in chapter 2 (page 141). Where indicated, differential protein 
regulation between control, normoxic and hypoxic samples was analysed by the Maxquant 
proteomics software package, and proteins were only considered differentially regulated 
with a protein and peptide PEP of 0.01, up or down regulation of ≥ 1.5-fold and a p-value of 
p < 0.05. 
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Figure 4.1: The hypoxia protocol.  Cells were incubated at either 0.6 % O2 (hypoxic samples) or at 21 % O2 (control, normoxic samples) for 6, 
18 and 24 hours respectively.  The 6 and 18 hour timepoints were only used to investigate cell viability, and all other investigations were based 
on samples exposed to 24 hour hypoxia. 
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Figure 4.2: Workflow for proteomic analyses of CMECs under hypoxic conditions. The 
proteins were trypsinized on the FASP membrane and then extracted and prepared for LC-
MS/MS. All MS/MS spectra were searched using Thermo Proteome Discoverer software 
(version 1.3) against in-house versions of Mascot, Sequest, X!tandem and Andromeda. For 
final data analyses, the identified proteins from all the search engines were combined to 
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4.3  Results 
 
4.3.1  Validation of the hypoxia protocol. 
CMECs exposed to hypoxia (O2 < 0.6 %), showed a decrease at 6 hours (56.01 ± 5.40 % vs. 
100 % control: p < 0.05), no change at 18 hours (109.25 ± 2.85 % vs. 100 % control: p < 0.05) 
and an increase at 24 hours (190.33 ± 5.25 % vs. 100 % control: p < 0.05) in the % propidium 
iodide (PI) staining cells (measuring necrosis) (see figure 4.3), compared to normoxic 
controls.  CMECs exposed to hypoxia (O2 < 0.6 %), showed a decrease at 6 hours (46.05 ± 
1.55 % vs. 100 % control: p < 0.05), an increase at 18 (174.59 ± 8.06 % vs. 100 % control: p < 
0.05) as well as 24 hours (370.16 ± 5.97 % vs. 100 % control: p < 0.05) in the % Annexin V 
staining cells (measuring apoptosis) (see figure 4.4), compared to normoxic controls.  In 
view of these pilot time-response studies, we continued with the 24 hour protocol for all 
subsequent investigations. In order to contextualise the necrosis and apoptosis results of 
the CMECs, we conducted separate experiments to compare the necrotic and apoptotic 
responses of the CMECs to those observed in another cardiac-derived cell line (H9C2 
myoblasts).  Results showed an increase in necrosis in hypoxic CMECs (162.34 ± 30.09 % vs. 
100 % control: p < 0.05) as well as in the H9C2 myoblasts (228.99 ± 9.19 % vs. 100 % control: 
p < 0.05) compared to control CMECs (see figure 4.5).  Results also showed an increase in 
apoptosis in hypoxic CMECs (219.41 ± 31.75 % vs. 100 % control: p < 0.05) as well as in 
hypoxic H9C2 myoblasts (601.79 ± 45.39 % vs. 100 % control: p < 0.05) compared to 
controls.  The necrosis observed in the H9C2 myoblasts was significantly more than in the 
CMECs (219.41 ± 31.75 % vs. 601.79 ± 45.39 %: p < 0.05) (see figure 4.6).  Exposing CMECs to 
24 hours of hypoxia led to a significant increase (1.33 ± 0.07 vs. 1.00 control: p < 0.05) (see 
figure 4.7) in the expression of HIF-1 α, compared to normoxic controls. The demonstration 
of HIF-1α stabilisation (i.e. increased expression) is a critical molecular validating marker of 
hypoxia, in addition to the fluorescence-based markers (PI and Annexin-V) described earlier 
with regard to necrosis and apoptosis. 
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Figure 4.3: Hypoxia time-response studies with necrosis expressed as % PI staining cells 
(expressed as a percentage of control; control = 100%).  Sample size:  n = 4 - 6 / group. 
 
Figure 4.4: Hypoxia time-response studies with apoptosis expressed as % Annexin V 
staining cells (expressed as a percentage of control; control = 100%).  Sample size:  n = 4 – 6 
/ group.     
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Figure 4.5: Necrosis in hypoxic CMECs compared to hypoxic H9C2 myoblasts at 24 hours 
with necrosis expressed as % PI staining cells (expressed as a percentage of control; control 
= 100%).  Sample size:  n = 10 - 14 / group. 
 
Figure 4.6: Apoptosis in hypoxic CMECs compared to hypoxic H9C2 myoblasts at 24 
hours with apoptosis expressed as % Annexin V staining cells (expressed as a percentage of 
control; control = 100%).  Sample size:  n = 10 - 14 / group. 
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Figure 4.7: HIF-1 α expression in hypoxic CMECs. Representative western blot of CMECs 
exposed to 24h hypoxia shows a significant increase in HIF-1 α expression compared to 
normoxic control, serving as a final validation of our hypoxia-inducing protocol.  ß-tubulin 
was used to validate equal protein loading.  All data were expressed as a ratio of control 
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4.3.2  eNOS-NO biosynthesis; oxidative stress; nitrosative stress: 
Exposing CMECs to 24 hours of hypoxia led to a significant increase (1.79 ± 0.03 vs. 1.00 
control: p < 0.05) (see figure 4.8) in the expression of eNOS, compared to normoxic controls. 
The hypoxia-induced up-regulation of eNOS expression was accompanied by an increase in 
mean DAF-2/DA mean fluorescence intensity (144.26 ± 11.78 % vs. 100 % control: p < 0.05) 
(see figure 4.9).  CMECs exposed to hypoxia showed an increase in mean DHR-123 
fluorescence intensity (129.88 ± 3.23 % vs. 100 % control: p < 0.05) (see figure 4.10). 
Exposing CMECs to 24 hours of hypoxia led to a significant decrease (0.55 ± 0.05 vs. 1.00 
control: p < 0.05) (see figure 4.11) in the expression of p22 phox, compared to normoxic 
controls. Exposing CMECs to 24 hours of hypoxia led to a significant increase (1.52 ± 0.08 vs. 
1.00 control: p < 0.05) (see figure 4.12) in the expression of nitrotyrosine, compared to 












Stellenbosch University  http://scholar.sun.ac.za






Figure 4.8:  Total eNOS expression in hypoxic CMECs. Representative western blot 
of CMECs exposed to 24h hypoxia shows a significant increase in eNOS expression 
compared to normoxic control. ß-tubulin was used to validate equal protein loading.  All 
data were expressed as a ratio of control with control adjusted to 1 (please refer to page 
134, chapter 2). Sample size:  n = 4 / group. 
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Figure 4.9: Hypoxia-induced (24 hours hypoxia) increase in NO production measured as 
mean 4,5-diaminofluorescein-2/diacetate (DAF-2/DA) fluorescence intensity expressed as 
percentage of control. Diethylamine NONOate diethylammonium salt (DEA/NO; 100 µM) 
was used as positive control (see figure 2.7, page 122 for DEA/NO protocol). Sample size:  n 
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Figure 4.10: Hypoxia-induced cell injury (24 hours hypoxia) demonstrated by increased 
oxidative stress measured as % dihydrorhodamine-123 (DHR-123) mean fluorescence 
intensity of control. Authentic peroxynitrite (ONOO-) was used as positive control (see figure 
2.11, page 128 for ONOO- protocol).  Sample size:  n = 4 - 11 / group. 
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Figure 4.11:  P22 phox expression in hypoxic CMECs. Representative western blot 
of CMECs exposed to 24h hypoxia shows a significant decrease in p22 phox expression 
compared to normoxic control.  All data were expressed as a ratio of control with control 
adjusted to 1 (please refer to page 134, chapter 2).  Sample size:  n = 4 / group. 
Note:  due to unforeseen circumstances at the time of this set of western blot analysis, we 
were unable to perform β-tubulin expression; however, the original Bradford protein 
determinations were used as confirmation of equal protein content in each sample.  
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Figure 4.12:  Nitrotyrosine expression in hypoxic CMECs. Representative western 
blot of CMECs exposed to 24h hypoxia shows a significant increase in nitrotyrosine 
expression compared to normoxic control. ß-tubulin was used to validate equal protein 
loading.  All data were expressed as a ratio of control with control adjusted to 1 (please 
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4.3.3  Proteomic analyses 
Proteomic analysis by Maxquant software revealed that there were 67 proteins uniquely 
identified in hypoxic CMECs only (not detected in normoxic, control CMECs), and 10 
significantly up regulated proteins (≥ 1.5-fold) in hypoxic CMECs relative to normoxic control 
cells as per the predetermined minimum criteria for protein regulation (Table 4.1). 
Conversely, 2 proteins were identified in control CMECs only (no detection in hypoxic 
CMECs), and 9 proteins in the hypoxic CMECs were ≥1.5-fold down regulated compared to 
normoxic control (Table 4.2). For a complete list of the differentially regulated proteins in 
hypoxia, please refer to supplementary data files that will be supplied electronically. Next, 
we submitted the list of the strongly represented proteins in hypoxic CMECs, i.e. proteins 
identified in hypoxia only samples (n = 67) plus proteins signifcantly upregulated by hypoxia 
(n = 10) to the DAVID functional annotation analysis tool. Figure 4.13 shows the highly 
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Table 4.1: List of hypoxia-induced up regulated proteins in CMECs (≥ 1.5-fold). 
Protein Name Accession Function* Fold regulation p-value 
     
1. Alpha-enolase P04764 Glycolytic enzyme; hypoxia tolerance 4.9-fold 0.01 
2. Glyceraldehyde-3-phosphate 
dehydrogenase 
P04797 Glycolytic enzyme; apoptosis 3.9-fold 0.03 
3. Pyruvate kinase isozymes 
M1/M2 
P11980 Glycolytic enzyme; interaction with hypoxia inducible 
factor (HIF1A) via EGLN3  under hypoxic conditions leads 
to hypoxia-induced promotion of transcription activity  
3.4-fold 0.02 
4. Moesin O35763 Connects cytoskeleton to cell membrane; cell adhesion 2.9-fold 0.005 
5. L-lactate dehydrogenase A chain P04642 Conversion of pyruvate to lactate under low oxygen 
conditions 
2.2-fold 0.0004 
6. ATP synthase subunit alpha, 
mitochondrial 
P15999 ATP synthesis 1.9-fold 0.04 
7. Phosphoglycerate kinase 1 P16617 Glycolytic enzyme 1.8-fold 0.04 
8. Elongation factor 2 P05197 Protein biosynthesis 1.7-fold 0.015 
9. Transforming protein RhoA P61589 Actin cytoskeleton organisation 1.6-fold 0.04 
10. Eukaryotic initiation factor 4A-
II 
Q5RKI1 Protein biosynthesis 1.6-fold 0.03 
*All protein functions were obtained from the UniProt database (http://www.uniprot.org/). 
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Table 4.2: List of hypoxia-induced down regulated proteins in CMECs (≥ 1.5-fold). 
Protein Name Accession Function* Fold regulation p-value 
     
1. Heterogeneous nuclear 
ribonucleoprotein M 
Q62826 mRNA processing and splicing 9.6-fold 0.01 
2. Superoxide dismutase [Cu-Zn] P07632 Anti-oxidant 7.7-fold 0.003 
3. D6.1A protein O55158 Multi-pass membrane protein; mediator of protein 
glycosylation and signal transduction; inhibitory 
regulation of coagulation 
5.7-fold 0.03 
4. Granulins P23785 Cytokine activity; possibly pro-inflammatory; cell 
growth and proliferation 
5.1-fold 0.01 
5. Aldose reductase P07943 Oxidoreductase activity; NADPH-dependent 
reduction reactions 
2.6-fold 0.03 
6. Transketolase P50137 Connects pentose-phosphate pathway with 
glycolysis; biosynthesis of NADPH 
2.3-fold 0.04 
7. Tropomyosin alpha-3 chain Q63610 Actin cytoskeleton stabilization 2.3-fold 0.03 
8. Macrophage-capping protein Q6AYC4 Actin capping; controls actin-based motility 2.1-fold 0.04 
9. Dihydropyrimidinase-related 
protein 2 
P47942 Cytoskeleton organization 2-fold 0.04 
*All protein functions were obtained from the UniProt database (http://www.uniprot.org/).   
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Figure 4.13: Functional annotation clusters of strongly represented proteins in hypoxic CMECs. Strongly represented proteins (n = 77) are 
defined as significantly upregulated proteins (n = 10) plus proteins identified in hypoxic CMECs only (n = 67). The top 4 most enriched 
annotation clusters associated with strongly represented proteins are shown with their respective enrichment scores and GO terms.
Enrichment Score 
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4.4  Discussion 
In view of their unique location and direct exposure to circulating blood, endothelial cells 
are often subjected to conditions of low PO2 (Graven KK and Farber, 1998), which could 
impair vascular homeostasis and, in the case of the cardiac microvasculature, impact on the 
viability and function of underlying cardiomyocytes.  
In this chapter we aimed to investigate the response of the CMECs to 24 hours hypoxia, by 
lowering the O2 concentration in the incubator to < 0.6 %. We decided not to manipulate 
the growth medium, e.g. lowering the FBS concentration, or adding factors that inhibit 
mitochondrial function. In this way, we ensured that the changes and responses observed 
were exclusively a result of the reduced atmospheric O2 concentration.  
 
4.4.1  Validation of hypoxia-inducing protocol. 
Historically, cell death by hypoxia was believed to manifest as necrosis (Wolle et al., 1995).  
However, other studies were also able to show the existence of hypoxia-induced apoptosis 
(Shostak et al., 1997; Muschel et al., 1995).  Cell responses to hypoxia depend on the 
severity and the duration of the decreased oxygen availability but also on the cell type.  A 
study by Hall JL et al. (2001), showed no significant change in the percentage of apoptotic 
nuclei at 6 or 18 hours in either calf pulmonary artery endothelial cells (CPAEs) or HUVECs, 
suggesting that the decrease in redox factor-1 (Ref-1) protein expression precedes the 
induction of apoptosis. This study also demonstrated that the transient up regulation of Ref-
1 significantly inhibited hypoxia-mediated endothelial cell apoptosis (Hall JL et al., 2001).  
However, after exposure to 24 hours of hypoxia, they showed an increase in apoptosis in 
both these cells types.  The data obtained from the above studies support our own 24 hours 
hypoxia findings. The finding in our study that 6 hours of hypoxia seemed to be anti-
apoptotic and anti-necrotic, was not surprising, as was also shown in one of the above 
studies, where Ref-1 was significantly upregulated after 6 hours of hypoxia and which 
subsequently led to the inhibition of apoptosis (Hall JL et al., 2001).  The reduction in 
apoptosis and necrosis observed at shorter periods of hypoxia may be due to an initial 
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protective / adaptive response by the endothelial cells. To place the relative resistance of 
the CMECs to hypoxia in context, we compared their apoptotic and necrotic responses to 
the same hypoxia protocol in another cardiac cell line, H9C2 myoblasts (see figures 4.5 & 
4.6), and it was clear that the CMECs were more resistant. Indeed, endothelial cells are 
known to be quite resistant to hypoxic injury, as was shown in a study that subjected 
HUVECs to hypoxia, where apoptosis was only evident after prolonged hypoxic exposure (48 
hours) (Graven KK and Farber, 1998).  This phenomenon was also demonstrated in coronary 
endothelial cells where mitochondrial oxygen consumption only started to decrease when 
the PO2 was < 3 mm Hg, and ATP levels remained constant at PO2 levels as low as 0.1 mm Hg 
(Mertens et al., 1990).  
Numerous previous studies have found HIF-1 expression to be increased as a result of in 
vitro exposure of endothelial cells (Manalo et al., 2005), cardiac endothelial cells (Sano et 
al., 2007) and specifically CMECs (Li J et al., 2011) to hypoxia.  In our study, exposure of 
CMECs to 24 hours hypoxia also resulted in a significant increase (see figure 4.7) in the 
expression of HIF-1 α, compared to normoxic controls, thereby further validating our 
hypoxia-inducing protocol.  It was suggested by many researchers that the mitochondria are 
a likely site of oxygen sensing, which results in downstream HIF-1α induction.   In a study by 
Guzy and Schumacker (2006) it was proposed that the electron transport chain acts as an O2 
sensor by releasing ROS in response to hypoxia. The ROS released during hypoxia acted as 
signalling agents that triggered diverse functional responses, including activation of gene 
expression through the stabilization of HIF-1 α.   
The physiological implications of HIF-1α up-regulation will be discussed in more detail in 
Section 4.4.3. 
 
4.4.2  eNOS-NO biosynthesis, oxidative stress and nitrosative stress: 
We showed that 24 hours hypoxia induced an up-regulation of eNOS, the most important 
NOS isoform in endothelial cells, accompanied by an increase in intracellular NO-production. 
The demonstration of increased eNOS expression could serve as an indication that the 24 
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hours hypoxia protocol induced activation of the PKB/Akt – eNOS – NO pathway in CMECs 
as previously shown by Strijdom et al. (2009b).  Other endothelial cell-based studies also 
demonstrated increased production in NO in BAECs exposed to 24 hours of hypoxia (Min et 
al., 2006). Hoffmann A et al. (2001), observed up-regulation of the eNOS gene in porcine 
aortic endothelial cells (PAEC) after exposing them to 6 – 24 hours of hypoxia. In a study in 
bovine aortic endothelial cells (BAECs) it was shown that the amount of eNOS mRNA 
increases to almost twice the basal levels after only 6 hours of hypoxia (Arnet et al., 1996).  
In another study on cerebral endothelial cells, it was shown that hypoxia leads to an 
increase in the expression of iNOS, which subsequently produces high amounts of NO (Xu J 
et al., 2000).  Another study also showed an increase in eNOS protein (after 2 hours of 
hypoxia) in two porcine endothelial cell lines derived from different coronary artery vascular 
beds (Justice et al., 2000). Conversely, a study performed on human aortic endothelial cells 
showed that 24 hours hypoxia resulted in a decrease in NO production (due to a down-
regulation of eNOS) (Olszewska-Pazdrak et al., 2009). However, overall, there seems to be 
general consensus in the literature that myocardial tissue responds to hypoxia by increasing 
eNOS-NO biosynthesis.  In a review by Massion et al. (2003), it was stated that both 
myocardial eNOS and iNOS are up-regulated after exposure to hypoxia, and that eNOS is 
induced by both acute and chronic hypoxia exposure. This was confirmed in other review 
papers on the topic (Shah and MacCarthy, 2000; Kolář and Ošťádal, 2004). Our findings are 
therefore in line with reports in the literature, both with regards to myocardial tissue as a 
whole and with regards to vascular endothelium. 
The development of oxidative stress in hypoxia is an important, if seemingly counterintuitive 
response observed in most cell types. One of the major sources of increased ROS production 
in hypoxic cells are the mitochondria, and it is now widely accepted that mitochondrial ROS 
generation during hypoxia may serve as a signalling system which eventually leads to the 
induction of HIF-1 (Guzy et al., 2006). In vascular endothelial cells, NADPH-oxidase has 
traditionally been viewed as one of the major ROS generating systems; however, the role of 
endothelial mitochondrial ROS generation has recently become a focus of attention (Zhang 
M et al., 2006). Endothelial mitochondria have been shown to respond to hypoxia by 
increased ROS production (Zhang M et al., 2006; Pearlstein et al., 2002), and our own data 
with the mitochondrial ROS-sensitive fluorophore, DHR-123, appear to confirm these 
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findings. There are also several reports in the literature of hypoxia-induced ROS increases 
that are not necessarily derived from mitochondria. In a study by Ali et al. (1999) performed 
on HUVECs, it was shown that ROS production was significantly increased after 24 hours of 
hypoxia, and another study, also found increased levels of mitochondrial ROS in CMECs, at 4 
hours hypoxia (Liu  Y et al., 2011).  Increased ROS generation can occur after only 10-30 
minutes of hypoxia in both HUVECs and PAECs) (Shen Y et al., 2013; Abdallah et al., 2007).  
Studies where endothelial cells were exposed to longer periods of hypoxia also showed 
increased ROS.  For instance, HUVECs exposed to 6 hours of hypoxia led to a significant 
increase in 2',7'- dichlorofluorescein (DCF) and dihydroethidium (DHE) fluorescence 
indicating increased ROS production (Pearlstein et al., 2002).  Exposing BAECs to 18 hours of 
hypoxia also increased ROS production significantly in these cells (Walford et al., 2004). 
In order to further explore the oxidative stress response of the CMECs to hypoxia, we 
measured the expression of p22 phox, which is a surrogate marker of NADPH-oxidase 
activity (Griendling KK et al., 2000a). Interestingly, we found a significant down-regulation of 
p22 phox, which is suggestive of reduced NADPH-oxidase activation.  This finding is 
contradictory to most other studies that found increased NADPH-oxidase activation after 
exposure to hypoxia.  In a study performed on rats exposed to 17 days of hypoxia, an 
increase in p22 phox was found in Leydig cells isolated from the testes of rats exposed to 
hypoxia (Zhang GL et al., 2013). Lastly, a study by Rathore et al. (2008) also showed an 
increase in p22 phox after hypoxia in pulmonary artery smooth muscle cells (PASMCs). It is 
not clear why the CMECs responded by reduced activation of NADPH-oxidase in our hands. 
It could possibly be a response unique to this endothelial cell type; furthermore, it could 
also be suggestive of a less important role for the NADPH-oxidase system as a source of ROS 
in our cells. Despite the significant increase in DHR-123 fluorescence, we could not show 
increased fluorescence when using the general intracellular O2- probe, dihydro-ethidium 
(DHE) (see figure 4.14), which further supports the p22 phox / NADPH-oxidase findings. It 
has to be borne in mind that our protocol took a snapshot view of intracellular responses at 
24 hours. It is possible that this chosen time-point may have missed an earlier transient 
increase in O2- generation which was not detected by the DHE probe at 24 hours. 
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Figure 4.14: Hypoxia-induced cell injury (24 hours hypoxia) was not demonstrated by 
decreased oxidative stress measured as % dihydroethiudium (DHE) mean fluorescence 
intensity of control. 2, 3-Dimethoxy-1,4-naphthoquinone (DMNQ, 100µM) was used as 
positive control.  Please refer to figure 2.9 (page 126) for complete protocol.  Sample size:  n 
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Finally, we investigated whether hypoxia would alter the nitrosative stress status in the 
cells. Nitrotyrosine, a known marker of nitrosative stress (Dalle‐Donne et al., 2005), was 
measured by western blotting, and our data showed a significant increase in nitrotyrosine 
levels, indicative of the development of nitrosative stress.  This was also shown in a study on 
cerebral endothelial cells, where hypoxia led to an increase in the expression of 
nitrotyrosine (Xu J et al., 2000).  Demiryürek et al. (2000) also found increased levels of 
nitrotyrosine in sections from rat lungs subjected to hypoxia.  Lastly, a study performed on 
12-day-old rat pups, cerebral hypoxia–ischemia induced a transient increase nitrotyrosine 
(Van den Tweel et al., 2005).  From a thorough literature search, it appears that most 
studies demonstrating an increase in nitrotyrosine due to hypoxia, are performed on brain 
tissue, as elevated levels of nitrotyrosine after hypoxia in the brain is strongly associated 
with brain injury. As far as we are aware, this is the first study to show an increase in 
nitrosative stress in hypoxic CMECs.    
 
4.4.3  Proteomics analysis 
4.4.3.1  The CMEC proteome under hypoxic conditions: Up regulated and strongly 
represented proteins 
A total of 10 up regulated proteins were identified in the hypoxic CMECs using strict criteria 
(fold- up regulation ≥ 1.5 and p < 0.05), half of which was glycolytic enzymes (alpha enolase, 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH), pyruvate kinase, phosphoglycerate 
kinase and L-lactate dehydrogenase (LDH)) (Table 4.1). Our findings are similar to those of a 
2-D gel proteomics-based study of brain microvascular endothelial cells exposed to 24h 
hypoxia, in which 10 glycolytic enzymes were up regulated, including all of those identified 
in the CMECs (Haseloff et al., 2006).  In another study, the coronary effluent collected from 
human hearts after 60 min global ischaemia was analyzed (Li J et al., 2011), and several 
glycolytic proteins were shown to be up regulated, including LDH and GAPDH. GAPDH was 
one of the first glycolytic enzymes whose expression was shown to be up regulated by 
hypoxia in endothelial cells (Graven KK et al., 1993); since then several other studies have 
reported hypoxia-induced up regulation of glycolytic enzymes (Haseloff et al., 2006). The 
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gene promoters of many glycolytic enzymes, including alpha enolase and LDH, contain 
hypoxia response elements with binding sites for hypoxia inducible factor-1 (HIF-1) 
(Semenza GL et al., 1996), which could lead to activation of gene transcription and explain 
the increased expression of these enzymes under hypoxic conditions. HIF-1α stabilization in 
endothelial cells is known to happen at very low O2 concentrations; in fact, a study on 
HUVECs showed that HIF-1 α expression only appeared at 0.5 % O2 (Quintero et al., 2006).  
Although the CMECs showed some low grade HIF-1 α expression at normal O2 
concentrations, western blotting analysis demonstrated significant increased expression in 
the hypoxic CMECs (Figure 4.7), which could help explain the up regulation of several 
glycolytic enzymes.  
In addition to the 10 up regulated proteins, 67 unique proteins were detected in hypoxia 
samples, but not in normoxic control samples (please refer to electronic supporting data). 
Therefore, a total of 77 strongly represented hypoxia-induced proteins were identified, 
which were submitted to DAVID Bioinformatic Systems for functional annotation analyses. 
The top four most enriched annotation clusters, with which the strongly represented 
proteins associated, are shown in Figure 4.9. The up regulated expression of individual 
glycolytic enzymes discussed above is further underscored by the fact that the functional 
annotation cluster of glycolysis achieved the third highest enrichment in the hypoxic 
proteome (Cluster 3; enrichment score: 3.9). In addition, the GO term of glycolysis (GO 
term: 0006096) was particularly enriched (9.1 % protein count; p-value: 2.9 x 10-6; fold 
enrichment: 26), as was glucose metabolism (GO term: 0006006; 10.6% protein count; p-
value: 2.5 x 10-4; fold enrichment: 7.8). As mentioned earlier, endothelial cells are primarily 
glycolysis-driven for their metabolic needs, so the high enrichment of glycolysis and related 
processes under the stress-inducing condition of low PO2 comes as no surprise.  
Rather unexpectedly, the mitochondrial proton-transporting ATP synthase complex (GO 
term: 0005753) was 27-fold enriched (4.5 % protein count; p-value: 0.005), and 
mitochondrial oxidative phosphorylation (GO term: 0006119) was 8.2-fold enriched (4.6 % 
protein count; p-value: 0.04) in the hypoxic CMEC proteome. Furthermore, both ATP 
synthase gamma chain and ATP synthase subunit b, mitochondrial were detected in hypoxic 
CMECs only (please refer to electronic supporting data). These findings suggest that the 
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hypoxic CMECs were to some degree responding by significant up regulation of proteins 
involved with mitochondrial oxidative phosphorylation and ATP generation. This is 
surprising for two reasons; first, mitochondria are not the primary energy source in 
endothelial cells regardless of the oxygen levels (Davidson and Duchen, 2007), and second, 
all metazoan cells respond to hypoxia by attenuating mitochondrial ATP-generation via 
oxidative phosphorylation (Semenza GL, 2011; Solaini et al., 2010).  Furthermore, there 
seems to be consensus in the literature that ATP synthase activity is inhibited in conditions 
of hypoxia; however, the exact regulation of ATP synthase in hypoxia remains to be 
elucidated (Solaini et al., 2010).     
The paradoxical and disproportionate overexpression of mitochondrial oxidative 
phosphorylation and ATP synthesis proteins may merely reflect a transient compensatory 
stress response by the mitochondria. However, it may also be the result of hypoxia-induced 
protein dysregulation, which, when regarded in conjunction with the increased 
mitochondrial ROS production, could suggest the development of mitochondrial 
dysfunction. It has to be borne in mind that the high enrichment of these proteins does not 
necessarily account for increased mitochondrial oxidative phosphorylation and ATP 
synthase activity. The mitochondrial protein regulation data observed in the hypoxic CMECs 
are intriguing, and warrant further investigations.  
Overall, the 77 strongly represented proteins in hypoxic CMECs associated most significantly 
with the biological process cluster that includes translation, translation elongation, 
ribosomes and structural molecule activity (Cluster 1; enrichment score: 17; Figure 4.7). 
Furthermore, functional annotation analysis of the GO terms describing translation 
(GO:0006412; 33 % protein count; p-value: 6.4 x 10-16; fold enrichment: 10) and translation 
elongation (GO:0006414; 29 % protein count; p-value: 2.4 x 10-24; fold enrichment: 39) 
featured prominently in the hypoxic cells. Increased regulation of translation is an adaptive 
cellular response to hypoxia traditionally observed in solid tumours, which is to a large 
extent mediated by the family of HIF-1 transcription factors (Van den Beucken et al., 2006).  
HIF-1 leads to the transcriptional activation of several genes involved with, among others, 
anaerobic glycolysis and angiogenesis (Van den Beucken et al., 2006).  Our data suggest that 
the hypoxic CMECs responded in a similar fashion, as observed by increased HIF-1 α and 
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glycolytic enzyme expression. Increased translation regulatory activity during hypoxia is, 
however, not exclusively a function of HIF-1 α (Van den Beucken et al., 2006; Liu L and 
Simon, 2004).  It has for example previously been reported that hypoxia increases the 
expression of the eukaryotic initiation factor eIF4E (eukaryotic translation initiation factor 
4E) - binding protein (4E-BP) (Hidalgo et al., 2012), and attenuates the activity of eukaryotic 
elongation factor-2 (eEF-2) (Liu L et al., 2006), both of which result in reduced overall gene 
translation in the cell. Interestingly, our proteomic data showed a 1.7-fold up regulation of 
elongation factor-2 and 1.6-fold up regulation of eukaryotic initiation factor 4A-II (Table 
4.1); in addition, elongation factor 1-gamma and eukaryotic translation initiation factor 5A-1 
were detected in hypoxic CMECs only, with no detection in normoxic cells (please refer to 
electronic supporting data). It therefore appears as if the CMECs responded to hypoxia by a 
net increase in processes leading to protein biosynthesis, which seems to contradict 
previous reports in literature (Van den Beucken et al., 2006; Liu L and Simon, 2004; Wouters 
et al., 2005; Chen Z et al., 2013).    
Increased heat shock protein 90 (HSP 90) expression has been shown to be an important 
hypoxia-induced response in endothelial cells, both on mRNA level (Polotsky et al., 2012), as 
well as protein level (Presley et al., 2008).  In the latter study (bovine aortic endothelial 
cells), hypoxia induced HSP 90 and eNOS expression, leading to increased HSP 90-eNOS 
binding and subsequent activation of eNOS. A protective response in the hypoxic cells is 
thus triggered via increased eNOS-derived NO production, which inhibits mitochondrial 
respiration and ultimately reduces cellular oxygen demand (Presley et al., 2008).  Our 
proteomic data, however, showed that HSP 90 expression was not up regulated in the 
hypoxic CMECs (Figure 4.15 A) and this observation was validated by subsequent Western 
blotting of HSP 90 (0.95 ± 0.02 vs. 1.00 control: p < 0.05) (See figure 4.15 B). Despite the 
absence of HSP 90 up regulation, we have previously shown that 24h hypoxia induced 
activation of the PKB/Akt – eNOS – NO pathway in CMECs (Strijdom et al., 2009b), and in the 
current study, eNOS was significantly up regulated in hypoxic cells, which was accompanied 
by increased NO levels (see figure 4.6).  It therefore seems that the hypoxic CMECs are able 
to increase eNOS-derived NO biosynthesis via a mechanism that apparently does not 
require HSP 90 induction.  
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Figure 4.15:  A: Proteomic analysis with the Maxquant software package 
revealed that hypoxia had no significant effect on the mean LFT intensity count of heatshock 
protein-90 (HSP 90) beta (Accession No: P34058), which was independently validated by 
Western blot analysis of HSP 90 α/ß expression (see figure 4.15B below).  Sample size:  n = 3 
/ group. 
B: Total HSP 90 expression in hypoxic CMECs. Representative western blot of CMECs 
exposed to 24 hours hypoxia shows no change in HSP90 expression compared to normoxic 
control.  ß-tubulin was used to validate equal protein loading.  All data were expressed as a 
ratio of control with control adjusted to 1 (please refer to page 134, chapter 2). Sample size:  
n = 4 / group. 
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4.4.3.2  The CMEC proteome under hypoxic conditions: Down regulated proteins 
An outstanding feature of the down regulated proteins (Table 4.2) was the manner in which 
the hypoxic CMECs responded with regard to anti-oxidant systems. Superoxide dismutase 
[Cu-Zn] (SOD 1) was the second most significantly down regulated protein in the hypoxic 
CMECs. Hypoxia-induced SOD 1 suppression has previously been shown by proteomic 
analysis of hypoxic rat renal tissue (Son et al., 2008), and in hearts of rats subjected to 
chronic hypoxia (Zhou W et al., 2012).  In addition, aldose reductase and transketolase, both 
associated with NADPH function and biosynthesis, were also down regulated in our cells. 
NADPH is regarded as a critical regulator of cellular antioxidant systems, including the 
glutathione system, catalase and SOD (Stanton, 2012; Santos et al., 2011).  Interestingly, a 
proteomics-based study on hypoxic brain capillary endothelial cells found a 15-fold up 
regulation of the spot intensity of transketolase (Haseloff et al., 2006), which is in contrast 
to our own data (2.3-fold down regulation; Table 4.2); The profound up regulation of 
transketolase in the brain capillary endothelial study was, however, not matched by 
increased activity of the enzyme (Stempien-Otero et al., 1999).  In addition to the down 
regulation of major anti-oxidant systems in our cells, we observed increased mitochondrial 
ROS production (Figure 4.5). On the other hand, separate experiments conducted on 
hypoxic CMECs showed a significant down regulation of p22-phox (0.55 ± 0.05 vs. 1.00 
control: p < 0.05) (an indicator of NADPH-oxidase activity; see Figure 4.11), pointing to 
possible reduced NADPH-oxidase-derived ROS production. In summary, our data suggests 
that the hypoxic CMECs responded in an apparent contrasting fashion with regard to redox 
regulation; however, on the balance there seemed to be a net drive towards the 
development of oxidative stress, mainly as a result of reduced anti-oxidant systems such as 
SOD 1 and increased mitochondrial ROS levels.  
Three of the nine significantly down regulated proteins observed in the hypoxic CMECs 
(tropomyosin, macrophage capping-protein and dihydropyrimidinase-related protein) are 
known to have regulatory effects on cytoskeleton organization and stabilization (Table 4.2), 
which could possibly suggest a disruption of the actin cytoskeleton and by extension, 
indicate early signs of barrier dysfunction (Dudek and Garcia, 2001).  On the other hand, the 
cytoskeletal proteins, catenin-delta (involved with adherens junction organisation and cell 
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adhesion), and capping protein (actin filament) muscle Z-line, beta (involved with actin 
cytoskeleton organisation) were strongly represented in hypoxic cells with no detection in 
normoxic cells (please refer to electronic supporting data). It therefore seems that the 
response of the hypoxic CMECs was variable in this regard, similar to observations made in a 
study on hypoxic brain capillary endothelial cells in which 7 cytoskeletal proteins were 
differentially regulated, with 3 up regulated and 4 down regulated respectively (Stempien-
Otero et al., 1999).  Another family of cytoskeletal proteins, the ß-tubulins, has previously 
been shown to be regulated by hypoxia (Saussede-Aim and Dumontet, 2009; Raspaglio et 
al., 2008); however, our proteomic data showed that the expression of ß-tubulin remained 














Stellenbosch University  http://scholar.sun.ac.za




Figure 4.16: A: Maxquant analysis showed no significant changes in the mean LFT 
intensity count of either tubulin beta-5 (Accession No: P69897) or tubulin beta-2C 
(Accession No: Q6P9T8) in hypoxic CMECs, which was independently validated by Western 
blot analysis of HSP 90 α/ß expression (see figure 4.16 (B) below).  Sample size:  n = 3 / 
group. 
B: Total ß-tubulin expression in hypoxic CMECs. Representative western blot of CMECs 
exposed to 24 hours hypoxia shows no change in ß-tubulin expression compared to 
normoxic control.  All data were expressed as a ratio of control with control adjusted to 1 
(please refer to page 134, chapter 2). Sample size:  n = 4 / group. 
Stellenbosch University  http://scholar.sun.ac.za
P a g e  | - 208 - 
 
Chapter Four 
4.5  Conclusion 
In conclusion, the findings of this chapter are novel in that no previous studies have 
characterised the hypoxic response in CMECs in an equally comprehensive manner. We 
approached the studies in this chapter by making use of various endpoints, protocols and 
techniques. A combination of cutting edge technology was applied, from fluorophore-FACS 
analysis assays to an extensive proteomic analysis. We investigated intracellular events, 
(including the measurement of nitric oxide and ROS), important endothelial signalling 
proteins and large-scale differential protein regulation. The following findings are in our 
view of particular interest: 
 Validation of cellular hypoxia by demonstrating increased HIF-1α expression 
(regarded by many as the most sensitive marker of cellular hypoxia), necrosis and 
apoptosis. This was achieved, despite what many would regard as a “mild” hypoxic 
insult (i.e. no manipulation of the growth medium composition to artificially enhance 
the injurious effects); hence, the cellular responses are exclusively due to the 
lowering of atmospheric O2 concentrations. When the injury observed in the CMECs 
was contextualised by subjecting a different cardiac-derived cell line (H9C2 
myoblasts) to the same hypoxia protocol, it was interesting to note that the CMECs 
were relatively more resistant to the injury-inducing effects of the hypoxic insult. 
These observations confirm the widely held notion that vascular endothelial cells are 
often notoriously resistant to hypoxia, which makes sense from a physiological point 
of view, since these cells form the inner lining of blood vessels where they are often 
exposed to low oxygen tension, particularly in the capillary networks of the body. 
 Demonstration of an up-regulation of the eNOS-NO biosynthesis pathway. This 
finding is in agreement with various previous studies, not only in other vascular 
endothelial cell types, but also in the myocardium at large. These results 
furthermore confirm previous studies from our own laboratory on the same cell 
type, which showed a major role for the PKB/Akt-eNOS pathway. The eNOS-NO data 
appear to suggest that the CMECs were not yet switching to a dysfunctional state, at 
least not at the 24 hour time-point. In separate experiments (data not shown), it was 
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interesting to observe that the increased trends were still present at 48 hours 
hypoxia.  
 Oxidative stress: The various endpoints used to assess the overall oxidative stress 
status of the hypoxic CMECs revealed an interesting, if conflicting picture. On the 
one hand, DHR-123 fluorescence indicated increased ROS production, probably 
derived from the mitochondria (although the DHR-123 probe has also been shown to 
have some sensitivity for peroxynitrite species). This was accompanied by a 
concomitant reduction in important anti-oxidant systems in the cells, most notably 
an almost 8-fold downregulation of SOD1. On the other hand, NADPH-oxidase 
activity as measured by p22 phox expression was significantly reduced, accompanied 
by decreased O2- levels as measured by the DHE probe. And finally, we demonstrated 
a clear increase in cellular nitrosative stress by observing elevated levels of 
nitrotyrosine. Clearly, the cells’ overall oxidative stress status was quite fluid at 24 
hours of hypoxia. On the whole, however, it is our belief that a pro-oxidative and 
pro-nitrosative stress scenario had developed at 24 hours, as is evident by the large 
down-regulation of SOD-1, accompanied by increases in DHR-123 fluorescence and 
nitrotyrosine expression. 
 The response of mitochondrial protein regulation as demonstrated by our proteomic 
analysis was intriguing. Particularly the up-regulation of proteins involved with 
oxidative phosphorylation and mitochondrial ATP synthase are seemingly 
counterintuitive, as hypoxia is generally accepted to down-regulate aerobic energy 
metabolic processes. However, despite the novelty of these findings, it must be 
borne in mind that up-regulation of protein expression does not necessarily signify 
increased functional activity. In the absence of functional data, it can be speculated 
that there was at least some early signs of dysregulation of these mitochondrial 
proteins at play, at least at the 24 hour snapshot view. 
 The significant enrichment of glycolysis and up-regulation of several glycolytic 
enzymes as shown in the proteomic data came as no surprise, and served to confirm 
that the CMECs behave in a similar fashion to most other eukaryotic cells when 
facing a hypoxic insult.  Despite the fact that these data were not surprising, it does 
not reduce the significance and novelty of these findings as ours is the first study to 
demonstrate this phenomenon in CMECs. 
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 The significant enrichment of translational processes such as elongation and 
initiation are interesting and somewhat contradictory to studies on other cell types 
in the literature, which usually describe an overall down-regulation of protein 
biosynthetic processes during hypoxia. It is not clear why our cells responded in this 
fashion, and the absence of any previous similar studies on CMECs further 
complicates our ability to place our findings in perspective. We therefore speculate 
that this phenomenon could merely be a transient observation at the 24 hour time-
point, or it could indeed be a response unique to our endothelial cell type. The effect 
of HIF-1α stabilisation and resulting increased transcriptional activity of HIF-α target 
genes could also be a contributing factor in this regard. 
Note: Some parts of this chapter were submitted to the International Journal of Proteomics 
for publication in September 2013. The manuscript was under review at the time of 
submitting this dissertation. 
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Figure 4.17:  A cartoon depicting the major findings in the hypoxic CMECs. 
Stellenbosch University  http://scholar.sun.ac.za
P a g e  | - 212 - 
 
  Chapter Five 
CHAPTER FIVE 
TNF-α-induced responses in CMECs: Baseline investigations 
 
5.1  Introduction  
TNF-α has been shown to induce a wide range of intracellular mechanisms and effects in the 
vascular endothelium, which seem to be strongly dose- and time-dependent (please refer to 
table 1.3, page 51, chapter 1).  One of the most prominent and biologically important 
pathways in endothelial cells is the eNOS-NO biosynthesis pathway. This pathway captures 
the essence of vascular endothelial function, namely to maintain and regulate the dilatory 
state of the vasculature and thereby securing effective perfusion to the body. The eNOS-
derived generation of NO is physiologically very closely related to the intracellular levels of 
ROS, and a fine balance exists between the generation of NO (and activity of eNOS) on the 
one hand, and the generation of ROS on the other. It should therefore come as no surprise 
that one of the primary objectives of this study was to comprehensively investigate the 
eNOS-NO biosynthesis pathway and the relative oxidative stress status of our endothelial 
cells when exposed to TNF-α administration. In this chapter, we will provide data obtained 
from several experiments in which we attempted to systematically evoke responses from 
our cells under different conditions.  
 
5.1.1  TNF-α induces a down-regulation of NOS-NO biosynthesis 
Evidence from the literature suggests that TNF-α can impair endothelium-dependent and 
NO-mediated vasodilation in various vascular beds, e.g. mouse coronary arterioles (Gao et 
al., 2007), rat coronary arterioles (Picchi et al., 2006) and bovine small coronary arteries 
(Ahmad et al., 2002). Picchi et al. (2006) demonstrated that endothelial dysfunction in pre-
diabetic metabolic syndrome is both a result of the effects of TNF-α and subsequent 
production of O2-.  Gao et al. (2007) showed that AGE (advanced glycation end-
product)/RAGE (receptor for AGEs) and nuclear factor κB (NF-κB) signalling play a pivotal 
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role in elevating circulating and/or local vascular TNF-α production. The increased TNF-α 
expression induces the production of ROS, leading to endothelial dysfunction in Type 2 
diabetes. Endothelial dysfunction associated with TNF-α in pathophysiological conditions 
are linked to excess production of ROS and a decrease in NO bioavailability (Zhang W et al., 
2009). 
TNF-α appears to decrease the bioavailability of NO by (i) diminishing the production of NO 
(Goodwin BL et al., 2007; Picchi et al., 2006; Ahmad et al., 2002; Greenberg et al., 1993), 
and (ii) enhancing the removal of NO (Gao et al., 2007).  Picchi et al. (2006) reported that 
the real-time production of NO in isolated coronary arteries from ZOF rats (Zucker Obese 
Fatty rats; a model of pre-diabetic metabolic syndrome) and ACh (acetylcholine)-induced 
NO production were significantly lower in ZOF rats compared with the lean control rats. 
These findings suggested that higher concentrations of circulating and protein expression of 
TNF-α diminished NO bioavailability in ZOF rat coronary arteries via the decreased 
expression of eNOS. Many studies have shown that the direct effects of TNF-α on eNOS are 
via down-regulating eNOS expression and diminishing NO production in diverse vasculatures 
(Goodwin BL et al., 2007; De Palma et al., 2006; Picchi et al., 2006; Gao et al., 2007).  In 
addition to eNOS, other factors are also involved in regulating NO production, and one of 
those factors is a functional citrulline/NO cycle (Xie et al., 2000; Hattori et al., 1994; Husson 
et al., 2003). The citrulline/NO cycle is regulated by ASS (argininosuccinate synthase). NO is 
synthesized from the conversion of L-arginine into L-citrulline mediated by eNOS, and ASS 
catalyses the rate-limiting step in the arginine regeneration through the citrulline/NO cycle 
and appears to be co-ordinately regulated with eNOS activity (Oyadomari et al., 2001). 
Goodwin BL et al. (2007) showed that TNF-α diminished the mRNA and protein expression 
of ASS in aortic ECs and directly resulted in the reduced production of NO.  Gao et al., 2007 
and Picchi et al., 2006) reported that TNF-α impaired NO-mediated vasodilation in Type 2 
diabetic coronary arterioles by  stimulating the endothelial generation of ROS via activation 
of NADPH oxidase. When a neutralizing antibody to TNF-α was administered, the formation 
of ROS (O2−, ONOO− and H2O2) was decreased and NO-mediated vasodilation improved.   
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5.1.2  TNF-α induces an up-regulation of NOS-NO biosynthesis 
Contrary to the above studies, others have demonstrated opposite effects of TNF-α on the 
NOS-NO pathway. Several mechanisms have been suggested for the induction/activation of 
NOS by TNF-α. Yoshizumi et al. (1993) demonstrated that TNF-α markedly reduced mRNA 
levels of eNOS in HUVECs in a dose- and time-dependent manner without changing the rate 
of eNOS gene transcription. TNF-α appeared to decrease eNOS mRNA levels by increasing 
the rate of mRNA degradation.  Another study, however, suggested that TNF-α increases 
eNOS activity in HUVECs (De Palma et al., 2006). Activation of eNOS by TNF-α requires 
activation of PKB/Akt (protein kinase B), a known eNOS activator, via Sph1P (sphingosine-1-
phosphate) receptor activation. Sph1P receptor is activated by Sph1P, a sphingolipid 
involved in proliferation, survival, migration and differentiation of these cells, generated 
through N-SMase2 (neutral sphingomyelinase 2) and SK1 (sphingosine kinase 1) activation 
(De Palma et al., 2006).    
TNF-α mediated activation of eNOS is accompanied by increased NO generation, which 
exerts protective effects on DC (dendritic cell) adhesion to endothelium induced by TNF-α 
itself.  It has also been suggested that TNF-α may increase iNOS expression by activating NF-
κB (Zhong L et al., 1999).  TNF-α-induced iNOS mRNA expression in microvascular ECs could 
be decreased by rooperol (a dicatechol from the South African plant Hypoxis rooperi) 
administration, which is an anti-inflammatory agent in the treatment of several 
inflammatory disorders (Bereta et al., 1997).  In HUVECs, the effect of TNF-α on iNOS 
expression was not affected by statin treatment, whereas reduced eNOS expression was 
reversed by rosuvastatin and ceruvastatin by inhibiting HMG-CoA (3-hydroxy-3-
methylglutaryl-CoA) reductase and subsequent blocking of isoprenoid synthesis (Jantzen et 
al., 2007). 
From the above literature review, it is quite clear that the effects of TNF-α are indeed time-, 
dose- and even cell type-dependent. It is also interesting to note that the responses can in 
fact be in direct opposition to each other (down-regulation of eNOS-NO vs. up-regulation of 
eNOS-NO). Please refer to table 1.3 in chapter 1 (page 51) for a summary of TNF-α 
treatment studies performed at various time points, concentrations, endothelial cell types 
and endpoints measured, which further confirms the above statement. 
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5.2  Specific Aims 
For the purposes of this chapter, our approach was based on three essential research 
questions: 
 What is the effect of the TNF-α concentration administered to the CMECs?   
 What is the effect of short term TNF-α incubation time on the CMEC responses? 
 What is the effect of modifying the serum content of the growth medium on the 
CMEC responses to TNF-α treatment?  
 
5.3  Methods  
 
5.3.1  The effects of different TNF-α concentrations. 
CMECs were cultured and grown as described in chapter two (page 111).  CMECs were 
treated with 3 different concentrations of TNF-α (0.5 ng /ml, 5 ng /ml and 20 ng / ml) for 24 
hours (see figure 5.1 for the protocol).  The respective TNF-α concentrations and periods of 
treatment were selected based on an extensive literature research performed on previous 
in vitro endothelial cell studies (please refer to table 1.3, page 51). It was our intention to 
choose three different concentrations, ranging from low to high. After each of these 
respective treatments, cells were stained with: (i) propidium iodide (PI) (no analysis for 0.5 
ng / ml at 48 hours); (ii) Annexin V (as described on page 118 in chapter 2) (no analysis for 
0.5 ng / ml at 48 hours) to measure cell viability; (iii) DAF-2/DA (as described on page 121, 
chapter 2) to measure NO; (iv) dihydroethium (DHE), 2′, 7′-dichlorofluorescein (DCF) (as 
described on page 124, chapter 2) to measure oxidative stress; and (v) dihydrorhodamine-1, 
2, 3 (DHR-123) (as described on page 124, chapter 2) to measure oxidative and nitrosative 
stress by means of flow cytometric analysis.  Positive controls were incorporated for NO (as 
described on page 121, chapter 2) and oxidative stress measurements (as described on page 
124, chapter 2) (refer to figure 5.1 for complete protocol). The mean fluorescence intensity 
(expressed as % of control) of each of the above fluorescent probes was compared with that 
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of the TNF-α treated samples to determine the effect of TNF-α at different concentrations 
(24 hours treatment).  
In a separate series, cells were either treated with 0.5 ng / ml, 5 ng / ml and 20 ng /ml TNF-α 
for 24 hours or with 5 ng / ml TNF-α for 24 and 48 hours and subsequently prepared for 
western blot analysis (as described on page 132 – 134 in chapter two, see figures 2.15 & 
2.16) (see figure 5.1 for treatment protocol).  The expression and activation of the following 
proteins were investigated (please refer to chapter 2, page 132 for the concentration and 
exposure time of each protein): 
NOS Signalling: Total and phosphorylated eNOS and PKB / Akt, and total HSP 90 and 
caveolin-1 were measured to investigate NOS signalling mechanisms.  
Oxidative Stress: The membrane bound NADPH oxidase subunit, p22-phox, was used to 
measure nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activity as 
previously described (Griendling KK et al., 2000a). 
Nitrosative Stress: The ability of the highly reactive NO-derived radical, ONOO- 
(peroxynitrite) to nitrosylate tyrosine residues of cellular proteins and form nitrotyrosine, is 
an indication of nitrosative stress (Dalle‐Donne et al., 2005). Nitrotyrosine expression was 
therefore measured as a marker of nitrosative stress. 
NF-κβ signalling: Activation of the NF-κβ pathway is usually an indication of a pro-
inflammatory response (Ben-Neriah and Karin, 2011), and a prominent intracellular pathway 
known to be induced by TNF-α.  Upon activation of this pathway, IКβα dislodges from the 
NF-κβ complex and undergoes proteasomal degradation; therefore, a reduction in IКβα 
protein levels is a marker of NF-κβ activation (Hoffmann A et al., 2002). IКβα protein 
expression was therefore measured to investigate activity of the NFКβ pathway.   
Equal protein loading validation: β-tubulin expression was measured to confirm equal 
protein loading in all samples. 
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Figure 5.1: Protocol for treatment of CMECs with 0.5 ng / ml, 5 ng / ml or 20 ng / ml (24 hours) for subsequent FACS and western blot 
analyses. 
Stellenbosch University  http://scholar.sun.ac.za
Stellenbosch University  http://scholar.sun.ac.za
P a g e  | - 218 - 
 
  Chapter Five 
5.3.2  Short term treatment of CMECs with TNF-α (20 ng / ml) for 30 minutes. 
  
In order to assess whether the measurements at the end of the standard 24 hour TNF-α 
treatment protocol might have failed to detect important intracellular responses at early 
time-points, we conducted a separate series of experiments in which the CMECs were 
treated with TNF-α for 30 minutes. From the literature, it is apparent that many authors 
evaluated TNF-α-effects at early time points, such as 10 minutes (Kim HJ et al., 2006a), 30 
minutes (Li C et al., 2002, 2005; Bove et al. 2001) and 1 hour (De Palma et al., 2006; Corda et 
al., 2001).  CMECs were cultured and grown as described in chapter two (page 111) and 
treated with TNF-α (20 ng / ml) for 30 minutes (see figure 5.3 for the protocol).  In order to 
contextualise the TNF-α data, we included experiments in which CMECs were treated with 
another known harmful stimulus, ox-LDL (40 µM) for 30 minutes. After each of these 
respective treatments, cells were removed from culture by trypisinisation and subsequently 
treated with DAF-2/DA to measure NO, and DHE, DCF and DHR-123 to measure 
oxidative/nitrosative stress by means of flow cytometric analysis.  Positive controls were 
used for NO (as described on page 121, chapter 2) and oxidative stress measurements (as 
described on page 124, chapter 2) (refer to figure 5.2 for complete protocol). The mean 
fluorescence intensity (expressed as % of control) was determined for each of the 
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Figure 5.2:  Protocol for treatment of CMECs with 20 ng / ml TNF-α and Ox-LDL (40µg / ml) for 30 minutes for subsequent FACS analysis NO 
production, oxidative stress and nitrosative stress. 
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5.3.3 Investigating the effects of modification of the serum content of growth 
medium on ROS production. 
From the literature, it appears that many authors prefer to investigate oxidative stress in 
cell models that were incubated in either low serum or serum-free growth medium (Ago et 
al., 2004; Li JM et al., 2007b; Monaghan-Benson and Burridge, 2009) The rationale for this 
intervention is apparently to stimulate the ROS-producing enzyme systems in the cells and 
thereby remove the possible masking effects that normal or high serum-containing growth 
medium may exert on ROS production in cells. The NADPH-oxidase enzyme, one of the 
major ROS generators in endothelial cells, has for example been shown to be up-regulated 
by, inter alia, nutrient deprivation (Li H et al., 2008). Furthermore, we almost consistently, 
with very few exceptions, found that my TNF-α-treated CMECs either responded with no 
changes in ROS generation, or even reduced ROS generation, which contradicts what is 
generally published in the literature. In view of this, we performed a separate series of 
experiments in which the foetal bovine serum (FBS) concentration of the growth medium 
was reduced in order to evaluate the effects of serum reduction and deprivation on 
superoxide production. CMECs were treated with TNF-α (20 ng / ml) in medium containing 
either 0, 5 or 10 % serum for 24 hours (see figure 5.3 for the protocol).  After each of these 
respective treatments, cells were removed from culture by trypisinisation and subsequently 
treated with dihydroethium (DHE) (as described on page 124, chapter 2) to measure 
oxidative stress by means of flow cytometric analysis.  Positive controls were also included 
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Figure 5.3:  Protocol for treatment of CMECs with 20 ng / ml TNF-α for 24 hours in medium supplemented with either 0, 5 or 10 % foetal 
bovine serum (FBS) for subsequent FACS analysis of superoxide production (DHE fluorescence). 
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5.4  Results 
5.4.1  The effects of different TNF-α concentrations: 0.5, 5 and 20 ng / ml. 
 
5.4.1.1  Cell viability measurements (FACS analysis). 
CMECs exposed to TNF-α (0.5 ng / ml for 24 hours), showed no change (87.62 ± 7.22 % vs. 
100 % control: p < 0.05) in propidium iodide (PI) fluorescence (measuring necrosis) (see 
figure 5.4), compared to untreated controls.  Similarly, CMECs exposed to TNF-α (0.5 ng / ml 
for 24 hours), showed no change (116.57 ± 19.72 % vs. 100 % control: p < 0.05) in Annexin V 
fluorescence (measuring apoptosis) (see figure 5.5), compared to untreated controls.  When 
increasing the TNF-α concentration to 5 ng / ml, CMECs showed a decrease (77.65 ± 6.58 % 
vs. 100 % control: p < 0.05) in PI fluorescence (see figure 5.4), and a decrease (66.18 ± 5.21 
% vs. 100 % control: p < 0.05) in Annexin V fluorescence (see figure 5.5), compared to the 
untreated controls respectively. When a relatively high concentration of TNF-α was 
administered to the cells (20 ng / ml for 24 hours), there was a decrease in both PI 
fluorescence (50.36 ± 6.48 % vs. 100 % control: p < 0.05) (see figure 5.4) and Annexin V 
fluorescence (79.59 ± 6.22 % vs. 100 % control: p < 0.05) (see figure 5.5), compared to 
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Figure 5.4: TNF-α effects on necrosis at different concentrations (0.5, 5 and 20 ng / ml 
for 24 hours). Necrosis expressed as % PI stained cells (as a percentage of control; control = 
100 %).  Sample size:  n = 4 – 6 / group. 
 
Figure 5.5: TNF-α effects on apoptosis at different concentrations (0.5, 5 and 20 ng / ml 
for 24 hours). Apoptosis expressed as % Annexin V stained cells (as a percentage of control; 
control = 100 %).  Sample size:  n = 4 – 6 / group. 
Stellenbosch University  http://scholar.sun.ac.za
P a g e  | - 224 - 
 
  Chapter Five 
5.4.1.2  NO production measurements (FACS analysis). 
CMECs exposed to 0.5 ng /ml TNF-α (24 hours) showed a significant decrease in DAF-2/DA 
mean fluorescence intensity (81.24 ± 2.78 % vs. 100 % control: p < 0.05) compared to 
untreated controls (see figure 5.6). CMECs exposed to 5 ng / ml TNF-α (24 hours), showed 
no change (100.71 ± 5.04 % vs. 100 % control: p < 0.05) in DAF-2/DA fluorescence (see figure 
5.6), compared to untreated controls. CMECs exposed to 20 ng / ml TNF-α (24 hours), 
showed a significant decrease (74.02 ± 1.61 % vs. 100 % control: p < 0.05) in DAF-2/DA 
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Figure 5.6: TNF-α effects on mean DAF-2/DA fluorescence at different concentrations 
(0.5, 5 and 20 ng / ml for 24 hours). Data presented as % DAF-2/DA fluorescence (expressed 
as a percentage of control; control = 100%).  The NO-donor, DEA/NO (100µM) was used as a 
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5.4.1.3  Reactive oxygen species measurements (FACS analysis) 
 
5.4.1.3.1 TNF-α 0.5 ng /ml for 24 hours 
Dihydroethidium (DHE) fluorescence (sensitive for O2-): A decrease in mean DHE 
fluorescence was observed: 71.86 ± 4.21 % vs. 100 % control: p < 0.05 (see figure 5.7). 
2′, 7′-dichlorofluorescein (DCF) fluorescence (sensitive for H2O2): A decrease in mean DCF 
fluorescence was observed: 46.22 ± 2.00 % vs. 100 % control: p < 0.05 (see figure 5.8). 
Dihydrorhodamine-123 (DHR-123) fluorescence (sensitive for mitochondrial ROS and 
peroxynitrite): No changes were observed in mean DHR-123 fluorescence: 95.15 ± 2.41 % 
vs. 100 % control) (see figure 5.9). 
 
5.4.1.3.2 TNF-α 5 ng /ml for 24 hours   
Dihydroethidium (DHE) fluorescence (sensitive for O2-): A decrease in mean DHE 
fluorescence was observed: 83.39 ± 2.37 % vs. 100 % control: p < 0.05 (see figure 5.7). 
2′, 7′-dichlorofluorescein (DCF) fluorescence (sensitive for H2O2): A decrease in mean DCF 
fluorescence was observed: 69.89 ± 3.72 % vs. 100 % control: p < 0.05 (see figure 5.8). 
Dihydrorhodamine-123 (DHR-123) fluorescence (sensitive for mitochondrial ROS and 
peroxynitrite): A decrease in mean DHR-123 fluorescence was observed: 85.54 ± 2.11 % vs. 
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5.4.1.3.3 TNF-α 20 ng /ml for 24 hours 
Dihydroethidium (DHE) fluorescence (sensitive for O2-): A decrease in mean DHE 
fluorescence was observed: 80.55 ± 2.53 % vs. 100 % control: p < 0.05 (see figure 5.7). 
2′, 7′-dichlorofluorescein (DCF) fluorescence (sensitive for H2O2): An increase in mean DCF 
fluorescence was observed: 113.72 ± 2.88 % vs. 100 % control: p < 0.05 (see figure 5.8). 
Dihydrorhodamine-123 (DHR-123) fluorescence (sensitive for mitochondrial ROS and 
peroxynitrite): A decrease in mean DHR-123 fluorescence was observed: 71.91 ± 1.01 % vs. 
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Figure 5.7: TNF-α effects on mean DHE fluorescence at different concentrations (0.5, 5 
and 20 ng / ml for 24 hours). Data presented as % DHE fluorescence (expressed as a 
percentage of control; control = 100%).  DMNQ (10µM) was used as a positive control.  
Sample size:  n = 4 – 6 / group. 
 
Figure 5.8: TNF-α effects on mean DCF fluorescence at different concentrations (0.5, 5 
and 20 ng / ml for 24 hours). Data presented as % DCF fluorescence (expressed as a 
percentage of control; control = 100%). H2O2 (100µM) was used as a positive control.  
Sample size:  n = 4 – 6 / group. 
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Figure 5.9: TNF-α effects on mean DHR-123 fluorescence at different concentrations 
(0.5, 5 and 20 ng / ml for 24 hours). Data presented as % DHR-123 fluorescence (expressed 
as a percentage of control; control = 100%). Authentic peroxynitrite (100µM) was used as a 
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5.4.1.4.1.1 TNF-α 0.5 ng /ml for 24 hours 
Phosphorylated eNOS:  A decrease in phospho eNOS was observed: 0.58 ± 0.04 vs. 1.00 
control: p < 0.05 (see figure 5.10). 
Total eNOS:  An increase in total eNOS was observed: 1.45 ± 0.12 vs. 1.00 control: p < 0.05 
(see figure 5.11). 
Phospho eNOS expressed as a ratio of total eNOS:  A decrease in the ratio of phospho / 
total eNOS was observed: 0.41 ± 0.04 vs. 1.00 control: p < 0.05 (see figure 5.12). 
 
5.4.1.4.1.2 TNF-α 5 ng /ml for 24 hours 
Phosphorylated eNOS:  A decrease in phospho eNOS was observed: 0.67 ± 0.08 vs. 1.00 
control: p < 0.05 (see figure 5.10). 
Total eNOS:  An increase in total eNOS was observed: 1.74 ± 0.36 vs. 1.00 control: p < 0.05 
(see figure 5.11). 
Phospho eNOS expressed as a ratio of total eNOS:  A decrease in the ratio of phospho / 
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5.4.1.4.1.3 TNF-α 20 ng /ml for 24 hours 
Phosphorylated eNOS:  A decrease in phospho eNOS was observed: 0.50 ± 0.02 vs. 1.00 
control: p < 0.05 (see figure 5.10). 
Total eNOS:  An increase in total eNOS was observed: 2.73 ± 0.12 vs. 1.00 control: p < 0.05 
(see figure 5.11). 
Phospho eNOS expressed as a ratio of total eNOS:  A decrease in the ratio of phospho / 
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Figure 5.10: TNF-α effects on phosphorylated eNOS (phospho Ser 1177) at different 
concentrations (0.5, 5 and 20 ng / ml for 24 hours).  Phosphorylated eNOS is expressed as a 
ratio of control; control adjusted to 1 (please refer to page 134, chapter 2).  Sample size:  n = 




Stellenbosch University  http://scholar.sun.ac.za
P a g e  | - 233 - 
 




Figure 5.11: TNF-α effects on total eNOS expression at different concentrations (0.5, 5 
and 20 ng / ml for 24 hours).  Total eNOS expression is expressed as a ratio of control; 
control adjusted to 1 (please refer to page 134, chapter 2).  Sample size:  n = 4 / group. 
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Figure 5.12: TNF-α effects on the phosphorylated eNOS / total eNOS expression at 
different concentrations (0.5, 5 and 20 ng / ml for 24 hours).  Phospho / Total eNOS levels 
are expressed as a ratio of control; control adjusted to 1 (please refer to page 134, chapter 
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5.4.1.4.2 PKB/Akt 
 
5.4.1.4.2.1 TNF-α 0.5 ng /ml for 24 hours 
Phosphorylated PKB/Akt:  A decrease in phospho PKB/Akt was observed: 0.42 ± 0.05 vs. 
1.00 control: p < 0.05 (see figure 5.13). 
Total PKB/Akt:  A decrease in total PKB/Akt was observed: 0.51 ± 0.08 vs. 1.00 control: p < 
0.05 (see figure 5.14). 
Phospho PKB/Akt expressed as a ratio of total PKB/Akt:  No change in the ratio of phospho 
/ total PKB/Akt was observed: 0.88 ± 0.12 vs. 1.00 control) (see figure 5.15). 
 
5.4.1.4.2.2 TNF-α 5 ng /ml for 24 hours 
Phosphorylated PKB/Akt:  No change in phospho PKB/Akt was observed: 0.82 ± 0.09 vs. 
1.00 control) (see figure 5.13). 
Total PKB/Akt:  A decrease in total PKB/Akt was observed: 0.59 ± 0.06 vs. 1.00 control: p < 
0.05 (see figure 5.14). 
Phospho PKB/Akt expressed as a ratio of total PKB/Akt:  No change in the ratio of phospho 
/ total PKB/Akt was observed: 1.48 ± 0.25 vs. 1.00 control) (see figure 5.15). 
 
5.4.1.4.2.3 TNF-α 20 ng /ml for 24 hours 
Phosphorylated PKB/Akt:  A decrease in phospho PKB/Akt was observed: 0.39 ± 0.03 vs. 
1.00 control: p < 0.05 (see figure 5.13). 
Total PKB/Akt:  A decrease in total PKB/Akt was observed: 0.71 ± 0.01 vs. 1.00 control: p < 
0.05 (see figure 5.14). 
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Phospho PKB/Akt expressed as a ratio of total PKB/Akt:  A decrease in the ratio of phospho 
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Figure 5.13: TNF-α effects on phosphorylated PKB/Akt (phospho Ser 473) at different 
concentrations (0.5, 5 and 20 ng / ml for 24 hours).  Phosphorylated PKB/Akt is expressed as 
a ratio of control; control adjusted to 1 (please refer to page 134, chapter 2).  Sample size:  n 
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Figure 5.14: TNF-α effects on total PKB/Akt expression at different concentrations (0.5, 5 
and 20 ng / ml for 24 hours).  Total PKB/Akt expression is expressed as a ratio of control; 
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Figure 5.15: TNF-α effects on the phosphorylated PKB/Akt / total PKB/Akt expression at 
different concentrations (0.5, 5 and 20 ng / ml for 24 hours).  Phospho / Total PKB/Akt levels 
are expressed as a ratio of control; control adjusted to 1 (please refer to page 134, chapter 
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5.4.1.4.3 HSP 90 
 
5.4.1.4.3.1 TNF-α 0.5 ng /ml for 24 hours 
HSP 90:  A decrease in HSP 90 was observed: 0.70 ± 0.04 vs. 1.00 control: p < 0.05 (see 
figure 5.16). 
 
5.4.1.4.3.2 TNF-α 5 ng /ml for 24 hours 
HSP 90:  A decrease in HSP 90 was observed: 0.64 ± 0.06 vs. 1.00 control: p < 0.05 (see 
figure 5.16). 
 
5.4.1.4.3.3 TNF-α 20 ng /ml for 24 hours 
HSP 90:  A decrease in HSP 90 was observed: 0.79 ± 0.02 vs. 1.00 control: p < 0.05 (see 
figure 5.16). 
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Figure 5.16: TNF-α effects on total HSP 90 expression at different concentrations (0.5, 5 
and 20 ng / ml for 24 hours).  Total HSP 90 expression is expressed as a ratio of control; 
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5.4.1.4.4 Caveolin-1 
 
5.4.1.4.4.1 TNF-α 0.5 ng /ml for 24 hours 
Caveolin-1:  No change in caveolin-1 was observed: 0.89 ± 0.12 vs. 1.00 control) (see figure 
5.17). 
 
5.4.1.4.4.2 TNF-α 5 ng /ml for 24 hours 
Caveolin-1:  A decrease in caveolin-1 was observed: 0.72 ± 0.05 vs. 1.00 control: p < 0.05 
(see figure 5.17). 
 
5.4.1.4.4.3 TNF-α 20 ng /ml for 24 hours 
Caveolin-1:  No change in caveolin-1 was observed: 0.92 ± 0.11 vs. 1.00 control) (see figure 
5.17). 
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Figure 5.17: TNF-α effects on total caveolin-1 expression at different concentrations (0.5, 
5 and 20 ng / ml for 24 hours).  Total caveolin-1 expression is expressed as a ratio of control; 
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5.4.1.5  Western blot analysis of proteins associated with oxidative stress: p22-phox: 
 
5.4.1.5.1 TNF-α 0.5 ng /ml for 24 hours 
P22 phox:  No change in p22 phox was observed: 1.01 ± 0.01 vs. 1.00 control) (see figure 
5.18). 
 
5.4.1.5.2 TNF-α 5 ng /ml for 24 hours 
P22 phox:  An increase in p22 phox was observed: 1.25 ± 0.08 vs. 1.00 control: p < 0.05 (see 
figure 5.18). 
 
5.4.1.5.3 TNF-α 20 ng /ml for 24 hours 
P22 phox:  An increase in p22 phox was observed: 1.34 ± 0.11 vs. 1.00 control: p < 0.05 (see 
figure 5.18). 
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Figure 5.18: TNF-α effects on total p22-phox expression at different concentrations (0.5, 5 
and 20 ng / ml for 24 hours).  Total p22-phox expression is expressed as a ratio of control; 
control adjusted to 1 (please refer to page 134, chapter 2).  Sample size:  n = 4 / group. 
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5.4.1.6 Western blot analysis of proteins associated with nitrosative stress: 
nitrotyrosine: 
 
5.4.1.6.1 TNF-α 0.5 ng /ml for 24 hours 
Nitrotyrosine:  No change in nitrotyrosine was observed: 0.99 ± 0.05 vs. 1.00 control) (see 
figure 5.19). 
 
5.4.1.6.1 TNF-α 5 ng /ml for 24 hours 
Nitrotyrosine:  A decrease in nitrotyrosine was observed: 0.87 ± 0.04 vs. 1.00 control: p < 
0.05 (see figure 5.19). 
 
5.4.1.6.1 TNF-α 20 ng /ml for 24 hours 
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Figure 5.19: TNF-α effects on nitrotyrosine expression at different concentrations (0.5, 5 
and 20 ng / ml for 24 hours).  Nitrotyrosine expression is expressed as a ratio of control; 
control adjusted to 1 (please refer to page 134, chapter 2).  Sample size:  n = 4 / group. 
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5.4.1.7 Western blot analysis of proteins associated with NF-κβ signalling: IKß-α: 
 
5.4.1.7.1 TNF-α 0.5 ng /ml for 24 hours 
Total IΚβα:  A decrease in total IΚβα was observed: 0.78 ± 0.02 vs. 1.00 control: p < 0.05 (see 
figure 5.20). 
 
5.4.1.7.2 TNF-α 5 ng /ml for 24 hours 
Total IΚβα:  A decrease in total IΚβα was observed: 0.74 ± 0.02 vs. 1.00 control: p < 0.05 (see 
figure 5.20). 
 
5.4.1.7.3 TNF-α 20 ng /ml for 24 hours 
Total IΚβα:  A decrease in total IΚβα was observed: 0.50 ± 0.01 vs. 1.00 control: p < 0.05 (see 
figure 5.20). 
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Figure 5.20: TNF-α effects on IKß-α expression at different concentrations (0.5, 5 and 20 
ng / ml for 24 hours).  IKß-α expression is expressed as a ratio of control; control adjusted to 
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5.4.2  The effects of short term treatment with TNF-α (20 ng / ml): 30 minutes 
 
5.4.2.1  NO production measurements (FACS analysis). 
CMECs exposed to TNF-α (20 ng / ml for 30 minutes), showed a significant decrease (89.85 ± 
2.19 % vs. 100 % control: p < 0.05) in mean DAF-2/DA fluorescence compared to untreated 
controls (see figure 5.21). In order to contextualise the TNF-α data, we included 
experiments in which the CMECs were exposed to another harmful stimulus, ox-LDL (40 µg / 
ml for 30 minutes). Data showed unchanged mean DAF-2/DA fluorescence intensity: 97.07 ± 
3.37 % vs. 100 % control: p < 0.05 (see figure 5.21).   
 
5.4.2.2  ROS measurements (FACS analysis). 
CMECs exposed to TNF-α (20 ng / ml for 30 minutes), showed no change in mean DHE 
fluorescence intensity (97.38 ± 4.04 % vs. 100 % control) (see figure 5.22). CMECs exposed 
to TNF-α (20 ng / ml for 30 minutes), showed no change in mean DCF fluorescence intensity 
(92.99 ± 3.25 % vs. 100 % control) (see figure 5.23). CMECs exposed to TNF-α (20 ng / ml for 
30 minutes), showed no change in mean DHR-123 fluorescence intensity (106.16 ± 3.55 % 
vs. 100 % control) (see figure 5.24). CMECs exposed to Ox-LDL (40 µg / ml for 30 minutes), 
showed an increase in mean DHE fluorescence intensity (116.11 ± 4.73 % vs. 100 % control: 
p < 0.05); a decrease in mean DCF fluorescence intensity (90.73 ± 0.39 % vs. 100 % control: p 
< 0.05); and no change in mean DHR-123 fluorescence intensity (100.77 ± 3.77 % vs. 100 % 
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Figure 5.21: Effects of TNF-α (20 ng / ml) and Ox-LDL (40 µg / ml) on mean DAF-2/DA 
fluorescence intensity for 30 minutes. DAF-2/DA fluorescence expressed as a percentage of 
control; control = 100%.  DEA/NO (100 µM) was used as a positive control.  Sample size:  n = 
4 – 6 / group. 
 
Figure 5.22: Effects of TNF-α (20 ng / ml) and Ox-LDL (40 µg / ml) on mean DHE 
fluorescence intensity for 30 minutes. DHE fluorescence expressed as a percentage of 
control; control = 100%.  DMNQ (10 µM) was used as a positive control.  Sample size:  n = 4 
– 6 / group. 
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Figure 5.23: Effects of TNF-α (20 ng / ml) and Ox-LDL (40 µg / ml) on mean DCF 
fluorescence intensity for 30 minutes. DCF fluorescence expressed as a percentage of 
control; control = 100%.  H2O2 (100 µM) was used as a positive control.  Sample size:  n = 4 – 
6 / group. 
 
Figure 5.24: Effects of TNF-α (20 ng / ml) and Ox-LDL (40 µg / ml) on mean DHR-123 
fluorescence intensity for 30 minutes. DHR-123 fluorescence expressed as a percentage of 
control; control = 100%. Authentic peroxynitrite (100 µM) was used as a positive control.  
Sample size:  n = 4 – 6 / group. 
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5.4.3  The effects of reduced serum content in growth medium on superoxide 
production in CMECs treated with TNF-α (20 ng / ml): 24 hours 
CMECs exposed to TNF-α (20 ng / ml for 24 hours) (growth medium = 0 % serum), showed a 
significant decrease in mean DHE fluorescence intensity (62.77 ± 4.41 % vs. 100 % control: p 
< 0.05). CMECs exposed to TNF-α (20 ng / ml for 24 hours) (growth medium = 5 % serum), 
showed a significant decrease in mean DHE fluorescence intensity (73.21 ± 3.07 % vs. 100 % 
control: p < 0.05). When CMECs were exposed to TNF-α (20 ng / ml for 24 hours) in 10% 
serum-containing growth medium, a significant decrease in mean DHE fluorescence 
intensity was again observed (93.98 ± 3.78 % vs. 100 % control: p < 0.05). See figure 5.25 for 
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Figure 5.25: Effects of growth media with different serum contents (0%, 5% and 10% FBS) 
on mean DHE fluorescence intensity in CMECs treated with TNF-α (20 ng / ml) for 24 hours. 
DHE fluorescence expressed as a percentage of control; control = 100%. Data presented as 
DHE fluorescence expressed as a percentage of control; control = 100%).  DMNQ (10µM) 
was used as a positive control.  Sample size:  n = 4 – 6 / group. 
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5.5  Discussion 
 
5.5.1  The effects of different TNF-α concentrations: 0.5, 5 and 20 ng / ml (24 hours) 
24 hours treatment with the lowest concentration of TNF-α administered in this series of 
experiments (0.5 ng / ml), had no effect on apoptosis (as measured by Annexin V 
fluorescence) or necrosis (propidium iodide staining), although the two higher 
concentrations (5 and 20 ng / ml) seemed to be both anti-necrotic and anti-apoptotic (see 
figures 5.4 & 5.5).  In contrast to our findings, other studies found both an increase in 
necrosis as well as apoptosis, with TNF-α concentrations ranging from 10 – 50 ng / ml and 
treatment periods ranging from 1 – 30 hours (Corda et al., 2001; Wang P et al., 1994; Luo et 
al., 2006; Polunovsky et al., 1994).  In support of our findings, a study performed on HUVECs 
treated with 20 ng /ml TNF-α for 1-24 hours also found a decrease in apoptosis (Desphande 
et al., 2000). The apoptosis data are interesting, as TNF-α is often considered in the 
literature to be a pro-apoptotic agent (Van den Oever et al., 2010; Ji et al., 2003; Stefanec, 
2000).  However, a closer inspection of the multitude of pathways that are switched on by 
TNF-binding to its receptors indicate that TNF-α can equally lead to pro-apoptotic and anti-
apoptotic effects even within the same signal transduction pathway (Gaur and Aggarwal, 
2003; Li H and Lin, 2008; Chen G and Goeddel, 2002). In further support of our Annexin V 
data, we performed subsequent measurements of cleaved caspase-3 expression, which was 
also down-regulated (see Chapter 6). 
TNF-α regulates eNOS expression and/or activity, which exerts direct effects on NO 
production. Many studies have shown that TNF-α significantly decreased eNOS expression 
in ECs (Zhang J et al., 1997; Goodwin BL et al., 2007; Xia et al., 2006; Seidel et al., 2006), and 
down-regulated eNOS expression with reduced NO production in diverse vasculatures 
(Goodwin BL et al., 2007; Gao et al., 2007; Picchi et al., 2006). However, in our hands eNOS 
expression was increased at all three concentrations (namely 0.5, 5 and 20 ng / ml) (see 
figure 5.11). The activation of eNOS (serine 1177 phosphorylation), however, was 
significantly decreased by all three TNF-α concentrations (figure 5.10), a trend that was even 
more pronounced when the relative phosphorylated eNOS / total eNOS was calculated 
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(figure 5.12). TNF-α-induced reduction of phosphorylated eNOS was previously also shown 
in BAECs (Kim HJ et al., 2006a; see Table 1.3).   
PKB/Akt is a major upstream activator of eNOS (Manning and Cantley, 2007), and for this 
reason, we included measurements of PKB/Akt in our experiments. Whereas PKB/Akt 
expression was down-regulated at all three TNF-α concentrations, activated PKB/Akt 
(phosphorylated PKB/Akt at serine 473) was decreased at 0.5 ng / ml and 20 ng / ml TNF-α 
(figures 5.14 & 5.13 respectively), and the relative activation of PKB/Akt (phosphorylated 
PKB/Akt / total PKB/Akt) was only decreased at 20 ng / ml (figure 5.15).  In contrast to our 
findings, studies that investigated the effects of TNF-α-treatment in endothelial cells (De 
Palma et al., 2006) and in cardiomyocytes (Hiroaka et al., 2001) showed increased levels of 
phosphorylated PKB/Akt. However, in support of our findings, a study by Kim F et al. (2001) 
showed that fluid shear stress (FSS) increased phosphorylation of PKB/Akt at Serine 473 in 
BAECs, but that brief pretreatment with TNF-α (10 ng / ml)  before FSS stimulation led to 
decreased levels of phosphorylation of Serine 473 in PKB/Akt. 
Another protein that is closely involved with the eNOS-NO biosynthesis pathway, is HSP 90. 
HSP 90 is a chaperone protein that plays an important role in post-translational activation of 
eNOS by increasing eNOS sensitivity to Ca2+/calmodulin via HSP 90 – eNOS interaction 
(Balligand et al., 2009). In addition to the decreased eNOS activation and general trends of 
PKB/Akt down-regulation, we also found decreased HSP 90 expression (see figure 5.16), 
which is further indicative of a generalised down-regulation of the PKB/Akt-HSP 90-eNOS 
enzyme complex.  The fact that we did not observe an increase in caveolin-1 at any of three 
concentrations of TNF-α (see figure 5.17), in fact a decreased expression was found at  TNF-
α 5 ng / ml, does not fit well with the scenario described above as caveolin-1 is known to 
inhibit the activity of NOS (Bucci et al., 2000). In view of the overall down-regulated eNOS 
activity seen in the CMECs, we would have expected caveolin-1 expression to increase, as 
was shown in a study on BAECs treated with TNF-α (0.5 ng / ml) (Wang L et al. 2008).  
In human aortic ECs treated with TNF-α for 8 hours, in addition to observing a down-
regulation of eNOS expression, the authors found an induction in the mRNA expression of 
the inducible NOS isoform, iNOS. (MacNaul and Hutchinson, 1993). TNF-α-induced increased 
expression of iNOS has also been observed in other endothelial cells studies (Chen X et al., 
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2008; Bereta et al., 1997; Zhang C et al., 2006b). In view of this, in a separate series of 
investigations, we investigated whether TNF-α (20 ng / ml; 24 hours) would increase iNOS 
expression in our cells. Our results showed a significant increase in iNOS expression (see 
figure 5.27). As far as we are aware, this is a novel finding in this cell type. 
Most other studies measured the breakdown products of NO as an indication of NO 
production following TNF-α treatment. In our study, we made use of a direct intracellular 
and NO-specific measurement assay by FACS analysis of DAF-2/DA fluorescence. Regardless 
of the method used, a few studies found similar decreases in NO as observed in our study 
with the 0.5 and 20 ng / ml TNF-α concentrations (Bove et al., 2001; Goodwin BL et al., 
2007;  Kim HJ et al., 2006a).  In order to investigate whether how the TNF-α-induced NO 
results in the CMECs compared with a different endothelial cell line, we employed a 
separate series of experiments where we subjected rat aortic endothelial cells (AECs) to 
TNF-α treatment. Generally, the overall trends were similar between the two cell lines, 
although it was interesting to note that at TNF-α 5 ng / ml, the NO-production in the AECs 
was significantly more reduced than in the CMECs and that TNF-α (20 ng / ml) did not exert 
any effects in the AECs whereas the CMECs responded with a reduction in NO production 
(see figure 5.28). In order to investigate whether the NO-lowering effects observed in the 
CMECs at a TNF-α concentration of 20 ng / ml (24 hours) were reversible, we pre-treated 
the cells with oleanolic acid (OA), a known inducer of the eNOS-NO pathway (Rodriguez-
Rodriguez et al., 2008). We pre-administered OA at a concentration of 40 µg / ml, followed 
by TNF-α (20 ng / ml) for 24 hours (following the same protocol as described in section 
5.3.1). The results showed that pre-treatment with OA abolished the NO-lowering effects of 
TNF-α, suggesting that the TNF-α effects on NO production were indeed reversible. (see 
figure 5.26). 
In view of the attenuation of NO-production observed in both the CMECs and AECs at 5 ng / 
ml TNF-α, a fellow postgraduate student in our research group investigated whether pre-
treatment with 5 ng /ml TNF-α would negatively affect acetylcholine-induced vasorelaxation 
in isolated rat aortic ring segments. The data showed attenuation in aortic relaxation, which 
is indicative of endothelial dysfunction (see figure 5.29).  
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Collectively, therefore, the investigations so far suggest that TNF-α treatment was able to 
induce a dysfunctional state in our cells, as is evident from the down-regulation of the 
eNOS-NO biosynthesis pathway, and further supported by the functional data obtained in 
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Figure 5.26: The effects of 40 µg / ml OA pre-treatment on the mean DAF-2/DA 
fluorescence intensity in TNF-α-treated CMECs (20 ng / ml; 24 hours). Data presented as % 
DAF-2/DA fluorescence (expressed as a percentage of control; control = 100%).  The NO-






Stellenbosch University  http://scholar.sun.ac.za
P a g e  | - 260 - 
 
  Chapter Five 
 
 
Figure 5.27: The effects of 20 ng / ml TNF-α on iNOS expression.  iNOS expression is 
expressed as a ratio of control; control adjusted to 1 (please refer to page 134, chapter 2). 
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Figure 5.28: TNF-α effects on mean DAF-2/DA fluorescence at different concentrations 
(0.5, 5 and 20 ng / ml for 24 hours) in CMECs and AECs. Data presented as % DAF-2/DA 
fluorescence (expressed as a percentage of control; control = 100%).  The NO-donor, 
DEA/NO (100µM) was used as a positive control   Sample size:  n = 4 – 6 / group. (Graph 
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Figure 5.29: Acetylcholine-induced aortic ring relaxation. Rings were pre-contracted with 
phenylephrine, followed by treatment with 10 ng / ml TNF-α for 30 minutes and finally 
acummulative acetylcholine administrations to induce endothelial- and NO-dependent 
vasorelaxation. Data are expressed as % relaxation of maximum pre-contraction.  Sample 
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TNF-α is often associated with increased ROS production in endothelial cells (for review, 
see: Chen W et al., 2008). TNF-α was shown to induce O2− production in neutrophils and 
ECs, reportedly via CAPK (ceramide-activated protein kinase), NADPH oxidase (Sorescu and 
Griendling, 2002), XO (Downey et al., 1991), and NOS (Pritchard et al., 1995; Cai and 
Harrison DG, 2000).  With the exception of a modest increase in DCF fluorescence at TNF-α 
20 ng / ml, all the other fluorescent probe results demonstrated an overall reduction in ROS 
generation following TNF-α treatment (see figures 5.7 – 5.9). This was surprising and 
difficult to explain in view of the overwhelming evidence in the literature to the contrary, 
albeit it mainly in other endothelial cell types. We will discuss our strategies to further 
investigate this phenomenon in the next sections. We further assessed the oxidative stress 
status of the cells by measuring the expression of p22 phox. As mentioned previously, p22 
phox is regarded as a marker of NADPH-oxidase activity, which has been suggested to be the 
principal source of O2− production in several animal models of vascular disease (Warnholtz 
et al., 1999). In endothelial cells, NADPH oxidase activation has been shown to occur in 
response to TNF-α (Frey et al., 2002). Our p22 phox data were suggestive of a TNF-α dose-
dependent increase in NADPH-oxidase-derived oxidative stress (see figure 5.18).   
Confirmation of NF-κβ activation: TNF-α is known to induce the transcription of NF-κβ, 
which regulates the expression of genes involved in inflammation, oxidative stress and 
endothelial dysfunction (Dela Paz et al., 2007; Rimbach et al., 2000; Kumar A et al., 2004). 
TNF-α initiates the signalling cascades via IKKα and IKKβ (Zhang H et al., 2009). Following 
TNF-α binding to its receptor 1, the NF-κβ inhibitory protein IΚBα is phosphorylated, 
biquitinated and degraded by the proteasome, thus releasing NF-ΚB to translocate into the 
nucleus (Zhang H et al., 2009). In our study, we found a dose-dependent decrease in IΚβα 
(see figure 5.20) which is an indication of increased NF-KB activation and an ensuing 
inflammatory response. Although we did not specifically investigate the association 
between the NF-KB activation and increased iNOS expression in our CMECs, it is quite 
possible that the iNOS induction was a result of NF-κβ activation, as iNOS is a known gene 
target of the activated NF-κβ transcription factor (Aktan, 2004). Furthermore, the activation 
of NF-κβ may also partly explain the anti-apoptotic findings discussed earlier, as activation 
of the TNF-α - TNF Receptor 1 – NF-KB pathway is considered by many to inhibit apoptosis 
(Chen G et al., 2002).   
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5.5.2 Short term treatment of CMECs with TNF-α (20 ng / ml) for 30 minutes. 
An overview of the literature demonstrates that the effects that TNF-α are time-dependent, 
in addition to being concentration-dependent (Yoshimi et al., 1993; Li C et al., 2002; Li YSJ et 
al., 2005; Polunovsky et al., 1994; Yan et al., 2008).  Whereas some studies have shown an 
increase in NO production after 24 hours (Wang P et al., 1994; Xia et al., 2006) others 
showed a decrease in NO after shorter periods of treatment (10 minutes and 1 hours) (Kim 
HJ et al., 2006;  Corda et al., 2001).  Furthermore, as mentioned in the previous section, our 
24 hour TNF-α data showed a general trend of reduced ROS production, which is contrary to 
most reports in the literature. Therefore, in the light of this fact, we were interested to 
determine whether a shorter treatment time would perhaps reveal an early burst of ROS 
generation which could have been missed at 24 hours. Our data showed that, overall, NO 
production and ROS production as measured by our various fluorescent probes followed 
similar trends to the 24 hour findings when exposed to 30 minutes of TNF-α treatment 
(figures 5.6 – 9 and figures 5.21 - 24).    
 
5.5.3  The effects of reduced serum content in growth medium on superoxide 
production in CMECs treated with TNF-α (20 ng / ml): 24 hours 
Serum reduction or starvation is widely used as a method to induce cell cycle arrest in order 
to ensure that all cells in a specific tissue culture dish are synchronized (Chen M et al., 
2012), similar to the effects achieved when allowing cells to grow to confluency. However, 
many studies have implemented the method of serum starvation not for the above purpose, 
but because it is believed that the presence or the amount of serum in the culture medium 
can “mask” the effect of treatment on oxidative stress or superoxide production in in vitro 
experiments (Tey et al., 2010; Lee SB et al., 2005).  Therefore, many studies that measured 
superoxide production in vitro, implemented the serum starvation protocol by either 
reducing the amount of serum in the medium or culturing the cells in serum-free medium.  
In the present study, cells that were serum deprived (0% and 5 % FBS-containing growth 
media) and treated with TNF-α (20 ng / ml) for 24 hours, showed similar decreasing trends 
in DHE fluorescence than observed in the normal serum-containing medium (10% FBS) 
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investigations (see figure 5.25). These results show that reducing the serum content, or 
even removing it completely from the growth medium had no effect on the trends observed 
with the ROS data in cells incubated with 10% serum-containing growth media. Our data 
contradict the findings of previous studies conducted on other endothelial cell types. In a 
study by Basuroy et al. (2006), cerebral microvessel endothelial cells (CMVECs) were serum 
starved (0.1% FBS) overnight and subsequently treated with 15 ng / ml TNF-α for 3 – 6 
hours.  They found an increase in ROS formation detected by Rh123 and ethidium 
fluorescence microscopy. In another study, HUVECs were serum starved for 2 hours and 
treated with 10 ng / ml TNF-α for 8 hours (Szotowskia et al., 2007).  They found increased 
ROS levels as was indicated by a lucigenin chemiluminescence assay.  An increase in ROS 
production, as measured by DCF fluorescence, was also found in a study where serum 
starved HUVECs were treated with 10 ng / ml TNF-α for 1 hour (Lee SJ et al., 2011).  In 
conclusion, our serum reduction experiments suggest that, in our hands, the CMECs did not 
respond to TNF-α treatment with higher ROS production (as measured by DHE fluorescence) 
compared to CMECs incubated in normal (10%) serum-containing growth medium. It 
therefore appears that a possible increase in ROS production was not masked by our choice 
of 10% FBS enriched growth medium. 
 
5.6  Conclusion 
In conclusion and as far as we are aware, the findings of this chapter are novel in that no 
previous studies have characterised the responses to TNF-α treatment at different 
concentrations and time-points in CMECs in an equally comprehensive manner. We 
approached the studies in this chapter by making use of various concentrations of TNF-α as 
well as “short-term” vs. “long-term” treatments. Another factor, namely the amount of 
serum present in the growth medium was also investigated as a possible contributor to 
some puzzling results we found in earlier parts of the study, particularly with regard to the 
surprising observations in the ROS production experiments.  Various endpoints were 
measured to address the different effects of TNF-α on the CMECs.  Again (as in the previous 
chapter), we investigated various intracellular parameters as well as important endothelial 
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signalling proteins.  In our view, the following findings are the most important of this 
chapter: 
• eNOS-NO biosynthesis:  As was indicated by many other previous studies, we found 
an overall down-regulation of the eNOS-NO biosynthesis pathway in a dose-dependent 
manner, as indicated by the down-regulation of eNOS activity as well as its chaperone HSP 
90. This was further supported by the decrease in NO production at 0.5ng / ml and 20 ng / 
ml, in spite of the modest increase in iNOS expression.  Because of the strong link between 
TNF-α and vascular endothelial dysfunction, these findings come as no surprise, and are in 
general agreement with the literature.  Short-term treatment with the highest 
concentration of TNF-α had the same effect as long-term treatment (a decrease in NO 
production).  Our data were well supported by additional experiments in which we 
compared the effects of TNF-α treatment on NO production in the CMECs with a different 
endothelial cell line (AECs), and we could also demonstrate the probable dysfunctional 
effect of TNF-α in isolated aortic ring segments.   
• ROS production and oxidative stress: The ROS production in TNF-α-treated CMECs 
was thoroughly investigated, and we made use of no less than three independent probes 
(DHE, DCF and DHR-123). Surprisingly, the fluorescent probe results pointed to an oxidative- 
and nitrosative stress free scenario. On the other hand, we also measured NADPH-oxidase 
activity, which did indeed show concentration-dependent increases (p22 phox expression), 
whereas nitrotyrosine expression (an important marker of nitrosative stress), was reduced. 
For these reasons, we found it necessary to re-investigate the ROS production in our cells 
after TNF-α treatment in two different scenarios.  Firstly, with reduced serum in the media, 
as we speculated that the normal presence (10 %) of serum might be “masking” the effects 
of TNF-α on ROS production. Secondly, we investigated the effect of TNF-α on ROS 
production at a shorter incubation time (30 minutes) as the initial ROS production response 
might have already been lost at 24 hours.  Despite all these efforts, the findings remained 
the same, leading us to speculate, in our hands, the CMECs seemingly did not respond to 
TNF-α by increasing intracellular ROS production as measured by our chosen fluorescent 
probes. 
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CHAPTER SIX 
A characterization and investigation of TNF-α-induced responses in CMECs:  A proteomic 
analysis. 
 
6.1  Introduction  
As previously shown in chapter 4, the technique of proteomics allows for large-scale 
characterization and analysis of protein expression and regulation in cells in response to 
certain experimental manipulations (Anderson and Anderson, 1998). As such, data obtained 
from proteomic analysis can add valuable insights into protein pathways and mechanisms 
induced by experimental interventions. Relatively few papers have been published in the 
field of vascular endothelial proteomics, which is surprising given the importance of 
endothelial cells in cardiovascular physiology and pathology (Richardson et al., 2010).  More 
particularly, there is a lack of data available on proteomic characterization and regulation in 
TNF-α stimulated endothelial cells with only a few studies that have exclusively focused on 
this aspect (Ma et al., 2006; Freed and Greene, 2010).  As mentioned before, CMECs are an 
endothelial cell phenotype found mainly in myocardial capillaries where they participate in 
an intimate interaction with surrounding cardiomyocytes (Brutsaert, 2003). Consequently, 
CMECs are regarded as important regulators of myocardial function via the actions of 
various secretory products such as NO and endothelin-1.  CMECs are a distinct member of 
the vascular endothelial cell family in terms of location, structure, function and role in end-
organ myocardial pathology such as ischaemic heart disease (Aird, 2007a).  However, there 
is limited information available on the total protein expression and regulation patterns in 
this endothelial cell subtype, both with regard to normal and TNF-α stimulated cells. The 
importance of comprehensively investigating the large-scale protein expression patterns in 
the context of TNF-α stimulation lies in the fact that many cardiovascular risk factors (e.g. 
diabetes mellitus and obesity) and cardiovascular diseases (e.g. atherosclerosis and heart 
failure) have been shown to be associated with a pro-inflammatory environment and thus 
elevated circulating TNF-α levels (Dandona et al., 2005; Lau et al., 2005; Bruunsgaard et al., 
2000; Torre-Amione et al., 1996). One of the primary targets of the actions of harmful 
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circulating TNF-α is the vascular endothelium. A thorough literature review has revealed 
that very few proteomics-based studies have been conducted on the effects of TNF-α 
stimulation, not only in the context of vascular endothelium in general, but more specifically 
in the context of CMECs. Therefore, in this chapter, we investigated and analysed the CMEC 
proteome following treatment with TNF-α. With the help of an on-line functional annotation 
analysis software program, we were able to make observations in terms of protein 
networks, clusters and pathways that were either strongly represented in the TNF-α-treated 
cells, or those that were down-regulated. We supplemented the proteomics data with 
directed additional investigations to further validate the findings. 
 
6.2  Methods  
For the purposes of the proteomics studies, we decided to treat the cells with 5 ng / ml TNF-
α for 24 hours. The rationale behind this decision was mainly determined by the fact that 
we observed sufficient changes in the flow cytometry and western blot endpoints at this 
concentration and treatment time. Furthermore, due to budgetary constraints, we did not 
have the luxury of submitting samples for 0.5, 5 and 20 ng/ml TNF-α treatments. Initially, 
before we commenced with the main proteomic studies (performed by Dr Salome Smit of 
the Proteomics Unit of Stellenbosch University), we approached Applied Biomics (San 
Francisco, USA) to perform a small series of pilot analyses on untreated control and TNF-α (5 
ng / ml; 24 hours) treated CMECs. Cells were prepared by performing a protein extraction of 
TNF-α treated and untreated (control) samples as described in chapter 2 (page 131).  A total 
of 3 samples were prepared for control, untreated and TNF-α treated groups respectively. A 
protein content of 50 µg / ml was used as final protein concentration.  Protein was 
subsequently precipitated by adding 1 volume of protein solution to 9 volumes of cold 
ethanol (100 %). It was then mixed and kept for at least 60 minutes at –20 ˚C.  Following the 
precipitation of the proteins, the suspension was centrifuged for 15 minutes at 4˚C in a 
microcentrifuge at maximum speed (15000 g).  The supernatant was carefully discharged 
and the pellet retained and dried.  The pellet was resuspended in ethanol (100 %) and 
couriered (at room temperature) to Applied Biomics for analysis. The company performed 2-
dimensional differential gel electrophoresis (2D-DIGE) from which the spots of interest were 
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selected. Our instructions to Applied Biomics were to investigate the top differentially 
regulated (up- or down-regulated) phospho-proteins in the TNF-α samples compared to 
untreated controls.  
 
Following the pilot studies, we approached the Proteomics Unit of Stellenbosch University 
to perform the main proteomic analyses on our samples (untreated control CMECs vs. TNF-
α-treated CMECs; TNF-α: 5 ng / ml for 24 hours). Preparation of samples for proteomics 
analysis was performed by one dimensional SDS-PAGE, followed by in gel trypsin digestion 
(as described in chapter 2, page 135).  Thermo Proteome Discoverer 1.3 (Thermo Scientific, 
Bremen, Germany) was used to identify proteins via automated database searching 
(Mascot, Matrix Science, London, UK, and Sequest) of all tandem mass spectra against the 
Uniprot rat database. For the determination of proteins that were only present in either the 
treated or untreated sample the protein had to be detected in 2 of the 3 replicates but 
absent in all 3 replicates from the other sample. For protein regulation, SIEVE 1.3 (Thermo 
Scientific, Bremen, Germany) and Maxquant Proteomics software packages were used. 
Proteins were only considered differentially regulated with a protein and peptide PEP of 
0.01, up or down regulation of ≥ 1.5-fold and a p-value of p < 0.05. These strict criteria were 
used to ensure that differences in abundance are real and not due to parent ions that had 
not been detected due to random fluctuations during MS/MS data-dependent acquisition. 
See figure 5.3 for overview of the proteomic procedures followed in the TNF-α 
investigations. Data analysis (including functional annotation analyses of proteins) of 
proteomics results, were performed as described in chapter 2 (page 139). 
  
Additional investigations (e.g. western blots, FACS analyses and fluorescence microscopy) 
were performed based on standard methods described previously in this dissertation to 
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Figure 6.1: Workflow for the proteomic analyses of untreated, control and TNF-α-
treated (TNF-α: 5 ng / ml for 24 hours) samples. An equal amount of protein (50 ug / 10 ul) 
was loaded onto the SDS-PAGE gel. The gel was stained using Coomassie blue and cut into 5 
fractions for in-gel trypsin digestion. Peptides from the gel were extracted and prepared for 
LC-MS/MS. All MS/MS spectra were searched using Thermo Proteome Discoverer software 
(version 1.3) against in-house versions of Mascot, Sequest, X!tandem and Andromeda. For 
final data analyses, the identified proteins from all the search engines were combined to 
obtain a final list of proteins present in the TNF-α treated CMEC proteome. Sample sizes 
were as follows: Control, untreated: n = 3 and TNF-α treatment: n = 3. 
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6.3  Results 
6.3.1  Pilot studies: 2D-DIGE-phosphoproteomics (Applied Biomics) 
A photograph of the 2D-gel with the full proteome of untreated, control CMECs is shown in 
figure 6.2. The top high confidence, differentially regulated phospho-proteins in the TNF-α-
treated samples, as analysed by Applied Biomics, are shown in Table 6.1. Of note is the 
pronounced upregulation of heterogeneous nuclear ribonucleoprotein K (hnRNP K) and the 
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Figure 6.2: A two dimensional gel from Applied Biomics, from which differentially 
regulated spots were eventually selected for further analysis. 
 
Table 6.1: High confidence differentially expressed phosphorylated proteins in TNF-α 
treated (5 ng/ml; 24 h) CMECs as determined by 2-D DIGE. 
 
Protein identity Fold Regulation 
Heterogeneous nuclear ribonucleoprotein K, isoform 
CRA_b [Rattus norvegicus] 
1.9-fold 
Profilin [Rattus norvegicus]  1.7-fold 
Beta-actin [Rattus norvegicus]  1.6-fold 
Ras-related protein Rab-23 [Rattus norvegicus]  1.6-fold 
Zinc finger protein 347 [Rattus norvegicus]  1.6-fold 
Heat shock protein HSP 90-alpha [Rattus norvegicus]  1.6-fold 
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Figure 6.3: The location of the HSP 90-alpha spot indicated on the 2D gel showing 
reduction in abundance between control (left) and TNF-α-treated (right) samples. Below are 
the in-gel image analyses of the control and TNF-α HSP 90-alpha spots showing a graphical 
representation of their 3-dimensional characteristics. Subsequent calculations indicated that 
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6.3.2  Large-scale protein expression and regulation analyses: Main Study: 
Collectively, the Maxquant and SIEVE search engines identified a total of 232 unique 
proteins that were detected in TNF-α-treated cells only, and not detected in control 
samples. See Table 6.2 for a selected list of proteins that were detected in TNF-α-treated 
samples only. Furthermore, the search engines detected a total of 83 proteins that were 
significantly up-regulated (≥ 1.5-fold) in TNF-α-treated samples vs. control (see Table 6.3 for 
a selected list of up-regulated proteins). Conversely, 72 proteins were uniquely expressed in 
control CMECs only, and whose detection was subsequently lost when cells were treated 
with TNF-α; furthermore, 153 proteins were significantly down-regulated (≥ 1.5-fold) in TNF-
α-treated samples. The complete lists of differentially expressed proteins will be supplied 
electronically. 
 
Clearly, it is impossible to give a complete description of the changes we observed in the 
expression and regulation of individual proteins. However, some interesting results, which 
have bearing on the aims of this chapter and dissertation will be listed here and discussed 
later: 
 Similarities with Applied Biomics 2D-DIGE-proteomics analysis: HSP 90-α was 5.8-
fold and HSP 90-β 4.2-fold down-regulated respectively in TNF-α-treated CMECs (See 
Table 6.4), which follows the same trend observed in the Applied Biomics data (HSP-
90 alpha: 1.6 down-regulation; see figure 6.3). 
 Validation of TNF-α-signalling: TNF-R1 Death Associated Protein (TRADD) and NF-κβ 
were expressed only in TNF-α-treated cells, and not untreated control cells (See 
Table 6.2). 
 Regulation of apoptosis: Bid (pro-apoptotic; in TNF-α-treated cells only), PEA-15 
(anti-apoptotic; in TNF-α-treated cells only), BOK (pro-apoptotic; in TNF-α-treated 
cells only), metadherin (anti-apoptotic; in TNF-α-treated cells only), and gelsolin 
(anti-apoptotic; 43-fold down-regulation). See Tables 6.2 – 6.4. 
 Proteins involved with oxidative stress status: Park-7 (anti-oxidant; in TNF-α cells 
only), SOD-2, mitochondrial (anti-oxidant; 2-fold up-regulation), SOD-1 (anti-oxidant; 
2.4-fold down-regulation). See Tables 6.2-6.4. 
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 Mitochondrial proteins: Acetyl transferase component of pyruvate dehydrogenase 
(3-fold up-regulation), carnitine-acylcarnitine carrier protein (3-fold up-regulation), 
acyl CoA dehydrogenase (5-fold up-regulation), isocitrate dehydrogenase (in TNF-α-
treated cells only), ADP/ATP translocase 2 (7.6-fold up-regulation), cytochrome C1 
(2-fold up-regulation), electron transfer flavoprotein (2-fold up-regulation), VDAC-1 
(2-fold up-regulation), cytochrome C oxidase (in TNF-α-treated cells only) and 
glycerol-3-phosphate dehydrogenase (in TNF-α-treated cells only). See Tables 6.2-
6.4. 
 Proteins involved with inflammatory / immune response: RT1 class I 
histocompatibility antigen (in TNF-α-treated cells only), complement C4 (2.2-fold up-
regulation), intercellular adhesion molecule 1 (7.2-fold up-regulation), interferon-
induced guanylate-binding protein 2 (6.9-fold up-regulation), interleukin 1 family (in 
TNF-α-treated cells only), and prostaglandin E synthase 3 (1.58-fold up-regulation). 
See Tables 6.2-6.4. 
 
It is customary to validate proteomic analysis data by reproducing the trends observed in 
differentially regulated proteins with an alternative measurement technique. We chose to 
validate the down-regulation of HSP 90, as shown by both Applied Biomics (see figure 6.3) 
and by the Proteomics Unit of Stellenbosch University (see Table 6.4)  by performing 
western blot analysis of HSP 90 in control and TNF-α-treated cells. The western blot results 
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Table 6.2:  Selected list of strongly represented proteins (detected in TNF-α samples only)
Accession Number Protein IDs 
Q5U318 Astrocytic phosphoprotein PEA-15 
Q6QI09 ATP synthase gamma chain 
P31399 ATP synthase subunit d, mitochondrial 
Q792S6 Bcl-2-related ovarian killer protein (BOK) 
Q9JLT6 BH3-interacting domain death agonist (BID) 
P05503 Cytochrome c oxidase subunit 1 
P10888 Cytochrome c oxidase subunit 4 isoform 1, mitochondrial 
P04904 Glutathione S-transferase alpha-3 
P24473 Glutathione S-transferase kappa 1 
D3ZGW4 Glutathione S-transferase Mu 1 
P35571 Glycerol-3-phosphate dehydrogenase, mitochondrial 
D4A1I2 Interleukin 1 family, member 6 (Predicted) 
P41565 Isocitrate dehydrogenase [NAD] subunit gamma 1, mitochondrial 
F1LQ51 Jak1 
Q5U2Z4 Nuclear factor of kappa light polypeptide gene enhancer in B-cells 2, p49/p100 
D3ZVI9 Parkinson disease 7 domain containing 1 (PARK-7) 
D3ZGX7 Metadherin 
P16391 RT1 class I histocompatibility antigen, AA alpha chain 
D3Z8V9 Signal transducer and activator of transcription 3 (Stat3)  
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Table 6.3:  Selected list of strongly represented proteins (up-regulated in TNF-α samples)
Accession 
No 
Protein Name Fold Up-Regulation p-value 
Q09073 ADP/ATP translocase 2  7.6 0.001 
P08649 Complement C4 2.2 0.03 
D3ZFQ8 Cytochrome c_1  1.8 9.6x10-9 
P08461 Acetyltransferase component of pyruvate dehydrogenase complex, 
mitochondrial 
2.8 0.04 
P13803 Electron transfer flavoprotein subunit alpha_ mitochondrial  1.6 9.9x10-20 
P63245 RACK-1; Guanine nucleotide-binding protein subunit beta-2-like 1 2.7 0.01 
Q00238 Intercellular adhesion molecule 1 7.2 0.01 
Q63663 Interferon-induced guanylate-binding protein 2 6.9 0.0005 
P97521 Mitochondrial carnitine /acylcarnitine carrier protein 2.7 0.04 
O35244 Peroxiredoxin_6  2.0 9.9x10-20 
P83868 Prostaglandin E synthase 3 1.58 0.0004 
P07895 Superoxide dismutase [Mn], mitochondrial; SOD-2 2.0 0.0005 
P45953 Acyl-CoA dehydrogenase, mitochondrial 5.1 0.02 
Q9Z2L0 Voltage-dependent anion-selective channel protein 1 (VDAC-1) 1.6 3.3x10-16 
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Protein Name Fold Down-
Regulation 
p-value 
Q68FP1 Gelsolin 42.9 7.6x10-12 
P04906 Glutathione S-transferase P  2.6 9.9x10-20 
P30713 Glutathione S-transferase theta-2 1.5 0.03 
P82995 Heat shock protein HSP 90-alpha 5.8 0.008 
P34058 Heat shock protein HSP 90-beta 42.1 9x10-11 
Q9R063 Peroxiredoxin-5-mitochondrial  2.0 0.0002 
P35704 Peroxiredoxin-2 5.6 7.7x10-13 
O35244 Peroxiredoxin-6  11.5 9.9x10-20 
P07632 Superoxide dismutase [Cu_Zn]; SOD-1  2.4 5x10-9 
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Figure 6.4: A western blot analysis of CMECs treated with 0.5, 5 and 20 ng / ml TNF-α for 
24 hours, showing a decrease in HSP 90 expression when compared to control. Data 
expressed as a ratio of control; control adjusted to 1 (please refer to page 134, chapter 2). 
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Next, we submitted the list of the strongly represented proteins in TNF-α-treated CMECs, 
i.e. proteins identified only in TNF-α-treated samples (n = 232 proteins) plus proteins 
signifcantly upregulated by TNF-α (n = 83) to the DAVID functional annotation analysis tool 
in order to gain insight into the functional processes and pathways with which the strongly 
represented proteins were associated. See Tables 6.2, 6.3 and 6.4 for the cellular 
components, biological processes and molecular functions respectively associated with the 
strongly represented proteins. Similarly, we submitted the list of underrepresented 
proteins in TNF-α-treated CMECs, i.e. proteins that were identified in control samples, but 
whose detection was lost in TNF-α-treated samples (n=72) and proteins that were 
significantly down-regulated in TNF-α samples (n=153) for functional annotation analysis. 
See Tables 6.5, 6.6 and 6.7 for the cellular components, biological components and 
molecular functions respectively associated with the underrepresented proteins. The most 
prominent findings from the functional annotation analyses are as follows: 
Strongly represented proteins in TNF-α-treated CMECs: From the cellular component 
analyses (Table 6.5) it is clear that mitochondrial proteins were well represented and highly 
enriched. Cytoskeletal and proteasomal proteins were also well represented. The biological 
processes analyses (Table 6.6) revealed a high enrichment and representation of translation, 
protein transport and proteasomal degradation. Furthermore proteins involved with 
responses to oxidative stress, ROS, glutathione metabolism and oxidation-reduction 
reactions were highly enriched, as were the processes of nitric oxide biosynthesis and 
apoptosis. In the molecular functions category (Table 6.7), anti-oxidant and oxido-reductase 
activity featured prominently, as did glutathione peroxidase activity. 
Underrepresented proteins in TNF-α-treated CMECs: Proteins involved with cellular 
components that were highly enriched included actin cytoskeletal proteins and ribosomal 
proteins (Table 6.8). In the biological processes category (Table 6.9), cytoskeleton 
organisation, proteasomal catabolic processes, vesicle-mediated transport and cell cycle 
were enriched. Ribosomal biogenesis also featured prominently, as did glutathione 
metabolism. Interestingly, glutathione metabolism was equally enriched in the strongly 
represented and underrepresented category, pointing to an equal “gain” and “loss” of 
proteins involved with this aspect of anti-oxidant activity with TNF-α-treatment. Glycolysis 
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was also highly enriched, despite the modest number of proteins associated with this 
process. With regard to the molecular function analyses (Table 6.10), ribosome binding was 
significantly enriched. Structural molecule activity also featured prominently. Interestingly, 
peroxiredoxin (a ubiquitous anti-oxidant system) activity was very highly enriched in the 
underrepresented protein list, as was GTP-ase activity. 
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Table 6.5: Cellular components associated with TNF-α-induced up regulated proteins and proteins detected only in TNF-α stimulated cells. 
CELLULAR COMPONENT (GO TERMS) NUMBER OF PROTEINS P-VALUE FOLD ENRICHMENT 
1. Cytosol 50 8 x 10-13 3.0 
2. Mitochondrion 51 1 x 10-11 2.7 
3. Mitochondrial inner membrane 19 2 x 10-7 4.5 
4. Mitochondrial matrix 13 0.00001 5.0 
5. Cytoskeleton 28 0.0006 2.0 
6. Proteasome complex 6 0.001 7.5 
7. Cytoplasmic membrane-bounded vesicle 16 0.01 2.0 
8. Internal side of the plasma membrane 8 0.01 3.3 
9. Extrinsic to membrane / peripheral membrane proteins 10 0.04 2.2 
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Table 6.6: Biological processes associated with TNF-α-induced up regulated proteins and proteins detected only in TNF-α stimulated cells. 
BIOLOGICAL PROCESS (GO TERMS) NUMBER OF PROTEINS P-VALUE FOLD ENRICHMENT 
1. Protein transport 21 0.00006 2.77 
2. Translation 18 0.00008 3.05 
3. Coenzyme metabolism 10 0.0004 4.5 
4. Glutathione metabolism 5 0.0006 12.5 
5. Response to oxidative stress 10 0.0009 4.0 
6. Response to reactive oxygen species 7 0.002 5.5 
7. Response to hydrogen peroxide 6 0.004 5.8 
8. Mitochondrial organisation and biogenesis 8 0.001 5.1 
9. Mitochondrial transport 5 0.004 7.7 
10. Apoptosis 14 0.005 2.5 
11. Regulation of nitric oxide biosynthesis 4 0.006 10.7 
12. Inhibition of cellular protein metabolism 8 0.008 3.5 
13. Mitochondrial membrane organization 4 0.009 9.0 
14. Oxidation reduction process 17 0.01 2.0 
15. Intermediary metabolism 9 0.02 2.7 
16. Nicotinamide metabolism 4 0.02 6.9 
17. Immune system development 9 0.03 2.5 
18. Regulation of protein ubiquitination 5 0.03 6.3 
19. Oxidoreduction coenzyme metabolic process 4 0.03 5.6 
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Table 6.7: Molecular functions associated with TNF-α-induced up regulated proteins and proteins detected only in TNF-α stimulated cells. 
MOLECULAR FUNCTION (GO TERMS) NUMBER OF PROTEINS P-VALUE FOLD ENRICHMENT 
1. Antioxidant activity 6 0.0003 9.9 
2. Nucleotide binding 46 0.0003 1.7 
3. Oxidoreductase activity, acting on peroxide as acceptor 5 0.0006 12.7 
4. Unfolded protein binding 6 0.005 5.3 
5. Glutathione peroxidase activity 3 0.01 19.4 
6. Protein kinase binding 8 0.01 3.2 
7. Coenzyme binding (acyl-CoA; FAD; FMN; NAD; NADP) 9 0.01 2.8 
8. Lipid binding 11 0.03 2.2 
9. Phospholipid binding 6 0.04 3.1 
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Table 6.8: Cellular components associated with TNF-α-induced down regulated proteins and proteins detected only in control (untreated) 
cells. 
CELLULAR COMPONENT (GO TERMS) NUMBER OF PROTEINS P-VALUE FOLD ENRICHMENT 
1. Cytosol 50 8 x 10-15 3.3 
2. Cytoskeleton 42 3 x 10-12 3.3 
3. Non-membrane-bounded organelle 58 5 x 10-11 2.4 
4. Intermediate filament: cytoskeleton 10 0.00001 7.2 
5. Ribosomal subunit 9 0.00001 8.1 
6. Actin cytoskeleton 13 0.00002 4.6 
7. Cytoplasmic membrane-bounded vesicle 20 0.00006 2.9 
8. Proteasome complex 7 0.00008 9.7 
9. Protein-RNA (ribonucleoprotein) complex 16 0.003 2.4 
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Table 6.9: Biological processes associated with TNF-α-induced down regulated proteins and proteins detected only in control (untreated) 
cells 
BIOLOGICAL PROCESS (GO TERMS) NUMBER OF PROTEINS P-VALUE FOLD ENRICHMENT 
1. Cytoskeleton organization 21 0.0000001 5.0 
2. Regulation of protein ubiquitination 9 0.000006 8.9 
3. Protein transport 20 0.00001 3.1 
4. Proteasomal protein catabolic process 8 0.00004 8.5 
5. Translation 16 0.0001 3.3 
6. Cell cycle 16 0.0002 3.0 
7. Regulation of protein metabolism 15 0.0003 3.2 
8. Activation of enzyme activity 15 0.0005 3.0 
9. Vesicle-mediated transport 14 0.001 2.8 
10. Protein catabolic process 12 0.001 3.2 
11. Ribosome biogenesis 6 0.004 5.8 
12. Response to reactive oxygen species 6 0.004 5.7 
13. Glutathione metabolism 4 0.004 12.1 
14. Small GTPase mediated signal transduction 9 0.004 3.5 
15. Cell redox homeostasis 5 0.006 7.0 
16. Oxidation reduction 15 0.009 2.1 
17. Regulation of apoptosis 16 0.01 2.1 
18. Response to hydrogen peroxide 5 0.01 5.8 
19. Cellular homeostasis 12 0.01 2.3 
20. Glycolysis 4 0.01 7.8 
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Table 6.10: Molecular functions associated with TNF-α-induced down regulated proteins and proteins detected only in control (untreated) 
cells. 
MOLECULAR FUNCTION (GO TERMS) NUMBER OF PROTEINS P-VALUE FOLD ENRICHMENT 
1. Structural molecule activity 27 6 x 10-9 3.8 
2. GTP-ase activity 11 3 x 10-7 9.1 
3. Nucleotide binding 48 1 x 10-6 2.0 
4. Cytoskeleton protein binding 15 0.0003 3.1 
5. Ribosome binding 4 0.0008 20.0 
6. Structural component of ribosome 12 0.001 3.3 
7. Peroxiredoxin activity 3 0.003 34.8 
8. ATP binding 27 0.004 1.8 
9. RNA binding 13 0.008 2.4 
10. Antioxidant activity 4 0.02 7.6 
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6.4  Discussion 
6.4.1  Pilot Studies: Applied Biomics 
In this series of investigations, we subjected our control and TNF-α stimulated CMECs (5 ng / 
ml; 24h) to a 2D-DIGE-based proteomic analysis. In Table 6.1 those phosphorylated proteins 
that demonstrated the greatest degree of differential expression are highlighted. For the 
purposes of this chapter, we will only discuss the up-regulation of heterogeneous nuclear 
ribonucleoprotein K, isoform CRA_b (HnRNP K), which showed the greatest up-regulation in 
the TNF-α-treated cells (1.9-fold increase). In a previous study on cultured cell lines, hnRNP 
K was responsible for repression of the pro-apoptotic Bcl-хs isoform of Bcl-x (Revil et al., 
2009). It is therefore possible that the significant upregulation of hnRNP K formed part of a 
pro-survival (anti-apoptotic) phenotype elicited in our TNF-α stimulated CMECs. The down-
regulation of HSP 90 will be discussed later, as this was also observed in the analyses 
conducted at our university’s proteomics unit. 
 
6.4.2  The main study: Proteomic analysis of TNF-alpha (5 ng / ml) treated CMECs 
(performed at the Proteomics Unit, Stellenbosch University). 
Two protein identification and quantification software packages were used to analyse the 
control and TNF-α-treated proteomes, namely MaxQuant (http://www.maxquant.org/) and 
Sieve (http://www.thermo.com/eThermo/CMA/PDFs/Various/File_53659.pdf). Maxquant 
software identified a total of 1102 proteins and Sieve a total of 1511 proteins. Collectively, 
there were 232 proteins that were identified in TNF-α-treated samples only, and 83 proteins 
that were up-regulated in TNF-α-treated samples compared to control. Conversely, there 
were 72 proteins detected only in control samples and 153 down-regulated proteins in TNF-
α-treated samples vs. control. As a comparison, in one of only a few studies that 
comprehensively analysed the proteome in TNF-α-treated endothelial cells, Ma et al. (2006) 
treated HUVECs with 25 ng / ml TNF-α for 18 hours. There were 1243 ± 48 protein spots on 
the 2D-gel map.  Differential analysis showed 21 protein spots that were different in 
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intensity including 9 expression increased protein spots and 11 expression decreased 
protein spots following TNF-α stimulation (Ma et al., 2006).  
In order to simplify the discussion, the differentially regulated proteins in TNF-α-treated 
CMECs are categorised as either “strongly represented proteins” or “underrepresented 
proteins”. Strongly represented proteins refer to those identified proteins that were unique 
to the TNF-α-treated CMECs, i.e. they were not detected in untreated control samples. 
Proteins that were significantly up-regulated (≥1.5-fold; p < 0.05) in TNF-α-treated cells 
were also included in the strongly represented protein category. The underrepresented 
protein category was made up of proteins that were detected in control CMECs, but whose 
detection was lost in the TNF-α-treated cells as well as proteins that were significantly 
down-regulated (≥1.5-fold; p < 0.05) in TNF-α-treated cells. For reference, please see Tables 
6.2 – 6.4 for selected lists of differentially regulated proteins identified in the CMECs. 
Complete lists of all the differentially regulated proteins will be supplied electronically.  
TNF-α-signalling: Activated TNF-α receptor 1 (TNFR1) recruits TNFR1-associated death 
domain protein (TRADD), which in turn triggers two opposite signalling pathways leading to 
caspase activation for apoptosis induction and NF-κβ activation for anti-apoptotic, pro-
inflammatory protein upregulation (Wang Y et al., 2000) (see figure 6.5).  TRADD as well as 
NF-κβ were strongly represented in our TNF-α treated CMECs (see Table 6.2) and this 
suggests that both the classical TNF-α – TNF receptor 1 – TRADD and TNF-α – TNF-α 
receptor 1 - NF-κβ pathways were induced by exogenous TNF-α administration in our 
CMECs. As shown in Chapter 5, we investigated the induction of the NF-κβ pathway by 
measuring the expression of the NF-κβ inhibiting protein, IKß-α (surrogate marker of NF-κβ 
activation), and the western blot results showed a significant down-regulation of IKß-α, 
indicative of proteasomal degradation and hence NF-κβ activation (see figure 6.5).  
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Figure 6.5: A: Classical signalling pathways of TNF-α receptor type 1 (TNFR1), showing activation of TRADD and NF-κβ (Corda et al., 
2001). 
B: Western blot analysis of CMECs treated with 5 ng / ml TNF-α for 24 hours, showing a decrease in IΚβα expression when compared to 
control. Data were expressed as a ratio of control with control adjusted to 1 (please refer to page 134, chapter 2). Sample size: n = 4 / group.
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Apoptosis: The apoptotic regulation that ensued from the intracellular TNF-α-signalling 
revealed a mixed picture, including evidence of the induction of both pro-apoptotic and 
anti-apoptotic pathways. This phenomenon is not surprising, in view of the fact that 
activation of the TNF-α receptor 1 complex can give rise to apoptosis (via TRADD) and anti-
apoptosis (via NF-κβ). Activation of the TNF-α receptor 1 – TRADD complex can give rise to a 
signalling pathway that eventually activates caspase-8, which in turn activates (cleaves) 
caspase-3 leading to the induction of apoptosis (see figure 6.6). The proteomic data showed 
that astrocytic phosphoprotein PEA-15 (PEA-15), which is a known inhibitor of  TNF-R1-
mediated caspase 8 activity, was strongly represented in TNF-α treated CMECs (see Table 
6.2). The inhibition of caspase 8 was further validated by western blot analysis of cleaved 
caspase-3 (downstream target of caspase-8). Results showed that cleaved caspase-3 
expression was significantly down-regulated in the TNF-α-treated CMECs (see figure 6.7). In 
contrast to our findings, another study found a significant increase in caspase-3 activity in 
TNF-α treated (10 ng / ml for 12 hours) rat vascular endothelial cells (Freed and Greene, 
2010). In summary, our findings indicate that although TRADD was up-regulated, the 
caspase-8 – caspase-3 pathway appeared to be down-regulated, possibly by the actions of 
PEA-15.  Another example of an anti-apoptotic effect elicited by TNF-α-treatment was the 
strong representation of metadherin (see Table 6.2). On the other hand, the proteomic data 
showed that other pro-apoptotic proteins were strongly represented in the TNF-α-treated 
samples. Examples of such proteins included BH3-interacting domain death agonist (BID) 
and Bcl-2-related ovarian killer protein (BOK) (see Table 6.5). BID is involved with a pro-
apoptotic signalling cascade leading to the release of cytochrome C from mitochondria (see 
figure 6.8). BOK is also thought to mediate apoptosis via mitochondrial release of 
cytochrome C (Rodriguez et al., 2006). Finally, the proteomic data showed a significant 
underrepresentation of the anti-apoptotic protein, gelsolin (~ 43-fold down-regulation; see 
Table 6.4). With regard to functional annotation analyses, TNF-α-treatment induced a strong 
representation of 14 proteins associated with the biological process of apoptosis (2.5-fold 
enrichment; p = 0.005) (Table 6.6), whereas 16 proteins associated with apoptosis 
regulation were underrepresented in the TNF-α cells (2.1-fold enrichment; p = 0.01) (Table 
6.9), which suggests a small trend in favour of increased apoptosis. 
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Figure 6.6: PEA-15 regulates TNF-α-induced apoptosis.  PEA-15 participates in the 
formation of the death inducing signalling complex (DISC) (formed by the receptor, FADD 
and caspase-8), where it may bind to FADD and/or pro-caspase-8, blocking the activation of 
the caspase 8, further leading to inactivation of caspase 3 and decreased apoptosis (adapted 





Caspase 3  
TRADD 
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Figure 6.7: Western blot analysis of TNF-α treated (5 ng / ml for 24 hours) CMECs,  
showing a decrease in cleaved caspase-3 when compared to control. Data were expressed 
as a ratio of control with control adjusted to 1 (please refer to page 134, chapter 2). Sample 
size:  n = 4 / group. 
 
 
Figure 6.8: The BID pro-apoptotic signalling pathway activated by TNF-α-TNF R1 
activation.  (adapted from Guicciardi et al., 2005). 
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Oxidative stress: According to the literature, exposure of vascular endothelial cells to TNF-α 
is generally associated with increased oxidative stress (Chen W et al., 2008). However, in our 
hands, the oxidative stress response of the CMECs to TNF-α was similarly mixed as was the 
case with the apoptosis response. Proteomic data showed significant up-regulation of two 
major anti-oxidant systems, namely Parkinson disease 7 domain containing 1 (PARK-7), 
which was detected in TNF-α-treated samples only (Table 6.2) and mitochondrial superoxide 
dismutase [Mn] (also known as SOD-2), which was 2-fold up-regulated (Table 6.3). Park 7 
functions as a redox-sensitive chaperone or as a sensor for oxidative stress (Bonifati et al., 
2003). Our SOD-2 data are supported by the findings of a previous study by Franzén et al. 
(2003), in which HUVECs were treated with 250 U/ ml TNF-α for up to 7 hours; this study 
demonstrated a 3.5-fold upregulation of SOD2. On the other hand, the other SOD isoform, 
superoxide dismutase [Cu_Zn] (SOD-1) was underrepresented showing a 2.4-fold down-
regulation in TNF-α-treated cells (Table 6.4). In order to supplement our proteomic data, the 
oxidative stress response in TNF-α-treated CMECs was further investigated by western blot 
analysis of p22-phox (marker of NADPH-oxidase activity; see Chapter 5). The results showed 
a significant up-regulation in the expression of this protein, indicative of TNF-α-induced 
NADPH-oxidase activation. Interestingly, as was extensively discussed in Chapter 5, 
increased NADPH-oxidase activity did not result in the detection of increased DHE, DCF or 
DHR-123 sensitive ROS generation, either at 30 minutes or 24 hours of TNF-α-treatment.  
Although the lack of increased intracellular ROS levels could be explained by experimental 
and protocol related reasons, this could also be the result of an anti-oxidant processes and 
functions in the cells that were, on balance, perhaps slightly more enriched in the 
overrepresented protein category than in the underrepresented protein category (compare 
Tables 6.6 and 6.7 with Tables 6.9 and 6.10).  Finally, in our supplementary investigations, 
we evaluated whether there was any increased mitochondrial ROS generation in response 
to TNF-α-treatment. This phenomenon has previously been described (Corda et al., 2001; 
Figure 6.9). In this series of experiments, we treated CMECs with 5 ng / ml TNF-α for 24 
hours, followed by incubation with MitoTracker Green to localise the mitochondria (Figure 
6.10 A and B: top panels). This was followed by incubation with MitoTracker Red, a 
mitochondrial ROS-sensitive fluorophore (Figure 6.10 C and D: bottom panels). From the 
photographs, it is clear that the mitochondria of TNF-α-treated cells stained significantly 
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more than the untreated, control samples, which indicated increased mitochondrial ROS 
production in the TNF-α cells. In summary, clearly the TNF-α cells sensed oxidative stress, 
which is evident from the overrepresented anti-oxidant proteins and systems, which could 
possibly explain why our general ROS probes were unable to record increased ROS 
generation. However, conversely, there were also a few anti-oxidant proteins and systems 
that were down-regulated; furthermore, we detected significant increases in NADPH-
oxidase activity as well as mitochondrial ROS generation. Clearly, the oxidative stress status 
and the cellular responses were still in flux at the 24 hour time period.  
When one considers the functional annotation data, several biological processes involved 
with oxidative stress and the response to oxidative stress were strongly represented in TNF-
α-treated cells, including: glutathione metabolism (5 proteins, 12.5-fold enrichment, p = 
0.0006); response to oxidative stress (10 proteins, 4-fold enrichment, p = 0.0009); response 
to reactive oxygen species (7 proteins, 5.5-fold enrichment, p = 0.002); response to 
hydrogen peroxide (6 proteins, 5.8-fold enrichment, p = 0.004) and oxidation reduction 
process (17 proteins, 2-fold enrichment, p = 0.01) (Table 6.6). With regard to molecular 
functions associated with strongly represented proteins, antioxidant activity featured 
prominently (6 proteins, 9.9-fold enrichment, p = 0.0003), as well as oxidoreductase activity 
acting on peroxide as acceptor (5 proteins, 12.7-fold enrichment, p = 0.0006) and 
glutathione peroxidase activity (3 proteins, 19.4-fold enrichment, p = 0.01) (Table 6.7). In 
the underrepresented category, the biological process of response to reactive oxygen 
species featured prominently (6 proteins, 5.7-fold enrichment, p = 0.004), as did glutathione 
metabolism (4 proteins, 12.2-fold enrichment, p = 0.004), cell redox homeostasis (5 
proteins, 7-fold enrichment, p = 0.006), oxidation reduction (15 proteins, 2.1-fold 
enrichment, p = 0.009) and response to hydrogen peroxide (5 proteins, 5.8-fold enrichment, 
p = 0.01) (Table 6.9). Underrepresented proteins associated with the following molecular 
functions: peroxiredoxin activity (3 proteins, 34.8-fold enrichment, p = 0.003) and 
antioxidant activity (4 proteins, 7.6-fold enrichment, p = 0.02) (Table 6.10). On the whole, 
the functional annotation data suggest a modest trend in favour of antioxidant responses. 
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Figure 6.9: The proposed mechanism of TNF-α-induced mitochondrial ROS production 
(Corda et al., 2001). 
 
Figure 6.10: Fluorescence microscopy (Olympus IX-81 inverted fluorescent microscope, 
with CellR imaging software) of CMECs stained with MitoTracker Green to identify the 
mitochondria (Panels A and B: control and TNF-α-treated cells respectively), followed by 
addition of mitochondrial ROS-sensitive MitoSox, detecting mitochondrial ROS production 
(red stain) (Panels C and D: control and TNF-α-treated cells respectively). 
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HSP 90: As previously mentioned, HSP 90 acts as a scaffold protein, presenting substrates 
such as eNOS to PKB/Akt for phosphorylation (Brazil et al., 2002); therefore, HSP 90 plays an 
integral role in the activation of eNOS via phosphorylation at the serine 1177 residue.  
Although the treatment with TNF-α 5 ng / ml for 24 hours did not change DAF-2/DA 
fluorescence (See Chapter 5), both the lower (0.5 ng / ml) and higher (20 ng / ml) 
concentrations decreased DAF-2/DA fluorescence (intracellular NO production). 
Furthermore, a reduction in the relative activation of eNOS was observed in TNF-α-treated 
cells (Chapter 5). From the proteomic data (Figure 6.3 and Table 6.4), and subsequent 
western blot analysis (Figure 6.4), it is clear that there was a significant down-regulation of 
HSP 90 in the TNF-α-treated cells, which could be one of the mechanisms underlying the 
reduction observed in the eNOS-NO biosynthesis pathway.  
Unfortunately, as the reader will appreciate, it is an impossible task to discuss all the 
proteomic data and functional annotation analyses in detail here. We have attempted to 
focus on those responses that are of importance to this dissertation as whole. 
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6.5  Conclusions 
In conclusion, the findings of this chapter are novel in that no previous studies have 
characterised the TNF-α stimulated response in CMECs in an equally comprehensive 
manner. We approached the study in this chapter by investigating large-scale differential 
protein regulation, intracellular events, and important endothelial signalling proteins.  The 
results suggest that, in our hands, TNF-α treatment induced a state of relative flux at 24 
hours, with some subtle signs of endothelial dysfunction and oxidative stress. We have 
attempted to somehow summarise the most important findings (in our view) in figure 6.11. 
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Figure 6.11: A cartoon depicting the summary of the most significant intracellular events 
in TNF-α-treated CMECs based on the results in this chapter. Generally, the proteomic data 
suggested that the TNF-α – TNFR1 – TRADD and TNF-α – TNFR1 – NF-κβ pathways were 
activated. This resulted in the activation of both pro-apoptotic the one hand, and pro-
survival / pro-inflammatory / anti-apoptotic mechanisms on the other. Supplementary 
investigations showed a down-regulation of cleaved caspase-3, which suggests that the 
TRADD - caspase-3 pathway was attenuated, possibly via PEA 15. Mitochondrial-derived 
apoptosis may have been induced via the BID system. The response to oxidative stress was 
mixed, with some antioxidant systems strongly represented in the TNF-α cells, whereas 
others were underrepresented. TNF-α induced a strong up-regulation of mitochondrial 
proteins (51 in total), which was associated with induction of AMP-kinase and increased 
fatty acid metabolism and reduced glycolysis. Other responses as suggested by the 
proteomic data included decreased actin cytoskeleton organisation and cell cycle arrest. 
Taken together with the findings of Chapter 5, it appears as if a modest state of endothelial 
dysfunction was induced (decreased eNOS activity), together with increased oxidative stress 
which elicited an antioxidant response in the cells; however, outspoken apoptosis had not 
yet been established at 24 hours treatment. (Adapted from: Strijdom H, Genis A, Smit S. 
Cardiac microvascular endothelial cells: characterization of total protein expression and 
responses to TNF-α. Paper presented at the SA / UK cardiovascular meeting; UCT; August 
2012). 
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CHAPTER SEVEN 
Investigating the role of the TNF receptors and subsequent signalling events. 
 
7.1  Introduction  
In view of the interesting results in the previous chapter, where the proteomic analyses and 
supplementary western blot data suggested a role for TNFR1 – TRADD – NF-κβ pathway 
activation in our exogenously TNF-α-treated CMECs, we aimed to further tease out the 
respective roles of TNFR1 and TNFR2 in this chapter by making use of commercially available 
TNFR1- and TNFR2-blockers. From the literature, it is clear that very few vascular 
endothelial cell studies have investigated the respective roles of TNFR1 and TNFR2 in cells 
exposed to exogenous TNF-α-treatment. Certainly, we found no studies performed on 
CMECs. Therefore, all the data contained in this chapter are novel, particularly with regard 
to the end-points we chose to investigate. 
TNF exerts its function by binding to and signalling via two distinct receptors (Hijdra et al., 
2012; Chandrasekharan et al., 2007). TNFR1 (CD120a) is constitutively expressed, albeit it at 
relatively low levels, on nearly all nucleated cell types (Vandenabeele et al., 1995), including 
endothelial cells (Kneilling et al., 2009). TNFR2 (CD120b) is inducible and expressed by cells 
of myeloid lineage, peripheral T cells and alveolar lymphocytes and macrophages (Ye et al., 
2001; Faustman et al., 2010; Kieszko et al., 2007). As most information regarding TNF 
signalling is derived from TNFR1, the role of TNFR2 is likely underestimated (Naudé et al., 
2001). 
 
7.1.1  TNFR1 
Upon contact with their ligand, TNF receptors also form trimers, their tips fitting into the 
grooves formed between TNF monomers. This binding causes a conformational change to 
occur in the receptor, leading to the dissociation of the inhibitory protein SODD from the 
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intracellular death domain. This dissociation enables the adaptor protein TRADD to bind to 
the death domain, serving as a platform for subsequent protein binding. Following TRADD 
binding, three pathways can be initiated (Wajant et al., 2003; Chen G et al., 2002) (please 
refer to figure 7.1 for a complete signalling pathway of TNFR1). 
 
7.1.1.1  Activation of NF-κB. 
Tumor necrosis factor receptor type 1-associated DEATH domain protein (TRADD) recruits 
TNF receptor-associated factor 2 (TRAF2) and receptor-interacting protein (RIP) (So et al., 
2011). TRAF2 in turn recruits the multicomponent protein kinase IκB kinase (IKK), enabling 
the serine-threonine kinase RIP to activate it.  An inhibitory protein, IκBα, that normally 
binds to NF-κB and inhibits its translocation (Morgan and Liu, 2010), is phosphorylated by 
IKK and subsequently degraded, releasing NF-κB. NF-κB is a heterodimeric transcription 
factor that translocates to the nucleus and mediates the transcription of a vast array of 
proteins involved in cell survival and proliferation, inflammatory response, and anti-
apoptotic factors (Ghosh et al., 2012). 
 
7.1.1.2  Activation of the MAPK pathways. 
Of the three major MAPK cascades, TNF induces a strong activation of the stress-related c-
Jun N-terminal kinase (JNK) family, evokes a moderate response from p38-MAPK, and is 
responsible for minimal activation of the classical extracellular signal-regulated kinases 
(ERKs) (Crisafulli et al., 2009).  JNK translocates to the nucleus and activates transcription 
factors such as c-Jun and ATF2 (Walczynski et al., 2013). The JNK pathway is involved in cell 
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7.1.1.3  Induction of death signalling. 
Like all death-domain-containing members of the TNFR superfamily, TNFR1 is involved in 
death signalling (Gaur et al., 2003).  However, TNF-induced cell death plays only a minor role 
compared to its overwhelming functions in the inflammatory process. Its death-inducing 
capability is weak compared to other family members (such as Fas), and often masked by 
the anti-apoptotic effects of NF-κB (Walczak, 2011). Nevertheless, TRADD binds Fas-
Associated protein with Death Domain (FADD), which then recruits the cysteine protease 
caspase-8 (Ikner and Ashkenazi, 2011). A high concentration of caspase-8 induces its 
autoproteolytic activation and subsequent cleaving of downstream executioners caspase-3 
and caspase-7, triggering the apoptotic demise of the cell (Ikner and Ashkenazi, 2011). 
The myriad and often-conflicting effects mediated by the above pathways indicate the 
existence of extensive cross-talk. Factors, such as cell type, concurrent stimulation with 
other cytokines or the amount of ROS generated can shift the balance in favor of one 
pathway or another. Such complicated signalling ensures that, whenever TNF is released, 
various cells with vastly diverse functions and conditions can all respond appropriately to 
inflammation (Locksley et al., 2001; Bouwmeester et al., 2004). 
 
7.1.2.  TNFR2 
TNFR2 is readily cleaved by the metalloprotease TNF-α converting enzyme (TACE) into its 
soluble shed form which is still capable of TNF binding, rapidly altering the number of 
functional TNFR2 receptors that can signal their proliferative or apoptotic actions (Pennica 
et al., 1992; Porteu and Hieblot, 1994; Higuchi and Aggarwal, 1994).  Although regulation of 
TNFR protein expression is not restricted purely to TNFR2 (Manna and Aggarwal, 1998), 
generally the more restrictive tissue distribution of TNFR2 and the flexible TNFR2 protein 
regulation suggest a physiological role for TNFR2 regulation in modulating TNF-
responsiveness (MacEwan, 2002).  TNFRs form homotrimers upon activation by TNF without 
the assembly of receptor heterotrimers (Moosmayer et al., 1994), however the TNFR1 : 
TNFR2 protein ratio has been found to be important in the way a cell predetermines its TNF 
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response (Medvedev et al., 1996; Declercq et al., 1998; Baxter et al., 1999). Deletion of 
TNFR2 in transgenic mice has uncovered that this receptor subtype is important in low dose 
TNF-induced lethality (Erickson et al., 1994).  In addition to a role in thymocyte proliferation 
(Grell et al., 1998), TNFR2 plays an important role in models of cerebral malaria and 
microvascular endothelial cell damage (Lucas R et al., 1997a, b; 1998).  Langerhans cell 
migration was depressed in mice lacking TNFR2 (Wang B et al., 1996), whereas TNFR2 plays 
a critical role in multiorgan inflammation (Douni and Kollias, 1998).  Clearly, TNFR2 has a 
role in certain tissues and diseased states, but the validity of direct comparisons between 
TNFR-null transgenic mice and normal cells and tissues which ubiquitously express TNFRs at 
altering TNFR1 : TNFR2 ratios, has to be considered when analysing the physiological role of 
TNFR1 and TNFR2 (MacEwan, 2002).  Please see figure 7.1 for a complete signalling pathway 
of TNFR2. 
 
It has also been shown that endothelial cells express a third TNF-α receptor, known as the 
lymphotoxin-β receptor (LTBR). This receptor is known to play an important role in the 
inflammatory responses of these cells (Pablos et al., 2005; Madge et al., 2008); however, it 
is not as extensively described in the literature as TNFR1 and TNFR2. For the purposes of 
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Figure 7.1: The downstream signalling pathways of TNF-α and TNFR1 and TNFR2. It is 
proposed that the downstream effects of activation of both receptors can activate different 
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7.2  Methods  
 
In order to determine the respective roles of TNFR1 and TNFR2 in TNF-α-treated CMECs, we 
purchased human TNF RI / TNFRSF1A (TNF-α receptor blocker 1 – TRB1) and TNF RII / 
TNFRSF1B (TNF-α receptor blocker 2 – TRB2) polyclonal (Goat IgG) antibodies from R&D 
Systems Inc. (Minneapolis, MN 55413, USA).  CMECs were pre-treated with either 1 µg / ml 
of TRB1 or TRB2 or TRB1+TRB2 for 30 minutes and then subsequently treated with TNF-α 
(20 ng / ml) for a further 30 minutes (see figure 7.2 for complete protocol).  We have chosen 
to use 30 minutes as incubation time, as pilot studies with the receptor blockers performed 
at 24 hours treatment showed inconclusive results.  Previous studies that investigated the 
effects of these specific antibodies, used concentrations of TNF RI / TNFRSF1A and TNF RII / 
TNFRSF1B ranging from 0 – 10 µg / ml (Cooper et al., 2007; Hase et al., 2004).  The 
datasheet from both products recommended a concentration of 1 µg / ml and after 
conducting dose-response studies (data not shown) we decided to use the recommended 
concentration. After treatment, the cells were removed from culture by trypsinisation and 
prepared for subsequent western blot analysis (as described on page 132 – 134 in chapter 
two, see figures 2.15 & 2.16) (see figure 7.2 – 7.4 for treatment protocols).  The expression 
and activation of the following proteins were investigated (please refer to chapter 2, page 
132 for the concentration and exposure time of each protein): 
NOS Signalling: Total and phosphorylated eNOS and PKB / Akt, and total HSP 90, 
caveolin-1 and iNOS were measured to investigate NOS signalling mechanisms.  
Oxidative Stress: The membrane bound NADPH oxidase subunit, p22-phox, was used to 
measure nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activity as 
previously described (Griendling KK et al., 2000a). 
Nitrosative Stress: The ability of the highly reactive NO-derived radical, ONOO- 
(peroxynitrite) to nitrosylate tyrosine residues of cellular proteins and form nitrotyrosine, is 
an indication of nitrosative stress (Dalle‐Donne et al., 2005). Nitrotyrosine expression was 
therefore measured as a marker of nitrosative stress. 
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NFКβ signalling: Activation of the NFКβ pathway is usually an indication of a pro-
inflammatory response (Ben-Neriah and Karin, 2011).  Upon activation of this pathway, IКβα 
dislodges from the NFКβ complex and undergoes proteasomal degradation; therefore, a 
reduction in IКβα protein levels is a marker of NFКβ activation (Hoffmann A et al., 2002). 
IКβα protein expression was therefore measured to investigate activity of the NFКβ 
pathway.   
Apoptosis: Cleaved caspase-3 and cleaved PARP were measured to investigate apoptosis 
signalling.   
Equal protein loading validation: β-tubulin expression was measured to confirm equal 
protein loading in all samples. 
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Figure 7.2: Protocol for treatment of CMECs with 20 ng / ml TNF-α with or without 1 µg / ml of TRB1 for 30 minutes for subsequent 
western blot analysis. 
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Figure 7.3: Protocol for treatment of CMECs with 20 ng / ml TNF-α with or without 1 µg / ml of TRB2 for 30 minutes for subsequent 
western blot analysis. 
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Figure 7.4: Protocol for treatment of CMECs with 20 ng / ml TNF-α with or without 1 µg / ml of TRB2 and 1 µg / ml of TRB2 for 30 minutes 
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7.3  Results 
 
7.3.1  NOS signalling: 
eNOS 
Exposing CMECs to 30 minutes of TNF-α (20 ng / ml) led to unchanged phosphorylated eNOS 
levels (0.98 ± 0.05 vs. 1.00 control) (see figure 7.5), unchanged total eNOS expression (0.92 
± 0.02 vs. 1.00 control) (see figure 7.6), and unchanged phosphorylated / total eNOS ratios 
(1.07 ± 0.05 vs. 1.00 control) (see figure 7.7) respectively.   
TNFR1 blockade: Exposing CMECs to 30 minutes of TNF-α (20 ng / ml) + TRB1 (1 µg / ml) led 
to decreased phosphorylated eNOS levels (0.78 ± 0.01 vs. 1.00 control: p < 0.05) (see figure 
7.5), decreased total eNOS expression (0.74 ± 0.02 vs. 1.00 control:  p < 0.05) (see figure 
7.6), and unchanged phosphorylated / total eNOS ratios (1.06 ± 0.05 vs. 1.00 control) (see 
figure 7.7) respectively.  
TNFR2 blockade: Exposing CMECs to 30 minutes of TNF-α (20 ng / ml) + TRB2 (1 µg / ml) led 
to unchanged phosphorylated eNOS levels (0.65 ± 0.13 vs. 1.00 control) (see figure 7.5), 
decreased total eNOS expression (0.66 ± 0.06 vs. 1.00 control:  p < 0.05) (see figure 7.6), and 
unchanged phosphorylated / total eNOS ratios (0.99 ± 0.18 vs. 1.00 control) (see figure 7.7) 
respectively.  
TNFR1 + TNFR2 blockade: Exposing CMECs to 30 minutes of TNF-α (20 ng / ml) + TRB1&2 (1 
µg / ml) led to decreased phosphorylated eNOS levels (0.10 ± 0.03 vs. 1.00 control:  p < 0.05) 
(see figure 7.5), decreased total eNOS expression (0.56 ± 0.02 vs. 1.00 control:  p < 0.05) 
(see figure 7.6), and decreased phosphorylated / total eNOS ratios (0.17 ± 0.06 vs. 1.00 
control:  p < 0.05) (see figure 7.7) respectively.  
When the different groups were compared to each other, it was evident that blocking both 
TNFR1 and TNFR2 resulted in outspoken decreases (~ 80%) in the relative activation of eNOS 
(phospho / total eNOS ratio) vs. TNFR1 only or TNFR2 only blockade (see Figure 7.7). 
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Figure 7.5: The effects of TNF-α receptor blockade (1 µg / ml) on phosphorylated eNOS 
in TNF-α (20 ng / ml)-treated CMECs.  Data are represented as phosphorylated eNOS 
(expressed as a ratio of control; control = 1).  ß-tubulin was used to validate equal protein 
loading.  All data were expressed as a ratio of control with control adjusted to 1 (please 
refer to page 134, chapter 2).  Sample size:  n = 3 / group. 
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Figure 7.6: The effects of TNF-α receptor blockade (1 µg / ml) on total eNOS expression 
in TNF-α (20 ng / ml)-treated CMECs.  Data are represented as total eNOS (expressed as a 
ratio of control; control = 1).  ß-tubulin was used to validate equal protein loading.  All data 
were expressed as a ratio of control with control adjusted to 1 (please refer to page 134, 
chapter 2).  Sample size:  n = 3 / group. 
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Figure 7.7:  The effects of TNF-α receptor blockade (1 µg / ml) on phosphorylated / total 
eNOS ratios in TNF-α (20 ng / ml)-treated CMECs.  Data are represented as phosphorylated 
eNOS / total eNOS (expressed as a ratio of control; control = 1).  All data were expressed as 
a ratio of control with control adjusted to 1 (please refer to page 134, chapter 2).  Sample 
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PKB/Akt 
Exposing CMECs to 30 minutes of TNF-α (20 ng / ml) led to unchanged phosphorylated 
PKB/Akt levels (1.00 ± 0.07 vs. 1.00 control) (see figure 7.8), unchanged total PKB/Akt 
expression (0.88 ± 0.04 vs. 1.00 control) (see figure 7.9), and increased phosphorylated / 
total PKB/Akt  ratios (1.30 ± 0.03 vs. 1.00 control:  p < 0.05) (see figure 7.10) respectively.   
TNFR1 blockade:  Exposing CMECs to 30 minutes of TNF-α (20 ng / ml) + TRB1 (1 µg / ml) led 
to unchanged phosphorylated PKB/Akt levels (1.10 ± 0.03 vs. 1.00 control) (see figure 7.8), 
unchanged total PKB/Akt expression (0.88 ± 0.01 vs. 1.00 control) (see figure 7.9), and 
increased phosphorylated / total PKB/Akt ratios (1.25 ± 0.05 vs. 1.00 control:  p < 0.05) (see 
figure 7.10) respectively.  
TNFR2 blockade:  Exposing CMECs to 30 minutes of TNF-α (20 ng / ml) + TRB2 (1 µg / ml) led 
to unchanged phosphorylated PKB/Akt levels (0.96 ± 0.07 vs. 1.00 control) (see figure 7.8), 
unchanged total PKB/Akt expression (0.85 ± 0.04 vs. 1.00 control) (see figure 7.9), and 
unchanged phosphorylated / total PKB/Akt  ratios (1.13 ± 0.03 vs. 1.00 control) (see figure 
7.10) respectively. 
TNFR1 + TNFR2 blockade: Exposing CMECs to 30 minutes of TNF-α (20 ng / ml) + TRB1&2 (1 
µg / ml) led to unchanged phosphorylated PKB/Akt levels (0.96 ± 0.03 vs. 1.00 control) (see 
figure 7.8), unchanged total PKB/Akt expression (0.91 ± 0.06 vs. 1.00 control) (see figure 
7.9), and unchanged phosphorylated / total PKB/Akt ratios (1.07 ± 0.03 vs. 1.00 control) (see 
figure 7.10) respectively. 
When the different groups were compared to each other, it was evident that blocking both 
TNFR1 and TNFR2 resulted in a modest, but significant decrease in the relative activation of 
PKB/Akt (phospho / total PKB/Akt) vs. the TNF-α-treated group, but not vs. TNFR1 only or 
TNFR2 only blockade (see Figure 7.10). 
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Figure 7.8: The effects of TNF-α receptor blockade (1 µg / ml) on phosphorylated 
PKB/Akt in TNF-α (20 ng / ml)-treated CMECs.  Data are represented as phosphorylated 
PKB/Akt (expressed as a ratio of control; control = 1).  ß-tubulin was used to validate equal 
protein loading.  All data were expressed as a ratio of control with control adjusted to 1 
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Figure 7.9: The effects of TNF-α receptor blockade (1 µg / ml) on total PKB/Akt 
expression in TNF-α (20 ng / ml)-treated CMECs.  Data are represented as total PKB/Akt 
(expressed as a ratio of control; control = 1).  ß-tubulin was used to validate equal protein 
loading.  All data were expressed as a ratio of control with control adjusted to 1 (please 
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Figure 7.10: The effects of TNF-α receptor blockade (1 µg / ml) on phosphorylated / total 
PKB/Akt ratios in TNF-α (20 ng / ml)-treated CMECs.  Data are represented as 
phosphorylated PKB/Akt / total PKB/Akt (expressed as a ratio of control; control = 1).  All 
data were expressed as a ratio of control with control adjusted to 1 (please refer to page 
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HSP 90 
 
Exposing CMECs to 30 minutes of TNF-α (20 ng / ml) led to unchanged HSP 90 expression 
levels (1.05 ± 0.05 vs. 1.00 control) (see figure 7.11). 
TNFR1 blockade: Exposing CMECs to 30 minutes of TNF-α (20 ng / ml) + TRB1 (1 µg / ml) led 
to unchanged HSP 90 expression levels (0.91 ± 0.06 vs. 1.00 control) (see figure 7.11).  
TNFR2 blockade: Exposing CMECs to 30 minutes of TNF-α (20 ng / ml) + TRB2 (1 µg / ml) led 
to decreased HSP 90 expression levels (0.64 ± 0.04 vs. 1.00 control:  p < 0.05) (see figure 
7.11). 
 TNFR1 + TNFR2 blockade: Exposing CMECs to 30 minutes of TNF-α (20 ng / ml) + TRB1 & 2 
(1 µg / ml) led to decreased HSP 90 expression levels (0.68 ± 0.05 vs. 1.00 control:  p < 0.05) 
(see figure 7.11). 
When the different groups were compared with each other, it was evident that blockade of 
TNFR2 resulted in a significant decrease in HSP 90 expression compared to TNF-α-treated 
groups as well as groups in which TNFR1 was blocked. Blockade of both TNFR1 and TNFR2 
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Figure 7.11: The effects of TNF-α receptor blockade (1 µg / ml) on HSP 90 expression in 
TNF-α (20 ng / ml)-treated CMECs.  Data are represented as HSP 90 expression (expressed 
as a ratio of control; control = 1).  ß-tubulin was used to validate equal protein loading.  All 
data were expressed as a ratio of control with control adjusted to 1 (please refer to page 
134, chapter 2).  Sample size:  n = 3 / group. 
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Caveolin-1 
 
Exposing CMECs to 30 minutes of TNF-α (20 ng / ml) led to unchanged caveolin-1 expression 
levels (0.83 ± 0.06 vs. 1.00 control) (see figure 7.12). 
TNFR1 blockade:  Exposing CMECs to 30 minutes of TNF-α (20 ng / ml) + TRB1 (1 µg / ml) led 
to decreased caveolin-1 expression levels (0.67 ± 0.04 vs. 1.00 control:  p < 0.05) (see figure 
7.12).   
TNFR2 blockade:   Exposing CMECs to 30 minutes of TNF-α (20 ng / ml) + TRB2 (1 µg / ml) 
led to unchanged caveolin-1 expression levels (0.86 ± 0.04 vs. 1.00 control) (see figure 7.12). 
TNFR1 + TNFR2 blockade: Exposing CMECs to 30 minutes of TNF-α (20 ng / ml) + TRB1 & 2 
(1 µg / ml) led to unchanged caveolin-1 expression levels (1.02 ± 0.11 vs. 1.00 control) (see 
figure 7.12). 
When the different groups were compared with each other, it was evident that the TNF-α-
treated cells in which TNFR1 was blocked was the only group in which the expression of 
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Figure 7.12: The effects of TNF-α receptor blockade (1 µg / ml) on caveolin-1 expression in 
TNF-α (20 ng / ml)-treated CMECs.  Data are represented as caveolin-1 expression 
(expressed as a ratio of control; control = 1).  ß-tubulin was used to validate equal protein 
loading.  All data were expressed as a ratio of control with control adjusted to 1 (please 





Stellenbosch University  http://scholar.sun.ac.za
P a g e  | - 322 - 
 
  Chapter Seven 
iNOS 
 
Exposing CMECs to 30 minutes of TNF-α (20 ng / ml) led to increased iNOS expression levels 
(1.32 ± 0.08 vs. 1.00 control:  p < 0.05) (see figure 7.13). 
TNFR1 blockade:  Exposing CMECs to 30 minutes of TNF-α (20 ng / ml) + TRB1 (1 µg / ml) led 
to unchanged iNOS expression levels (1.27 ± 0.08 vs. 1.00 control) (see figure 7.13).   
TNFR2 blockade:  Exposing CMECs to 30 minutes of TNF-α (20 ng / ml) + TRB2 (1 µg / ml) led 
to unchanged iNOS expression levels (0.94 ± 0.12 vs. 1.00 control) (see figure 7.13). 
TNFR1 + TNFR2 blockade: Exposing CMECs to 30 minutes of TNF-α (20 ng / ml) + TRB1 & 2 
(1 µg / ml) led to decreased iNOS expression levels (0.42 ± 0.05 vs. 1.00 control:  p < 0.05) 
(see figure 7.13). 
When the different groups were compared with each other, it was evident that the TNF-α-
treated cells in which both TNFR1 + TNFR2 were blocked resulted in outspoken down-
regulation of iNOS expression compared to all the other groups. Also noticeable was the up-
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Figure 7.13: The effects of TNF-α receptor blockade (1 µg / ml) on iNOS expression in TNF-
α (20 ng / ml)-treated CMECs.  Data are represented as iNOS expression (expressed as a 
ratio of control; control = 1).  ß-tubulin was used to validate equal protein loading.  All data 
were expressed as a ratio of control with control adjusted to 1 (please refer to page 134, 
chapter 2).  Sample size:  n = 3 / group. 
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7.3.2  Western blot analysis of oxidative stress: p22 phox 
 
Exposing CMECs to 30 minutes of TNF-α (20 ng / ml) led to increased p22 phox expression 
levels (1.55 ± 0.07 vs. 1.00 control:  p < 0.05) (see figure 7.14). 
TNFR1 blockade:  Exposing CMECs to 30 minutes of TNF-α (20 ng / ml) + TRB1 (1 µg / ml) led 
to increased p22 phox expression levels (1.89 ± 0.12 vs. 1.00 control:  p < 0.05) (see figure 
7.14).   
TNFR2 blockade:  Exposing CMECs to 30 minutes of TNF-α (20 ng / ml) + TRB2 (1 µg / ml) led 
to increased p22 phox expression levels (1.71 ± 0.12 vs. 1.00 control:  p < 0.05) (see figure 
7.14). 
TNFR1 + TNFR2 blockade:  Exposing CMECs to 30 minutes of TNF-α (20 ng / ml) + TRB1 & 2 
(1 µg / ml) led to unchanged p22 phox expression levels (1.41 ± 0.18 vs. 1.00 control) (see 
figure 7.14). 
When the different groups were compared with each other, it was evident that the up-
regulation of p22 phox by TNF-α could not be reversed by TNFR1 blockade only or by TNFR2 
blockade only. However, when both receptors were blocked, the significant increase in 
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Figure 7.14: The effects of TNF-α receptor blockade (1 µg / ml) on p22 phox expression in 
TNF-α (20 ng / ml)-treated CMECs.  Data are represented as p22 phox expression (expressed 
as a ratio of control; control = 1).  ß-tubulin was used to validate equal protein loading.  All 
data were expressed as a ratio of control with control adjusted to 1 (please refer to page 
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7.3.3  Western blot analysis of nitrosative stress: nitrotyrosine 
 
Exposing CMECs to 30 minutes of TNF-α (20 ng / ml) led to unchanged nitrotyrosine 
expression levels (0.97 ± 0.03 vs. 1.00 control) (see figure 7.15). 
TNFR1 blockade:  Exposing CMECs to 30 minutes of TNF-α (20 ng / ml) + TRB1 (1 µg / ml) led 
to unchanged nitrotyrosine expression levels (0.93 ± 0.01 vs. 1.00 control) (see figure 7.15).   
TNFR2 blockade:  Exposing CMECs to 30 minutes of TNF-α (20 ng / ml) + TRB2 (1 µg / ml) led 
to decreased nitrotyrosine expression levels (0.70 ± 0.02 vs. 1.00 control:  p < 0.05) (see 
figure 7.15). 
TNFR1 + TNFR2 blockade: Exposing CMECs to 30 minutes of TNF-α (20 ng / ml) + TRB1 & 2 
(1 µg / ml) led to unchanged nitrotyrosine expression levels (0.93 ± 0.04 vs. 1.00 control) 
(see figure 7.15). 
When the different groups were compared with each other, it was evident that the TNF-α-
treated cells in which TNFR2 was blocked resulted in a significant down-regulation of 
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Figure 7.15: The effects of TNF-α receptor blockade (1 µg / ml) on nitrotyrosine 
expression in TNF-α (20 ng / ml)-treated CMECs.  Data are represented as nitrotyrosine 
expression (expressed as a ratio of control; control = 1).  ß-tubulin was used to validate 
equal protein loading.  All data were expressed as a ratio of control with control adjusted to 
1 (please refer to page 134, chapter 2).  Sample size:  n = 3 / group. 
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7.3.4  Western blot analysis of NFΚβ signalling: IΚβα 
 
Exposing CMECs to 30 minutes of TNF-α (20 ng / ml) led to unchanged IΚβα expression 
levels (0.99 ± 0.08 vs. 1.00 control) (see figure 7.16). 
TNFR1 blockade:  Exposing CMECs to 30 minutes of TNF-α (20 ng / ml) + TRB1 (1 µg / ml) led 
to unchanged IΚβα expression levels (1.16 ± 0.03 vs. 1.00 control) (see figure 7.16).   
TNFR2 blockade:  Exposing CMECs to 30 minutes of TNF-α (20 ng / ml) + TRB2 (1 µg / ml) led 
to unchanged IΚβα expression levels (1.20 ± 0.10 vs. 1.00 control) (see figure 7.16). 
TNFR1 + TNFR2 blockade: Exposing CMECs to 30 minutes of TNF-α (20 ng / ml) + TRB1 & 2 
(1 µg / ml) led to increased IΚβα expression levels (1.56 ± 0.03 vs. 1.00 control:  p < 0.05) 
(see figure 7.16). 
When the different groups were compared with each other, it was interesting to note that 
TNF-α did not achieve reduction in IΚβα  expression as observed with 24 hour treatment 
investigations previously discussed in this dissertation. However, it was that the TNF-α-
treated cells in which both TNFR1 + TNFR2 were blocked resulted in a significant up-
regulation of IΚβα expression compared to all the other groups, except the TNFR2 blockade 
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Figure 7.16: The effects of TNF-α receptor blockade (1 µg / ml) on IΚβα expression in TNF-
α (20 ng / ml)-treated CMECs.  Data are represented as IΚβα expression (expressed as a ratio 
of control; control = 1).  ß-tubulin was used to validate equal protein loading.  All data were 
expressed as a ratio of control with control adjusted to 1 (please refer to page 134, chapter 
2).  Sample size:  n = 3 / group. 
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7.3.5  Western blot analysis of apoptosis signalling: 
 
Cleaved Caspase-3 
Exposing CMECs to 30 minutes of TNF-α (20 ng / ml) led to increased cleaved caspase-3 
expression levels (1.48 ± 0.11 vs. 1.00 control:  p < 0.05) (see figure 7.17). 
TNFR1 blockade:  Exposing CMECs to 30 minutes of TNF-α (20 ng / ml) + TRB1 (1 µg / ml) led 
to unchanged cleaved caspase-3 expression levels (1.16 ± 0.10 vs. 1.00 control) (see figure 
7.17).   
TNFR2 blockade:  Exposing CMECs to 30 minutes of TNF-α (20 ng / ml) + TRB2 (1 µg / ml) led 
to decreased cleaved caspase-3 expression levels (0.58 ± 0.21 vs. 1.00 control:  p < 0.05) (see 
figure 7.17). 
TNFR1 + TNFR2 blockade: Exposing CMECs to 30 minutes of TNF-α (20 ng / ml) + TRB1 & 2 
(1 µg / ml) led to decreased cleaved caspase-3 expression levels (0.78 ± 0.04 vs. 1.00 
control:  p < 0.05) (see figure 7.17). 
When the different groups were compared with each other, it was interesting to note that 
TNF-α significantly increased cleaved caspase-3 levels at this time point, something that was 
not observed in the 24 hours experiments (see Chapter 6). Furthermore, all three blockade 
scenarios succeeded in either partially or completely reversing the effects of TNF-α 
treatment. In fact, TNFR2 blockade alone and TNFR1 + TNFR2 blockade resulted in a 
significant reduction in cleaved caspase-3 levels compared to untreated controls and TNF-α 
treated cells (without blockers). Additionally, TNFR1 + TNFR2 blockade resulted in a 
significant reduction in cleaved caspase-3 levels compared to the TNFR1 blockade group 
(see Figure 7.17). 
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Figure 7.17: The effects of TNF-α receptor blockade (1 µg / ml) on cleaved caspase-3 
expression in TNF-α (20 ng / ml)-treated CMECs.  Data are represented as cleaved caspase-3 
expression (expressed as a ratio of control; control = 1).  ß-tubulin was used to validate 
equal protein loading.  All data were expressed as a ratio of control with control adjusted to 
1 (please refer to page 134, chapter 2).  Sample size:  n = 3 / group. 
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Cleaved PARP 
 
Exposing CMECs to 30 minutes of TNF-α (20 ng / ml) led to increased cleaved PARP 
expression levels (1.33 ± 0.07 vs. 1.00 control:  p < 0.05) (see figure 7.18). 
TNFR1 blockade:  Exposing CMECs to 30 minutes of TNF-α (20 ng / ml) + TRB1 (1 µg / ml) led 
to increased cleaved PARP expression levels (1.33 ± 0.07 vs. 1.00 control:  p < 0.05) (see 
figure 7.18).   
TNFR2 blockade:  Exposing CMECs to 30 minutes of TNF-α (20 ng / ml) + TRB2 (1 µg / ml) led 
to increased cleaved PARP expression levels (1.33 ± 0.07 vs. 1.00 control:  p < 0.05) (see 
figure 7.18). 
TNFR1 + TNFR2 blockade: Exposing CMECs to 30 minutes of TNF-α (20 ng / ml) + TRB1 & 2 
(1 µg / ml) led to increased cleaved PARP expression levels (1.78 ± 0.04 vs. 1.00 control:  p < 
0.05) (see figure 7.18). 
Exposing CMECs to 24 hours of TNF-α (20 ng / ml) + TRB1 & 2 (1 µg / ml) led to a significant 
increase (1.33 ± 0.07 vs. 1.00 control: p < 0.05) (see figure 7.18) in the expression of cleaved 
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Figure 7.18: The effects of TNF-α receptor blockade (1 µg / ml) on cleaved PARP 
expression in TNF-α (20 ng / ml)-treated CMECs.  Data are represented as cleaved PARP 
expression (expressed as a ratio of control; control = 1).  ß-tubulin was used to validate 
equal protein loading.  All data were expressed as a ratio of control with control adjusted to 
1 (please refer to page 134, chapter 2).  Sample size:  n = 3 / group. 
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7.4  Discussion 
A thorough literature search has revealed that there is a lack of studies that have 
investigated the intracellular effects (endpoints: NOS, oxidative and nitrosative stress, NF-
κβ, and apoptosis signalling) of exogenous TNF-α treatment in the context of 
pharmacological TNF receptor blockade in endothelial cells.  In the light of this, we will 
discuss a few studies that have investigated the effects of the TNF-α receptors in different 
scenarios. 
To determine the effects of anti-receptor antagonistic antibodies, human umbilical vein 
endothelial cells (HUVECs) were pretreated for 1 hour in the absence or presence of the 
appropriate antibody, before the addition of TNF-α (50 ng / ml) for 4 to 24 hours (Paleolog 
et al., 1994).  They found the following:  Anti-p55 (TNFR1) and anti-p75 (TNFR2) receptor 
antibodies inhibited endothelial adhesion molecule expression and cytokine release to 
different degrees; anti-p55 receptor agonistic antibody increased release of cytokines and 
adhesion molecule expression on endothelial cells; anti-p55 agonist Htr-9 inhibits 
endothelial cell proliferation and endothelial cell responses to lymphotoxin are significantly 
inhibited by anti-p55 but not by anti-p75 antibody.  Interestingly, another study investigated 
the involvement of both receptors in the activation of endothelial cells by TNF-α (Slowik et 
al., 1993).  They blocked HUVECs 2 hours prior to treatment with 6 ng / ml TNF-α for 
another 4 hours and concluded from their results that contrary to Mackay et al. (1993), both 
receptors are involved in endothelial cell activation.   
In a study on cardiac myocytes, cells were exposed to pre-treatment with anti-TNFR1 and 
anti-TNFR2 for 30 minutes to neutralize the receptors and then subsequently treated for a 
further 30 minutes with 25 ng / ml TNF-α, a clear role for the TNFR2 was shown in cardiac 
pathology (Defer et al., 2007).  Their results characterized a TNFR2-dependent signalling and 
illustrated the close interplay between TNFR1 and TNFR2 pathways in cardiac myocytes.  
Although apparently predominant, TNFR1-dependent responses were under the yoke of 
TNFR2, acting as a critical limiting factor.   
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In the present study, the pre-treatment of CMECs with 1µg / ml of either TRB1 or TRB2 or 
the combination and subsequent treatment with TNF-α (20 ng / ml) for a further 30 
minutes, yielded quite interesting and novel results and will be discussed below.   
NOS signalling:  We (see Chapter 5) and others (Gao et al., 2007; Picchi et al., 2006; Ahmad 
et al., 2002) have previously shown that TNF-α can impair NO- production. Therefore, the 
effects of TNF receptor blockade was also investigated with regard to its possible effects on 
NOS-NO biosynthesis.  Treatment of CMECs with TNF-α alone had no effect on eNOS 
expression or phosporylation, despite a relative increase in PKB/Akt activation. TNF-α 
treatment, however, did result in an increase in iNOS expression. Blocking of either TNFR1 
alone or TNFR2 alone had no effect on relative eNOS activation and iNOS expression in TNF-
α-treated cells; however, when both TNFR1 and TNFR2 were blocked, eNOS activation was 
profoundly decreased, even compared to untreated control groups. Blockade of both TNFR1 
and TNFR2 also significantly decreased iNOS expression. The large reduction in eNOS 
activation was accompanied by a reduction in HSP 90 (which is required for eNOS 
phosphorylation). These data are interesting, as it suggests that both TNFR1 and TNFR2 are 
required for eNOS activation, not only in the context of exogenous TNF-α-treatment, but 
possibly also for baseline, physiological levels of activated eNOS. Alternatively, although we 
could not substantiate this from evidence in the literature, it is theoretically possible that 
the exogenously administered TNF-α may have exerted non-receptor mediated effects on 
eNOS activation. Although we did not investigate this, it would be interesting to perform the 
double blockade experiments on normal, untreated cells to further unravel this 
phenomenon. Our data therefore also suggest that crosstalk between the two receptors is 
present in the regulation of NOS signalling. Interestingly, although some of the respective 
treatments had an effect on some of the key role-players in NOS-signalling (HSP 90 and 
caveolin-1) as well as one of the upstream activators of eNOS, it did not have any effect on 
eNOS.  For instance, with TNF-α treatment only, PKB/Akt was upregulated, but eNOS 
unchanged (see figure 7.19A).  Blocking TNFR1 also upregulated PKB/Akt and 
downregulated caveolin-1, but eNOS remained unchanged (see figure 7.19B).  Blocking 
TNFR2 decreased HSP 90, but eNOS remained unchanged (see figure 7.19C).  See figures 
7.19 (A-D) for a schematic representation of the findings of the NOS signalling 
investigations. 
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Figure 7.19: Simplified schematic overview of: 
A: TNF-α NOS-signalling. 
Note: Red letters indicate treatment, blue arrows indicate active pathways and black 
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Figure 7.19: Simplified schematic overview of: 
B: TNF-α + TRB1 NOS-signalling. 
Note: Red letters indicate treatment, blue arrows indicate active pathways and black 
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Figure 7.19: Simplified schematic overview of: 
C: TNF-α + TRB2 NOS-signalling. 
Note: Red letters indicate treatment, blue arrows indicate active pathways and black 
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Figure 7.19: Simplified schematic overview of: 
D: TNF-α + TRB1 & 2 NOS-signalling. 
Note: Red letters indicate treatment, blue arrows indicate active pathways and black 
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Oxidative / nitrosative stress: TNF-α is often associated with increased ROS production in 
endothelial cells (Chen W et al., 2008).  In light of this fact, we also set out to investigate the 
effects of TNF receptor blockade with regard to its possible effects on ROS production.   
CMECs treated with TNF-α caused an increase in p22 phox expression, but had no effect on 
nitrotyrosine expression (see figure 7.20A).  In view of the significant increase in p22 phox, 
we assume that some degree of oxidative stress had been induced. From the data it is 
evident that either TNFR1 or TNFR2 leads to TNF-α-induced up-regulation of p22 phox, but 
when both receptors are simultaneously blocked, the increased TNF-α-induced expression 
of p22 phox is lost (figure 7.20B & C). These results are again suggestive of crosstalk 
between the two receptor systems. With regard to nitrotyrosine expression, the data 
showed that nitrosative stress was not induced in any of the groups. See figures 7.20 (A-D) 
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Figure 7.20: Simplified schematic overview of: 
A: TNF-α oxidative/nitrosative stress-signalling. 
Note: Red letters indicate treatment, blue arrows indicate active pathways and black 
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Figure 7.20: Simplified schematic overview of: 
B: TNF-α + TRB1 oxidative/nitrosative stress-signalling. 
Note: Red letters indicate treatment, blue arrows indicate active pathways and black 
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Figure 7.20: Simplified schematic overview of: 
C: TNF-α + TRB2 oxidative/nitrosative stress-signalling. 
Note: Red letters indicate treatment, blue arrows indicate active pathways and black 
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Figure 7.20: Simplified schematic overview of: 
D: TNF-α + TRB1 & 2 oxidative/nitrosative stress-signalling. 
Note: Red letters indicate treatment, blue arrows indicate active pathways and black 
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NF-κβ signalling:  According to the literature, a reduction in IКβα protein levels is a marker 
of NF-κβ activation (Hoffmann et al., 2002).  Therefore, it was important for us to 
investigate the effects of TNF receptor blockade with regard to its possible effects on NF-κβ 
activation. Interestingly, TNF-α (20 ng / ml) treatment did not result in decreased IΚβα (as 
was seen in chapter 5 with the same concentration), although the duration of treatment 
seems to be an important factor here (see figure 7.21A).  In view of this, we assume that 
TNF-α in this experimental scenario did not lead to NF-κβ activation.  From the data it is 
evident that blockade of both receptors (TRB1+TRB2), led to a significant increase in IКβα 
protein levels, where blocking of either had no effect (see figure 7.21B & C) and from this 
we assume that both receptors are required for NF-κβ activation (see figure 7.21D).  
Therefore, we can assume that TNF-α probably elicits its pro-inflammatory effects through 
both receptors.    See figures 7.21 (A–D) for a schematic representation of the findings of the 
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Figure 7.21: Simplified schematic overview of: 
A: TNF-α IΚβα-signalling. 
Note: Red letters indicate treatment, blue arrows indicate active pathways and black 
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Figure 7.21: Simplified schematic overview of: 
B: TNF-α + TRB1 IΚβα-signalling. 
Note: Red letters indicate treatment, blue arrows indicate active pathways and black 
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Figure 7.21: Simplified schematic overview of: 
C: TNF-α + TRB2 IΚβα-signalling. 
Note: Red letters indicate treatment, blue arrows indicate active pathways and black 
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Figure 7.21: Simplified schematic overview of: 
D: TNF-α + TRB1 & 2 IΚβα-signalling. 
Note: Red letters indicate treatment, blue arrows indicate active pathways and black 
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Apoptosis:  According to many studies in the literature, apoptosis is often a consequence of 
TNF-α induced effects. Therefore, as has been the case throughout the chapters dealing 
with TNF-α in this dissertation, the effects of TNF receptor blockade was also investigated 
with regard to its possible effects on apoptosis. CMECs treated with TNF-α caused an 
increase in cleaved caspase-3, but had no effect on cleaved PARP (see figure 7.22). In view 
of the significant increase in cleaved caspase-3, it is sufficient for the purposes of the 
present chapter to assume that some degree of apoptosis had been induced. From the data 
it is evident that both TNFR1 and TNFR2 are required for the induction of the caspase-3 
apoptosis pathway, since all three blockade scenarios (see figure 7.22B, C & D) resulted in 
either a partial attenuation (TRB1 alone), or in fact a complete reversal (TRB2 alone and 
TRB1+TRB2; almost signifying an anti-apoptotic response) of the TNF-α effects. Our data 
therefore suggest that crosstalk between the two receptor systems is present in the 
regulation of caspase-3. Interestingly, none of the respective treatments had any effects on 
baseline cleaved PARP levels, indicating that, in our hands, this branch of apoptosis was not 
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Figure 7.22: Simplified schematic overview of: 
A: TNF-α apoptosis-signalling. 
Note: Red letters indicate treatment, blue arrows indicate active pathways and black 
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Figure 7.22: Simplified schematic overview of: 
B: TNF-α + TRB1 apoptosis-signalling. 
Note: Red letters indicate treatment, blue arrows indicate active pathways and black 
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Figure 7.22: Simplified schematic overview of: 
C: TNF-α + TRB2 apoptosis-signalling. 
Note: Red letters indicate treatment, blue arrows indicate active pathways and black 
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Figure 7.22: Simplified schematic overview of: 
D: TNF-α + TRB1 & 2 apoptosis-signalling. 
Note: Red letters indicate treatment, blue arrows indicate active pathways and black 




Stellenbosch University  http://scholar.sun.ac.za
P a g e  | - 355 - 
 
  Chapter Seven 
When reviewing the above results, it is important to bear in mind that there are also soluble 
forms of both TNF-α receptors (which represent the extracellular portions of membrane-
associated TNF receptors and are probably shed from them by proteolytic partition) (Diez-
Ruiz et al., 1995).  The existence of soluble TNF receptors provides a new insight into the 
regulation of TNF-α function since they may act as antagonists or inhibitors for endogenous 
TNF-α, serve as binding proteins to carry endogenously produced TNF-α out of the site of 
production and may stabilize or even enhance the effects of TNF-α (Diez-Ruiz et al., 1995).  
However, the antibodies that were used in this study to block the effects of the two TNF 
receptors are also sensitive for the soluble forms of these receptors (TNFRSF1A for TNFR1 
and TNFRSF1B for TNFR2) (Cooper et al., 2007; Hase et al., 2005) (see page 303). 
 
7.5  Conclusion 
In conclusion, the findings of this chapter are novel in that no previous studies have 
characterised the effects of the TNF-α receptors in conjunction with exogenous TNF-α 
treatment in CMECs.  We approached the study in this chapter by making use of western 
blot analysis to draw a clear picture of how the treatment used in this chapter will affect the 
various important signalling events present in endothelial cells. We therefore investigated 
intracellular events, (including the measurement of nitric oxide and ROS) and as mentioned 
important endothelial signalling proteins.  See figures 7.19 – 7.22 for a schematic summary 
of events.  
• It did not come as a surprise to find that TNF-α indeed increased cleaved caspase-3 
and seemed to exert pro-apoptotic effects. Interestingly, we could not observe this at 24 
hours TNF-α treatment (see previous chapters), which therefore suggests that the pro-
apoptotic response, at least where caspase-3 is involved, is an early event. When we 
blocked the different TNF-α receptors, we found that TNFR1 led to a decrease in cleaved 
caspase-3 and thus a have a partial attenuating effect on TNF-α induced apoptosis (this is a 
surprising finding as the receptor type 1 is usually referred to as the “death-receptor”) and 
that TNFR2 seemed to have no effect on apoptosis.  Interestingly, blocking both receptors 
almost seemed to have an anti-apoptotic effect. 
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• Our data also demonstrated that TNF-α treatment alone had no effect on the 
relative activation of eNOS.  This finding is not in agreement with various previous studies, 
among others also my own data as presented in previous chapters. However, it must be 
noted that in this chapter, the cells were only treated for 30 minutes and not 24 hours.  
Interestingly, TNF-α, at this shorter period of treatment, upregulated iNOS, which we also 
found to be the case at 24 hours (see chapter 5, page 261).  Blocking of the two receptors 
individually, although they had effects on key components of eNOS-activation (such as 
PKB/Akt, HSP 90 or caveolin-1) had no overall effect on eNOS activity, and neither did these 
interventions have any effects on iNOS expression.  Interestingly, blocking both receptors 
simultaneously seemed to profoundly suppress eNOS activation below baseline levels. This 
interesting finding opens itself up for some interesting speculative scenarios: Are both 
receptors required for baseline activation of eNOS (regardless of the presence of exogenous 
TNF-α)? Does the exogenously administered TNF-α exert direct down-regulating effects on 
eNOS activation via a non-receptor mediated process when both receptors are not available 
for binding? Unfortunately, time and resources did not allow for a further investigation of 
this observation; however, it is certainly something that should be explored, starting with a 
simple investigation of the effect of TNFR1 and TNFR2 blockade on control (i.e. baseline, 
untreated) CMECs. In similar fashion and equally intriguing, blocking of both receptors also 
decreased iNOS expression below baseline levels . 
• Oxidative / nitrosative stress: When CMECs were treated with TNF-α only, an 
upregulation in p22 phox was observed, which is not unexpected, and in agreement with 
our findings at 24 hours TNF-α treatment in previous chapters. This treatment, however, 
had no effects on nitrosative stress as measured by nitrotyrosine expression.  Blocking 
TNFR1 only caused an increase in p22 phox expression.   This is contradictory to popular 
belief, since there is an assumption in many studies that the TNF-α receptor 2 is usually not 
involved with oxidative stress (Shen HM and Pervaiz, 2006). The only receptor that stayed 
true to its reputation as the “bad” receptor was receptor type 1, because when we blocked 
type 2, we also observed an increase in p22 phox expression.  Interestingly, in this blockade 
scenario, we found a decrease in nitrotyrosine expression.  Not surprisingly, when both 
receptors were blocked, the TNF-α-induced up-regulation of p22 phox was abolished, which 
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again speaks in favour of TNFR1-TNFR2 crosstalk.  It is important to note that from the data 
it is clear that both receptors are involved in the up-regulation of p22 phox.      
• NF-κβ activation:  Treatment of CMECs for only 30 minutes did not seem to lead to 
NF-κβ activation as was the case for 24 hours treatment (as shown in chapter 5).  
Interestingly, when both receptors were blocked, a decrease in NF-κβ activity was observed, 
suggesting a role for both receptors in NF-κβ activity.  As previously mentioned in section 
7.1.1.1, it is known in the literature that NF-κβ mediates the transcription of a vast array of 
proteins involved in cell survival and proliferation, inflammatory response, and anti-
apoptotic factors (Ghosh et al., 2012).   
 
7.6 Limitations 
Please note that the observations made and conclusions drawn were based on one 
technique of investigation only (western blot analysis) and simply based on this alone.  The 
researchers do recognize the immense complexity of TNF-α signalling and the 
oversimplifying of the findings was aimed at creating an understanding of the results. 
We also acknowledge the limitations of using pharmalogical inhibitors to explore the role of 
receptors, as the researcher can never assume that the inhibitors are 100% specific.  
Lastly, due to time and logistical constraints, we were unable to include experiments 
investigating the effects of the receptor blockers on untreated, control groups. We are 
aware that this would have added value to the study, and will include control groups in 
future studies.   
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The original aim of this study was to investigate the responses of cardiac microvascular 
endothelial cells to various harmful stimuli, specifically paying focused and detailed 
attention to underlying mechanisms. The rationale behind this overall aim was the fact that 
vascular endothelial cells, by virtue of their location at the inner lining of blood vessels, are 
often the very first targets of harmful stimuli associated with cardiovascular risk factors and 
diseases. The choice of the specific endothelial cell type was mainly motivated by the fact 
that relatively little research has been performed on CMECs. It was anticipated, therefore, 
that this PhD study would add value and novel findings to existing literature. The first logical 
step was to perform a comprehensive characterisation of the cells under baseline, 
untreated conditions, on which we reported in Chapter 3. Once the baseline investigations 
were completed, we decided to focus on two important and clinically relevant harmful 
stimuli. In Chapter 4, we described the responses of CMECs to hypoxia. The relevance of 
hypoxia lies in the fact that capillary-derived endothelial cells such as the CMECs are 
frequently exposed to conditions of low oxygen supply. Furthermore, during a cardiac 
ischaemic event, it is conceivable that the CMECs represent the “first line of defense” of the 
myocardium during hypoxia. In Chapters 5-7 the focus shifted to creating an in vitro 
inflammatory microenvironment by treating the cells with one of the most important pro-
inflammatory cytokines, TNF-α, and to explore the cellular responses to this insult. 
Inflammation, and therefore high circulating TNF-α levels, are important features of many 
cardiovascular risk factors and diseases such as diabetes mellitus, obesity, ischaemic heart 
disease / atherosclerosis and heart failure to name but a few.  
All the experiments performed in these chapters were achieved by making use of previously 
established and several new techniques not previously used in our research group, 
accompanied by the measurement of various endpoints in order to generate a 
comprehensive view of the mechanisms of the responses of CMECs to the above two 
stimuli.  All in all, this study incorporated the following cutting edge techniques: 
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 Fluorescence-based flow cytometry assays for the detection of various intracellular 
molecules and species; 
 Western blotting measurements; 
 Proteomics; 
 Light microscopy and fluorescence microscopy  
Chapter 3: Here, we wanted to gain information on the CMECs under baseline conditions, 
before embarking on the investigation into the responses of these cells to harmful stimuli.   
Indeed, the fact that 1387 proteins were identified in the CMECs represented the most 
extensive documentation of any mammalian CMEC proteome to date and a novel addition 
to existing vascular proteomic databases.   
Chapter 4: It was important and necessary to investigate the CMECs in the context of 
hypoxia, as vascular endothelial cells are frequently exposed to low levels of PO2 as well as 
the fact that hypoxia is considered to be an independent risk factor for the development of 
endothelial dysfunction. Again, we made use of proteomic analysis to offer a comprehensive 
overview of the response of these cells subjected to hypoxia and the findings provided a 
novel addition to the study.  The CMECs responded by a general up-regulation of the eNOS-
NO biosynthesis pathway.  At 24 hours hypoxia, it seemed that these cells were still largely 
resistant to hypoxic damage. Although the intracellular ROS measurements were somewhat 
contradictory, the strong down-regulation of SOD1, accompanied by an increase in DHR123 
fluorescence did point towards a general state of oxidative- and nitrosative stress in the 
CMECs after 24 hours of hypoxia.  The proteomics results in Chapter 4 also provided further 
confirmation of adaptations in energy metabolism that one would expect in hypoxic 
endothelial cells, such as the significant enrichment of glycolysis and up-regulation of 
several glycolytic enzymes. However, the findings with regard to the changes in 
mitochondrial proteins were not that easy to explain, and further research into these 
phenomena is indicated.   
Chapters 5-7: In the remaining chapters, we investigated the responses of CMECs to 
exogenously administered TNF-α. Several different experimental protocols and 
interventions, such as pharmacological blockade of TNF-α receptors were implemented to 
rule out certain scenarios and narrow down the possible explanations for the findings.  In 
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Chapter 5, we showed that exogenous TNF-α-treatment induced an adaptive response in 
the cells, often signified by contradictory trends, yet, overall it is our belief that the 
observed effects were an indication that the cells were in a transitional state from being 
“functional” to “dysfunctional”, with early signs of oxidative and nitrosative stress and the 
activation of pathways that would conceivably result in a pro-inflammatory phenotype. In 
the final chapter, we were interested in the respective roles of the two TNF-α receptors. The 
so-called “death-receptor”, TNFR 1, stayed true to its reputation and we found several 
indications of damage when TNFR 2 was blocked. However, TNF-α-binding to TNFR 2 (in the 
presence of TNFR1 blockade), widely considered to be the “good” receptor, also caused an 
increase in oxidative stress in our CMECs.  The results obtained from blocking either one of 
the two receptors or both, led us to believe that both receptors are involved (to varying 
degrees) in the responses observed, with crosstalk between the two receptor-mediated 
downstream pathways presumably taking place. 
In summary, the findings of this study supplied a comprehensive, novel insight into the cells 
that line the microvasculature of the myocardium, which are to a great extent under-
researched in the field of ischaemic heart disease (IHD) and endothelial dysfunction (ED).  As 
originally stated in the introduction, the prevalence of heart disease, and ischaemic heart 
disease in particular, is rising and remains one of the top causes of morbidity and mortality 
world-wide. In view of the pivotal role of the vascular endothelium in the development of 
cardiovascular disease, as well as the fact that endothelial dysfunction is regarded as an 
early, potentially reversible predictor of future adverse cardiac events, it is imperative that 
we continue investigating the endothelium, and its responses to the various risk factors that 
ultimately lead to its functional demise. In this dissertation, we comprehensively 
investigated the responses of adult rat CMECs to two major harmful stimuli typically 
associated with the development of cardiovascular disease, namely hypoxia and TNF-α. We 
chose this cell type in view of the fact that it is generally neglected in the literature, yet at 
the same time, located within the cardiac muscle, which potentially renders it very 
important in the development of ischaemic heart disease.  The findings of my investigations 
were mixed: some results were in agreement with existing data in the literature, others 
contradicted the literature and yet others were novel. As with every research model, ours 
also had its limitations, but we firmly believe that this dissertation will form an important 
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part of the growing puzzle of understanding the role of endothelial cells in cardiovascular 
disease.   
 
Shortcomings of the present study: 
In hindsight, the following aspects would have added more value and depth to the present 
study, but due to time and cost restraints, these aspects were not addressed in the present 
study.  
 Supplementing the proteomics data with more extensive western blot analysis (as 
was done in chapter 5 with the TNF-α results).  The hypoxic data was obtained much 
earlier in the study and it was only towards the latter part of the study that we 
started to investigate a larger array of proteins with western blot analysis (including 
cleaved caspase-3, PARP and IΚβα). 
 The up-regulation of mitochondrial proteins in hypoxic CMECs was somewhat 
counterintuitive, as hypoxia is generally accepted to down-regulate aerobic energy 
metabolic processes.  We did mention that the up-regulation of proteins does not 
necessarily mean that the activity was increased. The lack of functional data on the 
CMEC mitochondria in this chapter was a shortcoming; however, future 
investigations could address this, as time and project funding did not allow for this in 
the current PhD study. 
 The proteomic data obtained from the 24 hour hypoxia experiments were also 
contradictory in terms of the significant enrichment of translational processes such 
as elongation and initiation. For the same reasons explained previously, we were not 
able to further investigate this aspect.  
 The work on the TNF-α receptor blockers was performed exclusively with western 
blot analyses, which, in hindsight, left several questions unanswered in view of the 
very interesting findings. The exclusion of control groups for the receptor blockers 
(without TNF-α) is also a limitation, as this would have added value to the data in 
that chapter.  However, these investigations were performed towards the end of the 
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PhD study and if allowed more time, we would have liked to conduct more 
comprehensive investigations, such as proteomic analyses.  
 Other shortcomings include the fact that for the largest part of this study, we 
focused on one endothelial cell type, which of course was the aim of the PhD. 
Although we tried to show some comparative data by including aortic endothelial 
cells in Chapter 5, if time and funding allowed, we would have preferred to do this 
more often throughout the study. 
 Lastly, in a study performed on a rat cardiac cell line, it is important to mention that 
the assumptions are made that: 
a. rat cells behave similarly to human cells under normal as well as pathological 
conditions, 
b. the in vitro environment corresponds well with the in vivo environment and 
c. experiments performed on cell lines that have undergone several passages have 
the limitation of only using the “stronger” surviving cells and not necessarily 
those that were included in the primary cells and this may skew results.    
 
Future directions 
As a direct and indirect consequence of the findings of this dissertation, we plan to conduct 
the following future studies:  
(i) Further investigations into the role of the mitochondrial proteins in hypoxia, in view 
of the interesting mitochondrial expression data obtained in Chapter 4. Experiments could 
include phospho-proteomic analyses, as well as other more function-directed studies such 
as mitochondrial respiration (with Oxygraph), 
(ii) Expansion of the TNFR antibody experiments to complement the western blot data 
obtained in Chapter 7, which could include proteomics and other intracellular end-points, 
(iii) Inclusion of a different vascular endothelial cell type for comparative purposes,  
(iv) Inclusion of ex vivo functional investigations (e.g. aortic vascular tissue),  
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(v) Inclusion of animal models in which the effects of cardiovascular risk factors (e.g. 
obesity and insulin resistance) on vascular endothelial function can be investigated,  
(vi) Development of endothelial cell harvesting techniques so that researchers in our 
research group can create our own primary endothelial cell cultures from healthy and 
diseased animals. 
 
Outputs that resulted directly or indirectly from this study: 
1. Peer-reviewed journal publications: 
Manuscript currently under review: Strijdom H, Genis A, Van Rensburg S, Westcott C, Mudau 
M, Van Vuuren D, Smit S. Novel characterization of the rat cardiac microvascular endothelial 
proteome and its regulation by hypoxia. Int J Proteomics 2013. 
Mudau M, Genis A, Lochner A, Strijdom H. Endothelial Dysfuntion – the early predictor of 
atherosclerosis. Cardiovasc J Africa 2012; 23(4): 222-231. 
 
2. Published Peer-reviewed Conference Abstracts: 
Genis A, Strijdom H, Westcott C, Mudau M.  Signalling responses in cardiac microvascular 
endothelial cells, following treatment with high dosage of TNF-alpha, with or without co-
treatment with Oleanolic Acid.  International Union of Physiological Sciences, Birminghman, 
UK.  2013. 
Strijdom H, Smit S, Westcott C, Genis A.  Proteomic characterization of cardiac endothelial 
cell responses to TNF-alpha, hypoxia and asymmetric dimethylarginine (ADMA) stimulation.  
SA Heart.  2012. 
Strijdom H, Mudau M, Westcott C, Genis A.  Tumor necrosis factor (TNF)-α: towards a model 
of endothelial dysfunction.  Scientific Research and Essays.  2012. 
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Genis A, Mudau M, Westcott C, Strijdom H.  Evidence of pro-survival responses in TNF-α 
stimulated microvascular endothelial cells.  Scientific Research and Essays.  2012. 
Genis A, Westcott C, Mudau M, Strijdom H.  Effect of low-dose TNF-α administration on 
oxidative/nitrosative stress:  the Akt/eNOS/NO pathway and viability in cardiac endothelial 
cells.  Atherosclerosis (Suppl.).  2011. 
Strijdom H, Westcott C, Mudau M, Genis A.  Microvascular endothelial cell responses to 
inflammatory stimulation.  SA Heart.  2011. 
Genis A, Westcott C, Mudau M, Strijdom H.  Tumor necrosis factor (TNF)-α induces 
endothelial dysfunction (ED) in cultured cardiac microvascular Endothelial Cells (CMECs) by 
downregulation of the PKB/Akt-eNOS signaling pathway.  J Mol Cell Cardiol.  2010. 
Genis A, Mudau E, Lochner A, Strijdom H.  A novel model of Endothelial Dysfunction (ED) in 
cultured cardiac microvascular endothelial cells (CMECs).  SA Heart.  2009. 
 
3. Conference outputs: 
Genis A, Westcott C, Strijdom H, Lochner A.  Evidence of pro-survival responses in TNF-α 
stimulated microvascular endothelial cells.  Physiology Society of Southern Africa Annual 
Congress.  2011.  Winner of poster competition. 
Genis A, Strijdom H, Westcott C, Mudau M.  Microvascular endothelial cell adaptive 
responses following TNF-stimulation.  Annual Research Day, Faculty of Health Sciences, 
Stellenbosch University.  2011. 
Van Rensburg S, Strijdom H, Westcott C, Mudau M, Genis A.  The role of tumour necrosis 
factor alpha (TNF-α) and hypoxia in microvascular endothelial cells.  Annual Research Day, 
Faculty of Health Sciences, Stellenbosch University.  2011. 
Van Rensburg S, Strijdom H, Westcott C, Mudau M, Genis A.  Tumor necrosis factor alpha 
(TNF-α) and hypoxia:  towards a model of endothelial dysfunction.  Physiology Society of 
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Southern Africa Annual Congress.  2011.  Selected to be presented in the Wyndham 
competition.  
Genis A, Mudau M, Lochner A, Strijdom H.  Tumor necrosis factor (TNF)-alpha induces 
endothelial dysfunction (ED) in cultured Cardiac Microvascular Endothelial Cells (CMECs), by 
downregulation of the PKB/Akt signalling pathway.  Society of International Heart Research, 
World Congress, Kyoto, Japan.  J Mol Cell Cardiol.  2010; 48 (5, S1): S94.  
Genis A, Strijdom H, Westcott C, Mudau M.  An In Vitro Model of Endothelial Dysfunction in 
Cultured Cardiac Microvascular Endothelial Cells (CMEC).  Physiology Society of Southern 
Africa, Annual Congress.  2009. 
Genis A, Mudau E, Lochner A, Strijdom H. A Novel Model of Endothelial Dysfunction (ED) in 
Cultured Cardiac Microvascular Endothelial Cells (CMECs).  SA Heart.  2009.  Winner of 
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4. Other outputs: 
Honours degrees of students I supervised:  
Sam van Rensburg: graduated 2012. 
Charlize van Nieuwenhuizen: graduates end 2013. 
Invited Commentary by the International Atherosclerosis Society: 
Strijdom H, Genis A. When traditional and non-traditional cardiovascular risk factors target 
the vascular endothelium: A double blow to the burden of disease in South Africa.  
International Atherosclerosis Society May 2013;  
http://www.athero.org/commentaries/comm1135.asp.    
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